PMID- 39936922 OWN - NLM STAT- MEDLINE DCOM- 20250507 LR - 20250507 IS - 1582-4934 (Electronic) IS - 1582-1838 (Print) IS - 1582-1838 (Linking) VI - 29 IP - 3 DP - 2025 Feb TI - Bu Yang Huan Wu Prevents Osteogenic Effect of Muscle-Derived Stromal Cells via Regulating JAK/STAT Pathway. PG - e70413 LID - 10.1111/jcmm.70413 [doi] LID - e70413 AB - Heterotopic ossification (HO) is a crucial pathological process in which bone or calcification develop in skeletal muscle and surrounding soft tissues. Muscle-derived stromal cells (MDSC) are important muscle-resident mesenchymal progenitor cells and macrophage-derived oncostatin M (OSM) can induce osteogenic differentiation. Bu Yang Huan Wu (BYHW), which has a long history of use in restraining inflammation, can prevent osteogenic differentiation and HO formation while underlying mechanism is still unclear. The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway is an important pathway to regulate osteogenic differentiation of related cells. In this study, we investigated whether BYHW could inhibit osteogenesis effect of MDSC through OSM mediated by macrophages, and whether JAK/STAT pathway regulated this biological process. We found that activated macrophages promoted osteogenic differentiation of MDSC through OSM and BYHW could decrease the level of OSM and osteogenic activity of MDSC. Further, we confirmed the regulatory effect of JAK/STAT pathway, blocking this pathway could suppress the level of OSM and osteogenic differentiation of MDSC. We showed that BYHW could suppress osteogenic differentiation of MDSC through JAK/STAT signalling. These findings expand the application scope of traditional Chinese medicine and provide a basis for the further investigation of the potential therapeutic role of HO. CI - © 2025 The Author(s). Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. FAU - Cao, Guorui AU - Cao G AD - Department of Knee Surgery, Luoyang Orthopedic Hospital of Henan Province, Orthopedic Hospital of Henan Province, Luoyang, Henan Province, People's Republic of China. FAU - Zhang, Shaoyun AU - Zhang S AD - Department of Orthopedics, The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, Sichuan Province, People's Republic of China. FAU - Liao, Yuanping AU - Liao Y AD - Hunan University of Chinese Medicine, Changsha, Hunan Province, People's Republic of China. FAU - Yue, Chen AU - Yue C AUID- ORCID: 0000-0003-4863-0864 AD - Department of Knee Surgery, Luoyang Orthopedic Hospital of Henan Province, Orthopedic Hospital of Henan Province, Luoyang, Henan Province, People's Republic of China. FAU - Yang, Lanbo AU - Yang L AD - Department of Knee Surgery, Luoyang Orthopedic Hospital of Henan Province, Orthopedic Hospital of Henan Province, Luoyang, Henan Province, People's Republic of China. FAU - Guo, Jiayi AU - Guo J AD - Department of Knee Surgery, Luoyang Orthopedic Hospital of Henan Province, Orthopedic Hospital of Henan Province, Luoyang, Henan Province, People's Republic of China. FAU - Tong, Peijian AU - Tong P AD - The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, People's Republic of China. FAU - Tan, Honglue AU - Tan H AUID- ORCID: 0000-0001-7455-5728 AD - Department of Knee Surgery, Luoyang Orthopedic Hospital of Henan Province, Orthopedic Hospital of Henan Province, Luoyang, Henan Province, People's Republic of China. LA - eng GR - 2024HLTJ17/Heluo Youth Talent Promotion Project/ GR - 2024ZY3067/Scientific Research of Traditional Chinese Medicine in Henan Province/ GR - 2024-04/Scientific Research of Returned Overseas Students in Henan Province/ GR - 82104896/National Natural Science Foundation of China/ PT - Journal Article PL - England TA - J Cell Mol Med JT - Journal of cellular and molecular medicine JID - 101083777 RN - EC 2.7.10.2 (Janus Kinases) RN - 0 (STAT Transcription Factors) RN - 106956-32-5 (Oncostatin M) RN - 0 (Drugs, Chinese Herbal) SB - IM MH - *Osteogenesis/drug effects MH - *Signal Transduction/drug effects MH - *Janus Kinases/metabolism MH - Animals MH - Cell Differentiation/drug effects MH - *STAT Transcription Factors/metabolism MH - Oncostatin M/metabolism MH - Mice MH - *Drugs, Chinese Herbal/pharmacology MH - Macrophages/metabolism/drug effects MH - Mesenchymal Stem Cells/metabolism/drug effects/cytology MH - *Stromal Cells/drug effects/metabolism/cytology PMC - PMC11816160 OTO - NOTNLM OT - Bu Yang Huan Wu OT - macrophage OT - muscle‐derived stromal cells OT - oncostatin M OT - the janus kinase/signal transducer and activator of transcription COIS- The authors declare no conflicts of interest. EDAT- 2025/02/12 12:27 MHDA- 2025/02/12 12:28 PMCR- 2025/02/12 CRDT- 2025/02/12 09:03 PHST- 2025/01/24 00:00 [revised] PHST- 2024/10/16 00:00 [received] PHST- 2025/01/30 00:00 [accepted] PHST- 2025/02/12 12:28 [medline] PHST- 2025/02/12 12:27 [pubmed] PHST- 2025/02/12 09:03 [entrez] PHST- 2025/02/12 00:00 [pmc-release] AID - JCMM70413 [pii] AID - 10.1111/jcmm.70413 [doi] PST - ppublish SO - J Cell Mol Med. 2025 Feb;29(3):e70413. doi: 10.1111/jcmm.70413. PMID- 39105318 OWN - NLM STAT- MEDLINE DCOM- 20241017 LR - 20250730 IS - 1612-1880 (Electronic) IS - 1612-1872 (Linking) VI - 21 IP - 9 DP - 2024 Sep TI - Exploration of the Mechanisms of Bu-Yang-Huan-Wu Decoction in the Treatment of Diabetic Peripheral Neuropathy by Integrating of Serum Pharmacochemistry and Network Pharmacology. PG - e202400910 LID - 10.1002/cbdv.202400910 [doi] AB - Diabetic peripheral neuropathy (DPN) is a significant and frequent complication of diabetes. Bu-Yang-Huan-Wu Decoction (BHD) is a classic traditional Chinese herbal prescription that is commonly used in modern clinical practice for the effective treatment of DPN, but the underlying mechanism is not yet clearly defined. The chemical constituents of BHD were characterized by UPLC-Q-Orbitrap HR MS/MS, and a total of 101 chemical components were identified, including 30 components absorbed into blood. An interaction network of "compound-target-disease" interactions was constructed based on the compounds detected absorbed in blood and their corresponding targets of diabetic neuropathy acquired from disease gene databases, and the possible biological targets and potential signalling pathways of BHD were predicted via network pharmacology analysis. Subsequently, methylglyoxal-induced (MGO-induced) Schwann cells (SCs) were used to identify the active ingredients in blood components of BHD and verify the molecular mechanisms of BHD. Through network topological analysis, 30 shared targets strongly implicated in the anti-DPN effects of BHD were identifed. Combined network pharmacology and in vitro cellular analysis, we found that the active ingredient of BHD may treat DPN by modulating the AGEs/RAGE pathway. This study provides valuable evidence for future mechanistic studies and potential therapeutic applications for patients with DPN. CI - © 2024 Wiley-VHCA AG, Zurich, Switzerland. FAU - Chen, Peng-Fei AU - Chen PF AD - Key Laboratory of Digital Quality Evaluation of Chinese Materia Medica of State Administration of TCM and Engineering & Technology Research Center for Chinese Materia Medica Quality of Guangdong Province, Guangdong Pharmaceutical University, Guangzhou, 510006, China. FAU - Huang, Guang-Xiao AU - Huang GX AD - Key Laboratory of Digital Quality Evaluation of Chinese Materia Medica of State Administration of TCM and Engineering & Technology Research Center for Chinese Materia Medica Quality of Guangdong Province, Guangdong Pharmaceutical University, Guangzhou, 510006, China. FAU - Gu, Wen-Ting AU - Gu WT AD - Key Laboratory of Digital Quality Evaluation of Chinese Materia Medica of State Administration of TCM and Engineering & Technology Research Center for Chinese Materia Medica Quality of Guangdong Province, Guangdong Pharmaceutical University, Guangzhou, 510006, China. FAU - Zhuang, Guo-Dong AU - Zhuang GD AD - Key Laboratory of Digital Quality Evaluation of Chinese Materia Medica of State Administration of TCM and Engineering & Technology Research Center for Chinese Materia Medica Quality of Guangdong Province, Guangdong Pharmaceutical University, Guangzhou, 510006, China. FAU - Chen, Chong AU - Chen C AD - Key Laboratory of Digital Quality Evaluation of Chinese Materia Medica of State Administration of TCM and Engineering & Technology Research Center for Chinese Materia Medica Quality of Guangdong Province, Guangdong Pharmaceutical University, Guangzhou, 510006, China. FAU - Wang, Shu-Mei AU - Wang SM AD - Key Laboratory of Digital Quality Evaluation of Chinese Materia Medica of State Administration of TCM and Engineering & Technology Research Center for Chinese Materia Medica Quality of Guangdong Province, Guangdong Pharmaceutical University, Guangzhou, 510006, China. FAU - Tang, Dan AU - Tang D AD - Key Laboratory of Digital Quality Evaluation of Chinese Materia Medica of State Administration of TCM and Engineering & Technology Research Center for Chinese Materia Medica Quality of Guangdong Province, Guangdong Pharmaceutical University, Guangzhou, 510006, China. LA - eng GR - 81703671/National Natural Science Foundation of China/ GR - 82074137/National Natural Science Foundation of China/ GR - 82374177/National Natural Science Foundation of China/ GR - 2022A1515220068/Guangdong Basic and Applied Basic Research Foundation/ GR - 2022ZDZX2032/Key Project of Department of Education of Guangdong Province/ PT - Journal Article DEP - 20240806 PL - Switzerland TA - Chem Biodivers JT - Chemistry & biodiversity JID - 101197449 RN - 0 (Drugs, Chinese Herbal) RN - 722KLD7415 (Pyruvaldehyde) SB - IM MH - *Drugs, Chinese Herbal/chemistry/pharmacology MH - *Diabetic Neuropathies/drug therapy/metabolism MH - *Network Pharmacology MH - Animals MH - Rats MH - Schwann Cells/drug effects/metabolism MH - Humans MH - Pyruvaldehyde/metabolism MH - Rats, Sprague-Dawley MH - Tandem Mass Spectrometry MH - Cells, Cultured OTO - NOTNLM OT - Bu-Yang-Huan-Wu decoction OT - Diabetic peripheral neuropathy OT - Network pharmacology OT - UPLC-Q-Orbitrap HRMS/MS EDAT- 2024/08/06 06:43 MHDA- 2024/10/17 23:58 CRDT- 2024/08/06 05:33 PHST- 2024/04/09 00:00 [received] PHST- 2024/10/17 23:58 [medline] PHST- 2024/08/06 06:43 [pubmed] PHST- 2024/08/06 05:33 [entrez] AID - 10.1002/cbdv.202400910 [doi] PST - ppublish SO - Chem Biodivers. 2024 Sep;21(9):e202400910. doi: 10.1002/cbdv.202400910. Epub 2024 Aug 6. PMID- 30573993 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240405 IS - 1179-1349 (Print) IS - 1179-1349 (Electronic) IS - 1179-1349 (Linking) VI - 10 DP - 2018 TI - The effects of Bu Yang Huan Wu Tang on post-stroke epilepsy: a nationwide matched study. PG - 1839-1850 LID - 10.2147/CLEP.S175677 [doi] AB - OBJECTIVE: To compare the long-term risk of epilepsy in stroke patients who use Bu Yang Huan Wu Tang (BYHWT) and those who do not. METHODS: In the Taiwanese national insurance claims data, we identified newly diagnosed stroke patients receiving inpatient care in the years 2000-2004. Using propensity score-matched pairs to balance the baseline characteristics, we selected eligible stroke patients who did (n=8,971) and did not (n=8,971) receive BYHWT. These two groups were followed up until the end of 2009 to track the occurrence of epilepsy. We used Cox proportional hazard models to calculate the adjusted HRs and 95% CIs for post-stroke epilepsy during the follow-up period according to BYHWT use. RESULTS: Compared with the control group, stroke patients with BYHWT had a reduced risk of epilepsy during the 5-9 years of the follow-up period (HR 0.69, 95% CI 0.61-0.77). The association between BYHWT and reduced post-stroke epilepsy was significant in various subgroups of stroke patients. There was a dose-dependent decrease in the frequency of epilepsy with increasing quantities of BYHWT use from 1 package (HR 0.77, 95% CI 0.66-0.90) to ≥6 packages (HR 0.52, 95% CI 0.42-0.65). CONCLUSION: Stroke patients who received BYHWT therapy had a reduced long-term risk of epilepsy, and the beneficial effect could be observed in various subgroups. However, future clinical trials will be necessary to corroborate the present findings and identify the biochemical mechanism involved. FAU - Weng, Shu-Wen AU - Weng SW AD - Department of Chinese Medicine, Taichung Hospital, Ministry of Health and Welfare, Taichung, Taiwan. FAU - Chen, Ta-Liang AU - Chen TL AD - Department of Anesthesiology, Taipei Medical University Hospital, Taipei, Taiwan. AD - Anesthesiology and Health Policy Research Center, Taipei Medical University Hospital, Taipei, Taiwan. AD - Department of Anesthesiology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. FAU - Yeh, Chun-Chieh AU - Yeh CC AD - Department of Surgery, China Medical University Hospital, Taichung, Taiwan. AD - Department of Surgery, University of Illinois, Chicago, IL, USA. FAU - Lane, Hsin-Long AU - Lane HL AD - School of Chinese Medicine for Post-Baccalaureate, I-Shou University, Kaohsiung, Taiwan, hwathai@seed.net.tw. FAU - Liao, Chien-Chang AU - Liao CC AD - Department of Anesthesiology, Taipei Medical University Hospital, Taipei, Taiwan. AD - Anesthesiology and Health Policy Research Center, Taipei Medical University Hospital, Taipei, Taiwan. AD - Department of Anesthesiology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. AD - School of Chinese Medicine, China Medical University, Taichung, Taiwan. FAU - Shih, Chun-Chuan AU - Shih CC AD - School of Chinese Medicine for Post-Baccalaureate, I-Shou University, Kaohsiung, Taiwan, hwathai@seed.net.tw. AD - Program for the Clinical Drug Discovery from Botanical Herbs, Taipei Medical University, Taipei, Taiwan, hwathai@seed.net.tw. LA - eng PT - Journal Article DEP - 20181210 PL - New Zealand TA - Clin Epidemiol JT - Clinical epidemiology JID - 101531700 PMC - PMC6292405 OTO - NOTNLM OT - Bu Yang Huan Wu Tang OT - epilepsy OT - long-term risk OT - stroke COIS- Disclosure The authors report no conflicts of interest in this work. EDAT- 2018/12/24 06:00 MHDA- 2018/12/24 06:01 PMCR- 2018/12/10 CRDT- 2018/12/22 06:00 PHST- 2018/12/22 06:00 [entrez] PHST- 2018/12/24 06:00 [pubmed] PHST- 2018/12/24 06:01 [medline] PHST- 2018/12/10 00:00 [pmc-release] AID - clep-10-1839 [pii] AID - 10.2147/CLEP.S175677 [doi] PST - epublish SO - Clin Epidemiol. 2018 Dec 10;10:1839-1850. doi: 10.2147/CLEP.S175677. eCollection 2018. PMID- 32714088 OWN - NLM STAT- MEDLINE DCOM- 20210601 LR - 20210601 IS - 1449-1907 (Electronic) IS - 1449-1907 (Linking) VI - 17 IP - 12 DP - 2020 TI - Anti-inflammatory effects of powdered product of Bu Yang Huan Wu decoction: Possible role in protecting against Transient Focal Cerebral Ischemia. PG - 1854-1863 LID - 10.7150/ijms.46581 [doi] AB - Bu Yang Huan Wu decoction (BYHW) is a traditional Chinese medicine (TCM) that consists of several herbs and has been used in patients with ischemic stroke for centuries. Although powdered formula of BYHW has widely been prescribed in clinic nowadays, evidence-based effectiveness and mechanism of action of BYHW powdered product in stroke remain to be characterized. Adult male Sprague-Dawley rats were subjected to middle cerebral artery occlusion (MCAO) for 90 min followed by reperfusion for 24 h (ischemia/reperfusion; I/R) or sham surgery. After I/R, the rats were then given low dose (0.5 g/kg) and high dose (2.5 g/kg) of BYHW or vehicle by oral gavage twice a day for seven consecutive days. The results showed that I/R induced obvious cerebral infarction and neurobehavioral defects, in parallel with histological aberrations and extensive signaling of proinflammatory cytokines, including tumor necrosis factor (TNF-α) and interleukin-6 (IL-6), in the stroke model. Post-I/R treatment with BYHW powdered product significantly reduced the infarct area and ameliorated neurofunctional defects in a dose-dependent manner. The dose dependence was associated with TNF-α downregulation and interleukin-10 (IL-10) induction. In summary, the present findings demonstrated that BYHW powdered product exhibited therapeutic efficacy for experimental stroke and a higher dose treatment may strengthen the effectiveness via inflammatory modulation. CI - © The author(s). FAU - Chen, Kuan-Yu AU - Chen KY AD - Department of Surgery, New Taipei City Hospital, New Taipei city, Taiwan. AD - Institute of Medical Sciences, Tzu Chi University, Hualien city, Taiwan. FAU - Wu, Kuo-Chen AU - Wu KC AD - School of Pharmacy, National Taiwan University, Taipei, Taiwan. FAU - Hueng, Dueng-Yuan AU - Hueng DY AD - Department of Neurosurgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan. FAU - Huang, Kuo-Feng AU - Huang KF AD - School of Medicine, Buddhist Tzu Chi University, Hualien, Taiwan. AD - Division of Neurosurgery, Department of Surgery, Taipei Tzu Chi Medical Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan. FAU - Pang, Cheng-Yoong AU - Pang CY AD - Institute of Medical Sciences, Tzu Chi University, Hualien city, Taiwan. AD - Department of Medical Research, Buddhist Tzu Chi General Hospital, Hualien city, Taiwan. LA - eng PT - Journal Article DEP - 20200711 PL - Australia TA - Int J Med Sci JT - International journal of medical sciences JID - 101213954 RN - 0 (Drugs, Chinese Herbal) RN - 0 (Interleukin-6) RN - 0 (Powders) RN - 0 (Tumor Necrosis Factor-alpha) RN - 130068-27-8 (Interleukin-10) SB - IM MH - Animals MH - Brain Ischemia/*drug therapy/genetics/pathology MH - Disease Models, Animal MH - Dose-Response Relationship, Drug MH - Drugs, Chinese Herbal/*pharmacology MH - Gene Expression Regulation/drug effects MH - Humans MH - Inflammation/*drug therapy/genetics/pathology MH - Interleukin-10/genetics MH - Interleukin-6/genetics MH - Ischemic Stroke/*drug therapy/genetics/pathology MH - Medicine, Chinese Traditional MH - Powders/pharmacology MH - Rats MH - Reperfusion Injury/*drug therapy/genetics/pathology MH - Treatment Outcome MH - Tumor Necrosis Factor-alpha/genetics PMC - PMC7378667 OTO - NOTNLM OT - Bu Yang Huan Wu decoction OT - Ischemic/reperfusion OT - Stroke OT - inflammation COIS- Competing Interests: The authors have declared that no competing interest exists. EDAT- 2020/07/28 06:00 MHDA- 2021/06/02 06:00 PMCR- 2020/01/01 CRDT- 2020/07/28 06:00 PHST- 2020/04/01 00:00 [received] PHST- 2020/06/17 00:00 [accepted] PHST- 2020/07/28 06:00 [entrez] PHST- 2020/07/28 06:00 [pubmed] PHST- 2021/06/02 06:00 [medline] PHST- 2020/01/01 00:00 [pmc-release] AID - ijmsv17p1854 [pii] AID - 10.7150/ijms.46581 [doi] PST - epublish SO - Int J Med Sci. 2020 Jul 11;17(12):1854-1863. doi: 10.7150/ijms.46581. eCollection 2020. PMID- 12776558 OWN - NLM STAT- MEDLINE DCOM- 20031202 LR - 20080206 IS - 1001-5302 (Print) IS - 1001-5302 (Linking) VI - 27 IP - 10 DP - 2002 Oct TI - [Effects of bu yang huan wu decoction on astrocytes after cerebral ischemia and reperfusion]. PG - 763-5 AB - OBJECTIVE: To study the effects of Bu Yang Huan Wu Decoction on astrocytes after cerebral ischemia and reperfusion. METHOD: Cerebral ischemia model in gerbils was produced by ligating bilateral common carotid artery. The dynamic expressin of GFAP were determined by immunochemistry after cerebyal ischemia for 15 min followed by reperfusion for 24 hours and 48 hours. RESULT: GFAP positive reactions reached a peak after cerebral ischemia for 15 min followed by reperfusion for 24 hours. Bu Yang Huan Wu Decoction decreased the expression. GFAP positive reactions decreased after cerebral ischemia for 15 min followed by reperfusion for 48 hours, Bu Yang Huan Wu Decoction increased the expression. CONCLUSION: The regulation of Bu Yang Huan Wu Decoction on astrocytes after cerebral ischemia and reperfusion may be related to repairing process after cerebral ischemia. FAU - Lai, Zhen AU - Lai Z AD - Shenzhen People's Hospital, Shenzhen 518020, Guangdong, China. FAU - Wang, Sha-yan AU - Wang SY FAU - Geng, Xiao-yin AU - Geng XY FAU - Deng, Chang-qing AU - Deng CQ FAU - Zhang, Ruan-zhang AU - Zhang RZ LA - chi PT - English Abstract PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - China TA - Zhongguo Zhong Yao Za Zhi JT - Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica JID - 8913656 RN - 0 (Drugs, Chinese Herbal) RN - 0 (Glial Fibrillary Acidic Protein) RN - 0 (buyang huanwu) SB - IM MH - Animals MH - Astrocytes/*drug effects MH - Brain Ischemia/complications MH - Drugs, Chinese Herbal/isolation & purification/*pharmacology MH - Female MH - Glial Fibrillary Acidic Protein/*metabolism MH - Hippocampus/metabolism MH - Male MH - *Plants, Medicinal/chemistry MH - Reperfusion Injury/etiology/metabolism/*pathology EDAT- 2003/06/05 05:00 MHDA- 2003/12/03 05:00 CRDT- 2003/06/05 05:00 PHST- 2003/06/05 05:00 [pubmed] PHST- 2003/12/03 05:00 [medline] PHST- 2003/06/05 05:00 [entrez] PST - ppublish SO - Zhongguo Zhong Yao Za Zhi. 2002 Oct;27(10):763-5. PMID- 30218809 OWN - NLM STAT- MEDLINE DCOM- 20181224 LR - 20181224 IS - 1872-7573 (Electronic) IS - 0378-8741 (Linking) VI - 228 DP - 2019 Jan 10 TI - Bu Yang Huan Wu decoction prevents reperfusion injury following ischemic stroke in rats via inhibition of HIF-1 α, VEGF and promotion β-ENaC expression. PG - 70-81 LID - S0378-8741(18)31694-5 [pii] LID - 10.1016/j.jep.2018.09.017 [doi] AB - ETHNOPHARMACOLOGICAL RELEVANCE: Bu Yang Huan Wu Decoction (BYHW) is a famous traditional Chinese medicine (TCM) formula used in China for the treatment of cerebral ischemic stroke. But the protective effects and underlining mechanisms of BYHW remain unclear. AIM OF THE STUDY: This study was designed to investigate the protective effects and underlining signaling mechanisms of BYHW on brain tissues in a rat model of cerebral ischemic reperfusion (I/R) injury. MATERIALS AND METHODS: Liquid chromatography was used to verify the composition of BYHW. The cerebral edema and infarct volume were measured by magnetic resonance imaging (MRI). The morphology and ultrastructure of ischemic penumbra brain tissues were observed by hematoxylin-eosin (HE) and transmission electron microscopy (TEM). The expression levels of HIF-1 α, VEGF and β-ENaC were tested using immunohistochemistry technique, western blot and quantitative PCR analysis, respectively. RESULTS: Administration of BYHW significantly decreased cerebral edema, rat neurological function scores, reduced brain infarct volume. At the same time, BYHW had protective effect on the blood-brain barrier (BBB), which improved the morphology and ultrastructure of ischemic penumbra brain tissues. BYHW treatment significantly decreased the protein and mRNA levels of HIF-1 α and VEGF compared with the model treatment. In addition, BYHW treatment significantly up-regulated the protein and mRNA levels of β-ENaC. CONCLUSIONS: BYHW protected against cerebral I/R injury in MCAO rats through inhibiting the activation of the HIF-1 α /VEGF pathway and stabilizing ion channel of β-ENaC in brain, indicating that BYHW shows potential for stroke treatment in acute stage. CI - Copyright © 2018 Elsevier B.V. All rights reserved. FAU - Chen, Zhen-Zhen AU - Chen ZZ AD - School of Traditional Chinese Medicine, Beijing Key Lab of TCM Collateral Disease Theory Research, Capital Medical University, Beijing, China. Electronic address: chenzhenzhen1@126.com. FAU - Gong, Xin AU - Gong X AD - Department of Gynecology, Dong Fang Hospital of Beijing University of Chinese Medicine, Beijing, China. Electronic address: zhongxiyigongxin@163.com. FAU - Guo, Qi AU - Guo Q AD - School of Traditional Chinese Medicine, Beijing Key Lab of TCM Collateral Disease Theory Research, Capital Medical University, Beijing, China. Electronic address: flag0403@qq.com. FAU - Zhao, Hui AU - Zhao H AD - School of Traditional Chinese Medicine, Beijing Key Lab of TCM Collateral Disease Theory Research, Capital Medical University, Beijing, China. Electronic address: Zhaohui8957@sina.com. FAU - Wang, Lei AU - Wang L AD - School of Traditional Chinese Medicine, Beijing Key Lab of TCM Collateral Disease Theory Research, Capital Medical University, Beijing, China. Electronic address: tmwangl@ccmu.edu.cn. LA - eng PT - Journal Article DEP - 20180913 PL - Ireland TA - J Ethnopharmacol JT - Journal of ethnopharmacology JID - 7903310 RN - 0 (Drugs, Chinese Herbal) RN - 0 (Epithelial Sodium Channels) RN - 0 (Hypoxia-Inducible Factor 1, alpha Subunit) RN - 0 (Neuroprotective Agents) RN - 0 (Vascular Endothelial Growth Factor A) RN - 0 (buyang huanwu) RN - 0 (vascular endothelial growth factor A, rat) SB - IM MH - Animals MH - Drugs, Chinese Herbal/*pharmacology/*therapeutic use MH - Epithelial Sodium Channels/metabolism MH - Hypoxia-Inducible Factor 1, alpha Subunit/metabolism MH - Infarction, Middle Cerebral Artery/*drug therapy/metabolism/pathology MH - Male MH - Neuroprotective Agents/*pharmacology/*therapeutic use MH - Rats, Sprague-Dawley MH - Reperfusion Injury/*drug therapy/metabolism/pathology MH - Stroke/*drug therapy/metabolism/pathology MH - Vascular Endothelial Growth Factor A/metabolism OTO - NOTNLM OT - BBB OT - Cerebral edema OT - Cerebral ischemia reperfusion OT - HIF-1 α OT - VEGF OT - β-ENaC EDAT- 2018/09/16 06:00 MHDA- 2018/12/26 06:00 CRDT- 2018/09/16 06:00 PHST- 2018/05/08 00:00 [received] PHST- 2018/09/06 00:00 [revised] PHST- 2018/09/11 00:00 [accepted] PHST- 2018/09/16 06:00 [pubmed] PHST- 2018/12/26 06:00 [medline] PHST- 2018/09/16 06:00 [entrez] AID - S0378-8741(18)31694-5 [pii] AID - 10.1016/j.jep.2018.09.017 [doi] PST - ppublish SO - J Ethnopharmacol. 2019 Jan 10;228:70-81. doi: 10.1016/j.jep.2018.09.017. Epub 2018 Sep 13. PMID- 33086171 OWN - NLM STAT- MEDLINE DCOM- 20201231 LR - 20201231 IS - 1618-095X (Electronic) IS - 0944-7113 (Linking) VI - 80 DP - 2021 Jan TI - Risk of diabetes in stroke patients who used Bu Yang Huan Wu Tang: A nationwide propensity-score matched study. PG - 153376 LID - S0944-7113(20)30207-5 [pii] LID - 10.1016/j.phymed.2020.153376 [doi] AB - BACKGROUND: The utilization of traditional Chinese medicine is a common therapeutic approach for stroke patients in Chinese population, but little is known about the effect of Bu Yang Huan Wu Tang (BYHWT) on post-stroke diabetes. PURPOSE: We aimed to evaluate the risk of diabetes in stroke patients who used BYHWT. STUDY DESIGN: A retrospective cohort study based on a real-world database was conducted. METHODS: Newly diagnosed stroke patients receiving inpatient care from 2000 to 2004 were identified using a large-scale insurance database in Taiwan. Propensity score matching was used to select eligible stroke patients who did (n = 9849) and did not (n = 9849) receive BYHWT. These two groups were followed up until the end of 2009 to track incident diabetes. Cox proportional hazard models were used to calculate the adjusted hazard rations (HRs) and 95% confidence intervals (CIs) for post-stroke diabetes associated with BYHWT during the follow-up period. RESULTS: Stroke patients who used BYHWT had a reduced incidence of diabetes (14.1% vs. 19.0%, p < 0.0001) and reduced risk of diabetes (HR 0.77; 95% CI 0.72 to 0.83) compared with the control group. The association between BYHWT and reduced risk of post-stroke diabetes was significant across sexe, age group, and stroke subtype. Additionally, the use of BYHWT was associated with a reduced risk of post-stroke diabetes even after excluding the initial three months of diabetes cases in the sensitivity analysis. CONCLUSIONS: Stroke patients who received BYHWT therapy had a reduced risk of diabetes, and a positive effect was observed in various subgroups. However, future clinical trials will be necessary to validate the present findings and identify the biochemical mechanism involved. CI - Copyright © 2020 Elsevier GmbH. All rights reserved. FAU - Weng, Shu-Wen AU - Weng SW AD - Department of Chinese Medicine, Taichung Hospital, Ministry of Health and Welfare, Taichung, Taiwan. FAU - Chang, Chuen-Chau AU - Chang CC AD - Department of Anesthesiology, Taipei Medical University Hospital, Taipei, Taiwan Hospital, Taipei, Taiwan; Department of Anesthesiology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; Anesthesiology and Health Policy Research Center, Taipei Medical University Hospital, Taipei, Taiwan. FAU - Chen, Ta-Liang AU - Chen TL AD - Department of Anesthesiology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; Anesthesiology and Health Policy Research Center, Taipei Medical University Hospital, Taipei, Taiwan; Department of Anesthesiology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. FAU - Yeh, Chun-Chieh AU - Yeh CC AD - Department of Surgery, China Medical University Hospital, Taichung, Taiwan; Department of Surgery, University of Illinois, Chicago, IL, United States. FAU - Hu, Chaur-Jong AU - Hu CJ AD - Department of Neurology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan. FAU - Lane, Hsin-Long AU - Lane HL AD - School of Chinese Medicine for Post-Baccalaureate, I-Shou University, Kaohsiung, Taiwan. FAU - Liao, Chien-Chang AU - Liao CC AD - Department of Anesthesiology, Taipei Medical University Hospital, Taipei, Taiwan Hospital, Taipei, Taiwan; Department of Anesthesiology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; Anesthesiology and Health Policy Research Center, Taipei Medical University Hospital, Taipei, Taiwan; Research Center of Big Data and Meta-Analysis, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan; School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan. FAU - Shih, Chun-Chuan AU - Shih CC AD - School of Chinese Medicine for Post-Baccalaureate, I-Shou University, Kaohsiung, Taiwan; Program for the Clinical Drug Discovery from Botanical Herbs, Taipei Medical University, Taipei, Taiwan. LA - eng PT - Journal Article DEP - 20201012 PL - Germany TA - Phytomedicine JT - Phytomedicine : international journal of phytotherapy and phytopharmacology JID - 9438794 RN - 0 (Drugs, Chinese Herbal) RN - 0 (bu-yang-huan-wu-tang) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Diabetes Mellitus/epidemiology/etiology/*prevention & control MH - Drugs, Chinese Herbal/*therapeutic use MH - Female MH - Hospitalization/statistics & numerical data MH - Humans MH - Incidence MH - Male MH - Middle Aged MH - Propensity Score MH - Retrospective Studies MH - Stroke/*complications/epidemiology MH - Taiwan/epidemiology OTO - NOTNLM OT - Bu Yang Huan Wu Tang OT - Chinese herbal medicine OT - diabetes OT - stroke EDAT- 2020/10/22 06:00 MHDA- 2021/01/01 06:00 CRDT- 2020/10/21 20:07 PHST- 2020/05/29 00:00 [received] PHST- 2020/09/25 00:00 [revised] PHST- 2020/10/11 00:00 [accepted] PHST- 2020/10/22 06:00 [pubmed] PHST- 2021/01/01 06:00 [medline] PHST- 2020/10/21 20:07 [entrez] AID - S0944-7113(20)30207-5 [pii] AID - 10.1016/j.phymed.2020.153376 [doi] PST - ppublish SO - Phytomedicine. 2021 Jan;80:153376. doi: 10.1016/j.phymed.2020.153376. Epub 2020 Oct 12. PMID- 38430615 OWN - NLM STAT- MEDLINE DCOM- 20240408 LR - 20240408 IS - 1873-264X (Electronic) IS - 0731-7085 (Linking) VI - 243 DP - 2024 Jun 15 TI - Deciphering the molecular mechanism of Bu Yang Huan Wu Decoction in interference with diabetic pulmonary fibrosis via regulating oxidative stress and lipid metabolism disorder. PG - 116061 LID - S0731-7085(24)00101-8 [pii] LID - 10.1016/j.jpba.2024.116061 [doi] AB - BACKGROUND: Diabetes mellitus type 2 and pulmonary fibrosis have been found to be closely related in clinical practice. Diabetic pulmonary fibrosis (DPF) is a complication of diabetes mellitus, but its treatment has yet to be thoroughly investigated. Bu Yang Huan Wu Decoction (BYHWD) is a well-known traditional Chinese prescription that has shown great efficacy in treating pulmonary fibrosis with hypoglycemic and hypolipidemic effects. METHODS: The active ingredients of BYHWD and the corresponding targets were retrieved from the Traditional Chinese Medicine Systematic Pharmacology Database (TCMSP) and SymMap2. Disease-related targets were obtained from the GeneCard, OMIM and CTD databases. GO enrichment and KEGG pathway enrichment were carried out using the DAVID database. AutoDock Vina software was employed to perform molecular docking. Molecular dynamics simulations of proteinligand complexes were conducted by Gromacs. Animal experiments were further performed to validate the effects of BYHWD on the selected core targets, markers of oxidative stress, serum lipids, blood glucose and pulmonary fibrosis. RESULTS: A total of 84 active ingredients and 830 target genes were screened in BYHWD, among which 56 target genes intersected with DPF-related targets. Network pharmacological analysis revealed that the active ingredients can regulate target genes such as IL-6, TNF-α, VEGFA and CASP3, mainly through AGE-RAGE signaling pathway, HIF-1 signaling pathway and TNF signaling pathway. Molecular docking and molecular dynamics simulations suggested that IL6-astragaloside IV, IL6-baicalein, TNFα-astragaloside IV, and TNFα-baicalein docking complexes could bind stably. Animal experiments showed that BYHWD could reduce the expression of core targets such as VEGFA, CASP3, IL-6 and TNF-α. In addition, BYHWD could reduce blood glucose, lipid, and MDA levels in DPF while increasing the activities of SOD, CAT and GSH-Px. BYHWD attenuated the expression of HYP and collagen I, mitigating pathological damage and collagen deposition within lung tissue. CONCLUSIONS: BYHWD modulates lipid metabolism disorders and oxidative stress by targeting the core targets of IL6, TNF-α, VEGFA and CASP3 through the AGE-RAGE signaling pathway, making it a potential therapy for DPF. CI - Copyright © 2024 Elsevier B.V. All rights reserved. FAU - Guo, Junfeng AU - Guo J AD - Endocrinology Department, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610072, China. FAU - Zhang, Yuwei AU - Zhang Y AD - Geriatric Department, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610072, China. FAU - Zhou, Rui AU - Zhou R AD - Geriatric Department, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610072, China. FAU - Hao, Yanwei AU - Hao Y AD - Geriatric Department, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610072, China. FAU - Wu, Xuanyu AU - Wu X AD - Geriatric Department, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610072, China. FAU - Li, Ganggang AU - Li G AD - Geriatric Department, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610072, China. FAU - Du, Quanyu AU - Du Q AD - Endocrinology Department, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610072, China; TCM Regulating Metabolic Diseases Key Laboratory of Sichuan Province, Chengdu, Sichuan 610072, China. Electronic address: quanydu@cdutcm.edu.cn. LA - eng PT - Journal Article DEP - 20240220 PL - England TA - J Pharm Biomed Anal JT - Journal of pharmaceutical and biomedical analysis JID - 8309336 RN - 0 (Tumor Necrosis Factor-alpha) RN - 3A592W8XKE (astragaloside A) RN - EC 3.4.22.- (Caspase 3) RN - 0 (Interleukin-6) RN - 0 (Blood Glucose) RN - 9007-34-5 (Collagen) RN - 0 (Drugs, Chinese Herbal) RN - 0 (Saponins) RN - 0 (Triterpenes) SB - IM MH - Animals MH - Tumor Necrosis Factor-alpha MH - *Pulmonary Fibrosis/drug therapy MH - Caspase 3 MH - Interleukin-6 MH - Blood Glucose MH - Lipid Metabolism MH - Molecular Docking Simulation MH - *Diabetes Mellitus, Type 2 MH - Oxidative Stress MH - *Lipid Metabolism Disorders MH - Collagen MH - *Drugs, Chinese Herbal/pharmacology/therapeutic use MH - *Saponins MH - *Triterpenes OTO - NOTNLM OT - Bu Yang Huan Wu Decoction OT - Diabetic pulmonary fibrosis OT - Lipid metabolism disorders OT - Network pharmacology OT - Oxidative stress COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/03/03 17:42 MHDA- 2024/04/08 06:42 CRDT- 2024/03/02 18:02 PHST- 2023/12/12 00:00 [received] PHST- 2024/01/27 00:00 [revised] PHST- 2024/02/17 00:00 [accepted] PHST- 2024/04/08 06:42 [medline] PHST- 2024/03/03 17:42 [pubmed] PHST- 2024/03/02 18:02 [entrez] AID - S0731-7085(24)00101-8 [pii] AID - 10.1016/j.jpba.2024.116061 [doi] PST - ppublish SO - J Pharm Biomed Anal. 2024 Jun 15;243:116061. doi: 10.1016/j.jpba.2024.116061. Epub 2024 Feb 20. PMID- 41261625 OWN - NLM STAT- MEDLINE DCOM- 20251120 LR - 20251123 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 104 IP - 44 DP - 2025 Oct 31 TI - Bu Yang Huan Wu Decoction controls synovitis via HIF-1/VEGF signaling for osteoarthritis therapy. PG - e45375 LID - 10.1097/MD.0000000000045375 [doi] LID - e45375 AB - Articular cartilage deterioration is a hallmark of osteoarthritis (OA). Articular cartilage is structurally destroyed as a result of mechanical, metabolic, and inflammatory factors that are part of the etiology of OA. Although the precise molecular processes in OA are still unclear, the hypoxic microenvironment is crucial. For the clinical therapy of orthopedic illnesses, particularly OA, the Bu Yang Huan Wu Decoction (BYHWD) is frequently utilized, however, the precise pharmacological mechanism behind its action is unclear. With the use of transcriptome and network pharmacology, we want to understand the molecular mechanisms behind OA and the pharmacological mechanism of BYHWD for OA treatment. The traditional Chinese medicine database and incoming blood component data were used to assess the therapeutic components and targets of action of BYHWD, while the transcriptome data was used to analyze the critical targets and possible immunological and inflammatory mechanisms of OA occurrence. Using gene ontology and Kyoto encyclopedia of genes and genomes, additional research was conducted based on the network pharmacological analysis to determine the biological mechanism of BYHWD for treating OA. Eight active components of BYHWD were found by drug screening, astragaloside, kaempferol, formononetin, and paeoniflorin may be significant players. The HIF-1/VEGF signaling way, EGFR tyrosine kinase inhibitor resistance, and Rap1 signaling pathway are the primary biological processes involved in BYHWD treatment OA. BYHWD reduces synovitis by taking part in HIF-1/VEGF signaling, which controls immune and inflammatory factors through important components like formononetin, kaempferol, paeoniflorin, astragaloside, etc. This offers a fresh perspective on treating OA and applying traditional Chinese medicine. CI - Copyright © 2025 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Li, Xue AU - Li X AD - Department of Clinical Laboratory, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan Province, China. FAU - Lv, Ying AU - Lv Y AD - Department of Clinical Laboratory, Chengdu Integrated TCM & Western Medicine Hospital, Chengdu, Sichuan Province, China. FAU - Yang, Xingyong AU - Yang X AD - Department of Clinical Laboratory, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan Province, China. FAU - Wang, Siyu AU - Wang S AD - Intensive Care Unit, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan Province, China. FAU - Liang, Qi AU - Liang Q AUID- ORCID: 0009-0004-8662-1445 AD - Department of Clinical Laboratory, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan Province, China. LA - eng PT - Journal Article PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R RN - 0 (Drugs, Chinese Herbal) RN - 0 (Vascular Endothelial Growth Factor A) RN - 0 (HIF1A protein, human) RN - 0 (Hypoxia-Inducible Factor 1, alpha Subunit) RN - 0 (Hypoxia-Inducible Factor 1) SB - IM MH - *Drugs, Chinese Herbal/pharmacology/therapeutic use MH - *Osteoarthritis/drug therapy MH - Humans MH - Signal Transduction/drug effects MH - *Synovitis/drug therapy MH - *Vascular Endothelial Growth Factor A/metabolism/drug effects MH - Network Pharmacology MH - Hypoxia-Inducible Factor 1, alpha Subunit/metabolism MH - *Hypoxia-Inducible Factor 1/metabolism PMC - PMC12582717 OTO - NOTNLM OT - arthritis OT - computer-assisted OT - herbal medicine OT - hypoxia OT - therapy COIS- The authors have no funding and conflicts of interest to disclose. EDAT- 2025/11/20 06:26 MHDA- 2025/11/20 06:27 PMCR- 2025/10/31 CRDT- 2025/11/20 01:01 PHST- 2025/04/24 00:00 [received] PHST- 2025/09/26 00:00 [accepted] PHST- 2025/11/20 06:27 [medline] PHST- 2025/11/20 06:26 [pubmed] PHST- 2025/11/20 01:01 [entrez] PHST- 2025/10/31 00:00 [pmc-release] AID - 00005792-202510310-00060 [pii] AID - MD-D-25-03926 [pii] AID - 10.1097/MD.0000000000045375 [doi] PST - ppublish SO - Medicine (Baltimore). 2025 Oct 31;104(44):e45375. doi: 10.1097/MD.0000000000045375. PMID- 36946047 OWN - NLM STAT- MEDLINE DCOM- 20230327 LR - 20250801 IS - 1673-4254 (Print) IS - 2663-0842 (Electronic) IS - 1673-4254 (Linking) VI - 43 IP - 2 DP - 2023 Feb 20 TI - [Bushen Huoxue Fang improves recurrent miscarriage in mice by down-regulating the JAK2/STAT3 pathway]. PG - 265-270 LID - 10.12122/j.issn.1673-4254.2023.02.15 [doi] AB - OBJECTIVE: To investigate the efficacy of Bushen Huoxue Fang (BSHXF, a traditional Chinese medicine formula) for improving recurrent spontaneous abortion (RSA) in mice and the role of tyrosine kinase (JAK2) and transcriptional activator (STAT3) signaling pathway in its therapeutic mechanism. METHODS: Female CBA/J mice were caged with male DBA/2 mice to establish RSA mouse models, which were randomly divided into model group, dydrogesterone group and BSHXF group, with the female mice caged with male BALB/c mice as the control group (n=6). From the first day of pregnancy, the mice were subjected to daily intragastric administration of BSHXF, dydrogesterone, or distilled water (in control and model groups) for 12 days. After the treatments, serum levels of antithrombin III (AT-III), activated protein C (APC), tissue plasminogen activator (t-PA), progesterone, human chorionic gonadotropin (HCG), and estradiol (E2) were detected in each group using ELISA. HE staining was used to observe the morphological changes of the endometrium of the mice. Western blotting was performed to determine the expressions of p-JAK2, p-Stat3 and Bcl-2 in the placenta of the mice. RESULTS: Compared with the control mice, the mouse models of RSA showed a significantly increased embryo loss rate with decreased serum levels of AT-III, T-PA, progesterone, APC and HCG, increased placental expressions of p-JAK2, p-STAT3 and Bax, and decreased expression of Bcl-2 (P < 0.05). Treatments with BSHXF and dydrogesterone both increased serum levels of AT-III, t-PA and HCG in the mouse models; Serum APC level was significantly reduced in BSHXF group and serum progesterone level was significantly increased in dydrogesterone group (P < 0.05). CONCLUSION: BSHXF can improve the prethrombotic state and inhibit cell apoptosis by downregulating the JAK2/STAT3 pathway to increase the pregnancy rate in mouse models of RSA. FAU - Zhao, J AU - Zhao J AD - First Clinical Medical College, Henan University of Chinese Medicine, Zhengzhou 450000, China. FAU - Chen, P AU - Chen P AD - Department of Obstetrics and Gynecology, First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, China. FAU - Xu, G AU - Xu G AD - Division II of Department of Reproductive Center, The first affiliated hospital of Henan University of Chinese Medicine, Henan Zhengzhou 450000, China. FAU - Sun, J AU - Sun J AD - Department of Obstetrics and Gynecology, First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, China. FAU - Ruan, Y AU - Ruan Y AD - First Clinical Medical College, Henan University of Chinese Medicine, Zhengzhou 450000, China. FAU - Xue, M AU - Xue M AD - First Clinical Medical College, Henan University of Chinese Medicine, Zhengzhou 450000, China. FAU - Wu, Y AU - Wu Y AD - First Clinical Medical College, Henan University of Chinese Medicine, Zhengzhou 450000, China. LA - chi PT - English Abstract PT - Journal Article PL - China TA - Nan Fang Yi Ke Da Xue Xue Bao JT - Nan fang yi ke da xue xue bao = Journal of Southern Medical University JID - 101266132 RN - 0 (bushen huoxue) RN - EC 2.7.10.2 (Jak2 protein, mouse) RN - 0 (Stat3 protein, mouse) SB - IM MH - Animals MH - Mice MH - *Abortion, Habitual/prevention & control MH - Signal Transduction MH - Down-Regulation MH - Disease Models, Animal PMC - PMC10034533 OTO - NOTNLM OT - Bushen Huoxue Fang OT - JAK2/STAT3 OT - prethrombotic state OT - recurrent spontaneous abortion EDAT- 2023/03/23 06:00 MHDA- 2023/03/24 06:00 PMCR- 2023/02/20 CRDT- 2023/03/22 03:53 PHST- 2023/03/22 03:53 [entrez] PHST- 2023/03/23 06:00 [pubmed] PHST- 2023/03/24 06:00 [medline] PHST- 2023/02/20 00:00 [pmc-release] AID - nfykdxxb-43-2-265 [pii] AID - 10.12122/j.issn.1673-4254.2023.02.15 [doi] PST - ppublish SO - Nan Fang Yi Ke Da Xue Xue Bao. 2023 Feb 20;43(2):265-270. doi: 10.12122/j.issn.1673-4254.2023.02.15. PMID- 40544977 OWN - NLM STAT- MEDLINE DCOM- 20250825 LR - 20250825 IS - 1872-7573 (Electronic) IS - 0378-8741 (Linking) VI - 352 DP - 2025 Aug 29 TI - Bu-Yang decoction attenuates OVX-induced sarcopenia by upregulating CXCR4 to suppress GPX4-mediated ferroptosis. PG - 120166 LID - S0378-8741(25)00854-2 [pii] LID - 10.1016/j.jep.2025.120166 [doi] AB - ETHNOPHARMACOLOGICAL RELEVANCE: Buyang Decoction (BYD), a traditional Chinese medicine formula, has demonstrated potential in strengthening muscles and bones, but its role in sarcopenia (SP) remains unclear. Ferroptosis is an iron-dependent form of regulated cell death triggered by lipid peroxidation, which plays a key role in the development of SP. PURPOSE: This study investigated whether BYD alleviates SP by modulating ferroptosis via the CXCR4-GPX4 signaling axis. MATERIALS AND METHODS: OVX was used to model SP in vivo, with BYD administered at different concentrations. Therapeutic effects were assessed using behavioral tests, histochemistry, qRT-PCR, TEM, MRI, and micro-CT. In vitro, Erastin was used as an intervention, and techniques including WB, qRT-PCR, Nile red staining, DAFH-DA staining, and immunofluorescence were employed. GEO database analysis identified CXCR4 as a key gene. CXCR4 inhibition was performed pharmacologically in vivo and genetically in vitro. RESULTS: In vivo, BYD enhanced muscle strength, differentiation, and GPX4 expression while reducing oxidative stress. In vitro, BYD promoted MuSCs (Muscle Satellite Cells) proliferation and differentiation while lowering oxidative stress and lipid peroxidation. In both in vivo and in vitro studies, CXCR4 inhibition resulted in the loss of BYD's therapeutic effects. CONCLUSION: BYD mitigates SP by inhibiting ferroptosis via CXCR4-mediated GPX4 upregulation, highlighting CXCR4 as a potential therapeutic target. CI - Copyright © 2025 Elsevier B.V. All rights reserved. FAU - Xie, Zhefei AU - Xie Z AD - The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China; The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310053, China. FAU - Xu, Pengchao AU - Xu P AD - The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China; The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310053, China. FAU - Xie, Jingbo AU - Xie J AD - The Graduate School, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, 330004, China; Department of Orthopaedics, The People's Hospital of Fengcheng City, Fengcheng, Jiangxi, 331100, China. FAU - Ma, Tianyou AU - Ma T AD - The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China; The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310053, China. FAU - Wang, Weixiang AU - Wang W AD - The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China; The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310053, China. FAU - Yang, Yiwen AU - Yang Y AD - The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China; The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310053, China. FAU - Sheng, Cenzhuo AU - Sheng C AD - The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China; The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310053, China. FAU - Wang, Jinglei AU - Wang J AD - The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China; The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310053, China. FAU - Wu, Mo AU - Wu M AD - The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China; The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310053, China. FAU - Zhou, Xing AU - Zhou X AD - The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China; The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310053, China; Department of Sports Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Jiaotong University, Shanghai, 200080, China. FAU - Liu, Jiangyuan AU - Liu J AD - The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China; The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310053, China; Department of Orthopaedics, Affiliated Hospital of Jiangxi University of Chinese Medicine, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, 330004, China. FAU - Zhou, Xingchen AU - Zhou X AD - The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), Hangzhou, Zhejiang, 310003, China. FAU - Tong, Peijian AU - Tong P AD - The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China; The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310053, China. Electronic address: tongpeijian@163.com. FAU - Xia, Hanting AU - Xia H AD - The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China; The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310053, China; Department of Orthopaedics, Affiliated Hospital of Jiangxi University of Chinese Medicine, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, 330004, China. Electronic address: xiahanting@zcmu.edu.cn. LA - eng PT - Journal Article DEP - 20250620 PL - Ireland TA - J Ethnopharmacol JT - Journal of ethnopharmacology JID - 7903310 RN - 0 (Receptors, CXCR4) RN - EC 1.11.1.12 (Phospholipid Hydroperoxide Glutathione Peroxidase) RN - 0 (Drugs, Chinese Herbal) RN - 0 (CXCR4 protein, mouse) RN - EC 1.11.1.9 (glutathione peroxidase 4, mouse) SB - IM MH - *Ferroptosis/drug effects MH - Animals MH - *Receptors, CXCR4/metabolism/genetics MH - *Phospholipid Hydroperoxide Glutathione Peroxidase/metabolism/genetics MH - Female MH - Up-Regulation/drug effects MH - *Drugs, Chinese Herbal/pharmacology/therapeutic use MH - Mice MH - *Sarcopenia/drug therapy/etiology/metabolism MH - Ovariectomy MH - Lipid Peroxidation/drug effects MH - Oxidative Stress/drug effects MH - Mice, Inbred C57BL MH - Signal Transduction/drug effects OTO - NOTNLM OT - Buyang Decoction OT - CXCR4 OT - Ferroptosis OT - GPX4 OT - Sarcopenia OT - muscle regeneration COIS- Declaration of Competing Interest We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product, service or company that could be construed as influencing the position presented in, or the review of, the manuscript entitled. EDAT- 2025/06/23 06:13 MHDA- 2025/09/08 08:02 CRDT- 2025/06/22 19:13 PHST- 2025/04/15 00:00 [received] PHST- 2025/06/03 00:00 [revised] PHST- 2025/06/17 00:00 [accepted] PHST- 2025/09/08 08:02 [medline] PHST- 2025/06/23 06:13 [pubmed] PHST- 2025/06/22 19:13 [entrez] AID - S0378-8741(25)00854-2 [pii] AID - 10.1016/j.jep.2025.120166 [doi] PST - ppublish SO - J Ethnopharmacol. 2025 Aug 29;352:120166. doi: 10.1016/j.jep.2025.120166. Epub 2025 Jun 20. PMID- 32534359 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250821 LR - 20250821 IS - 1618-095X (Electronic) IS - 0944-7113 (Linking) VI - 76 DP - 2020 Sep TI - Bushenhuoxue formula accelerates fracture healing via upregulation of TGF-β/Smad2 signaling in mesenchymal progenitor cells. PG - 153256 LID - S0944-7113(20)30087-8 [pii] LID - 10.1016/j.phymed.2020.153256 [doi] AB - BACKGROUND: Although Bushenhuoxue formula (BSHXF) is successfully used as a non-traumatic therapy in treating bone fracture in China, the molecular mechanism underlying its effects remains poorly understood. PURPOSE: The present study aims to explore the therapeutic effects of BSHXF on fracture healing in mice and the underlying mechanism. METHODS: We performed unilateral open transverse tibial fracture procedure in C57BL/6 mice which were treated with or without BSHXF. Fracture callus tissues were collected and analyzed by X-ray, micro-CT, biomechanical testing, histopathology and quantitative gene expression analysis. Tibial fracture procedure was also performed in Cre-negative and Gli1-CreER; Tgfbr2flox/flox conditional knockout (KO) mice (Tgfbr2(Gli1ER)) to determine if BSHXF enhances fracture healing in a TGF-β-dependent manner. In addition, scratch-wound assay and cell counting kit-8 (CCK-8) assay were used to evaluate the effect of BSHXF on cell migration and cell proliferation in C3H10T1/2 mesenchymal stem cells, respectively. RESULTS: BSHXF promoted endochondral ossification and enhanced bone strength in wild-type (WT) or Cre- control mice. In contrast, BSHXF failed to promote bone fracture healing in Tgfbr2(Gli1ER) conditional KO mice. In the mice receiving BSHXF treatment, TGF-β/Smad2 signaling was significantly activated. Moreover, BSHXF enhanced cell migration and cell proliferation in C3H10T1/2 cells, which was strongly attenuated by the small molecule inhibitor SB525334 against TGF-β type I receptor. CONCLUSION: These data demonstrated that BSHXF promotes fracture healing by activating TGF-β/Smad2 signaling. BSHXF may be used as a type of alternative medicine for the treatment of bone fracture healing. CI - Copyright © 2020 The Authors. Published by Elsevier GmbH.. All rights reserved. FAU - Hu, Songfeng AU - Hu S AD - Institute of Orthopaedics and Traumatology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang, China; The First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang, China; Department of Orthopaedics and Traumatology, Shaoxing Hospital of Traditional Chinese Medicine, Shaoxing 312000, Zhejiang, China. FAU - Ge, Qinwen AU - Ge Q AD - Institute of Orthopaedics and Traumatology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang, China; The First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang, China. FAU - Xia, Chenjie AU - Xia C AD - Institute of Orthopaedics and Traumatology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang, China; The First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang, China. FAU - Ying, Jun AU - Ying J AD - Institute of Orthopaedics and Traumatology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang, China; The First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang, China. FAU - Ruan, Hongfeng AU - Ruan H AD - Institute of Orthopaedics and Traumatology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang, China. FAU - Shi, Zhenyu AU - Shi Z AD - Institute of Orthopaedics and Traumatology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang, China; The First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang, China. FAU - Xu, Rui AU - Xu R AD - Institute of Orthopaedics and Traumatology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang, China; The First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang, China. FAU - Xu, Taotao AU - Xu T AD - Institute of Orthopaedics and Traumatology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang, China; Department of Orthopaedic Surgery, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, Zhejiang, China. FAU - Lv, Shuaijie AU - Lv S AD - Institute of Orthopaedics and Traumatology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang, China; The First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang, China; Department of Orthopaedic Surgery, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, Zhejiang, China. FAU - Fang, Liang AU - Fang L AD - Institute of Orthopaedics and Traumatology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang, China; The First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang, China. FAU - Zou, Zhen AU - Zou Z AD - Institute of Orthopaedics and Traumatology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang, China; The First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang, China. FAU - Xu, Huihui AU - Xu H AD - Institute of Orthopaedics and Traumatology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang, China; The First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang, China. FAU - Xiao, Luwei AU - Xiao L AD - Institute of Orthopaedics and Traumatology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang, China. FAU - Tong, Peijian AU - Tong P AD - Institute of Orthopaedics and Traumatology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang, China; Department of Orthopaedic Surgery, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, Zhejiang, China. FAU - Wang, Ping-Er AU - Wang PE AD - Institute of Orthopaedics and Traumatology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang, China. Electronic address: apple63209321@126.com. FAU - Jin, Hongting AU - Jin H AD - Institute of Orthopaedics and Traumatology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang, China. Electronic address: hongtingjin@163.com. LA - eng PT - Journal Article DEP - 20200601 PL - Germany TA - Phytomedicine JT - Phytomedicine : international journal of phytotherapy and phytopharmacology JID - 9438794 SB - IM OTO - NOTNLM OT - Bushenhuoxue formula OT - Fracture healing OT - Mesenchymal progenitor cells OT - TGF-β signaling COIS- Declaration of Competing Interest All the authors have declared that they have no conflicts of interest. EDAT- 2020/06/14 06:00 MHDA- 2020/06/14 06:01 CRDT- 2020/06/14 06:00 PHST- 2019/12/11 00:00 [received] PHST- 2020/05/10 00:00 [revised] PHST- 2020/05/29 00:00 [accepted] PHST- 2020/06/14 06:01 [medline] PHST- 2020/06/14 06:00 [pubmed] PHST- 2020/06/14 06:00 [entrez] AID - S0944-7113(20)30087-8 [pii] AID - 10.1016/j.phymed.2020.153256 [doi] PST - ppublish SO - Phytomedicine. 2020 Sep;76:153256. doi: 10.1016/j.phymed.2020.153256. Epub 2020 Jun 1. PMID- 21784143 OWN - NLM STAT- MEDLINE DCOM- 20120503 LR - 20220408 IS - 1872-7573 (Electronic) IS - 0378-8741 (Linking) VI - 138 IP - 1 DP - 2011 Oct 31 TI - Deciphering the neuroprotective mechanisms of Bu-yang Huan-wu decoction by an integrative neurofunctional and genomic approach in ischemic stroke mice. PG - 22-33 LID - 10.1016/j.jep.2011.06.033 [doi] AB - ETHNOPHARMACOLOGICAL RELEVANCE: Bu-yang Huan-wu decoction (BHD) is a famous traditional Chinese medicine formula that has been used clinically in Asia to treat stroke-induced disability for centuries, but the underlying neuroprotective mechanisms are not fully understood. AIM OF THE STUDY: In this study, we aim to investigate the mechanisms of action using an integrative neurofunctional and broad genomics approach. MATERIALS AND METHODS: Male ICR mice were subjected to an acute ischemic stroke by inducing a middle cerebral ischemic/reperfusion (CI/R) injury. To examine whether BHD could extend the lifespan of mice with a stroke, we used oral administration of BHD (0.5 and 1.0g/kg) twice daily starting from 2h after ischemia and compared this with vehicle control treatments, recombinant tissue-type plasminogen activator (rt-PA, 10mg/kg, i.v.), and MK-801 (0.2mg/kg, i.p.). An integrative neurofunctional and genomic approach was performed to elucidate the underlying molecular mechanisms of BHD. RESULTS: More than 80% of the mice died within 2 days after stroke induction in the vehicle control treatment group. However, the survival rates and life-spans of mice treated with BHD, rt-PA and MK-801 were significantly enhanced as compared to the vehicle-treated CI/R group in all three cases. Mice treated with BHD (1.0g/kg) showed the greatest protective effect across all groups. BHD successfully restored brain function, ameliorated the cerebral infarction, and significantly improved the neurological deficits of the mice with a stroke. BHD also reduced inflammation, oxidative stress, and apoptosis, as well as improved neurogenesis. The molecular impacts of BHD were assessed by genome-wide transcriptome analysis using brains from the CI/R mice. The results showed a total of 377 ischemia-induced probe-sets that were significantly influenced by BHD including 93 probe-sets that were commonly more abundant in BHD-treated and sham mice, and another 284 ischemia-induced probe sets that were suppressed by BHD. Mining the functional modules and genetic networks of these 377 genes revealed a significant upregulation of neuroprotective genes associated with neurogenesis (6 genes) and nervous system development (9 genes), and a significant down-regulation of destructive genes associated with the induction of inflammation (14 genes), apoptosis (15 genes), angiogenesis (11 genes) and blood coagulation (7 genes) by BHD. CONCLUSIONS: Our results suggested that BHD is able to protect mice against stroke and extend lifespan primarily through a significant down-regulation of genes involved in inflammation, apoptosis, angiogenesis and blood coagulation, as well as an up-regulation of genes mediating neurogenesis and nervous system development. The changes in expression after treatment with BHD are beneficial after ischemic stroke. CI - Copyright © 2011 Elsevier Ireland Ltd. All rights reserved. FAU - Wang, Hsei-Wei AU - Wang HW AD - Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan. FAU - Liou, Kuo-Tong AU - Liou KT FAU - Wang, Yea-Hwey AU - Wang YH FAU - Lu, Chung-Kuang AU - Lu CK FAU - Lin, Yun-Lian AU - Lin YL FAU - Lee, I-Jung AU - Lee IJ FAU - Huang, Sheng-Teng AU - Huang ST FAU - Tsai, Yuan-Hau AU - Tsai YH FAU - Cheng, Yi-Chieh AU - Cheng YC FAU - Lin, Hung-Jui AU - Lin HJ FAU - Shen, Yuh-Chiang AU - Shen YC LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20110708 PL - Ireland TA - J Ethnopharmacol JT - Journal of ethnopharmacology JID - 7903310 RN - 0 (Anti-Inflammatory Agents) RN - 0 (Antioxidants) RN - 0 (Drugs, Chinese Herbal) RN - 0 (Neuroprotective Agents) RN - 0 (buyang huanwu) RN - EC 3.4.21.68 (Tissue Plasminogen Activator) SB - IM MH - Animals MH - Anti-Inflammatory Agents/pharmacology/therapeutic use MH - Antioxidants/pharmacology/therapeutic use MH - Apoptosis/drug effects/genetics MH - Astragalus Plant MH - Blood Coagulation/drug effects/genetics MH - Brain/*drug effects/physiology MH - Brain Ischemia/*drug therapy/etiology/genetics MH - Cerebral Infarction/prevention & control MH - Drugs, Chinese Herbal/*pharmacology/therapeutic use MH - Gene Expression/*drug effects MH - Inflammation/drug therapy/genetics MH - Male MH - Mice MH - Mice, Inbred ICR MH - Neovascularization, Physiologic/drug effects/genetics MH - Neurogenesis/drug effects/genetics MH - Neuroprotective Agents/*pharmacology/therapeutic use MH - Oxidative Stress/drug effects/genetics MH - Phytotherapy MH - Stroke/*drug therapy/genetics/mortality MH - Tissue Plasminogen Activator/pharmacology EDAT- 2011/07/26 06:00 MHDA- 2012/05/04 06:00 CRDT- 2011/07/26 06:00 PHST- 2011/01/24 00:00 [received] PHST- 2011/06/03 00:00 [revised] PHST- 2011/06/21 00:00 [accepted] PHST- 2011/07/26 06:00 [entrez] PHST- 2011/07/26 06:00 [pubmed] PHST- 2012/05/04 06:00 [medline] AID - S0378-8741(11)00450-8 [pii] AID - 10.1016/j.jep.2011.06.033 [doi] PST - ppublish SO - J Ethnopharmacol. 2011 Oct 31;138(1):22-33. doi: 10.1016/j.jep.2011.06.033. Epub 2011 Jul 8. PMID- 32334373 OWN - NLM STAT- MEDLINE DCOM- 20210211 LR - 20210211 IS - 1950-6007 (Electronic) IS - 0753-3322 (Linking) VI - 127 DP - 2020 Jul TI - Bushenhuoxue formula promotes osteogenic differentiation of growth plate chondrocytes through β-catenin-dependent manner during osteoporosis. PG - 110170 LID - S0753-3322(20)30362-0 [pii] LID - 10.1016/j.biopha.2020.110170 [doi] AB - BACKGROUND: Bushenhuoxue formula (BSHXF) has shown excellent clinical effects on the treatment of osteoporosis in China. The aim of this study is to determine the anti-osteoporosis effects and precise molecular mechanisms of BSHXF on mouse models. METHODS: Ten-week-old female C57BL/6 J mice were subjected to ovariectomy and provided a daily treatment of BSHXF. At 8 weeks post-surgery, the femurs were harvested for tissue analyses including μCT, histology, qRT-PCR and immunohistochemical (IHC) staining of β-catenin, ALP and FABP4. To investigate the role of β-catenin in the anti-osteoporosis effects of BSHXF, relative experiments mentioned above were performed in β-catenin conditional knockout mice. RESULTS: Ovariectomized (OVX) mice presented severe bone loss and excessive fat accumulation in the chondro-osseous junction underneath the growth plate, with decreased expression of ALP and increased expression of FABP4. BSHXF significantly recovered the OVX-induced abnormal osteogenesis and adipogenesis with the activation of β-catenin in growth plate chondrocytes. Further, we generated growth plate chondrocyte-specific β-catenin knockout (β-catenin(Gli1ER)) mice that exhibited bone loss and fat accumulation in the chondro-osseous junction, similar to the OVX mice. However, BSHXF failed to rescue the osteoporosis-like phenotype in β-catenin(Gli1ER) mice, indicating the anti-osteoporosis effects of BSHXF act mainly through β-catenin signaling. No significant restoration of ALP and FABP4 was observed in β-catenin(Gli1ER) mice after the treatment of BSHXF. CONCLUSIONS: BSHXF attenuates osteoporosis by promoting osteogenic differentiation of growth plate chondrocytes mainly in β-catenin-dependent manner. BSHXF is considered as a new candidate for the treatment of osteoporosis. CI - Copyright © 2020 The Author(s). Published by Elsevier Masson SAS.. All rights reserved. FAU - Xia, Chenjie AU - Xia C AD - Institute of Orthopadics and Traumatology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China; The First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China; Department of Orthopedic Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo, China. FAU - Zou, Zhen AU - Zou Z AD - Institute of Orthopadics and Traumatology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China; The First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China. FAU - Fang, Liang AU - Fang L AD - Institute of Orthopadics and Traumatology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China; The First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China. FAU - Ge, Qinwen AU - Ge Q AD - Institute of Orthopadics and Traumatology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China; The First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China. FAU - Zhang, Peng AU - Zhang P AD - Institute of Orthopadics and Traumatology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China; The First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China. FAU - Xu, Huihui AU - Xu H AD - Institute of Orthopadics and Traumatology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China; The First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China. FAU - Xu, Rui AU - Xu R AD - Institute of Orthopadics and Traumatology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China; The First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China. FAU - Shi, Zhenyu AU - Shi Z AD - Institute of Orthopadics and Traumatology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China; The First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China. FAU - Lin, Houfu AU - Lin H AD - Institute of Orthopadics and Traumatology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China; The First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China. FAU - Ding, Xinyi AU - Ding X AD - Institute of Orthopadics and Traumatology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China; The First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China. FAU - Xiao, Luwei AU - Xiao L AD - Institute of Orthopadics and Traumatology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China. FAU - Tong, Peijian AU - Tong P AD - Department of Orthopedic Surgery, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China. FAU - Wang, Ping-Er AU - Wang PE AD - Institute of Orthopadics and Traumatology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China. Electronic address: apple63209321@126.com. FAU - Jin, Hongting AU - Jin H AD - Institute of Orthopadics and Traumatology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China. Electronic address: hongtingjin@163.com. LA - eng PT - Journal Article DEP - 20200422 PL - France TA - Biomed Pharmacother JT - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie JID - 8213295 RN - 0 (Drugs, Chinese Herbal) RN - 0 (beta Catenin) RN - 0 (bushen huoxue) SB - IM MH - Adipogenesis/drug effects MH - Animals MH - Cell Differentiation/drug effects MH - Chondrocytes/cytology/*drug effects MH - Drugs, Chinese Herbal/*pharmacology MH - Female MH - Growth Plate/metabolism MH - Mice MH - Mice, Inbred C57BL MH - Mice, Knockout MH - Osteogenesis/*drug effects MH - Osteoporosis/*drug therapy/pathology MH - Ovariectomy MH - Wnt Signaling Pathway/drug effects MH - beta Catenin/genetics/metabolism OTO - NOTNLM OT - Bushenhuoxue formula OT - Cell differentiation OT - Osteoporosis OT - β-catenin COIS- Declaration of Competing Interest All authors state that they have no conflicts of interest. EDAT- 2020/04/26 06:00 MHDA- 2021/02/12 06:00 CRDT- 2020/04/26 06:00 PHST- 2019/10/17 00:00 [received] PHST- 2020/04/07 00:00 [revised] PHST- 2020/04/13 00:00 [accepted] PHST- 2020/04/26 06:00 [pubmed] PHST- 2021/02/12 06:00 [medline] PHST- 2020/04/26 06:00 [entrez] AID - S0753-3322(20)30362-0 [pii] AID - 10.1016/j.biopha.2020.110170 [doi] PST - ppublish SO - Biomed Pharmacother. 2020 Jul;127:110170. doi: 10.1016/j.biopha.2020.110170. Epub 2020 Apr 22. PMID- 37277086 OWN - NLM STAT- MEDLINE DCOM- 20230619 LR - 20230619 IS - 1872-7573 (Electronic) IS - 0378-8741 (Linking) VI - 316 DP - 2023 Nov 15 TI - BSHXF-medicated serum combined with ADSCs regulates the TGF-β1/Smad pathway to repair oxidatively damaged NPCs and its component analysis. PG - 116692 LID - S0378-8741(23)00560-3 [pii] LID - 10.1016/j.jep.2023.116692 [doi] AB - ETHNOPHARMACOLOGICAL RELEVANCE: Lower back pain (LBP) is a common and frequent clinical condition, and intervertebral disc degeneration (IDD) is recognized as the leading cause of LBP, typically manifested by increased nucleus pulposus cell (NPC) senescence and death. In recent years, the treatment of IDD with stem cell injections has had great potential compared to surgical treatment. Combining the two may achieve better results, as BuShenHuoXueFang (BSHXF) is an herbal formula that improves the survival rate of transplanted stem cells and enhances their efficacy. AIM OF THE STUDY: We aimed to qualitatively and quantitatively analyze BSHXF-medicated serum and investigate the molecular mechanism of BSHXF-mediated serum in promoting the differentiation of adipose mesenchymal stem cells (ADSCs) into NPCs and delaying the senescence of NPCs by regulating the TGF-β1/Smad pathway. MATERIALS AND METHODS: In this study, an ultrahigh-performance liquid chromatography-quadrupole-time-of-flight mass spectrometer (UPLC-Q-TOF-MS) was used to establish a method for the analysis of rat serum samples to track the active components in vivo; the oxidative damage model of NPCs was induced by T-BHP, and a Transwell chamber was used to construct a coculture system of ADSCs and NPCs. Flow cytometry was used to determine the cell cycle; SA-β-Gal staining was used to assess cell senescence; ELISA was used to detect IL-1β, IL-6 inflammatory factors, CXCL-1, CXCL-3, CXCL-10 chemokines, and TGF-β1 in the supernatants of ADSCs and NPCs. WB was used to detect COL2A1, COL1A1, and Aggrecan in ADSCs to assess the manifestation of NP differentiation in ADSCs, and the WB method was used to detect COL2A1, COL1A1, Aggrecan, p16, p21, p53, and p-p53 protein expression in NPCs to reflect the cellular senescence status and to detect TGF-β1, Smad2, Smad3, p- Smad2, and p- Smad3 protein expression in NPCs to reflect the pathway condition. RESULTS: We finally identified 70 blood components and their metabolites, including 38 prototypes, from the BSHXF-medicated serum. Compared with that in the nonmedicated serum group, the TGF-β1/Smad pathway was activated in the medicated serum group, ADSCs moved toward NPC characteristics, the number of NPCs in the S/G2M phase increased, the number of senescent NPCs decreased, IL-1β and IL-6 inflammatory factors in the Transwell decreased, CXCL-1, CXCL-3, and CXCL-10 chemokines decreased, and the expression of p16, p21, p53 and p-p53 proteins in NPCs was inhibited. CONCLUSION: By regulating the TGF-β1/Smad pathway, BSHXF-medicated serum promoted ADSCs to NPCs, effectively alleviated the cycle blockage of NPCs after oxidative damage, encouraged the growth and proliferation of NPCs, delayed the aging of NPCs, improved the deteriorating microenvironment around NPCs, and repaired oxidatively damaged NPCs. The combination of BSHXF or its compounds with ADSCs has great potential for the treatment of IDD in the future. CI - Copyright © 2023 Elsevier B.V. All rights reserved. FAU - Duan, Jiahao AU - Duan J AD - Hunan University of TCM, Changsha, Hunan, 410208, China; The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, 410007, China. Electronic address: 286118761@qq.com. FAU - Li, Zhaoyong AU - Li Z AD - The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, 410007, China. Electronic address: 191644929@qq.com. FAU - Liu, Enxu AU - Liu E AD - Hunan University of TCM, Changsha, Hunan, 410208, China; The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, 410007, China. Electronic address: lexdoctor@163.com. FAU - Long, Hongping AU - Long H AD - The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, 410007, China. Electronic address: longhongping84@163.com. FAU - Chen, Long AU - Chen L AD - The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, 410007, China. Electronic address: 946196756@qq.com. FAU - Yang, Shaofeng AU - Yang S AD - The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, 410007, China. Electronic address: 574996585@qq.com. LA - eng PT - Journal Article DEP - 20230603 PL - Ireland TA - J Ethnopharmacol JT - Journal of ethnopharmacology JID - 7903310 RN - 0 (Transforming Growth Factor beta1) RN - 0 (Tumor Suppressor Protein p53) RN - 0 (Aggrecans) RN - 0 (Interleukin-6) SB - IM MH - Rats MH - Animals MH - *Transforming Growth Factor beta1/metabolism MH - Tumor Suppressor Protein p53 MH - Aggrecans/metabolism MH - Interleukin-6/metabolism MH - *Intervertebral Disc Degeneration/therapy/metabolism OTO - NOTNLM OT - Adipose mesenchymal stem cell OT - Bu Shen Huo Xue Fang OT - Cell senescence OT - Medicated serum OT - Nucleus pulposus cell OT - TGF-β1/smad COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/06/06 01:11 MHDA- 2023/06/19 13:08 CRDT- 2023/06/05 19:24 PHST- 2023/04/22 00:00 [received] PHST- 2023/05/14 00:00 [revised] PHST- 2023/05/26 00:00 [accepted] PHST- 2023/06/19 13:08 [medline] PHST- 2023/06/06 01:11 [pubmed] PHST- 2023/06/05 19:24 [entrez] AID - S0378-8741(23)00560-3 [pii] AID - 10.1016/j.jep.2023.116692 [doi] PST - ppublish SO - J Ethnopharmacol. 2023 Nov 15;316:116692. doi: 10.1016/j.jep.2023.116692. Epub 2023 Jun 3. PMID- 38204990 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240112 IS - 1178-7031 (Print) IS - 1178-7031 (Electronic) IS - 1178-7031 (Linking) VI - 17 DP - 2024 TI - Bushen Huoxue Formula Inhibits IL-1β-Induced Apoptosis and Extracellular Matrix Degradation in the Nucleus Pulposus Cells and Improves Intervertebral Disc Degeneration in Rats. PG - 121-136 LID - 10.2147/JIR.S431609 [doi] AB - BACKGROUND: The method of action of Bushen Formula (BSHXF) in the treatment of intervertebral disc degeneration (IVDD) was uncovered in this work using in vivo and in vitro tests. To clarify the mechanism of action of BSHXF, we validated the rat intervertebral disc degeneration model and the nucleus pulposus cell degeneration model. METHODS: In an in vivo model of IVDD the study explores the impact of BSHXF on mitochondrial function, pro-inflammatory cytokines, pro-apoptotic factors, and matrix metalloproteinases. Additionally, it evaluates the induced degeneration of nucleus pulposus (NP) cells in an in vitro model stimulated by interleukin-1 β (IL-1β). The study measures the effects of BSHXF on both the inflammatory response and mitochondrial function. RESULTS: The MRI results showed that BSHXF reduced intervertebral disc volume reduction and degradation of NP tissue. HE, SO-FG and immunofluorescence further confirmed the protective effect of BSHXF on degenerative intervertebral discs. BSHXF reduced the inflammatory levels of IL-6 IL-1β and TNF-α in degenerative intervertebral disc tissue. Meanwhile, JC-1, mPTP and ROS detection revealed that BSHXF can restore mitochondrial function by regulating the expression of antioxidant proteins, playing a protective role in NP cells. Finally, the WB results showed that BSHXF can alleviate IL-1β mediate the degeneration of NP cells. BSHXF can alleviate NP cell apoptosis by inhibiting the expression of bax, cleaved caspase-3, caspase-3, and cyt-c, and increasing the expression of Bcl-2. CONCLUSION: This study reveals that BSHXF inhibits the development of inflammatory factors, which may play a significant role in intervertebral disc degeneration. This implies that BSHXF is a suitable herbal medication for future research into inflammatory cytokine treatment. CI - © 2024 Gao et al. FAU - Gao, Shang AU - Gao S AD - The First Clinical Medical College of Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province, People's Republic of China. FAU - Wang, Chenmoji AU - Wang C AD - The First Clinical Medical College of Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province, People's Republic of China. FAU - Qi, Lijie AU - Qi L AD - Qilu Hospital of Shandong University, Jinan, Shandong Province, People's Republic of China. FAU - Liang, Songlin AU - Liang S AD - The First Clinical Medical College of Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province, People's Republic of China. FAU - Qu, Xintian AU - Qu X AD - The First Clinical Medical College of Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province, People's Republic of China. FAU - Liu, Wei AU - Liu W AD - Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province, People's Republic of China. FAU - Li, Nianhu AU - Li N AD - Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province, People's Republic of China. LA - eng PT - Journal Article DEP - 20240106 PL - New Zealand TA - J Inflamm Res JT - Journal of inflammation research JID - 101512684 PMC - PMC10777862 OTO - NOTNLM OT - BSHXF OT - apoptosis OT - inflammatory OT - intervertebral disc degeneration OT - nucleus pulposus cell COIS- The authors claim that they have no known competing financial interests or personal relationships that might affect this work. EDAT- 2024/01/11 07:41 MHDA- 2024/01/11 07:42 PMCR- 2024/01/06 CRDT- 2024/01/11 04:12 PHST- 2023/09/02 00:00 [received] PHST- 2023/12/27 00:00 [accepted] PHST- 2024/01/11 07:42 [medline] PHST- 2024/01/11 07:41 [pubmed] PHST- 2024/01/11 04:12 [entrez] PHST- 2024/01/06 00:00 [pmc-release] AID - 431609 [pii] AID - 10.2147/JIR.S431609 [doi] PST - epublish SO - J Inflamm Res. 2024 Jan 6;17:121-136. doi: 10.2147/JIR.S431609. eCollection 2024. PMID- 38545187 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240329 IS - 2405-8440 (Print) IS - 2405-8440 (Electronic) IS - 2405-8440 (Linking) VI - 10 IP - 6 DP - 2024 Mar 30 TI - Role of Bushen Huoxue Formula and transplanted endothelial progenitor cells play in promoting endplate microcirculation and attenuating intervertebral disc degeneration. PG - e28095 LID - 10.1016/j.heliyon.2024.e28095 [doi] LID - e28095 AB - OBJECTIVE: To explore whether Bushen Huoxue Formula (BSHXF) improves the angiogenesis ability of transplanted endothelial progenitor cells (EPCs) in endplate and its potential mechanism in delaying intervertebral disc degeneration (IDD). METHODS: BSHXF was analyzed via Ultra-High Performance Liquid Chromatography (UPLC). Rabbit axial compression lumbar IDD models were constructed and the effects of BSHXF, EPCs, and their combination in IDD were determined by MRI, histological evaluation, TUNEL, and immunofluorescence assays. Additionally, CCK-8 assay, flow cytometry, and tube formation assay were used to evaluate EPCs viability, proliferation, cell cycle and the angiogenesis ability of EPCs between groups. RESULTS: BSHXF and transplanted EPCs both attenuate the process of IDD in the rabbit model assessed by MRI, HE staining and Masson staining. TUNEL-positive NP cells were significantly reduced in the BSHXF group, EPCs group, and EPC + BSHXF group compared to the model group (P < 0.05), with the EPC + BSHXF group showing the most significant therapeutic effect. Immunofluorescence detection showed that VEGF, CD34 expression and quantity of microvessels in the endplate significantly increased in the EPC + BSHXF group compared to all the other groups (P < 0.05). Besides, the CCK-8 assay showed an upregulation of EPC viability and the tube formation assay demonstrated a significant increase in tube length and branching in EPCs cultured with BSHXF-containing serum (P < 0.05). Furthermore, BSHXF-containing serum increased VEGF expression in EPCs cultured in vitro (P < 0.05). CONCLUSIONS: Both BSHXF and EPCs transplantation play an important role in increasing endplate angiogenesis and attenuating IDD. BSHXF can enhance the viability and tube-forming ability of EPCs and endplate microcirculation. CI - © 2024 The Authors. FAU - Xie, Yue AU - Xie Y AD - Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. AD - Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200052, China. AD - Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai 200052, China. AD - Institute of Arthritis Research in Integrative Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai 200052, China. FAU - Zhang, Jianpo AU - Zhang J AD - Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200052, China. AD - Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai 200052, China. AD - Institute of Arthritis Research in Integrative Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai 200052, China. FAU - Yang, Shengqi AU - Yang S AD - Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. AD - Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200052, China. AD - Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai 200052, China. AD - Institute of Arthritis Research in Integrative Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai 200052, China. FAU - Zhai, Weifeng AU - Zhai W AD - Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200052, China. AD - Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai 200052, China. AD - Department of Orthopedics, Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital, Shanghai, 201318, China. FAU - Zhao, Hailiang AU - Zhao H AD - Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. AD - Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200052, China. AD - Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai 200052, China. AD - Institute of Arthritis Research in Integrative Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai 200052, China. FAU - Shen, Zhan AU - Shen Z AD - Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. AD - Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200052, China. AD - Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai 200052, China. AD - Institute of Arthritis Research in Integrative Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai 200052, China. FAU - Guo, Ji AU - Guo J AD - Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200052, China. AD - Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai 200052, China. AD - Institute of Arthritis Research in Integrative Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai 200052, China. FAU - Jia, Yongwei AU - Jia Y AD - Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200052, China. AD - Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai 200052, China. AD - Department of Orthopedics, Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital, Shanghai, 201318, China. LA - eng PT - Journal Article DEP - 20240319 PL - England TA - Heliyon JT - Heliyon JID - 101672560 PMC - PMC10966705 OTO - NOTNLM OT - Angiogenesis OT - Bushen huoxue formula OT - Endothelial progenitor cells OT - Endplate OT - Intervertebral disc degeneration COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/03/28 06:44 MHDA- 2024/03/28 06:45 PMCR- 2024/03/19 CRDT- 2024/03/28 04:05 PHST- 2023/09/14 00:00 [received] PHST- 2024/03/11 00:00 [revised] PHST- 2024/03/12 00:00 [accepted] PHST- 2024/03/28 06:45 [medline] PHST- 2024/03/28 06:44 [pubmed] PHST- 2024/03/28 04:05 [entrez] PHST- 2024/03/19 00:00 [pmc-release] AID - S2405-8440(24)04126-4 [pii] AID - e28095 [pii] AID - 10.1016/j.heliyon.2024.e28095 [doi] PST - epublish SO - Heliyon. 2024 Mar 19;10(6):e28095. doi: 10.1016/j.heliyon.2024.e28095. eCollection 2024 Mar 30. PMID- 29554973 OWN - NLM STAT- MEDLINE DCOM- 20190613 LR - 20220330 IS - 1479-5876 (Electronic) IS - 1479-5876 (Linking) VI - 16 IP - 1 DP - 2018 Mar 20 TI - Bushenhuoxue formula attenuates cartilage degeneration in an osteoarthritic mouse model through TGF-β/MMP13 signaling. PG - 72 LID - 10.1186/s12967-018-1437-3 [doi] LID - 72 AB - BACKGROUND: Articular cartilage degeneration plays a key role in the pathogenesis of osteoarthritis (OA). Bushenhuoxue formula (BSHXF) has been widely used in the treatment of OA in clinics. However, the molecular mechanisms responsible for the chondroprotective effect of BSHXF remain to be elucidated. The purpose of this study was to explore the effects of BSHXF on OA mice model. METHODS: In this study, we investigated the effects of BSHXF on destabilization of the medial meniscus (DMM)-induced chondrocyte degradation in OA mice model. At 12 weeks post-surgery, the joints were harvested for tissue analyses, including histology, histomorphometry, TUNEL, OARSI scoring, micro-CT and immunohistochemistry for COL2, TGFBR2, pSMAD2 and MMP13. Additionally, we also evaluated the effects of BSHXF on Mmp13 mRNA and protein expression in chondrogenic ATDC5 cells through real-time PCR and Western blot respectively. Moreover, we investigated the chondroprotective effect of BSHXF on mice with Tgfbr2 conditional knockout (Tgfbr2 (Col2ER) mice) in chondrocyte, including the relative experiments mentioned above. We transfected Tgfbr2 siRNA in ATDC5 to further evaluate the changes of Mmp13 mRNA and protein expression followed by BSHXF treatment. RESULTS: Amelioration of cartilage degradation and chondrocyte apoptosis were observed in DMM-induced mice, with increases in cartilage area and thickness, proteoglycan matrix, COL2 content and decreases in OARSI score at 12 weeks post surgery. Moreover, the elevated TGFBR2 and pSMAD2, and reduced MMP13 positive cells were also revealed in DMM-induced mice treated with BSHXF. Besides, decreased Mmp13 mRNA and protein expression were observed inchondrogenic ATDC5 cells culture in serum containing BSHXF. As expected, Tgfbr2 (Col2ER) mice exhibited significant OA-like phenotype. Interestingly, obvious improvement in articular cartilage structure was still observed in Tgfbr2 (Col2ER) mice after BSHXF treatment via up-regulated pSMAD2 and down-regulated MMP13 expressional levels in articular cartilage. CONCLUSIONS: BSHXF could inhibit cartilage degradation through TGF-β/MMP13 signaling, and be considered a good option for the treatment of OA. FAU - Wang, Ping-Er AU - Wang PE AD - Institute of Orthopaedics and Traumatology, The First Affiliated Hospital of Zhejiang Chinese Medical University, No. 548 Binwen Road, Binjiang District, Hangzhou, 310053, Zhejiang, People's Republic of China. FAU - Zhang, Lei AU - Zhang L AD - Institute of Orthopaedics and Traumatology, The First Affiliated Hospital of Zhejiang Chinese Medical University, No. 548 Binwen Road, Binjiang District, Hangzhou, 310053, Zhejiang, People's Republic of China. AD - The First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, People's Republic of China. FAU - Ying, Jun AU - Ying J AD - Institute of Orthopaedics and Traumatology, The First Affiliated Hospital of Zhejiang Chinese Medical University, No. 548 Binwen Road, Binjiang District, Hangzhou, 310053, Zhejiang, People's Republic of China. AD - The First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, People's Republic of China. FAU - Jin, Xing AU - Jin X AD - Institute of Orthopaedics and Traumatology, The First Affiliated Hospital of Zhejiang Chinese Medical University, No. 548 Binwen Road, Binjiang District, Hangzhou, 310053, Zhejiang, People's Republic of China. AD - Department of Orthopaedics and Traumatology, Wangjiang Sub-District Community Health Service Center, Hangzhou, 310016, Zhejiang, People's Republic of China. FAU - Luo, Cheng AU - Luo C AD - Institute of Orthopaedics and Traumatology, The First Affiliated Hospital of Zhejiang Chinese Medical University, No. 548 Binwen Road, Binjiang District, Hangzhou, 310053, Zhejiang, People's Republic of China. AD - The First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, People's Republic of China. FAU - Xu, Shibing AU - Xu S AD - Institute of Orthopaedics and Traumatology, The First Affiliated Hospital of Zhejiang Chinese Medical University, No. 548 Binwen Road, Binjiang District, Hangzhou, 310053, Zhejiang, People's Republic of China. AD - The First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, People's Republic of China. FAU - Dong, Rui AU - Dong R AD - Institute of Orthopaedics and Traumatology, The First Affiliated Hospital of Zhejiang Chinese Medical University, No. 548 Binwen Road, Binjiang District, Hangzhou, 310053, Zhejiang, People's Republic of China. AD - The First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, People's Republic of China. FAU - Xiao, Luwei AU - Xiao L AD - Institute of Orthopaedics and Traumatology, The First Affiliated Hospital of Zhejiang Chinese Medical University, No. 548 Binwen Road, Binjiang District, Hangzhou, 310053, Zhejiang, People's Republic of China. FAU - Tong, Peijian AU - Tong P AD - Department of Orthopaedic Surgery, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310006, Zhejiang, People's Republic of China. FAU - Jin, Hongting AU - Jin H AD - Institute of Orthopaedics and Traumatology, The First Affiliated Hospital of Zhejiang Chinese Medical University, No. 548 Binwen Road, Binjiang District, Hangzhou, 310053, Zhejiang, People's Republic of China. hongtingjin@163.com. LA - eng GR - 81774332/National Natural Science Foundation of China/International GR - 81774346/National Natural Science Foundation of China/International GR - LY16H270010/Zhejiang grants funded by Provincial Natural Science Foundation of China/International GR - LZ12H27001/Zhejiang grants funded by Provincial Natural Science Foundation of China/International GR - 2018ZA034/State Administration of Traditional Chinese Medicine of Zhejiang Province/International GR - 2016ZA048/State Administration of Traditional Chinese Medicine of Zhejiang Province/International PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20180320 PL - England TA - J Transl Med JT - Journal of translational medicine JID - 101190741 RN - 0 (Drugs, Chinese Herbal) RN - 0 (Smad2 Protein) RN - 0 (Transforming Growth Factor beta) RN - EC 2.7.11.30 (Receptor, Transforming Growth Factor-beta Type II) RN - EC 3.4.24.- (Matrix Metalloproteinase 13) SB - IM MH - Animals MH - Cartilage, Articular/drug effects/*pathology MH - Chondrocytes/drug effects/metabolism/pathology MH - Disease Models, Animal MH - Disease Progression MH - Drugs, Chinese Herbal/pharmacology/*therapeutic use MH - Matrix Metalloproteinase 13/*metabolism MH - Menisci, Tibial/drug effects/pathology MH - Mice, Inbred C57BL MH - Osteoarthritis/*drug therapy/pathology MH - Phenotype MH - Phosphorylation/drug effects MH - Rats, Sprague-Dawley MH - Receptor, Transforming Growth Factor-beta Type II/metabolism MH - *Signal Transduction MH - Smad2 Protein/metabolism MH - Transforming Growth Factor beta/*metabolism MH - Up-Regulation/drug effects PMC - PMC5859632 OTO - NOTNLM OT - Articular cartilage OT - Bushenhuoxue formula OT - Conditional knockout OT - Osteoarthritis OT - TGF-β/MMP13 signaling EDAT- 2018/03/21 06:00 MHDA- 2019/06/14 06:00 PMCR- 2018/03/20 CRDT- 2018/03/21 06:00 PHST- 2017/08/18 00:00 [received] PHST- 2018/03/05 00:00 [accepted] PHST- 2018/03/21 06:00 [entrez] PHST- 2018/03/21 06:00 [pubmed] PHST- 2019/06/14 06:00 [medline] PHST- 2018/03/20 00:00 [pmc-release] AID - 10.1186/s12967-018-1437-3 [pii] AID - 1437 [pii] AID - 10.1186/s12967-018-1437-3 [doi] PST - epublish SO - J Transl Med. 2018 Mar 20;16(1):72. doi: 10.1186/s12967-018-1437-3. PMID- 40421263 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250530 IS - 1178-7031 (Print) IS - 1178-7031 (Electronic) IS - 1178-7031 (Linking) VI - 18 DP - 2025 TI - The Inhibitory Effect of the Active Ingredients in the Bushen Huoxue Formula on the IL-17A Signaling Pathway and Its Alleviating Effect on Osteoarthritis. PG - 6505-6527 LID - 10.2147/JIR.S506716 [doi] AB - OBJECTIVE: Osteoarthritis (OA) stands as a prevalent degenerative disease worldwide. Despite the demonstrated therapeutic efficacy of the Bushen Huoxue formula (BSHXF) in treating OA, its underlying mechanism remains elusive. Network pharmacology is commonly employed for investigating drug-disease associations and processes. In this study, we employed network pharmacology alongside in vitro and in vivo experiments to elucidate the molecular mechanism by which BSHXF treats OA. METHODS: Based on the TCMSP database, active components of BSHXF were screened, and OA-related targets were retrieved from GeneCard and DisGeNET to construct a "component-target-pathway" network using Cytoscape. Core target functions and pathways (KEGG/GO) were analyzed through STRING and Metascape, while component-target binding affinity was validated via Autodock. For in vitro experiments, an IL-1β-induced chondrocyte inflammation model was established, and key protein expression was detected by Western blot and immunofluorescence. For in vivo experiments, an OA model was created by medial meniscectomy of the knee joint in rats, and therapeutic efficacy was assessed using histological staining and micro-CT. RESULTS: This study screened 89 active ingredients of BSHXF and identified 189 common targets. Network pharmacological analysis revealed luteolin and tanshinone IIA as the most crucial active ingredients in treating OA with BSHXF. The potential mechanisms of action for BSHXF in OA treatment involve inflammation inhibition, immune function regulation, and resistance to oxidative stress, with a significant regulatory role played by the IL-17 signaling pathway. Molecular docking results demonstrated luteolin's strong binding affinity to key targets such as B-cell lymphoma 2 (Bcl-2), Matrix metalloproteinase-9 (Mmp-9), and IL-6.In vitro experiments demonstrated that BSHXF significantly suppressed IL-1β-induced inflammatory responses in chondrocytes, downregulating IL-17A expression (p < 0.05), reducing the expression of MMP-9 (p < 0.05) and IL-6 (p < 0.05), and inhibiting apoptosis. Additionally, in vivo experiments revealed that the high-dose BSHXF group (150 mg/kg) markedly alleviated cartilage damage in OA rats, with OARSI scores significantly decreased compared to the model group (p < 0.05). Micro-CT analysis showed that BSHXF inhibited osteophyte formation and ameliorated OA pathological conditions. CONCLUSION: BSHXF has the potential to alleviate OA by suppressing inflammation, inhibiting cartilage apoptosis and hindering extracellular matrix degradation via the IL-17 signaling pathway. Our study elucidated the molecular mechanisms underlying the therapeutic effects of BSHXF on OA, thus highlighting its further research implications as a novel drug candidate. CI - © 2025 Wang et al. FAU - Wang, Xuan AU - Wang X AD - Department of Foot and Ankle Surgery, Honghui Hospital, Xi'an Jiaotong University, Xi'an, People's Republic of China. FAU - Zhang, Yunheng AU - Zhang Y AD - Department of Foot and Ankle Surgery, Honghui Hospital, Xi'an Jiaotong University, Xi'an, People's Republic of China. FAU - Chang, Xin AU - Chang X AUID- ORCID: 0009-0006-3547-7492 AD - Department of Foot and Ankle Surgery, Honghui Hospital, Xi'an Jiaotong University, Xi'an, People's Republic of China. FAU - Wen, Xiaodong AU - Wen X AD - Department of Foot and Ankle Surgery, Honghui Hospital, Xi'an Jiaotong University, Xi'an, People's Republic of China. FAU - Tian, Feng AU - Tian F AD - Department of Foot and Ankle Surgery, Honghui Hospital, Xi'an Jiaotong University, Xi'an, People's Republic of China. FAU - Yu, Hanjie AU - Yu H AD - Laboratory for Functional Glycomics, College of Life Sciences, Northwest University, Xi'an, People's Republic of China. FAU - Li, Yi AU - Li Y AD - Department of Foot and Ankle Surgery, Honghui Hospital, Xi'an Jiaotong University, Xi'an, People's Republic of China. LA - eng PT - Journal Article DEP - 20250521 PL - New Zealand TA - J Inflamm Res JT - Journal of inflammation research JID - 101512684 PMC - PMC12104672 OTO - NOTNLM OT - Bushen Huoxue formula OT - experimental verification OT - network pharmacology OT - osteoarthritis OT - pharmacological mechanism COIS- The authors declare that there are no conflicts of interest. EDAT- 2025/05/27 06:27 MHDA- 2025/05/27 06:28 PMCR- 2025/05/21 CRDT- 2025/05/27 04:31 PHST- 2024/11/15 00:00 [received] PHST- 2025/05/08 00:00 [accepted] PHST- 2025/05/27 06:28 [medline] PHST- 2025/05/27 06:27 [pubmed] PHST- 2025/05/27 04:31 [entrez] PHST- 2025/05/21 00:00 [pmc-release] AID - 506716 [pii] AID - 10.2147/JIR.S506716 [doi] PST - epublish SO - J Inflamm Res. 2025 May 21;18:6505-6527. doi: 10.2147/JIR.S506716. eCollection 2025. PMID- 38405577 OWN - NLM STAT- MEDLINE DCOM- 20240227 LR - 20240227 IS - 1177-8881 (Electronic) IS - 1177-8881 (Linking) VI - 18 DP - 2024 TI - Network Pharmacology with Metabolomics Study to Reveal the Mechanisms of Bushen Huoxue Formula in Intervertebral Disc Degeneration Treatment. PG - 493-512 LID - 10.2147/DDDT.S451197 [doi] AB - BACKGROUND: Intervertebral disc degeneration (IVDD) is a pathophysiological process that leads to severe back pain or neurological deficits. The Bushen Huoxue Formula (BSHXF) is a traditional herbal remedy widely used to treat diseases related to IVDD. However, its pharmacological mechanism needs further exploration. OBJECTIVE: This study aimed to elucidate the mechanisms through which BSHXF treats IVDD-related diseases by integrating metabolomics with network pharmacology. METHODS: Network pharmacology was utilized to identify potential targets of BSHXF against IVDD. Additionally, an animal model of needle puncture-induced disc degeneration was established to assess the effect of BSHXF. Mice were randomly assigned to the sham group, model group, and BSHXF group. Various techniques, including PCR, CCK-8 assay, MRI, histological examinations, and immunohistochemical analyses, were employed to evaluate degenerative and oxidative stress conditions in mouse disc tissue and cultured nucleus pulposus (NP) cells. UHPLC-HRMS/MS was used to differential distinct metabolites in the disc tissue from different groups, and MetaboAnalyst 5.0 was employed to enrich the metabolic pathways. RESULTS: Through network pharmacology, 15 core proteins were identified through protein-protein interaction (PPI) network construction. Functional enrichment analysis highlighted the critical role of BSHXF in addressing IVDD by influencing the response to oxidative stress. Furthermore, experimental evidence demonstrated that BSHXF significantly improved the pathological progression of IVDD and increased oxidative stress markers SOD-1 and GPX1, both in the disc degeneration model and cultured NP cells. Metabolomics identified differential metabolites among the three groups, revealing 15 metabolic pathways between the sham and model groups, and 13 metabolic pathways enriched between the model and BSHXF groups. CONCLUSION: This study, integrating network pharmacology and metabolomics, suggests that BSHXF can alleviate IVDD progression by modulating oxidative stress. Key metabolic pathways associated with BSHXF-mediated reduction of oxidative stress include the citrate cycle, cysteine and methionine metabolism, alanine, aspartate and glutamate metabolism, glycine, serine and threonine metabolism, D-glutamine and D-glutamate metabolism, glutathione metabolism, and tryptophan metabolism. While this research demonstrates the therapeutic potential of BSHXF in reducing oxidative stress levels in IVDD, further research is needed to thoroughly understand its underlying mechanisms. CI - © 2024 Guo et al. FAU - Guo, Ji AU - Guo J AD - Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200052, People's Republic of China. AD - Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, 200052, People's Republic of China. AD - Institute of Arthritis Research in Integrative Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai, 200052, People's Republic of China. FAU - Yang, Shengqi AU - Yang S AD - Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200052, People's Republic of China. AD - Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, 200052, People's Republic of China. AD - Institute of Arthritis Research in Integrative Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai, 200052, People's Republic of China. AD - Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China. FAU - Zhai, Weifeng AU - Zhai W AD - Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200052, People's Republic of China. AD - Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, 200052, People's Republic of China. AD - Institute of Arthritis Research in Integrative Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai, 200052, People's Republic of China. AD - Department of Orthopedics, Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital, Shanghai, 201318, People's Republic of China. FAU - Xie, Yue AU - Xie Y AD - Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200052, People's Republic of China. AD - Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, 200052, People's Republic of China. AD - Institute of Arthritis Research in Integrative Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai, 200052, People's Republic of China. AD - Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China. FAU - Shen, Zhan AU - Shen Z AD - Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200052, People's Republic of China. AD - Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, 200052, People's Republic of China. AD - Institute of Arthritis Research in Integrative Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai, 200052, People's Republic of China. AD - Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China. FAU - Zhang, Jianpo AU - Zhang J AD - Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200052, People's Republic of China. AD - Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, 200052, People's Republic of China. AD - Institute of Arthritis Research in Integrative Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai, 200052, People's Republic of China. FAU - Jia, Yongwei AU - Jia Y AD - Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200052, People's Republic of China. AD - Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, 200052, People's Republic of China. AD - Institute of Arthritis Research in Integrative Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai, 200052, People's Republic of China. AD - Department of Orthopedics, Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital, Shanghai, 201318, People's Republic of China. LA - eng PT - Journal Article DEP - 20240221 PL - New Zealand TA - Drug Des Devel Ther JT - Drug design, development and therapy JID - 101475745 RN - 0 (bushen huoxue) RN - 0 (Drugs, Chinese Herbal) SB - IM MH - Rats MH - Mice MH - Animals MH - *Intervertebral Disc Degeneration/metabolism MH - Rats, Sprague-Dawley MH - Network Pharmacology MH - *Nucleus Pulposus/metabolism MH - *Drugs, Chinese Herbal PMC - PMC10894601 OTO - NOTNLM OT - Bushen Huoxue formula OT - intervertebral disc degeneration OT - metabolomics OT - network pharmacology OT - oxidative stress COIS- The authors report no conflicts of interest in this work. EDAT- 2024/02/26 06:45 MHDA- 2024/02/27 06:45 PMCR- 2024/02/21 CRDT- 2024/02/26 04:46 PHST- 2023/11/22 00:00 [received] PHST- 2024/02/14 00:00 [accepted] PHST- 2024/02/27 06:45 [medline] PHST- 2024/02/26 06:45 [pubmed] PHST- 2024/02/26 04:46 [entrez] PHST- 2024/02/21 00:00 [pmc-release] AID - 451197 [pii] AID - 10.2147/DDDT.S451197 [doi] PST - epublish SO - Drug Des Devel Ther. 2024 Feb 21;18:493-512. doi: 10.2147/DDDT.S451197. eCollection 2024. PMID- 29393545 OWN - NLM STAT- MEDLINE DCOM- 20200914 LR - 20200914 IS - 1097-4644 (Electronic) IS - 0730-2312 (Linking) VI - 120 IP - 12 DP - 2019 Dec TI - Bu-Shen-Huo-Xue-Fang modulates nucleus pulposus cell proliferation and extracellular matrix remodeling in intervertebral disk degeneration through miR-483 regulation of Wnt pathway. PG - 19318-19329 LID - 10.1002/jcb.26760 [doi] AB - Intervertebral disk degeneration (IDD) has been widely considered as one of the main causes for low back pain, which can cause a severe impact to human health and huge economic burden to worldwide society. IDD pathogenesis can be affected by extensive degradation of extracellular matrix (ECM) and the hyperproliferation of nucleus pulposus (NP) cells. During the IDD process, expression of the ECM degradation enzymes matrix metalloproteinase and ADAMTS increases, whereas expression of ECM synthesis-related aggrecan and COL2A1 decreases. In addition, the Wnt signaling pathway is reportedly involved in the process of IDD. Bu-Shen-Huo-Xue-Fang (BSHXF), a Chinese traditional medicine formula that contains six Chinese traditional medicinal herbs, is widely used in the treatment of IDD. Herein, we obtained the serum containing BSHXF from BSHXF-fed rat and demonstrated that the BSHXF promoted NP cell proliferation and ECM synthesis through the Wnt signaling pathway. By using DIANA online tools and luciferase reporter gene assays, we confirmed that miR-483-3p and miR-23c regulated CTNNB1 and GSK3B, respectively, through direct targeting, thereby affecting the effect of BSHXF on NP cell proliferation and ECM synthesis through the Wnt signaling pathway. Taken together, we demonstrated the function and mechanism of BSHXF in regulating NP cell proliferation and ECM remodeling through the Wnt signaling pathway during IDD. CI - © 2018 Wiley Periodicals, Inc. FAU - Yang, Shaofeng AU - Yang S AUID- ORCID: 0000-0003-4053-2119 AD - Department of Spine, The First Hospital of Hunan University of Chinese Medicine, Changsha, China. FAU - Li, Linghui AU - Li L AD - Department of General Orthopedics, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, China. FAU - Zhu, Liguo AU - Zhu L AD - Department of General Orthopedics, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, China. FAU - Zhang, Chao AU - Zhang C AD - Department of Spine, The First Hospital of Hunan University of Chinese Medicine, Changsha, China. FAU - Li, Zhaoyong AU - Li Z AD - Department of Spine, The First Hospital of Hunan University of Chinese Medicine, Changsha, China. FAU - Guo, Yantao AU - Guo Y AD - Department of Spine, The First Hospital of Hunan University of Chinese Medicine, Changsha, China. FAU - Nie, Ying AU - Nie Y AD - Department of Spine, The First Hospital of Hunan University of Chinese Medicine, Changsha, China. FAU - Luo, Zhenhua AU - Luo Z AD - Department of Spine, The First Hospital of Hunan University of Chinese Medicine, Changsha, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190825 PL - United States TA - J Cell Biochem JT - Journal of cellular biochemistry JID - 8205768 RN - 0 (Drugs, Chinese Herbal) RN - 0 (MIRN483 microRNA, human) RN - 0 (MicroRNAs) SB - IM MH - Animals MH - Blotting, Western MH - Cell Proliferation/drug effects MH - Cells, Cultured MH - Drugs, Chinese Herbal/*therapeutic use MH - Extracellular Matrix/drug effects/*metabolism MH - Humans MH - Intervertebral Disc Degeneration/*metabolism MH - Male MH - MicroRNAs/genetics/*metabolism MH - Nucleus Pulposus/*drug effects/*metabolism MH - Rats MH - Rats, Sprague-Dawley MH - Wnt Signaling Pathway/drug effects OTO - NOTNLM OT - Bu-Shen-Huo-Xue-Fang OT - extracellular matrix OT - intervertebral disk degeneration OT - miR-23c OT - miR-483-3p OT - nucleus pulposus cell EDAT- 2018/02/03 06:00 MHDA- 2020/09/15 06:00 CRDT- 2018/02/03 06:00 PHST- 2017/09/27 00:00 [received] PHST- 2018/01/18 00:00 [accepted] PHST- 2018/02/03 06:00 [pubmed] PHST- 2020/09/15 06:00 [medline] PHST- 2018/02/03 06:00 [entrez] AID - 10.1002/jcb.26760 [doi] PST - ppublish SO - J Cell Biochem. 2019 Dec;120(12):19318-19329. doi: 10.1002/jcb.26760. Epub 2019 Aug 25. PMID- 2934155 OWN - NLM STAT- MEDLINE DCOM- 19860211 LR - 20081121 IS - 0254-0029 (Print) IS - 0254-0029 (Linking) VI - 10 IP - 5 DP - 1985 May TI - [Improvement on the preparation of "bu-yang-huan-wu-tang" used for cerebral thrombosis]. PG - 27 LA - chi PT - Journal Article PL - China TA - Zhong Yao Tong Bao JT - Zhong yao tong bao (Beijing, China : 1981) JID - 8303080 RN - 0 (Plant Extracts) SB - IM MH - Humans MH - Intracranial Embolism and Thrombosis/*drug therapy MH - *Medicine, Chinese Traditional MH - *Medicine, East Asian Traditional MH - Plant Extracts/therapeutic use MH - *Plants, Medicinal EDAT- 1985/05/01 00:00 MHDA- 1985/05/01 00:01 CRDT- 1985/05/01 00:00 PHST- 1985/05/01 00:00 [pubmed] PHST- 1985/05/01 00:01 [medline] PHST- 1985/05/01 00:00 [entrez] PST - ppublish SO - Zhong Yao Tong Bao. 1985 May;10(5):27. PMID- 37688906 OWN - NLM STAT- Publisher LR - 20231014 IS - 1873-264X (Electronic) IS - 0731-7085 (Linking) VI - 236 DP - 2023 Nov 30 TI - Traditional Chinese Medicine formula Bu-Shen-Huo-Xue-Fang (BSHXF) protects nucleus pulposus cells against the inflammatory and oxidative stress-induced degenerative changes. PG - 115656 LID - S0731-7085(23)00425-9 [pii] LID - 10.1016/j.jpba.2023.115656 [doi] AB - Degeneration of the intervertebral disc is primarily caused by the loss of nucleus pulposus cells (NPCs) and extracellular matrix (ECM) (IDD). Bu-Shen-Huo-Xue-Fang (BSHXF), a traditional Chinese medicine decoction, has been used to treat IDD in clinical; nevertheless, the active components and underlying molecular mechanisms remain unknown. BSHXF improved IL-1β and H(2)O(2) stimulation-induced injuries on NPCs by promoting cell viability, increasing ECM deposition, inhibiting cell senescence, and decreasing the levels of inflammatory factors. The active ingredients in BSHXF were identified by LC-MS/MS analysis; three active ingredients from the principal drugs, Aucubin, Tanshinol, and Tanshinone II A promoted NPC viability; and Aucubin and Tanshinol promoted NPC viability more. Aucubin and Tanshinol, respectively, improved H(2)O(2) stimulation-induced injuries on NPCs by promoting cell viability, increasing ECM deposition, inhibiting cell senescence, and decreasing the levels of inflammatory factors. The activator of NF-κB and Wnt signaling pathways attenuated Aucubin and Tanshinol's protective effects by promoting ECM degradation and NPC senescence. Aucubin, Tanshinol, and Tanshinone II A were identified as the most potent compounds in BSHXF protection against degenerative changes in NPCs. The NF-κB and Wnt signaling pathways might be involved in the protective effects of Aucubin and Tanshinol against H(2)O(2)-induced degenerative changes. CI - Copyright © 2023. Published by Elsevier B.V. FAU - Li, Linghui AU - Li L AD - Department of General Orthopedics, Wangjing Hospital, China Academy of Chinese Medical Sciences, Huajiadi Street, Chaoyang District, Beijing 100102, China. FAU - Wei, Xu AU - Wei X AD - Department of Academic Development, Wangjing Hospital, China Academy of Chinese Medical Sciences, Huajiadi Street, Chaoyang District, Beijing 100102, China. FAU - Li, Kaiming AU - Li K AD - Department of General Orthopedics, Wangjing Hospital, China Academy of Chinese Medical Sciences, Huajiadi Street, Chaoyang District, Beijing 100102, China. FAU - Gong, Hao AU - Gong H AD - Department of Orthopaedics, Changping Hospital of Integrated Chinese and Western Medicine, No. 219 Huangping Street, Changping District, Beijing 102208, China. FAU - Zhu, Liguo AU - Zhu L AD - Department of General Orthopedics, Wangjing Hospital, China Academy of Chinese Medical Sciences, Huajiadi Street, Chaoyang District, Beijing 100102, China. Electronic address: tcmspine@163.com. FAU - Yang, Shaofeng AU - Yang S AD - Department of General Orthopedics, Wangjing Hospital, China Academy of Chinese Medical Sciences, Huajiadi Street, Chaoyang District, Beijing 100102, China; Department of Spine, The First Hospital of Hunan University of Chinese Medicine, Changsha 410007, China. Electronic address: spineyangshaofeng@163.com. FAU - Wang, Shangquan AU - Wang S AD - Department of General Orthopedics, Wangjing Hospital, China Academy of Chinese Medical Sciences, Huajiadi Street, Chaoyang District, Beijing 100102, China. FAU - Gu, Jinyu AU - Gu J AD - Department of General Orthopedics, Wangjing Hospital, China Academy of Chinese Medical Sciences, Huajiadi Street, Chaoyang District, Beijing 100102, China. FAU - Chen, Ming AU - Chen M AD - Department of General Orthopedics, Wangjing Hospital, China Academy of Chinese Medical Sciences, Huajiadi Street, Chaoyang District, Beijing 100102, China. FAU - Yin, Xunlu AU - Yin X AD - Department of General Orthopedics, Wangjing Hospital, China Academy of Chinese Medical Sciences, Huajiadi Street, Chaoyang District, Beijing 100102, China. FAU - Zhan, Jiawen AU - Zhan J AD - Department of General Orthopedics, Wangjing Hospital, China Academy of Chinese Medical Sciences, Huajiadi Street, Chaoyang District, Beijing 100102, China. FAU - Feng, Minshan AU - Feng M AD - Department of General Orthopedics, Wangjing Hospital, China Academy of Chinese Medical Sciences, Huajiadi Street, Chaoyang District, Beijing 100102, China. FAU - Yu, Jie AU - Yu J AD - Department of General Orthopedics, Wangjing Hospital, China Academy of Chinese Medical Sciences, Huajiadi Street, Chaoyang District, Beijing 100102, China. FAU - Sun, Wu AU - Sun W AD - Department of General Orthopedics, Wangjing Hospital, China Academy of Chinese Medical Sciences, Huajiadi Street, Chaoyang District, Beijing 100102, China. FAU - Chen, Xin AU - Chen X AD - Department of General Orthopedics, Wangjing Hospital, China Academy of Chinese Medical Sciences, Huajiadi Street, Chaoyang District, Beijing 100102, China. LA - eng PT - Journal Article DEP - 20230816 PL - England TA - J Pharm Biomed Anal JT - Journal of pharmaceutical and biomedical analysis JID - 8309336 SB - IM OTO - NOTNLM OT - Aucubin OT - Bu-Shen-Huo-Xue-Fang (BSHXF) OT - Intervertebral disc degeneration (IDD) OT - Nucleus pulposus cells (NPCs) OT - Senescence OT - Tanshinol COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/09/10 00:42 MHDA- 2023/09/10 00:42 CRDT- 2023/09/09 18:03 PHST- 2023/02/14 00:00 [received] PHST- 2023/07/14 00:00 [revised] PHST- 2023/08/15 00:00 [accepted] PHST- 2023/09/10 00:42 [pubmed] PHST- 2023/09/10 00:42 [medline] PHST- 2023/09/09 18:03 [entrez] AID - S0731-7085(23)00425-9 [pii] AID - 10.1016/j.jpba.2023.115656 [doi] PST - ppublish SO - J Pharm Biomed Anal. 2023 Nov 30;236:115656. doi: 10.1016/j.jpba.2023.115656. Epub 2023 Aug 16. PMID- 32763417 OWN - NLM STAT- MEDLINE DCOM- 20210225 LR - 20210225 IS - 1872-7573 (Electronic) IS - 0378-8741 (Linking) VI - 263 DP - 2020 Dec 5 TI - Predication of the underlying mechanism of Bushenhuoxue formula acting on knee osteoarthritis via network pharmacology-based analyses combined with experimental validation. PG - 113217 LID - S0378-8741(20)33099-3 [pii] LID - 10.1016/j.jep.2020.113217 [doi] AB - ETHNOPHARMACOLOGICAL RELEVANCE: Knee osteoarthritis (KOA) is the most common chronic joint disorder worldwide, which is also a principle consideration for disability. The Bushenhuoxue formula (BSHXF) is a traditional herbal formula which widely applied to the treatment of KOA. However, its pharmacological mechanisms of action have not been clarified. AIMS OF THE STUDY: The study aimed to identify the potential targets and mechanisms of BSHXF in the treatment of KOA through pharmacology-based analyses and experimental validation. MATERIALS AND METHODS: The TCMSP database was applied to obtain the chemical compounds and targets of BSHXF, while the protein targets in KOA were determined through GeneCards and OMIM databases. The herb-compound-target and protein-protein interaction (PPI) networks were constructed for topological analyses and hub-targets screening. GO and KEGG enrichment analyses were performed on these core nodes to identify the critical biological processes and signaling pathways. Then destabilization of medial meniscus (DMM)-induced C57BL/6J mice model was established to detect the level of apoptosis via TUNEL assessment, while the expressions of CASP3, CASP8 and CASP9 were determined by immunohistochemistry. RESULTS: A total of 154 active compounds and 58 targets were predicted. DAVID, ClueGO and Metascape enrichment analyses all proved that BSHXF plays an essential role in regulating apoptosis. Moreover, 3 central nodes of BSHXF are recognized as the active factors involved in the main biological functions, suggesting a potential mechanism of BSHXF for KOA treatment. In vivo experiment revealed that BSHXF significantly inhibited apoptosis and down-regulated the expressions of CASP3, CASP8 and CASP9. CONCLUSION: Based on network pharmacology and experimental validation, our study indicated that BSHXF exerted anti-apoptosis effect through inhibiting the expressions of CASP3, CASP8 and CASP9, which could be considered as an effective method for KOA treatment. CI - Copyright © 2020 Elsevier B.V. All rights reserved. FAU - Xu, Hui-Hui AU - Xu HH AD - The First Clinical College, Zhejiang Chinese Medical University, Hangzhou, 310051, Zhejiang, China. Electronic address: xhh960509@163.com. FAU - Li, Suo-Mi AU - Li SM AD - The First Clinical College, Zhejiang Chinese Medical University, Hangzhou, 310051, Zhejiang, China. Electronic address: 962528272@qq.com. FAU - Xu, Rui AU - Xu R AD - The First Clinical College, Zhejiang Chinese Medical University, Hangzhou, 310051, Zhejiang, China. Electronic address: jiangxixurui@163.com. FAU - Fang, Liang AU - Fang L AD - The First Clinical College, Zhejiang Chinese Medical University, Hangzhou, 310051, Zhejiang, China. Electronic address: zjzyy26@163.com. FAU - Xu, Hui AU - Xu H AD - The First Clinical College, Zhejiang Chinese Medical University, Hangzhou, 310051, Zhejiang, China. Electronic address: 837898408@qq.com. FAU - Tong, Pei-Jian AU - Tong PJ AD - The First Clinical College, Zhejiang Chinese Medical University, Hangzhou, 310051, Zhejiang, China; Department of Orthopaedics, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310006, China. Electronic address: tongpeijianhztcm@163.com. LA - eng PT - Journal Article DEP - 20200805 PL - Ireland TA - J Ethnopharmacol JT - Journal of ethnopharmacology JID - 7903310 RN - 0 (Drugs, Chinese Herbal) SB - IM MH - Animals MH - Databases, Factual/*standards MH - Drug Evaluation, Preclinical/methods/standards MH - Drugs, Chinese Herbal/isolation & purification/*therapeutic use MH - Mice MH - Mice, Inbred C57BL MH - Osteoarthritis, Knee/*drug therapy/metabolism MH - Reproducibility of Results OTO - NOTNLM OT - Apoptosis OT - Bushenhuoxue formula OT - Knee osteoarthritis OT - Network pharmacology EDAT- 2020/08/09 06:00 MHDA- 2021/02/26 06:00 CRDT- 2020/08/09 06:00 PHST- 2020/04/12 00:00 [received] PHST- 2020/07/26 00:00 [revised] PHST- 2020/07/27 00:00 [accepted] PHST- 2020/08/09 06:00 [pubmed] PHST- 2021/02/26 06:00 [medline] PHST- 2020/08/09 06:00 [entrez] AID - S0378-8741(20)33099-3 [pii] AID - 10.1016/j.jep.2020.113217 [doi] PST - ppublish SO - J Ethnopharmacol. 2020 Dec 5;263:113217. doi: 10.1016/j.jep.2020.113217. Epub 2020 Aug 5. PMID- 32311483 OWN - NLM STAT- MEDLINE DCOM- 20210212 LR - 20211204 IS - 1872-7573 (Electronic) IS - 0378-8741 (Linking) VI - 258 DP - 2020 Aug 10 TI - Tandem mass tag-based proteomic analysis reveals the treatment mechanism of Bushen Huoxue Formula on psychological stress-induced premature ovarian insufficiency. PG - 112870 LID - S0378-8741(20)30106-9 [pii] LID - 10.1016/j.jep.2020.112870 [doi] AB - ETHNOPHARMACOLOGICAL RELEVANCE: Bushen Huoxue formula (BSHXF) is a Chinese herbal prescription composed of eleven herbs widely used to treat psychological stress-induced premature ovarian insufficiency (POI) in clinical. However, the underlying mechanism is still unclear. AIM OF THE STUDY: The purpose of this study was to clarify the underlying molecular mechanisms of BSHXF in the treatment of psychological stress-induced POI. MATERIALS AND METHODS: The rat model was induced by corticosterone (CORT, 40mg/kg). Drugs were administered to rats once daily for 21 days. The serum E(2), FSH and AMH levels were examined by enzyme-linked immunosorbent assays. Tandem mass tag-based proteomic analysis was used to identify differentially expressed proteins. Western blot was used to verify the results of proteomic. RESULTS: Our results indicate that BSHXF can improve ovarian disfunction. The levels of serum FSH were signally enhanced in model group compared to control group. As respected, BSHXF treatment for 3 weeks led to the decreased FSH levels than the model group. The concentrations of AMH showed an obvious decrease in the model group and were increased by BSHXF treatment. Moreover, the size and number of follicles in the BSHXF groups were similar to those in the control group. The proteomic screened out that Np4 and Angptl4 were simultaneously enriched by GO and KEGG, thus these two proteins were chosen for further study. CONCLUSIONS: These findings revealed that BSHXF might regulate the expression of Np4 and Angptl4 to improve psychological stress-induced POI. CI - Copyright © 2020 Elsevier B.V. All rights reserved. FAU - Miao, Mengqi AU - Miao M AD - Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210028, PR China. FAU - Gao, Meng AU - Gao M AD - Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210028, PR China; Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028, PR China. FAU - Li, Tian AU - Li T AD - Department of TCMs Pharmaceuticals & State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, 210009, PR China. FAU - Jiang, Cuihua AU - Jiang C AD - Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210028, PR China; Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028, PR China. FAU - Lu, Yan AU - Lu Y AD - Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210028, PR China; Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028, PR China. FAU - Chen, Si AU - Chen S AD - Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210028, PR China; Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028, PR China. FAU - Chen, Yue AU - Chen Y AD - Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210028, PR China; Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028, PR China. FAU - Wang, Peijuan AU - Wang P AD - Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210028, PR China; Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028, PR China. Electronic address: pjwang@vip.sohu.com. FAU - Zhang, Jian AU - Zhang J AD - Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210028, PR China; Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028, PR China. Electronic address: zjwonderful@hotmail.com. LA - eng PT - Journal Article DEP - 20200418 PL - Ireland TA - J Ethnopharmacol JT - Journal of ethnopharmacology JID - 7903310 RN - 0 (ANGPTL4 protein, rat) RN - 0 (Angiopoietin-Like Protein 4) RN - 0 (Drugs, Chinese Herbal) RN - 0 (bushen huoxue) RN - W980KJ009P (Corticosterone) SB - IM MH - Angiopoietin-Like Protein 4/metabolism MH - Animals MH - Corticosterone MH - Disease Models, Animal MH - Drugs, Chinese Herbal/*pharmacology MH - Female MH - Primary Ovarian Insufficiency/*drug therapy/etiology MH - Proteomics/*methods MH - Rats MH - Rats, Sprague-Dawley MH - Stress, Psychological/complications/*drug therapy MH - Tandem Mass Spectrometry OTO - NOTNLM OT - Angptl4 OT - Bushen huoxue formula OT - Np4 OT - Premature ovarian insufficiency OT - Proteomics OT - Psychological stress EDAT- 2020/04/21 06:00 MHDA- 2021/02/13 06:00 CRDT- 2020/04/21 06:00 PHST- 2020/01/08 00:00 [received] PHST- 2020/04/09 00:00 [revised] PHST- 2020/04/09 00:00 [accepted] PHST- 2020/04/21 06:00 [pubmed] PHST- 2021/02/13 06:00 [medline] PHST- 2020/04/21 06:00 [entrez] AID - S0378-8741(20)30106-9 [pii] AID - 10.1016/j.jep.2020.112870 [doi] PST - ppublish SO - J Ethnopharmacol. 2020 Aug 10;258:112870. doi: 10.1016/j.jep.2020.112870. Epub 2020 Apr 18. PMID- 35669720 OWN - NLM STAT- MEDLINE DCOM- 20220608 LR - 20240830 IS - 2314-6141 (Electronic) IS - 2314-6133 (Print) VI - 2022 DP - 2022 TI - Bushen Huoxue Formula Modulates Autophagic Flux and Inhibits Apoptosis to Protect Nucleus Pulposus Cells by Restoring the AMPK/SIRT1 Pathway. PG - 8929448 LID - 10.1155/2022/8929448 [doi] LID - 8929448 AB - BACKGROUND: Low back pain (LBP) has the characteristics of chronic and persistence, which is a heavy social burden. Intervertebral disc degeneration (IVDD) is a major cause of LBP. The typical features of IVDD are extracellular matrix (ECM) degradation and nucleus pulposus cell (NP) apoptosis. Bushen Huoxue Formula (BSHXF) has good clinical effects on LBP. However, the mechanism of BSHXF affecting ECM and NP cells is still unclear. Aim of the Study. In this study, the impact of BSHXF on autophagy and apoptosis of NP cells was studied through the AMPK/SIRT1 pathway. Material and Methods. NP cells were extracted through the digestion of collagenase and trypsin, and the components of BSHXF were identified. Cell Counting Kit-8 was applied to detect the impact of BSHXF on NP cells. Mitochondrial function was detected using MitoTracker assay, ATP kit, and SOD kit. Autophagy and apoptosis were detected by RT-qPCR, western blotting, and flow cytometry. RESULTS: BSHXF promoted NP cell survival in a concentration-dependent manner, and the elimination of rat serum did not increase cell proliferation; TNF-α accelerated ECM degradation, ROS accumulation, and NP cell apoptosis and decreased autophagic flux. BSHXF restored mitochondrial function and autophagic flux. In addition, AMPK/SIRT1 pathway activation was associated with IVDD. CONCLUSIONS: BSHXF regulates autophagy and enhances autophagic flux to suppress excessive ROS production and restore mitochondrial function in an AMPK/SIRT1-dependent manner. However, the protection of BSHXF on TNF-α-treated cells was eliminated by 3-MA. Furthermore, the protective impact of BSHXF on ECM degradation and apoptosis induced by TNF-α was restrained by an AMPK inhibitor. Therefore, maintaining the proper autophagy illustrates treatment strategy for IVDD. CI - Copyright © 2022 Shang Gao et al. FAU - Gao, Shang AU - Gao S AUID- ORCID: 0000-0002-8679-2162 AD - First Clinical Medical College of Shandong University of Traditional Chinese Medicine, Jinan, China. FAU - Li, Nianhu AU - Li N AUID- ORCID: 0000-0002-9260-8261 AD - Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China. FAU - Chen, Renchang AU - Chen R AD - First Clinical Medical College of Shandong University of Traditional Chinese Medicine, Jinan, China. FAU - Su, Youxiang AU - Su Y AD - First Clinical Medical College of Shandong University of Traditional Chinese Medicine, Jinan, China. FAU - Song, Yun AU - Song Y AD - First Clinical Medical College of Shandong University of Traditional Chinese Medicine, Jinan, China. FAU - Liang, Songlin AU - Liang S AD - First Clinical Medical College of Shandong University of Traditional Chinese Medicine, Jinan, China. LA - eng PT - Journal Article DEP - 20220527 PL - United States TA - Biomed Res Int JT - BioMed research international JID - 101600173 RN - 0 (Drugs, Chinese Herbal) RN - 0 (Reactive Oxygen Species) RN - 0 (Tumor Necrosis Factor-alpha) RN - 0 (bushen huoxue) RN - EC 2.7.11.31 (AMP-Activated Protein Kinases) RN - EC 3.5.1.- (Sirt1 protein, rat) RN - EC 3.5.1.- (Sirtuin 1) SB - IM MH - AMP-Activated Protein Kinases/metabolism MH - Animals MH - Apoptosis MH - Autophagy MH - Cells, Cultured MH - Drugs, Chinese Herbal MH - *Intervertebral Disc Degeneration/metabolism MH - *Nucleus Pulposus MH - Rats MH - Reactive Oxygen Species/metabolism MH - Sirtuin 1/metabolism MH - Tumor Necrosis Factor-alpha/metabolism PMC - PMC9167005 COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/06/08 06:00 MHDA- 2022/06/09 06:00 PMCR- 2022/05/27 CRDT- 2022/06/07 02:43 PHST- 2022/02/24 00:00 [received] PHST- 2022/04/27 00:00 [revised] PHST- 2022/05/05 00:00 [accepted] PHST- 2022/06/07 02:43 [entrez] PHST- 2022/06/08 06:00 [pubmed] PHST- 2022/06/09 06:00 [medline] PHST- 2022/05/27 00:00 [pmc-release] AID - 10.1155/2022/8929448 [doi] PST - epublish SO - Biomed Res Int. 2022 May 27;2022:8929448. doi: 10.1155/2022/8929448. eCollection 2022. PMID- 39494153 OWN - NLM STAT- MEDLINE DCOM- 20241104 LR - 20241105 IS - 1177-8881 (Electronic) IS - 1177-8881 (Linking) VI - 18 DP - 2024 TI - Bu Shen Huo Xue Formula Provides Neuroprotection Against Spinal Cord Injury by Inhibiting Oxidative Stress by Activating the Nrf2 Signaling Pathway. PG - 4779-4797 LID - 10.2147/DDDT.S487307 [doi] AB - PURPOSE: Spinal cord injury (SCI) is an irreversible neurological disease that can result in severe neurological dysfunction. The Bu Shen Huo Xue Formula (BSHXF) has been clinically shown to assist in the recovery of limb function in patients with SCI. However, the underlying mechanisms of BSHXF's therapeutic effects remain unclear. This study aimed to evaluate the effects of BSHXF in a mouse model of SCI and to identify potential therapeutic targets. METHODS: The composition of BSHXF was analyzed using high-performance liquid chromatography (HPLC). In vivo, SCI was induced in mice following established protocols, followed by administration of BSHXF. Motor function was assessed using the Basso-Beattie-Bresnahan (BBB) and footprint tests. Levels of superoxide dismutase (SOD) and malondialdehyde (MDA) were quantified with specific assay kits. Protein expression analysis was performed using Western blot and immunofluorescence. Additionally, reactive oxygen species (ROS) levels and apoptosis rates were evaluated with dedicated staining kits. In vitro, neurons were exposed to lipopolysaccharide (LPS) to investigate the effects of BSHXF on neuronal oxidative stress. The protective effects of BSHXF against LPS-induced neuronal injury were examined through RT-PCR, Western blot, and immunofluorescence. RESULTS: The eight primary bioactive constituents of BSHXF were identified using HPLC. BSHXF significantly reduced tissue damage and enhanced functional recovery following SCI. Meanwhile, BSHXF treatment led to significant reductions in oxidative stress and apoptosis rates. It also reversed neuronal loss and reduced glial scarring after SCI. LPS exposure induced neuronal apoptosis and axonal degeneration; however, after intervention with BSHXF, neuronal damage was reduced, and the protective effects of BSHXF were mediated by the activation of the Nrf2 pathway. CONCLUSION: BSHXF decreased tissue damage and enhanced functional recovery after SCI by protecting neurons against oxidative stress and apoptosis. The effects of BSHXF on SCI may be related to the activation of the Nrf2 pathway. CI - © 2024 Luo et al. FAU - Luo, Dan AU - Luo D AD - Research Laboratory of Spine Degenerative Disease, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China. AD - Spinal Minimally Invasive Department, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, People's Republic of China. AD - Laboratory of Osteology and Traumatology of Traditional Chinese Medicine, Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China. FAU - Hou, Yonghui AU - Hou Y AD - Research Laboratory of Spine Degenerative Disease, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China. AD - Spinal Minimally Invasive Department, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, People's Republic of China. AD - Laboratory of Osteology and Traumatology of Traditional Chinese Medicine, Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China. FAU - Zhan, Jiheng AU - Zhan J AD - Research Laboratory of Spine Degenerative Disease, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China. AD - Spinal Minimally Invasive Department, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, People's Republic of China. FAU - Hou, Yu AU - Hou Y AD - Research Laboratory of Spine Degenerative Disease, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China. AD - Spinal Minimally Invasive Department, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, People's Republic of China. AD - Laboratory of Osteology and Traumatology of Traditional Chinese Medicine, Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China. FAU - Wang, Zenglu AU - Wang Z AD - ICU Critical Care Medicine Department, Guangdong Second Provincial Traditional Chinese Medicine Hospital, Guangzhou, People's Republic of China. FAU - Li, Xing AU - Li X AD - Research Laboratory of Spine Degenerative Disease, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China. AD - Spinal Minimally Invasive Department, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, People's Republic of China. FAU - Sui, Lili AU - Sui L AD - The First College of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China. FAU - Chen, Shudong AU - Chen S AD - Research Laboratory of Spine Degenerative Disease, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China. AD - Spinal Minimally Invasive Department, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, People's Republic of China. FAU - Lin, Dingkun AU - Lin D AD - Research Laboratory of Spine Degenerative Disease, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China. AD - Spinal Minimally Invasive Department, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, People's Republic of China. LA - eng PT - Journal Article DEP - 20241025 PL - New Zealand TA - Drug Des Devel Ther JT - Drug design, development and therapy JID - 101475745 RN - 0 (Drugs, Chinese Herbal) RN - 0 (NF-E2-Related Factor 2) RN - 0 (Neuroprotective Agents) RN - 0 (Nfe2l2 protein, mouse) SB - IM MH - Animals MH - *Spinal Cord Injuries/drug therapy/metabolism/pathology MH - *Oxidative Stress/drug effects MH - *Drugs, Chinese Herbal/pharmacology/chemistry MH - Mice MH - *NF-E2-Related Factor 2/metabolism MH - *Signal Transduction/drug effects MH - *Neuroprotective Agents/pharmacology/chemistry MH - Male MH - Disease Models, Animal MH - Mice, Inbred C57BL MH - Apoptosis/drug effects MH - Dose-Response Relationship, Drug PMC - PMC11530378 OTO - NOTNLM OT - BSHXF OT - Bu Shen Huo Xue formula OT - Nrf2 signaling pathway OT - SCI OT - neuroprotection OT - oxidative stress OT - spinal cord injury COIS- The authors report no conflicts of interest in this work. EDAT- 2024/11/04 06:23 MHDA- 2024/11/04 12:23 PMCR- 2024/10/25 CRDT- 2024/11/04 05:15 PHST- 2024/07/17 00:00 [received] PHST- 2024/10/20 00:00 [accepted] PHST- 2024/11/04 12:23 [medline] PHST- 2024/11/04 06:23 [pubmed] PHST- 2024/11/04 05:15 [entrez] PHST- 2024/10/25 00:00 [pmc-release] AID - 487307 [pii] AID - 10.2147/DDDT.S487307 [doi] PST - epublish SO - Drug Des Devel Ther. 2024 Oct 25;18:4779-4797. doi: 10.2147/DDDT.S487307. eCollection 2024. PMID- 38363892 OWN - NLM STAT- MEDLINE DCOM- 20240219 LR - 20250503 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 103 IP - 7 DP - 2024 Feb 16 TI - A randomized controlled trial: The efficacy and safety of Bushen Huoxue formula in the management of lower back pain from lumbar disc herniation. PG - e37293 LID - 10.1097/MD.0000000000037293 [doi] LID - e37293 AB - BACKGROUND: Lower back pain (LBP) arising from lumbar disc herniation (LDH) poses a challenging health issue, often necessitating therapeutic interventions. Bushen Huoxue formula (BSHXF) has proved as a potential treatment option with great clinical effect. However, comprehensive investigations into its efficacy and safety in conjunction with celecoxib for managing LBP from LDH are lacking. The objective of this article is to investigate the efficacy and safety of BSHXF in the management of patients with LBP from LDH. METHODS: This single center, randomized clinical trial was conducted from March 2023 to September 2023 and all patients suffered from LBP of LDH. Participants were randomly assigned to the BSHXF group (celecoxib and BSHXF) or the control group (celecoxib and placebo). The patients received treatment for 2 weeks. Assessment was conducted before treatment, the last day of the treatment, 4 weeks and 8 weeks after the treatment. Oswestry Disability Index (ODI), Visual Analog Scale (VAS), Roland-Morris Disability Questionnaire (RMDQ), Timed up and go test (TUGT), trunk range of movement (Trunk ROM), Hospital Anxiety and Depression Scale (HADS) were used for the evaluation. RESULTS: A total of 206 subjects completed treatment, among whom 104 participants were randomized to the BSHXF group and 102 participants were randomized to the control group. There were no significant differences between groups in terms of the observed indicators (P > .05). After treatment, patients in BSHXF group obtained significant lower scores at 2-week, 4-week, 8-week of VAS, ODI, RMDQ, TUGT, Trunk ROM and HADS than the baseline data (P < .05). The ODI score was significantly lower than the control group at 2-week, 4-week, 8-week (2w: 11.30 ± 5.80 vs 14.23 ± 6.33, P < .001; 4w: 10.95 ± 4.93 vs 13.54 ± 6.35, P < .001; 8w: 10.27 ± 5.25 vs 12.84 ± 6.57, P = .002). Similarly, the scores of VAS, RMDQ, TUGT, Trunk ROM scores of the BSHXF group markedly decreased at 2, 4, and 8-week when compared to their control group (P < .05). Furthermore, no significant difference showed up in the score of HADS between the between the BSHXF and the control group after treatment (P > .05). CONCLUSION: This randomized clinical trial found that BSXHF can help significantly improve the clinical outcomes of celecoxib including pain intensity reduction and lumbar function improvement in LBP patients. CI - Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Yang, Shengqi AU - Yang S AD - Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China. AD - Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China. AD - Institute of Arthritis Research in Integrative Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China. FAU - Jia, Yongwei AU - Jia Y AD - Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China. AD - Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China. AD - Institute of Arthritis Research in Integrative Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China. AD - Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital, Shanghai, China. FAU - Zhang, Jianpo AU - Zhang J AD - Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China. AD - Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China. AD - Institute of Arthritis Research in Integrative Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China. FAU - Zhai, Weifeng AU - Zhai W AD - Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China. AD - Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China. AD - Institute of Arthritis Research in Integrative Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China. FAU - Xie, Yue AU - Xie Y AD - Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China. AD - Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China. AD - Institute of Arthritis Research in Integrative Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China. FAU - Guo, Ji AU - Guo J AUID- ORCID: 0000-0001-6060-4066 AD - Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China. AD - Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China. AD - Institute of Arthritis Research in Integrative Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China. LA - eng PT - Journal Article PT - Randomized Controlled Trial PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R RN - 0 (bushen huoxue) RN - JCX84Q7J1L (Celecoxib) RN - 0 (Drugs, Chinese Herbal) SB - IM MH - Humans MH - *Low Back Pain/drug therapy/etiology MH - *Intervertebral Disc Displacement/complications MH - Celecoxib/therapeutic use MH - Postural Balance MH - Treatment Outcome MH - Time and Motion Studies MH - Lumbar Vertebrae MH - *Drugs, Chinese Herbal PMC - PMC10869040 COIS- The authors have no conflicts of interest to disclose. EDAT- 2024/02/16 18:43 MHDA- 2024/02/19 06:42 PMCR- 2024/02/16 CRDT- 2024/02/16 14:13 PHST- 2024/02/19 06:42 [medline] PHST- 2024/02/16 18:43 [pubmed] PHST- 2024/02/16 14:13 [entrez] PHST- 2024/02/16 00:00 [pmc-release] AID - 00005792-202402160-00010 [pii] AID - 10.1097/MD.0000000000037293 [doi] PST - ppublish SO - Medicine (Baltimore). 2024 Feb 16;103(7):e37293. doi: 10.1097/MD.0000000000037293. PMID- 22952787 OWN - NLM STAT- MEDLINE DCOM- 20130219 LR - 20211021 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 7 IP - 8 DP - 2012 TI - HPLC-MS/MS analysis of a traditional Chinese medical formulation of Bu-Yang-Huan-Wu-Tang and its pharmacokinetics after oral administration to rats. PG - e43848 LID - 10.1371/journal.pone.0043848 [doi] LID - e43848 AB - Bu-yang-huan-wu-tang (BYHWT) is one of the most popular formulated traditional Chinese medicine prescriptions, and is widely for prevention of ischemic cardio-cerebral vascular diseases and stroke-induced disability. A specific high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) has been developed and validated for simultaneous quantification of the nine main bioactive components, i.e., astragaloside I, astragaloside II, astragaloside IV, formononetin, ononin, calycosin, calycosin-7-O-β-d-glucoside, ligustilide and paeoniflorin in rat plasma after oral administration of BYHWT extract. This method was applied to investigate the pharmacokinetics in conscious and freely moving rats. No significant matrix effects were observed. The overall analytical procedure was rapid and reproducible, which makes it suitable for quantitative analysis of a large number of samples. Among them, three astragalosides and four isoflavones in A. membranaceus, ligustilide in Radix Angelicae Sinensis and Rhizoma Ligustici Chuanxiong and paeoniflorin in Radix Paeoniae Rubra were identified. This developed method was then successfully applied to pharmacokinetic studies of the nine bioactive constituents after oral administration of BYHWT extracts in rats. The pharmacokinetic data demonstrated that astragaloside I, astragaloside II, astragaloside IV and ligustilide presented the phenomenon of double peaks. The other herbal ingredients of formononetin, ononin, calycosin, calycosin-7-O-β-d-glucoside and paeoniflorin appeared together in a single and plateau absorption phase. These phenomenona suggest that these components may have multiple absorption sites, regulation of enterohepatic circulation or the gastric emptying rate, or there is ingredient-ingredient interaction. These pharmacokinetic results provide a constructive contribution to better understand the absorption mechanism of BYHWT and to support additional clinical evaluation. FAU - Shaw, Lee-Hsin AU - Shaw LH AD - Institute of Traditional Medicine, National Yang-Ming University, Taipei, Taiwan. FAU - Lin, Lie-Chwen AU - Lin LC FAU - Tsai, Tung-Hu AU - Tsai TH LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20120829 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Drugs, Chinese Herbal) RN - 0 (buyang huanwu) SB - IM MH - Absorption MH - Administration, Oral MH - Animals MH - Chemistry, Pharmaceutical MH - Chromatography, High Pressure Liquid/*methods MH - Drug Prescriptions MH - Drug Stability MH - Drugs, Chinese Herbal/administration & dosage/*analysis/isolation & purification/*pharmacokinetics MH - Limit of Detection MH - Male MH - Rats MH - Rats, Sprague-Dawley MH - Tandem Mass Spectrometry/*methods PMC - PMC3430621 COIS- Competing Interests: The authors have declared that no competing interests exist. EDAT- 2012/09/07 06:00 MHDA- 2013/02/21 06:00 PMCR- 2012/08/29 CRDT- 2012/09/07 06:00 PHST- 2012/05/22 00:00 [received] PHST- 2012/07/26 00:00 [accepted] PHST- 2012/09/07 06:00 [entrez] PHST- 2012/09/07 06:00 [pubmed] PHST- 2013/02/21 06:00 [medline] PHST- 2012/08/29 00:00 [pmc-release] AID - PONE-D-12-14766 [pii] AID - 10.1371/journal.pone.0043848 [doi] PST - ppublish SO - PLoS One. 2012;7(8):e43848. doi: 10.1371/journal.pone.0043848. Epub 2012 Aug 29. PMID- 29545848 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240316 IS - 1792-0981 (Print) IS - 1792-1015 (Electronic) IS - 1792-0981 (Linking) VI - 15 IP - 4 DP - 2018 Apr TI - Protective function of Bu Shen Huo Xue formula on the immunity of B6AF1 mice with experimental autoimmune premature ovarian failure. PG - 3302-3310 LID - 10.3892/etm.2018.5804 [doi] AB - Autoimmune abnormality is one of the main causes of premature ovarian failure (POF). Bu Shen Huo Xue formula (BSHXF), a traditional Chinese medicine formula, has been clinically used for the treatment of patients with POF in China. Regulatory T cells (Tregs) are important in the pathogenesis of autoimmune POF. The aim of the present study was to evaluate the immunoprotective effects of BSHXF on POF and the underlying mechanisms. An experimental autoimmune POF model was induced in B6AF1 mice with zona pellucida 3 (ZP3) fragments. Following modeling, BSHXF (31.53 g/kg/day) was orally administered for 4 weeks. CD4(+) T lymphocytes, Tregs, anti-zona pellucida (anti-ZP) antibodies and cytokines were detected using flow cytometry, enzyme-linked immunosorbent assays, reverse transcription-quantitative polymerase chain reaction and immunohistochemistry. The results revealed that BSHXF exhibited an immunoprotective function and reduced inflammatory cell infiltration and damage to the ovary. BSHXF upregulated the percentage of CD4(+) CD25(+) forkhead box P3(+) T cells in the spleen, effectively inhibiting the activation of CD4(+) T lymphocytes. The proliferation of Tregs was increased in serum obtained from mice in the BSHXF group in vitro. Anti-ZP antibodies and interleukin-10 and interferon-γ levels were decreased in the serum in the BSHXF-treated group. The present study demonstrated that BSHXF had an immunoprotective effect on POF model mice. Additionally, it indicated that the protective mechanisms of BSHXF may be associated with an increase in Treg cells. FAU - Wang, Peijuan AU - Wang P AD - Department of Obstetrics and Gynecology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210028, P.R. China. AD - Department of Obstetrics and Gynecology, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, Jiangsu 210028, P.R. China. FAU - Lu, Yan AU - Lu Y AD - Department of Obstetrics and Gynecology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210028, P.R. China. AD - Department of Obstetrics and Gynecology, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, Jiangsu 210028, P.R. China. FAU - Chen, Si AU - Chen S AD - Department of Obstetrics and Gynecology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210028, P.R. China. AD - Department of Obstetrics and Gynecology, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, Jiangsu 210028, P.R. China. FAU - Chen, Yue AU - Chen Y AD - Department of Obstetrics and Gynecology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210028, P.R. China. AD - Department of Obstetrics and Gynecology, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, Jiangsu 210028, P.R. China. FAU - Hu, Chunping AU - Hu C AD - Department of Obstetrics and Gynecology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210028, P.R. China. AD - Department of Obstetrics and Gynecology, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, Jiangsu 210028, P.R. China. FAU - Zuo, Yawei AU - Zuo Y AD - Infirmary, 8724 Forces Health Teams, Wuxi, Jiangsu 214000, P.R. China. LA - eng PT - Journal Article DEP - 20180129 PL - Greece TA - Exp Ther Med JT - Experimental and therapeutic medicine JID - 101531947 PMC - PMC5840928 OTO - NOTNLM OT - Bu Shen Huo Xue formula OT - CD4+ T lymphocyte OT - experimental autoimmune premature ovarian failure OT - protective immunity effect OT - regulatory T cells EDAT- 2018/03/17 06:00 MHDA- 2018/03/17 06:01 PMCR- 2018/01/29 CRDT- 2018/03/17 06:00 PHST- 2016/09/14 00:00 [received] PHST- 2017/07/27 00:00 [accepted] PHST- 2018/03/17 06:00 [entrez] PHST- 2018/03/17 06:00 [pubmed] PHST- 2018/03/17 06:01 [medline] PHST- 2018/01/29 00:00 [pmc-release] AID - ETM-0-0-5804 [pii] AID - 10.3892/etm.2018.5804 [doi] PST - ppublish SO - Exp Ther Med. 2018 Apr;15(4):3302-3310. doi: 10.3892/etm.2018.5804. Epub 2018 Jan 29. PMID- 16107035 OWN - NLM STAT- MEDLINE DCOM- 20060224 LR - 20061115 IS - 1001-4454 (Print) IS - 1001-4454 (Linking) VI - 28 IP - 3 DP - 2005 Mar TI - [The effect of Bu Yang Huan Wu soup and Tong Mai soup on D-Di, PLC and Pagt of traumatic fracture]. PG - 251-4 AB - OBJECTIVE: To research the effect of Bu Yang Huan Wu Soup (BYHWS) and Tong Mai Soup (TMS) within varieties on D-Di, PLC, Pagt of traumatic fracture. METHOD: 48 cases are choosen, those are femoral-fractured, age between 18 to 45-year-old and in level I - II of ASA. The cases were randomly arranged into 3 groups, 16 cases are in each group. Group I is the controlled one, it isn't used any medicine which affects cruor. Group II is used BYHWS. Group III is used TMS. Group II and III are used medicine for 7 days from the first day in hospital. All patients in 3 groups are checked D-Di, PLC, Pagt in blood in the first day and the seventh day,and their results are compared with the healthy adult's. RESULTS: (1) Comparing the D-Di of all 3 groups with the healthy adult's on the second day, P <0.01. The D-Di value of group I and group III grows up in 7 days, group I's is higher than group III's, but both of them P > 0.01. Value of group II is decreased in 7 days, P < 0.05. (2)PLC of all 3 groups is compared with healthy adult's, P > 0.01. On the seventh day, PLC of group I and group III increase obviously, P < 0.01. Group II's increases to P <0.05. (3) Pagt of 1st day of 3 groups is compared with the healthy adult's, P <0.05. On the 7th day, Pagt increases,in group I P < 0.01, in group II P < 0. 05. in group III P > 0.01. CONCLUSION: Pagt rises after traumatic fracture, the blood is in high-agglomerate situation. Chinese traditional medicine BYHWS and TMS can decrease the blood platelet assemble after trauma a certain extent. FAU - Wu, Zhengjie AU - Wu Z AD - Foshan Hospital of TCM, Guangdong Foshan. FAU - Ou, Jinyan AU - Ou J FAU - Luo, Furong AU - Luo F FAU - Liao, Rongzong AU - Liao R FAU - Zhou, Shu AU - Zhou S LA - chi PT - English Abstract PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PL - China TA - Zhong Yao Cai JT - Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials JID - 9426370 RN - 0 (Drugs, Chinese Herbal) RN - 0 (Fibrin Fibrinogen Degradation Products) RN - 0 (Platelet Aggregation Inhibitors) SB - IM MH - Adolescent MH - Adult MH - Drug Therapy, Combination MH - Drugs, Chinese Herbal/isolation & purification/*therapeutic use MH - Female MH - Femoral Fractures/*drug therapy/metabolism MH - Fibrin Fibrinogen Degradation Products/metabolism MH - Humans MH - Male MH - Middle Aged MH - *Phytotherapy MH - Plants, Medicinal/*chemistry MH - Platelet Aggregation/*drug effects MH - Platelet Aggregation Inhibitors/*therapeutic use MH - Platelet Count MH - Time Factors EDAT- 2005/08/19 09:00 MHDA- 2006/02/25 09:00 CRDT- 2005/08/19 09:00 PHST- 2005/08/19 09:00 [pubmed] PHST- 2006/02/25 09:00 [medline] PHST- 2005/08/19 09:00 [entrez] PST - ppublish SO - Zhong Yao Cai. 2005 Mar;28(3):251-4. PMID- 38814209 OWN - NLM STAT- MEDLINE DCOM- 20240530 LR - 20240606 IS - 1165-158X (Electronic) IS - 0145-5680 (Linking) VI - 70 IP - 5 DP - 2024 May 27 TI - Network pharmacology and transcriptomics analysis reveal the mechanism of BushenHuoxue formula attenuates premature ovarian failure via modulation PI3K/AKT pathway. PG - 226-232 LID - 10.14715/cmb/2024.70.5.33 [doi] AB - This study aims to analyze the active components and mechanism of Bushen Huoxue (BSHX) formula on the autoimmune premature ovarian insufficiency (POI) by combining network pharmacology and Transcriptomics. The active components and targets of BSHXF were screened through Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP). POI-related targets were identified through Therapeutic Targets Database (TTD), DisGeNET and drugbank database. The Veen diagram was performed to obtain the action targets. The active compound-target network and Protein-Protein Interaction (PPI) network were built by using STRING database and Cytoscape software. Key targets and active compounds were further identified by topological analysis. Molecular docking shows that Kaempferol, Isorhamnetin and Anhydroicaritin have strong binding to AKT. Finally, a zp3-induced autoimmune ovarian function deficiency mouse model was used to explore the potential mechanism of POI. The potential pathways of BSHXF for the treatment of POI were identified by Transcriptomic analysis. PI3K-AKT and NF-kb pathways were the common pathways between network pharmacology and transcriptomics. Our results revealed that BSHXF could reduce the FSH expression levels and raise the E2, and AMH levels in the serum. Western bloting demonstrates that BSHXF could upregulate the expression of p-PI3K and p-AKT. FAU - Zhao, Weibo AU - Zhao W AD - Third Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing 210028, China. zweibo025@126.com. FAU - Chen, Yue AU - Chen Y AD - Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, China. 595236995@qq.com. FAU - He, Jianing AU - He J AD - Third Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing 210028, China. 834014635@qq.com. FAU - Chen, Si AU - Chen S AD - Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, China. chensi8828@163.com. FAU - Shen, Jiayun AU - Shen J AD - Third Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing 210028, China. sjybio@163.com. FAU - Jiao, Beibei AU - Jiao B AD - Third Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing 210028, China. 47082000@qq.com. FAU - Li, Tian AU - Li T AD - Laboratory of Central, Nanjing Lishui District Hospital of Traditional Chinese Medicine, Nanjing 211200, China. littian26@163.com. FAU - Su, Mengqing AU - Su M AD - Third Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing 210028, China. 737298362@qq.com. FAU - Mao, Tianjiao AU - Mao T AD - Third Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing 210028, China. miaomyay@163.com. FAU - Wang, Peijuan AU - Wang P AD - Third Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing 210028, China. pjwang2021@126.com. LA - eng PT - Journal Article DEP - 20240527 PL - France TA - Cell Mol Biol (Noisy-le-grand) JT - Cellular and molecular biology (Noisy-le-Grand, France) JID - 9216789 RN - 0 (Drugs, Chinese Herbal) RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) RN - EC 2.7.1.- (Phosphatidylinositol 3-Kinases) RN - 0 (bushen huoxue) SB - IM MH - *Primary Ovarian Insufficiency/drug therapy/genetics/metabolism MH - Female MH - *Drugs, Chinese Herbal/pharmacology/chemistry/therapeutic use MH - *Proto-Oncogene Proteins c-akt/metabolism MH - Animals MH - *Phosphatidylinositol 3-Kinases/metabolism MH - *Network Pharmacology MH - *Signal Transduction/drug effects MH - *Protein Interaction Maps/drug effects MH - *Molecular Docking Simulation MH - Mice MH - Gene Expression Profiling MH - Transcriptome/drug effects/genetics MH - Disease Models, Animal MH - Humans EDAT- 2024/05/30 12:42 MHDA- 2024/05/30 12:43 CRDT- 2024/05/30 10:18 PHST- 2024/01/29 00:00 [received] PHST- 2024/05/30 12:43 [medline] PHST- 2024/05/30 12:42 [pubmed] PHST- 2024/05/30 10:18 [entrez] AID - 10.14715/cmb/2024.70.5.33 [doi] PST - epublish SO - Cell Mol Biol (Noisy-le-grand). 2024 May 27;70(5):226-232. doi: 10.14715/cmb/2024.70.5.33. PMID- 35840851 OWN - NLM STAT- MEDLINE DCOM- 20221026 LR - 20221026 IS - 1993-0402 (Electronic) IS - 1672-0415 (Linking) VI - 28 IP - 11 DP - 2022 Nov TI - Efficacy and Safety of Bushen Huoxue Formula in Patients with Discogenic Low-Back Pain: A Double-Blind, Randomized, Placebo-Controlled Trial. PG - 963-970 LID - 10.1007/s11655-022-3505-4 [doi] AB - OBJECTIVE: To assess the efficacy and safety of Bushen Huoxue Formula (BSHXF) for the treatment of discogenic low-back pain (DLBP). METHODS: This was a parallel, double-blind, randomized, clinical trial performed between May 2019 and June 2020. Seventy patients were assigned by computerized random number table to the treatment group (lumbar traction and BSHXF, 35 cases) or the control group (lumbar traction and placebo, 35 cases). The patients received intervention for 3 weeks. Assessment was conducted before treatment and at week 1, 2, 3 during treatment. Primary outcome was the self-reported score of Oswestry Disability Index (ODI). Secondary outcomes included Visual Analog Scale (VAS), clinical efficacy rate by minimal clinically important difference (MCID) as well as lumbar tenderness, muscle tone and lumbar spine mobility. Adverse reactions were recorded. Follow-up was performed at 1 and 3 months after the end of treatment. RESULTS: In the treatment group, ODI score was significantly decreased compared with baseline (P<0.05) and the control group at 2- and 3- week treatment. Similarly, VAS score decreased compared with the baseline (P<0.05) and was lower than that in the control group at 2- and 3- week treatment (P<0.05). The clinical efficacy rate of the treatment group was higher than that of the control group after treatment [32.35% (11/34) vs. 3.13% (1/32), P<0.05). Moreover, the tenderness, and muscle tone, as well as the back extension and left flexion in lumbar spine mobility in the treatment group at 3-week treatment were significantly improved compared with the control group (P<0.05). Follow-up showed that at 1-month after treatment, the treatment group had better outcomes than the control group with regard to a total score of ODI and VAS scores, as well as clinical efficacy rate (all P<0.05). Moreover, VAS score was still significantly lower than the control group at 3-month follow-up (P<0.05). No adverse reactions were reported during the study. CONCLUSION: BSXHF combined with lumbar traction can significantly improve the clinical symptoms including pain intensity, functionality, muscle tone, and lumbar spine mobility in DLBP patients. (Registration No. ChiCTR1900027777). CI - © 2022. The Chinese Journal of Integrated Traditional and Western Medicine Press and Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Zhan, Jia-Wen AU - Zhan JW AD - General Orthopedics Department, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, 100102, China. AD - Key Laboratory of Beijing of Traditional Chinese Medicine Bone Setting, Beijing, 100102, China. FAU - Li, Kai-Ming AU - Li KM AD - Orthopedics Department, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China. FAU - Zhu, Li-Guo AU - Zhu LG AD - Key Laboratory of Beijing of Traditional Chinese Medicine Bone Setting, Beijing, 100102, China. 532414151@qq.com. AD - The Second Department of Spine, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, 100102, China. 532414151@qq.com. FAU - Wang, Shang-Quan AU - Wang SQ AD - General Orthopedics Department, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, 100102, China. FAU - Feng, Min-Shan AU - Feng MS AD - Key Laboratory of Beijing of Traditional Chinese Medicine Bone Setting, Beijing, 100102, China. AD - The Second Department of Spine, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, 100102, China. FAU - Wei, Xu AU - Wei X AD - Key Laboratory of Beijing of Traditional Chinese Medicine Bone Setting, Beijing, 100102, China. FAU - Yu, Jie AU - Yu J AD - The Second Department of Spine, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, 100102, China. FAU - Tang, Bin AU - Tang B AD - The Second Department of Spine, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, 100102, China. FAU - Yin, Xun-Lu AU - Yin XL AD - Key Laboratory of Beijing of Traditional Chinese Medicine Bone Setting, Beijing, 100102, China. AD - The Second Department of Spine, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, 100102, China. FAU - Han, Tao AU - Han T AD - General Orthopedics Department, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, 100102, China. AD - Key Laboratory of Beijing of Traditional Chinese Medicine Bone Setting, Beijing, 100102, China. FAU - Zhang, Ping AU - Zhang P AD - Key Laboratory of Beijing of Traditional Chinese Medicine Bone Setting, Beijing, 100102, China. FAU - Li, Ling-Hui AU - Li LH AD - General Orthopedics Department, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, 100102, China. FAU - Chen, Ming AU - Chen M AD - General Orthopedics Department, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, 100102, China. FAU - Shao, Chen-Chen AU - Shao CC AD - General Orthopedics Department, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, 100102, China. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20220715 PL - China TA - Chin J Integr Med JT - Chinese journal of integrative medicine JID - 101181180 RN - 0 (bushen huoxue) SB - IM MH - Humans MH - *Intervertebral Disc Degeneration/therapy MH - *Low Back Pain/drug therapy MH - Lumbar Vertebrae MH - Pain Measurement MH - Treatment Outcome OTO - NOTNLM OT - Bushen Huoxue Formula OT - discogenic low-back pain OT - intervertebral disc degeneration OT - randomized controlled trial EDAT- 2022/07/16 06:00 MHDA- 2022/10/27 06:00 CRDT- 2022/07/15 23:35 PHST- 2021/07/11 00:00 [accepted] PHST- 2022/07/16 06:00 [pubmed] PHST- 2022/10/27 06:00 [medline] PHST- 2022/07/15 23:35 [entrez] AID - 10.1007/s11655-022-3505-4 [pii] AID - 10.1007/s11655-022-3505-4 [doi] PST - ppublish SO - Chin J Integr Med. 2022 Nov;28(11):963-970. doi: 10.1007/s11655-022-3505-4. Epub 2022 Jul 15. PMID- 41477980 OWN - NLM STAT- MEDLINE DCOM- 20260117 LR - 20260117 IS - 1618-095X (Electronic) IS - 0944-7113 (Linking) VI - 150 DP - 2026 Jan TI - Bushen Huoxue Formula alleviates lipid accumulation in premature ovarian insufficiency by activating the LRP6/β-catenin signaling pathway. PG - 157726 LID - S0944-7113(25)01360-1 [pii] LID - 10.1016/j.phymed.2025.157726 [doi] AB - BACKGROUND: Bushen Huoxue Formula (BSHXF), a traditional Chinese medicine, effectively treats premature ovarian insufficiency (POI) by modulating of lipid metabolism. PURPOSE: This study aimed to investigate the underlying mechanism through which BSHXF improves POI by regulating lipid metabolism. METHODS: Network pharmacology identified potential pathways associated with BSHXF in POI. A POI rat model was induced using subcutaneous corticosterone injections and treated with BSHXF to assess its efficacy. The impact of BSHXF on lipid metabolism, autophagy, and the LRP6/β-catenin signaling pathway was evaluated in these rats. Additionally, palmitic acid (PA)-induced granulosa cells (KGN cells) were used in vitro. A LRP6 inhibitor (Salinomycin sodium salt, Sal) was applied to these cells, followed by a series of molecular biology experiments to elucidate the specific regulatory role of BSHXF on lipid metabolism. RESULTS: Network pharmacology analysis indicated that the Wnt/β-catenin signaling pathway is a potential target of BSHXF in POI. In vivo, BSHXF alleviated POI-like symptoms in rats, reduced lipid accumulation, suppressed excessive autophagy, and activated the LRP6/β-catenin signaling pathway. In vitro, Sal inhibited the ability of BSHXF-containing serum to activate LRP6/β-catenin signaling, reduce lipid accumulation, and counteract excessive autophagy in PA-induced KGN cells. This was accompanied by increased expression of LRP6 and β-catenin, enhanced lipogenesis, elevated lipid droplet formation, decreased lipid catabolism, and oxidation, and enhanced autophagic flux. Cycloheximide chase and Western blot analyses further confirmed that BSHXF stabilizes LRP6 by inhibiting its ubiquitin-proteasomal degradation. CONCLUSIONS: BSHXF activates LRP6/β-catenin signaling pathway by inhibiting the ubiquitination degradation of LRP6, thereby improving POI. This study reveals that BSHXF may improve POI by modulating LRP6 stability, thereby affecting lipid metabolism. CI - Copyright © 2025. Published by Elsevier GmbH. FAU - Hao, Rui AU - Hao R AD - Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China. FAU - Li, Tian AU - Li T AD - Nanjing Lishui District Hospital of Traditional Chinese Medicine, Nanjing, China; Clinical College of Traditional Chinese Medicine Hospital in Lishui, Jiangsu Health Vocational College, Nanjing, China. FAU - Zhou, Beibei AU - Zhou B AD - Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China. FAU - Shao, Jiaxin AU - Shao J AD - Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China. FAU - Zhao, Weibo AU - Zhao W AD - Department of Gynecology, Wuxi Affiliated Hospital of Nanjing University of Chinese Medicine, Wuxi, China. FAU - Jiao, Beibei AU - Jiao B AD - Tonglu Hospital of Traditional Chinese Medicine, Tonglu, China. Electronic address: hljb_2004@126.com. FAU - Sun, Xia AU - Sun X AD - Nanjing Lishui District Hospital of Traditional Chinese Medicine, Nanjing, China; Clinical College of Traditional Chinese Medicine Hospital in Lishui, Jiangsu Health Vocational College, Nanjing, China. Electronic address: 2898737@qq.com. FAU - Zhang, Jian AU - Zhang J AD - Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China. Electronic address: zhangjian@jsatcm.com. LA - eng PT - Journal Article DEP - 20251224 PL - Germany TA - Phytomedicine JT - Phytomedicine : international journal of phytotherapy and phytopharmacology JID - 9438794 RN - 0 (Drugs, Chinese Herbal) RN - 0 (Low Density Lipoprotein Receptor-Related Protein-6) RN - 0 (beta Catenin) SB - IM MH - Animals MH - Female MH - *Drugs, Chinese Herbal/pharmacology MH - *Low Density Lipoprotein Receptor-Related Protein-6/metabolism MH - *Lipid Metabolism/drug effects MH - *beta Catenin/metabolism MH - *Primary Ovarian Insufficiency/drug therapy/metabolism MH - Rats, Sprague-Dawley MH - Rats MH - Autophagy/drug effects MH - Wnt Signaling Pathway/drug effects MH - Granulosa Cells/drug effects/metabolism MH - Signal Transduction/drug effects MH - Humans MH - Disease Models, Animal MH - Network Pharmacology OTO - NOTNLM OT - Autophagy OT - Bushen Huoxue Formula OT - Lipid accumulation OT - Low density of lipoprotein receptor-related protein 6 OT - Premature ovarian insufficiency COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/01/02 00:33 MHDA- 2026/01/17 06:32 CRDT- 2026/01/01 18:05 PHST- 2025/08/19 00:00 [received] PHST- 2025/12/10 00:00 [revised] PHST- 2025/12/18 00:00 [accepted] PHST- 2026/01/17 06:32 [medline] PHST- 2026/01/02 00:33 [pubmed] PHST- 2026/01/01 18:05 [entrez] AID - S0944-7113(25)01360-1 [pii] AID - 10.1016/j.phymed.2025.157726 [doi] PST - ppublish SO - Phytomedicine. 2026 Jan;150:157726. doi: 10.1016/j.phymed.2025.157726. Epub 2025 Dec 24. PMID- 41218795 OWN - NLM STAT- Publisher LR - 20251111 IS - 1557-8577 (Electronic) IS - 1549-1684 (Linking) DP - 2025 Nov 10 TI - Bushenhuoxue Formula Protects Against Lumbar Facet Joint Osteoarthritis via Acting on TDP-43-Mediated Pyroptosis to Loose Caspase-11/NLRP3 Interaction. LID - 10.1177/15491684251382419 [doi] AB - Background: Facet joint osteoarthritis (FJOA) is a serious facet joint cartilage degeneration disorder, which is an important cause of low back pain and disability. Bushenhuoxue formula (BSHXF), a traditional Chinese herbal compound, has been demonstrated to exhibit the ability to improve osteoarthritis. This study aimed to uncover the therapeutic effect and potential mechanism of BSHXF in FJOA. Methods: FJOA rats were treated with BSHXF. Histological staining, immunohistochemistry, TUNEL staining, and flow cytometry were performed for detecting pathological damage, molecule expressions in articular cartilage, chondrocyte apoptosis, and pyroptosis, respectively. Interleukin (IL)-18 and IL-1β levels were quantified with enzyme-linked immunosorbent assay. RT-qPCR and Western blot were carried out for evaluating mRNA and protein expressions. Immunofluorescence and coimmunoprecipitation were used to study the colocalization and interaction between Caspase-11 and Nod-like receptor protein-3 (NLRP3) in chondrocytes. Results: In FJOA rats, BSHXF attenuated articular cartilage pathological damage. Specifically, BSHXF inhibited matrix degradation, as indicated by increasing collagen II and decreasing matrix metalloproteinase 13. BSHXF inhibited articular chondrocyte apoptosis and promoted chondrocyte proliferation. BSHXF decreased Caspase-1 and NLRP3, reduced the rate of Caspase-1/propidium iodide-stained chondrocytes, and inhibited inflammatory cytokines, indicating the attenuated articular chondrocyte pyroptosis. BSHXF downregulated Caspase-11, loosened the interaction between NLRP3 and Caspase-11, as well as upregulated transactive response DNA-binding protein 43 (TDP-43) in FJOA rats. Additionally, in H(2)O(2)-exposed chondrocytes, TDP-43 overexpression decreased TLR4, p-IκBα, NF-κB P65, and Caspase-11 and declined the co-localization of Caspase-11 and NLRP3. Importantly, TDP-43 knockdown reversed BSHXF-mediated protective effects in FJOA rats. Conclusion: BSHXF inhibited chondrocyte pyroptosis by increasing TDP-43 to protect against FJOA via loosening the interaction of Caspase-11 and NLRP3, which may provide a fundamental basis for treating FJOA cartilage damage. [Figure: see text]. FAU - Zhou, Biao AU - Zhou B AD - Department of Orthopedics, Wangjing Hospital of Chinese Academy of Chinese Medical Science, Beijing, P.R. China. AD - Department of Orthopedics, Xiangtan Hospital Affiliated to Nanhua University, Xiangtan, P.R. China. FAU - Wei, Xu AU - Wei X AD - Department of Orthopedics, Wangjing Hospital of Chinese Academy of Chinese Medical Science, Beijing, P.R. China. FAU - Lu, Xiaolong AU - Lu X AD - Department of Orthopedics, The First Hospital of Hunan University of Chinese Medicine, Changsha, P.R. China. FAU - Luo, Zhiqiang AU - Luo Z AD - Department of Orthopedics, The First Hospital of Hunan University of Chinese Medicine, Changsha, P.R. China. FAU - Zhou, Can AU - Zhou C AD - Department of Orthopedics, Xiangtan Hospital Affiliated to Nanhua University, Xiangtan, P.R. China. FAU - Yu, Jie AU - Yu J AD - Department of Orthopedics, Wangjing Hospital of Chinese Academy of Chinese Medical Science, Beijing, P.R. China. FAU - Sun, Kai AU - Sun K AD - Department of Orthopedics, Wangjing Hospital of Chinese Academy of Chinese Medical Science, Beijing, P.R. China. FAU - Zhu, Liguo AU - Zhu L AD - Department of Orthopedics, Wangjing Hospital of Chinese Academy of Chinese Medical Science, Beijing, P.R. China. LA - eng PT - Journal Article DEP - 20251110 PL - United States TA - Rejuvenation Res JT - Rejuvenation research JID - 101213381 SB - IM OTO - NOTNLM OT - Bushenhuoxue formula OT - Caspase-11 OT - NLRP3 OT - TDP-43 OT - facet joint osteoarthritis OT - pyroptosis EDAT- 2025/11/12 00:26 MHDA- 2025/11/12 00:26 CRDT- 2025/11/11 19:24 PHST- 2025/11/12 00:26 [medline] PHST- 2025/11/12 00:26 [pubmed] PHST- 2025/11/11 19:24 [entrez] AID - 10.1177/15491684251382419 [doi] PST - aheadofprint SO - Rejuvenation Res. 2025 Nov 10. doi: 10.1177/15491684251382419. PMID- 21179787 OWN - NLM STAT- MEDLINE DCOM- 20121203 LR - 20220408 IS - 1000-6834 (Print) IS - 1000-6834 (Linking) VI - 18 IP - 2 DP - 2002 May TI - [Study of the effects of Bu Yang Huan Wu Tang on SOD and MDA brain tissue in cerebral ischemia and reperfusion of rats]. PG - 108, 131 FAU - Guo, Ping AU - Guo P FAU - Wang, Jing AU - Wang J FAU - Wang, Hao AU - Wang H LA - chi PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PL - China TA - Zhongguo Ying Yong Sheng Li Xue Za Zhi JT - Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology JID - 9426407 RN - 0 (Drugs, Chinese Herbal) RN - 0 (buyang huanwu) RN - 4Y8F71G49Q (Malondialdehyde) RN - EC 1.15.1.1 (Superoxide Dismutase) SB - IM MH - Animals MH - Brain/drug effects/*metabolism MH - Brain Ischemia/drug therapy/*metabolism MH - Drugs, Chinese Herbal/*pharmacology/therapeutic use MH - Male MH - Malondialdehyde/metabolism MH - Phytotherapy MH - Rats MH - Rats, Wistar MH - Reperfusion Injury/drug therapy/*metabolism MH - Superoxide Dismutase/metabolism EDAT- 2002/05/01 00:00 MHDA- 2012/12/10 06:00 CRDT- 2010/12/25 06:00 PHST- 2010/12/25 06:00 [entrez] PHST- 2002/05/01 00:00 [pubmed] PHST- 2012/12/10 06:00 [medline] PST - ppublish SO - Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2002 May;18(2):108, 131. PMID- 24036516 OWN - NLM STAT- MEDLINE DCOM- 20140321 LR - 20211021 IS - 1420-3049 (Electronic) IS - 1420-3049 (Linking) VI - 18 IP - 9 DP - 2013 Sep 12 TI - Identification of multiple ingredients for a Traditional Chinese Medicine preparation (bu-yang-huan-wu-tang) by liquid chromatography coupled with tandem mass spectrometry. PG - 11281-98 LID - 10.3390/molecules180911281 [doi] AB - Bu-yang-huan-wu-tang (BYHWT) is a popular Traditional Chinese Medicine formula consisting of seven herbal medicines (Astragalus membranaceus, Angelica sinensis, Paeonia lactiflora, Ligusticum chuanxiong, Carthamus tinctorius, Amygdalus persica and Pheretima aspergillum), that has been used in China for centuries to overcome stroke-induced disability. To ensure the consistency of quality, a reliable analytical method is required, therefore, we developed a liquid chromatography with tandem mass spectrometry (LC-MS/MS) method for quantitative analysis of the major constituents in BYHWT. The herbal ingredients consisting of the cycloartane-type triterpene glycosides of astragaloside I, astragaloside II and astragaloside IV; isoflavones of formononetin, ononin calycosin, calycosin-7-O-β-d-glucoside; ligustilide and paeoniflorin were separated on a C18 column with gradient elution of methanol/10 mM ammonium acetate buffer-formic acid (100:0.1, v/v). This study was performed by a mass spectrometer using electrospray ionization (ESI) with positive ionization ions monitored in the multiple reaction-monitoring (MRM) mode. The linearity, accuracy, precision, limit of detection (LOD) and lower limit of quantification (LLOQ) were validated for this quantification method, and the sensitivity, reliability and reproducibility were all confirmed. The experiments provided a good method for analyzing BYHWT extracts. This study also quantitated the active components in various brands of commercially available products. The results indicated that the pharmaceutical industrial products of BYHWT exhibited considerable variation in their contents of the herbal compounds. FAU - Shaw, Lee-Hsin AU - Shaw LH AD - Institute of Traditional Medicine, National Yang-Ming University, Taipei 112, Taiwan. lychee0130@hotmail.com FAU - Chen, Wei-Ming AU - Chen WM FAU - Tsai, Tung-Hu AU - Tsai TH LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20130912 PL - Switzerland TA - Molecules JT - Molecules (Basel, Switzerland) JID - 100964009 RN - 0 (Benzoates) RN - 0 (Bridged-Ring Compounds) RN - 0 (Drugs, Chinese Herbal) RN - 0 (Glucosides) RN - 0 (Isoflavones) RN - 0 (Monoterpenes) RN - 0 (Saponins) RN - 0 (Triterpenes) RN - 0 (astragaloside II) RN - 0 (bu-yang-huan-wu-tang) RN - 0 (calycosin-7-O-beta-D-glucoside) RN - 09N3E8P7TA (7,3'-dihydroxy-4'-methoxyisoflavone) RN - 21AIQ4EV64 (peoniflorin) RN - 295DQC67BJ (formononetin) RN - 3A592W8XKE (astragaloside A) RN - 4431-01-0 (ligustilide) RN - 73K4184T59 (Digoxin) RN - OL659KIY4X (4-Butyrolactone) SB - IM MH - 4-Butyrolactone/analogs & derivatives/chemistry/isolation & purification MH - Benzoates/chemistry/isolation & purification MH - Bridged-Ring Compounds/chemistry/isolation & purification MH - Chromatography, High Pressure Liquid MH - Digoxin/chemistry/isolation & purification MH - Drugs, Chinese Herbal MH - Glucosides/chemistry/isolation & purification MH - Humans MH - Isoflavones/chemistry/isolation & purification MH - Limit of Detection MH - *Medicine, Chinese Traditional MH - Monoterpenes MH - Reproducibility of Results MH - Saponins/chemistry/isolation & purification MH - Spectrometry, Mass, Electrospray Ionization MH - Tandem Mass Spectrometry MH - Triterpenes/*chemistry/isolation & purification PMC - PMC6269995 EDAT- 2013/09/17 06:00 MHDA- 2014/03/22 06:00 PMCR- 2013/09/12 CRDT- 2013/09/17 06:00 PHST- 2013/07/19 00:00 [received] PHST- 2013/09/05 00:00 [revised] PHST- 2013/09/10 00:00 [accepted] PHST- 2013/09/17 06:00 [entrez] PHST- 2013/09/17 06:00 [pubmed] PHST- 2014/03/22 06:00 [medline] PHST- 2013/09/12 00:00 [pmc-release] AID - molecules180911281 [pii] AID - molecules-18-11281 [pii] AID - 10.3390/molecules180911281 [doi] PST - epublish SO - Molecules. 2013 Sep 12;18(9):11281-98. doi: 10.3390/molecules180911281. PMID- 39733802 OWN - NLM STAT- MEDLINE DCOM- 20250429 LR - 20250520 IS - 1872-7573 (Electronic) IS - 0378-8741 (Linking) VI - 341 DP - 2025 Feb 11 TI - Naoxintong capsule attenuates heart damage after ischemic stroke via Nuclear factor-κB / Pyrin domain-containing protein 3 / Caspase-1 signaling. PG - 119240 LID - S0378-8741(24)01539-3 [pii] LID - 10.1016/j.jep.2024.119240 [doi] AB - ETHNOPHARMACOLOGICAL RELEVANCE: Ischemic stroke (IS) is a major cause of mortality. Inflammation exerts an essential part of brain-heart communication after IS. Naoxintong capsule (NXT), derived from the classical Traditional Chinese Medicine (TCM) formulation Bu-Yang-Huan-Wu-Tang, are extensively employed in China to manage IS, myocardial infarction (MI), and atherosclerosis. Previous clinical studies have demonstrated the protective effects of NXT in anti-atherosclerosis, cerebral infarction, angina, and acute coronary syndrome. However, the potential therapeutic mechanism of NXT for IS remains unknown. AIM OF THE STUDY: This study aims to investigate a potential mechanism for enhancing brain-heart interaction following an ischemic stroke. MATERIALS AND METHODS: C57BL/6J mice underwent permanent middle cerebral artery occlusion (MCAO) for durations of 6, 12, and 24 h. The effects of NXT on the brain were observed via TTC, Nissl and TUNEL staining, immunofluorescence staining, and Zea-Longa scores. Simultaneously, the effects of NXT on the heart were evaluated via H&E staining and echocardiography. Inflammatory factors in heart and serum were determined via ELISA or luminex liquid suspension chip detection. Network pharmacology predicted the targets and signaling pathways of NXT. The binding affinity between potential targets and active compounds of NXT was assessed through molecular docking. The expression levels of IκBα, IKKβ, NF-κB, NLRP3, and caspase-1 were evaluated via Western blotting. RESULTS: The Zea-Longa scores, infarct rate, and the rate of apoptosis in the brain at 6, 12, and 24 h of MCAO mice were markedly decreased by NXT. Additionally, they clearly enhanced the NeuN positive rate and prevented microglia from activating at 24 h. NXT significantly reduced the level of myocardial injury biomarkers (Lactate dehydrogenase (LDH) and Creatine kinase isoenzyme MB (CK-MB) at 24 h, N-terminal pro-brain natriuretic peptide (NT-pro BNP) at 6, 12, and 24 h), improved ejection fraction, fractional shortening, stroke volume, and cardiac output at 24 h. The levels of MIP-1α in cardiac tissue and IL-1β in serum were both markedly lowered by NXT. Furthermore, the NF-κB/NLRP3/caspase-1 signaling pathways may be potential mechanisms of NXT. Molecular docking indicated that IKKβ, IκBα, NF-κB, NLRP3, and caspase-1 may serve as potential targets for the action of representative active ingredients in NXT. NXT could reduce the expression levels of IKKβ, NF-κB, NLRP3, and caspase-1 in brain and heart tissues while increasing the expression of IκBα. CONCLUSIONS: Our study illustrates that NXT efficiently attenuated inflammation in the brain and heart by blocking the NF-κB/NLRP3/caspase-1 signaling pathway. These findings provide appealing insights into the multi-organ perspective on human health via identifying shared inflammatory impacts and heart-brain linkages. CI - Copyright © 2024. Published by Elsevier B.V. FAU - Zhang, Jing AU - Zhang J AD - Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, 100700, Beijing, China. FAU - Li, Yu AU - Li Y AD - Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, 100700, Beijing, China. FAU - Chang, Mengli AU - Chang M AD - Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, 100700, Beijing, China. FAU - Lei, Yuxin AU - Lei Y AD - Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, 100700, Beijing, China. FAU - Xu, He AU - Xu H AD - Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, 100700, Beijing, China. FAU - Zhang, Yi AU - Zhang Y AD - Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, 100700, Beijing, China. FAU - Xu, Jing AU - Xu J AD - Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, 100700, Beijing, China. Electronic address: jxu0930@icmm.ac.cn. FAU - Zhang, Jingjing AU - Zhang J AD - Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, 100700, Beijing, China. Electronic address: jjzhang@icmm.ac.cn. FAU - Tang, Shihuan AU - Tang S AD - Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, 100700, Beijing, China; State Key Laboratory for Quality Assurance and Sustainable Use of Dao-di Herbs, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, 100700, Beijing, China. Electronic address: shtang@icmm.ac.cn. LA - eng PT - Journal Article DEP - 20241227 PL - Ireland TA - J Ethnopharmacol JT - Journal of ethnopharmacology JID - 7903310 RN - 0 (Drugs, Chinese Herbal) RN - 0 (NLR Family, Pyrin Domain-Containing 3 Protein) RN - 0 (NF-kappa B) RN - EC 3.4.22.36 (Caspase 1) RN - 0 (naoxintong) RN - 0 (Nlrp3 protein, mouse) RN - EC 3.4.22.36 (Casp1 protein, mouse) RN - 0 (Capsules) SB - IM MH - Animals MH - *Drugs, Chinese Herbal/pharmacology/therapeutic use MH - *NLR Family, Pyrin Domain-Containing 3 Protein/metabolism MH - Mice, Inbred C57BL MH - NF-kappa B/metabolism MH - Signal Transduction/drug effects MH - Male MH - Caspase 1/metabolism MH - Mice MH - *Infarction, Middle Cerebral Artery/drug therapy/complications MH - Capsules MH - *Ischemic Stroke/drug therapy/complications/metabolism MH - Disease Models, Animal MH - Brain/drug effects/pathology/metabolism OTO - NOTNLM OT - Heart-brain interaction OT - IKKβ/IκBα/NF-κB OT - Ischemic stroke OT - NLRP3/Caspase-1 OT - Naoxintong capsules COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/12/30 00:19 MHDA- 2025/02/02 05:10 CRDT- 2024/12/29 19:48 PHST- 2024/08/21 00:00 [received] PHST- 2024/12/09 00:00 [revised] PHST- 2024/12/11 00:00 [accepted] PHST- 2025/02/02 05:10 [medline] PHST- 2024/12/30 00:19 [pubmed] PHST- 2024/12/29 19:48 [entrez] AID - S0378-8741(24)01539-3 [pii] AID - 10.1016/j.jep.2024.119240 [doi] PST - ppublish SO - J Ethnopharmacol. 2025 Feb 11;341:119240. doi: 10.1016/j.jep.2024.119240. Epub 2024 Dec 27. PMID- 27090345 OWN - NLM STAT- MEDLINE DCOM- 20170303 LR - 20220330 IS - 1872-7573 (Electronic) IS - 0378-8741 (Linking) VI - 186 DP - 2016 Jun 20 TI - Characteristics of traditional Chinese medicine usage in patients with stroke in Taiwan: A nationwide population-based study. PG - 311-321 LID - S0378-8741(16)30209-4 [pii] LID - 10.1016/j.jep.2016.04.018 [doi] AB - ETHNOPHARMACOLOGICAL RELEVANCE: Stroke has been the leading causes of death worldwide. Traditional Chinese medicine (TCM) has been used for stoke patients for thousands of years. This study aimed to investigate TCM usage and prescription patterns in stroke patients in Taiwan. MATERIALS AND METHODS: We analyzed a random sample of one million individuals representing the 23 million enrollees selected from the National Health Insurance Research Database in Taiwan. Demographic characteristics, TCM usage, prescription patterns and mortality rate among stroke patients were analyzed. RESULTS: We identified 23,816 patients who were newly diagnosed with stroke between 2001 and 2009 by their diagnostic codes (ICD-9-CM 430-438). Among them, 4302 patients had hemorrhagic stroke while 19,514 patients had ischemic stroke. Overall, 12% of the stroke patients (n=2862) were TCM users. The median interval between stroke onset to the first TCM consultation is 12.2 months. Among the TCM users, more than half (52.7%) of the patients received both Chinese herbal remedies and acupuncture/traumatology treatment. Bu-yang-huan-wu-tang and Dan-shen (Radix Salviae Miltiorrhizae; Salvia miltiorrhiza Bunge) was the most commonly prescribed Chinese herbal formula and single herb, respectively. TCM users had a higher incidence rate ratio in myalgia, myositis, fasciitis and insomnia than non-TCM users. Mental disorders such as anxiety and depression are common in both TCM and non-TCM users. Comparing with the non-TCM users, the TCM users had a lower mortality rate (adjusted hazard ratios were 0.44 in overall stroke, 0.50 in ischemic stroke and 0.25 in hemorrhagic stroke). CONCLUSION: Adjunctive TCM use may reduce the risk of mortality rate among stroke patients. Bu-yang-huan-wu-tang and Dan-shen are the most common prescribed Chinese herbal formula and single herb for stroke patients, respectively. Future study investigating the anti-inflammatory and neuroprotective efficacy of Bu-yang-huan-wu-tang and Dan-shen in stroke is warranted. CI - Copyright © 2016 Elsevier Ireland Ltd. All rights reserved. FAU - Chang, Chia-Chi AU - Chang CC AD - Department of Chinese Medicine, China Medical University Hospital, Taichung 404, Taiwan; Research Center for Traditional Chinese Medicine, Department of Medical Research, China Medical University Hospital, Taichung 404, Taiwan. Electronic address: cheerpachang@gmail.com. FAU - Lee, Yu-Chen AU - Lee YC AD - Department of Chinese Medicine, China Medical University Hospital, Taichung 404, Taiwan; Research Center for Chinese Medicine & Acupuncture, China Medical University, Taichung 404, Taiwan; Graduate Institute of Acupuncture Science, China Medical University, Taichung 404, Taiwan. Electronic address: d5167@mail.cmuh.org.tw. FAU - Lin, Che-Chen AU - Lin CC AD - Health Data Management Office, China Medical University Hospital, Taichung 404, Taiwan. Electronic address: a21745@mail.cmuh.org.tw. FAU - Chang, Chin-Hsien AU - Chang CH AD - Department of Traditional Chinese Medicine, En Chu Kong Hospital, New Taipei City 237, Taiwan; Department of Cosmetic Science, Chang Gung University of Science and Technology, Taoyuan 333, Taiwan. Electronic address: 01399@km.eck.org.tw. FAU - Chiu, Cheng-Di AU - Chiu CD AD - Department of Neurosurgery, China Medical University Hospital, Taichung 404, Taiwan; School of Medicine, China Medical University, Taichung 404, Taiwan. Electronic address: cdchiu@yahoo.com.tw. FAU - Chou, Li-Wei AU - Chou LW AD - Research Center for Chinese Medicine & Acupuncture, China Medical University, Taichung 404, Taiwan; Graduate Institute of Acupuncture Science, China Medical University, Taichung 404, Taiwan; School of Chinese Medicine, China Medical University, Taichung 404, Taiwan; Department of Physical Medicine and Rehabilitation, China Medical University Hospital, Taichung 404, Taiwan. Electronic address: chouliwe@gmail.com. FAU - Sun, Mao-Feng AU - Sun MF AD - Department of Chinese Medicine, China Medical University Hospital, Taichung 404, Taiwan; Research Center for Chinese Medicine & Acupuncture, China Medical University, Taichung 404, Taiwan; School of Chinese Medicine, China Medical University, Taichung 404, Taiwan. Electronic address: maofeng@mail.cmuh.org.tw. FAU - Yen, Hung-Rong AU - Yen HR AD - Department of Chinese Medicine, China Medical University Hospital, Taichung 404, Taiwan; Research Center for Traditional Chinese Medicine, Department of Medical Research, China Medical University Hospital, Taichung 404, Taiwan; Research Center for Chinese Medicine & Acupuncture, China Medical University, Taichung 404, Taiwan; School of Chinese Medicine, China Medical University, Taichung 404, Taiwan. Electronic address: hungrongyen@gmail.com. LA - eng PT - Journal Article DEP - 20160414 PL - Ireland TA - J Ethnopharmacol JT - Journal of ethnopharmacology JID - 7903310 RN - 0 (Drugs, Chinese Herbal) RN - 0 (bu-yang-huan-wu-tang) RN - 1693AM5SBN (dan-shen root extract) SB - IM MH - Aged MH - Drugs, Chinese Herbal/therapeutic use MH - Female MH - Humans MH - Male MH - Medicine, Chinese Traditional/*statistics & numerical data MH - Middle Aged MH - Practice Patterns, Physicians'/statistics & numerical data MH - Salvia miltiorrhiza MH - Stroke/*drug therapy/mortality MH - Taiwan/epidemiology OTO - NOTNLM OT - Bu-Yang-Huan-Wu-Tang OT - Cerebrovascular accident OT - National Health Insurance Research Database OT - Salvia miltiorrhiza Bunge OT - Stroke OT - Traditional Chinese medicine EDAT- 2016/04/20 06:00 MHDA- 2017/03/04 06:00 CRDT- 2016/04/20 06:00 PHST- 2015/10/28 00:00 [received] PHST- 2016/04/11 00:00 [revised] PHST- 2016/04/12 00:00 [accepted] PHST- 2016/04/20 06:00 [entrez] PHST- 2016/04/20 06:00 [pubmed] PHST- 2017/03/04 06:00 [medline] AID - S0378-8741(16)30209-4 [pii] AID - 10.1016/j.jep.2016.04.018 [doi] PST - ppublish SO - J Ethnopharmacol. 2016 Jun 20;186:311-321. doi: 10.1016/j.jep.2016.04.018. Epub 2016 Apr 14. PMID- 40356987 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250514 IS - 1663-9812 (Print) IS - 1663-9812 (Electronic) IS - 1663-9812 (Linking) VI - 16 DP - 2025 TI - Investigating the regulation of the miR-199a-3p/TGF-β/Smad signaling pathway by BSHXF drug-containing serum combined with ADSCs for delaying intervertebral disc degeneration. PG - 1583635 LID - 10.3389/fphar.2025.1583635 [doi] LID - 1583635 AB - BACKGROUND: Intervertebral disc degeneration (IDD) significantly contributes to low back pain (LBP), yet effective treatment options are scarce. BSHXF, a classical traditional Chinese medicine formula, demonstrates dual pharmacological actions: tonifying kidneys, strengthening bones, activating blood circulation, and resolving stasis. It has been widely used in IDD management. Given its potential, combining BSHXF with miRNA regulation and stem cell therapy may enhance therapeutic outcomes by targeting molecular and cellular pathways underlying IDD pathogenesis. AIM OF THE STUDY: IDD is recognized as one of the primary causes of low back pain, yet effective therapeutic interventions for this condition remain limited. This study explores the role of BSHXF drug-containing serum combined with adipose-derived stem cells (ADSCs) in slowing IDD progression via the miR-199a-3p/TGF-β/Smad signaling pathway. By comprehensively investigating the synergistic effects of this combination therapy, we aim to propose a novel multi-target strategy that addresses the complex pathogenesis of IDD. MATERIALS AND METHODS: This study employed a combination of in vivo and in vitro models. An IDD model was induced in rat caudal intervertebral discs through needle puncture, while an oxidative stress-induced ADSCs injury model was created in vitro using tert-butyl hydroperoxide (T-BHP). Cell viability was measured with the CCK-8 assay. Cell cycle distribution and mitochondrial reactive oxygen species (ROS) levels were assessed using flow cytometry. Cellular senescence was assessed using SA-β-galactosidase staining. Lactate dehydrogenase (LDH) activity was quantified to evaluate cellular damage. Differentiation into nucleus pulposus-like cells was assessed using immunofluorescence double staining for CD73 and COL2A1. ELISA was used to measure inflammatory cytokines (TNF-α, IL-1β, IL-4, IL-10) in cell supernatants. miR-199a-3p expression was determined using RT-qPCR. Western blotting was employed to quantify COL2A1, SOX9, and ACAN protein levels, reflecting nucleus pulposus-like differentiation and extracellular matrix (ECM) synthesis capacity. Western blotting was employed to assess pathway activity by analyzing the protein expressions of TGF-β1, Smad2, Smad3, and their phosphorylated forms, P-Smad2 and P-Smad3. In vivo experiments assessed histopathological degeneration through hematoxylin-eosin (HE) and Safranin O-Fast Green staining. Immunohistochemistry (IHC) analyzed COL1A1 and COL2A1 expression levels. RT-qPCR quantified miR-199a-3p expression. Western blotting was employed to assess the expression levels of TGF-β1, Smad2, Smad3, P-Smad2, and P-Smad3 for pathway regulation evaluation. RESULTS: Our experimental results demonstrated that serum containing BSHXF significantly alleviated T-BHP-induced oxidative stress, improved the cellular microenvironment, promoted ADSCs proliferation, and decelerated cellular senescence. Further mechanistic analysis revealed that BSHXF significantly activated the TGF-β/Smad signaling pathway, driving the differentiation of ADSCs into nucleus pulposus-like cells and restoring normal cell cycle progression. Overexpression of miR-199a-3p inhibited the TGF-β/Smad pathway, leading to ECM degradation and elevated expression of inflammatory factors (TNF-α, IL-1β). In contrast, BSHXF restored TGF-β/Smad pathway activity by downregulating miR-199a-3p expression. In vivo experiments demonstrated that miR-199a-3p overexpression exacerbated IDD, characterized by reduced COL2A1 expression, elevated COL1A1 levels, and increased disc fibrosis. BSHXF intervention markedly attenuated IDD progression by downregulating miR-199a-3p expression, reducing disc fibrosis, and effectively restoring collagen expression. CONCLUSION: BSHXF activated the TGF-β/Smad pathway to promote the differentiation of ADSCs into nucleus pulposus-like cells. It exerted protective effects by alleviating oxidative stress damage, improving the microenvironment, delaying senescence, and enhancing cellular functions. This study is the first to reveal that miR-199a-3p overexpression exacerbates intervertebral disc fibrosis and degeneration. BSHXF restored TGF-β/Smad pathway activity by downregulating miR-199a-3p expression, thereby improving disc structure and function. This integrated approach offers a novel multi-target intervention strategy for IDD, demonstrating significant therapeutic potential. CI - Copyright © 2025 Liu, Sun, Yang, Jiang, Sun, Chen, Duan and Yang. FAU - Liu, Enxu AU - Liu E AD - Hunan University of Traditional Chinese Medicine, Graduate School, Changsha, Hunan, China. AD - The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Department of Orthopaedics, Changsha, Hunan, China. FAU - Sun, Yu AU - Sun Y AD - Hunan University of Traditional Chinese Medicine, Graduate School, Changsha, Hunan, China. AD - The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Department of Orthopaedics, Changsha, Hunan, China. FAU - Yang, Lei AU - Yang L AD - Hunan University of Traditional Chinese Medicine, Graduate School, Changsha, Hunan, China. AD - The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Department of Orthopaedics, Changsha, Hunan, China. FAU - Jiang, Haobo AU - Jiang H AD - Hunan University of Traditional Chinese Medicine, Graduate School, Changsha, Hunan, China. AD - The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Department of Orthopaedics, Changsha, Hunan, China. FAU - Sun, Fei AU - Sun F AD - Hunan University of Traditional Chinese Medicine, Graduate School, Changsha, Hunan, China. FAU - Chen, Long AU - Chen L AD - The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Department of Orthopaedics, Changsha, Hunan, China. FAU - Duan, Jiahao AU - Duan J AD - Hunan University of Traditional Chinese Medicine, Graduate School, Changsha, Hunan, China. AD - The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Department of Orthopaedics, Changsha, Hunan, China. FAU - Yang, Shaofeng AU - Yang S AD - Hunan University of Traditional Chinese Medicine, Graduate School, Changsha, Hunan, China. AD - The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Department of Orthopaedics, Changsha, Hunan, China. LA - eng PT - Journal Article DEP - 20250428 PL - Switzerland TA - Front Pharmacol JT - Frontiers in pharmacology JID - 101548923 PMC - PMC12067415 OTO - NOTNLM OT - adipose-derived stem cells OT - extracellular matrix synthesis OT - intervertebral disc degeneration OT - miR-199a-3p/TGF-β/Smad signaling pathway OT - oxidative stress COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/05/13 06:32 MHDA- 2025/05/13 06:33 PMCR- 2025/04/28 CRDT- 2025/05/13 04:48 PHST- 2025/02/26 00:00 [received] PHST- 2025/04/14 00:00 [accepted] PHST- 2025/05/13 06:33 [medline] PHST- 2025/05/13 06:32 [pubmed] PHST- 2025/05/13 04:48 [entrez] PHST- 2025/04/28 00:00 [pmc-release] AID - 1583635 [pii] AID - 10.3389/fphar.2025.1583635 [doi] PST - epublish SO - Front Pharmacol. 2025 Apr 28;16:1583635. doi: 10.3389/fphar.2025.1583635. eCollection 2025. PMID- 29212217 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20191120 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 8 IP - 55 DP - 2017 Nov 7 TI - TMED2 promotes epithelial ovarian cancer growth. PG - 94151-94165 LID - 10.18632/oncotarget.21593 [doi] AB - TMED2 is involved in morphogenesis of the mouse embryo and placenta. We found that expression of TMED2 was higher in epithelial ovarian cancer tissues than normal ovarian tissues. Silencing TMED2 decreased cell proliferation, migration, and invasion. Ectopic expression of TMED2 increased cell proliferation, migration and invasion. Silencing TMED2 inhibited ovarian cancer growth in mice. Silencing TMED2 inhibited IGF2/IGF1R/PI3K/Akt pathway. In agreement, ectopically expressed TMED2 activated IGF2/IGF1R/PI3K/Akt pathway. Mechanistic study revealed that TMED2 directly binds to AKT2, thereby facilitating its phosphorylation. We also found that TMED2 increased IGF1R expression by competing for miR-30a. Thus, TMED2 is oncogenic and a potential target for epithelial ovarian cancer therapy. FAU - Shi-Peng, Gong AU - Shi-Peng G AD - Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, P.R. China. FAU - Chun-Lin, Chen AU - Chun-Lin C AD - Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, P.R. China. FAU - Huan, Wu AU - Huan W AD - Department of Obstetrics and Gynecology, The Second Affiliated Hospital, Chongqing University of Medical Sciences, Chongqing 400010, P.R. China. FAU - Fan-Liang, Meng AU - Fan-Liang M AD - Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, P.R. China. FAU - Yong-Ning, Chen AU - Yong-Ning C AD - Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, P.R. China. FAU - Ya-Di, Zhang AU - Ya-Di Z AD - Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, P.R. China. FAU - Guang-Ping, Zhang AU - Guang-Ping Z AD - Department of Gynecology, People's Hospital of Huadu District, Guangzhou 510800, P.R. China. FAU - Ye-Ping, Cai AU - Ye-Ping C AD - Department of Gynecology, Maternal and Child Health Hospital of Duanzhou District, Zhaoqing 526000, P.R. China. LA - eng PT - Journal Article DEP - 20171006 PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 PMC - PMC5706863 OTO - NOTNLM OT - AKT OT - IGF1R OT - TMED2 OT - epithelial ovarian cancer OT - miR-30a COIS- CONFLICTS OF INTEREST There are no potential conflicts of interest to declare. EDAT- 2017/12/08 06:00 MHDA- 2017/12/08 06:01 PMCR- 2017/11/07 CRDT- 2017/12/08 06:00 PHST- 2017/08/06 00:00 [received] PHST- 2017/09/08 00:00 [accepted] PHST- 2017/12/08 06:00 [entrez] PHST- 2017/12/08 06:00 [pubmed] PHST- 2017/12/08 06:01 [medline] PHST- 2017/11/07 00:00 [pmc-release] AID - 21593 [pii] AID - 10.18632/oncotarget.21593 [doi] PST - epublish SO - Oncotarget. 2017 Oct 6;8(55):94151-94165. doi: 10.18632/oncotarget.21593. eCollection 2017 Nov 7. PMID- 26477801 OWN - NLM STAT- MEDLINE DCOM- 20160907 LR - 20220330 IS - 1793-6853 (Electronic) IS - 0192-415X (Linking) VI - 43 IP - 7 DP - 2015 TI - Chinese Herbal Products for Ischemic Stroke. PG - 1365-79 LID - 10.1142/S0192415X15500779 [doi] AB - Traditional Chinese herbal products (CHPs) have been described in ancient medicine systems as treatments for various stroke-associated ailments. This study is aimed to investigate the prescription patterns and combinations of CHPs for ischemic stroke in Taiwan. Prescriptions of CHPs for ischemic stroke were obtained from the National Health Insurance Research Database (NHIRD) of Taiwan. Every prescription with a leading diagnosis of ischemic stroke made during 2000-2010 was analyzed. Descriptive statistics were applied to the pattern of co-prescriptions. Multiple logistic regression models were used to assess demographic and risk factors that are correlated with CHP use. The dataset of inpatient claims data contained information on 15,896 subjects who experienced ischemic stroke from 2000 to 2010. There was an average of 5.82 CHPs in a single prescription for subjects with ischemic stroke. Bu-yang-huan-wu-tang (BYHWT) (40.32%) was by far the most frequently prescribed formula CHP for ischemic stroke, and the most commonly used combination of two-formula-CHP was BYHWT with Shu-jin-huo-xue-tang (SJHXT) (4.40%). Dan Shen (16.50%) was the most commonly used single CHP for ischemic stroke, and the most commonly used combination of two single CHPs was Shi Chang Pua with Yuan Zhi (4.79%). We found that BYHWT and Dan Shen were the most frequently prescribed formula and single CHP for ischemic stroke, respectively. These results provide information about individualized therapy and may contribute to further pharmacologic experiments and clinical trials. FAU - Hung, I-Ling AU - Hung IL AD - * Department of Chinese Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Hung, Yu-Chiang AU - Hung YC AD - * Department of Chinese Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. AD - ‡ School of Chinese Medicine for Post Baccalaureate, I-Shou University, Kaohsiung, Taiwan. FAU - Wang, Lin-Yi AU - Wang LY AD - † Department of Physical Medicine and Rehabilitation, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Hsu, Sheng-Feng AU - Hsu SF AD - § Department of Chinese Medicine, China Medical University Hospital, Taipei Branch, Taiwan. AD - ¶ Graduate Institute of Acupuncture Science, College of Public Health, China Medical University, Taichung, Taiwan. FAU - Chen, Hsuan-Ju AU - Chen HJ AD - ∥ Management Office for Health Data, College of Public Health, China Medical University,Taichung, Taiwan. FAU - Tseng, Ying-Jung AU - Tseng YJ AD - * Department of Chinese Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Kuo, Chun-En AU - Kuo CE AD - * Department of Chinese Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Hu, Wen-Long AU - Hu WL AD - * Department of Chinese Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. AD - †† Kaohsiung Medical University College of Medicine, Kaohsiung, Taiwan. AD - ‡‡ Fooyin University College of Nursing, Kaohsiung, Taiwan. FAU - Li, Tsai-Chung AU - Li TC AD - ** Graduate Institute of Biostatistics, College of Public Health, China Medical University, Taichung, Taiwan. AD - §§ Department of Healthcare Administration, College of Health Science, Asia University Taichung, Taiwan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20151018 PL - Singapore TA - Am J Chin Med JT - The American journal of Chinese medicine JID - 7901431 RN - 0 (Drugs, Chinese Herbal) RN - 0 (bu-yang-huan-wu-tang) SB - IM MH - Databases, Factual/statistics & numerical data MH - Drugs, Chinese Herbal/*administration & dosage MH - Female MH - Humans MH - Male MH - Medicine, Chinese Traditional/*statistics & numerical data MH - National Health Programs MH - Practice Patterns, Physicians'/*statistics & numerical data MH - Prescriptions/*statistics & numerical data MH - Salvia miltiorrhiza MH - Stroke/*drug therapy/*epidemiology MH - Taiwan/epidemiology OTO - NOTNLM OT - Chinese Herbal Products OT - Couplet Medicinal OT - Ischemic Stroke OT - Pharmaco-Epidemiology OT - Prescription Pattern EDAT- 2015/10/20 06:00 MHDA- 2016/09/08 06:00 CRDT- 2015/10/20 06:00 PHST- 2015/10/20 06:00 [entrez] PHST- 2015/10/20 06:00 [pubmed] PHST- 2016/09/08 06:00 [medline] AID - 10.1142/S0192415X15500779 [doi] PST - ppublish SO - Am J Chin Med. 2015;43(7):1365-79. doi: 10.1142/S0192415X15500779. Epub 2015 Oct 18. PMID- 38978225 OWN - NLM STAT- MEDLINE DCOM- 20240709 LR - 20240726 IS - 1555-8576 (Electronic) IS - 1538-4047 (Print) IS - 1538-4047 (Linking) VI - 25 IP - 1 DP - 2024 Dec 31 TI - BRG1 promotes liver cancer cell proliferation and metastasis by enhancing mitochondrial function and ATP5A1 synthesis through TOMM40. PG - 2375440 LID - 10.1080/15384047.2024.2375440 [doi] LID - 2375440 AB - Hepatocellular carcinoma (HCC) is one of the most lethal malignant tumors worldwide. Brahma-related gene 1 (BRG1), as a catalytic ATPase, is a major regulator of gene expression and is known to mutate and overexpress in HCC. The purpose of this study was to investigate the mechanism of action of BRG1 in HCC cells. In our study, BRG1 was silenced or overexpressed in human HCC cell lines. Transwell and wound healing assays were used to analyze cell invasiveness and migration. Mitochondrial membrane potential (MMP) and mitochondrial permeability transition pore (mPTP) detection were used to evaluate mitochondrial function in HCC cells. Colony formation and cell apoptosis assays were used to evaluate the effect of BRG1/TOMM40/ATP5A1 on HCC cell proliferation and apoptosis/death. Immunocytochemistry (ICC), immunofluorescence (IF) staining and western blot analysis were used to determine the effect of BRG1 on TOMM40, ATP5A1 pathway in HCC cells. As a result, knockdown of BRG1 significantly inhibited cell proliferation and invasion, promoted apoptosis in HCC cells, whereas BRG1 overexpression reversed the above effects. Overexpression of BRG1 can up-regulate MMP level, inhibit mPTP opening and activate TOMM40, ATP5A1 expression. Our results suggest that BRG1, as an oncogene, promotes HCC progression by regulating TOMM40 affecting mitochondrial function and ATP5A1 synthesis. Targeting BRG1 may represent a new and effective way to prevent HCC development. FAU - Hui, Yongfeng AU - Hui Y AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China. AD - Department of Hepatobiliary Surgery, Ningxia Hepatobiliary and Pancreatic Surgical Diseases Clinical Medical Research Center, Yinchuan, Ningxia, China. FAU - Leng, Junzhi AU - Leng J AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China. AD - Department of Hepatobiliary Surgery, Ningxia Hepatobiliary and Pancreatic Surgical Diseases Clinical Medical Research Center, Yinchuan, Ningxia, China. FAU - Jin, Dong AU - Jin D AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China. AD - Department of Hepatobiliary Surgery, Ningxia Hepatobiliary and Pancreatic Surgical Diseases Clinical Medical Research Center, Yinchuan, Ningxia, China. FAU - Wang, Genwang AU - Wang G AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China. AD - Department of Hepatobiliary Surgery, Ningxia Hepatobiliary and Pancreatic Surgical Diseases Clinical Medical Research Center, Yinchuan, Ningxia, China. FAU - Liu, Kejun AU - Liu K AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China. AD - Department of Hepatobiliary Surgery, Ningxia Hepatobiliary and Pancreatic Surgical Diseases Clinical Medical Research Center, Yinchuan, Ningxia, China. FAU - Bu, Yang AU - Bu Y AUID- ORCID: 0000-0003-0303-5607 AD - Department of Hepatobiliary Surgery, Ningxia Medical University, Yinchuan, Ningxia, China. AD - Department of Hepatobiliary Surgery, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, Ningxia, China. FAU - Wang, Qi AU - Wang Q AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China. AD - Department of Hepatobiliary Surgery, Ningxia Hepatobiliary and Pancreatic Surgical Diseases Clinical Medical Research Center, Yinchuan, Ningxia, China. LA - eng PT - Journal Article DEP - 20240708 PL - United States TA - Cancer Biol Ther JT - Cancer biology & therapy JID - 101137842 RN - EC 3.6.1.14 (ATP5F1A protein, human) RN - EC 3.6.4.- (DNA Helicases) RN - 0 (Mitochondrial Membrane Transport Proteins) RN - 0 (Mitochondrial Precursor Protein Import Complex Proteins) RN - EC 3.6.3.- (Mitochondrial Proton-Translocating ATPases) RN - 0 (Nuclear Proteins) RN - EC 3.6.1.- (SMARCA4 protein, human) RN - 0 (Transcription Factors) RN - 0 (TOMM40 protein, human) SB - IM MH - Humans MH - *Apoptosis MH - *Carcinoma, Hepatocellular/pathology/genetics/metabolism MH - Cell Line, Tumor MH - Cell Movement MH - *Cell Proliferation MH - *DNA Helicases/metabolism/genetics MH - Gene Expression Regulation, Neoplastic MH - *Liver Neoplasms/pathology/metabolism/genetics MH - Membrane Potential, Mitochondrial MH - *Mitochondria/metabolism MH - Mitochondrial Membrane Transport Proteins/metabolism/genetics MH - *Mitochondrial Precursor Protein Import Complex Proteins MH - Mitochondrial Proton-Translocating ATPases/metabolism/genetics MH - Neoplasm Metastasis MH - *Nuclear Proteins/metabolism/genetics MH - *Transcription Factors/metabolism/genetics PMC - PMC11236295 OTO - NOTNLM OT - BRG1 OT - TOMM40 OT - hepatocellular carcinoma OT - invasion OT - proliferation COIS- No potential conflict of interest was reported by the author(s). EDAT- 2024/07/09 06:42 MHDA- 2024/07/09 06:43 PMCR- 2024/07/08 CRDT- 2024/07/09 01:10 PHST- 2024/07/09 06:43 [medline] PHST- 2024/07/09 06:42 [pubmed] PHST- 2024/07/09 01:10 [entrez] PHST- 2024/07/08 00:00 [pmc-release] AID - 2375440 [pii] AID - 10.1080/15384047.2024.2375440 [doi] PST - ppublish SO - Cancer Biol Ther. 2024 Dec 31;25(1):2375440. doi: 10.1080/15384047.2024.2375440. Epub 2024 Jul 8. PMID- 30920303 OWN - NLM STAT- MEDLINE DCOM- 20190902 LR - 20190902 IS - 1557-7708 (Electronic) IS - 1075-5535 (Linking) VI - 25 IP - 6 DP - 2019 Jun TI - Chinese Herbal Medicine for Mild Cognitive Impairment Using Montreal Cognitive Assessment: A Systematic Review. PG - 578-592 LID - 10.1089/acm.2018.0346 [doi] AB - Background: Mild cognitive impairment (MCI) prevalence is estimated at 6%-12% of the population. It is possible that early treatment at the MCI stage could reduce progression to more severe cognitive impairment. The Montreal Cognitive Assessment (MoCA) is a sensitive measure used to assess changes in cognitive function. Various Chinese herbal medicines (CHMs) have been tested for effects on MCI using MoCA. Objectives: To evaluate the clinical evidence for CHMs on MoCA scores in MCI. Design: Five biomedical databases in English and Chinese language were searched for randomized controlled trials that compared orally administered CHMs with a control group and assessed changes in cognition using MoCA. Analyses were based on the comparison, control intervention, and study duration. Mean differences and 95% confidence intervals were calculated to evaluate treatment effects. For each study, risk of bias was assessed according to the Cochrane tool. Results: Nineteen studies were included with 16 contributing to the data analyses. Three studies were placebo controlled. Nine compared a CHM with a pharmacotherapy, three combined a CHM with a pharmacotherapy, and one combined CHM with cognitive training. In the two placebo-controlled studies of 24-week duration, results favored the CHMs at end of treatment. Conclusions: The systematic review suggests that the oral application of certain CHMs improved scores on MoCA by 1.76-2.34 points compared with placebo in people with MCI after 24 weeks of treatment. However, these two studies used different CHM formulations. Two studies that tested the same CHM formulation, Bu Yang Huan Wu Tang, in combination with donepezil, reported improvement in the integrative groups, but the studies were not blind and the durations were only 8-12 weeks. Overall, methodological weaknesses limited the strength of the evidence. The herbal formulae included ingredients that have received considerable research attention for their effects on memory and cognition. PROSPERO international prospective register of systematic reviews protocol registration number: CRD42018099650. FAU - Dong, Lin AU - Dong L AD - The China-Australia International Research Centre for Chinese Medicine, School of Health and Biomedical Sciences, RMIT University, Bundoora, Australia. FAU - Hyde, Anna J AU - Hyde AJ AD - The China-Australia International Research Centre for Chinese Medicine, School of Health and Biomedical Sciences, RMIT University, Bundoora, Australia. FAU - Zhang, Anthony Lin AU - Zhang AL AD - The China-Australia International Research Centre for Chinese Medicine, School of Health and Biomedical Sciences, RMIT University, Bundoora, Australia. FAU - Xue, Charlie Changli AU - Xue CC AD - The China-Australia International Research Centre for Chinese Medicine, School of Health and Biomedical Sciences, RMIT University, Bundoora, Australia. FAU - May, Brian H AU - May BH AD - The China-Australia International Research Centre for Chinese Medicine, School of Health and Biomedical Sciences, RMIT University, Bundoora, Australia. LA - eng PT - Journal Article PT - Systematic Review DEP - 20190328 PL - United States TA - J Altern Complement Med JT - Journal of alternative and complementary medicine (New York, N.Y.) JID - 9508124 RN - 0 (Drugs, Chinese Herbal) RN - 0 (bu-yang-huan-wu-tang) SB - IM MH - Cognition/*drug effects MH - Cognitive Dysfunction/*drug therapy MH - Drugs, Chinese Herbal/pharmacology/*therapeutic use MH - Humans MH - Mental Status and Dementia Tests MH - *Phytotherapy OTO - NOTNLM OT - Alzheimer's disease OT - Chinese herbal medicine OT - Montreal Cognitive Assessment OT - mild cognitive impairment OT - natural products OT - systematic review EDAT- 2019/03/29 06:00 MHDA- 2019/09/03 06:00 CRDT- 2019/03/29 06:00 PHST- 2019/03/29 06:00 [pubmed] PHST- 2019/09/03 06:00 [medline] PHST- 2019/03/29 06:00 [entrez] AID - 10.1089/acm.2018.0346 [doi] PST - ppublish SO - J Altern Complement Med. 2019 Jun;25(6):578-592. doi: 10.1089/acm.2018.0346. Epub 2019 Mar 28. PMID- 41027105 OWN - NLM STAT- MEDLINE DCOM- 20251017 LR - 20251017 IS - 1873-264X (Electronic) IS - 0731-7085 (Linking) VI - 267 DP - 2026 Jan 1 TI - Bushen Huoxue formula attenuates recurrent spontaneous abortion by modulating arginine metabolism and macrophage polarization at the maternal-fetal interface. PG - 117161 LID - S0731-7085(25)00502-3 [pii] LID - 10.1016/j.jpba.2025.117161 [doi] AB - The aim of this study was to clarify the effects of BSHXF on pregnancy outcome and macrophage polarization at the maternal-fetal interface in a mouse model of recurrent spontaneous abortion (RSA). The RSA model was established using the CBA/J × DBA/2 mating method. Network pharmacology predicted the mechanism of BSHXF intervention in RSA and verified by Western blotting. Immunofluorescence and RT-qPCR were used to measure the levels of macrophage-associated cytokines at the maternal-fetal interface. Placental metabolomics was used to analyze the mechanism of macrophage regulation by BSHXF and verified by ELISA. BSHXF improved embryonic resorption and hormone levels in RSA mice and restored abnormal NF-κB signaling, which was achieved in part by modulating macrophage polarisation status. BSHXF intervention decreased M1 macrophage polarization while elevating M2 macrophage levels. Metabolomics indicated that decreased inducible nitric oxide synthase (iNOS) pathway and elevated arginase-1 pathway (Arg-1) pathway in the placenta were the key mechanisms of macrophage polarization. This study provides innovative insights into the mechanism by which BSHXF ameliorates RSA in mice, providing a scientific basis for further pharmacological research. CI - Copyright © 2025 Elsevier B.V. All rights reserved. FAU - Song, Jingyi AU - Song J AD - Department of Obstetrics and Gynecology, Baoshan Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201999, China. FAU - Xu, Yuan AU - Xu Y AD - Spinal Disease Research Institute, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China; Central Laboratory, Baoshan Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201999, China. FAU - Liu, Jihong AU - Liu J AD - Department of Obstetrics and Gynecology, Baoshan Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201999, China. FAU - Zhong, Yuqing AU - Zhong Y AD - Department of Obstetrics and Gynecology, Baoshan Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201999, China. FAU - Hong, Ying AU - Hong Y AD - Department of Obstetrics and Gynecology, Baoshan Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201999, China. FAU - Liu, Shiqi AU - Liu S AD - Central Laboratory, Baoshan Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201999, China. FAU - Gou, Xiaojun AU - Gou X AD - Central Laboratory, Baoshan Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201999, China. FAU - Wu, Yan AU - Wu Y AD - Department of Obstetrics and Gynecology, Baoshan Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201999, China. Electronic address: wuyanivyang@163.com. FAU - Jin, Quanfang AU - Jin Q AD - Department of Obstetrics and Gynecology, Baoshan Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201999, China. Electronic address: 2439396821@qq.com. LA - eng PT - Journal Article DEP - 20250924 PL - England TA - J Pharm Biomed Anal JT - Journal of pharmaceutical and biomedical analysis JID - 8309336 RN - 94ZLA3W45F (Arginine) RN - 0 (Drugs, Chinese Herbal) RN - EC 3.5.3.1 (Arginase) RN - 0 (NF-kappa B) RN - EC 1.14.13.39 (Nitric Oxide Synthase Type II) RN - 0 (Cytokines) SB - IM MH - Animals MH - Female MH - Pregnancy MH - Mice MH - *Macrophages/drug effects/metabolism MH - *Abortion, Habitual/drug therapy/metabolism/prevention & control MH - *Arginine/metabolism MH - *Drugs, Chinese Herbal/pharmacology/therapeutic use MH - Placenta/metabolism/drug effects MH - Disease Models, Animal MH - Mice, Inbred DBA MH - Mice, Inbred CBA MH - Arginase/metabolism MH - NF-kappa B/metabolism MH - Nitric Oxide Synthase Type II/metabolism MH - Metabolomics/methods MH - Cytokines/metabolism MH - Macrophage Activation/drug effects MH - Signal Transduction/drug effects MH - Male MH - Maternal-Fetal Exchange/drug effects OTO - NOTNLM OT - Arginine metabolism OT - Bushen Huoxue formula OT - Macrophage OT - Maternal-fetal interface OT - Recurrent spontaneous abortion COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/10/01 00:28 MHDA- 2025/10/18 00:30 CRDT- 2025/09/30 18:03 PHST- 2025/02/05 00:00 [received] PHST- 2025/09/22 00:00 [revised] PHST- 2025/09/23 00:00 [accepted] PHST- 2025/10/18 00:30 [medline] PHST- 2025/10/01 00:28 [pubmed] PHST- 2025/09/30 18:03 [entrez] AID - S0731-7085(25)00502-3 [pii] AID - 10.1016/j.jpba.2025.117161 [doi] PST - ppublish SO - J Pharm Biomed Anal. 2026 Jan 1;267:117161. doi: 10.1016/j.jpba.2025.117161. Epub 2025 Sep 24. PMID- 39569409 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241122 IS - 2253-5969 (Print) IS - 2253-5969 (Electronic) IS - 2253-5969 (Linking) VI - 11 DP - 2024 TI - Construction of a 2.5D Deep Learning Model for Predicting Early Postoperative Recurrence of Hepatocellular Carcinoma Using Multi-View and Multi-Phase CT Images. PG - 2223-2239 LID - 10.2147/JHC.S493478 [doi] AB - PURPOSE: To construct a 2.5-dimensional (2.5D) CT radiomics-based deep learning (DL) model to predict early postoperative recurrence of hepatocellular carcinoma (HCC). PATIENTS AND METHODS: We retrospectively analyzed the data of patients who underwent HCC resection at 2 centers. The 232 patients from center 1 were randomly divided into the training (162 patients) and internal validation cohorts (70 patients); 91 patients from center 2 formed the external validation cohort. We developed a 2.5D DL model based on a central 2D image with the maximum tumor cross-section and adjacent slices. Multiple views (transverse, sagittal, and coronal) and phases (arterial, plain, and portal) were incorporated. Multi-instance learning techniques were applied to the extracted data; the resulting comprehensive feature set was modeled using Logistic Regression, RandomForest, ExtraTrees, XGBoost, and LightGBM, with 5-fold cross validation and hyperparameter optimization with Grid-search. Receiver operating characteristic curves, calibration curves, DeLong test, and decision curve analysis were used to evaluate model performance. RESULTS: The 2.5D DL model performed well in the training (AUC: 0.920), internal validation (AUC: 0.825), and external validation cohorts (AUC: 0.795). The 3D DL model performed well in the training cohort and poorly in the internal and external validation cohorts (AUCs: 0.751, 0.666, and 0.567, respectively), indicating overfitting. The combined model (2.5D DL+clinical) performed well in all cohorts (AUCs: 0.921, 0.835, 0.804). The Hosmer-Lemeshow test, DeLong test, and decision curve analysis confirmed the superiority of the combined model over the other signatures. CONCLUSION: The combined model integrating 2.5D DL and clinical features accurately predicts early postoperative HCC recurrence. CI - © 2024 Zhang et al. FAU - Zhang, Yu-Bo AU - Zhang YB AD - School of Clinical Medicine, Ningxia Medical University, Yinchuan, 750004, People's Republic of China. AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, 750004, People's Republic of China. FAU - Chen, Zhi-Qiang AU - Chen ZQ AD - School of Clinical Medicine, Ningxia Medical University, Yinchuan, 750004, People's Republic of China. AD - Department of Hepatobiliary Surgery, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, 750002, People's Republic of China. FAU - Bu, Yang AU - Bu Y AUID- ORCID: 0000-0003-1219-997X AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, 750004, People's Republic of China. FAU - Lei, Peng AU - Lei P AUID- ORCID: 0000-0002-5225-485X AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, 750004, People's Republic of China. FAU - Yang, Wei AU - Yang W AD - Department of Radiology, General Hospital of Ningxia Medical University, Yinchuan, 750004, People's Republic of China. FAU - Zhang, Wei AU - Zhang W AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, 750004, People's Republic of China. LA - eng PT - Journal Article DEP - 20241116 PL - New Zealand TA - J Hepatocell Carcinoma JT - Journal of hepatocellular carcinoma JID - 101674775 PMC - PMC11577935 OTO - NOTNLM OT - computed tomography OT - deep learning OT - hepatocellular carcinoma OT - liver resection OT - recurrence COIS- The authors report no conflicts of interest in this work. EDAT- 2024/11/21 06:21 MHDA- 2024/11/21 06:22 PMCR- 2024/11/16 CRDT- 2024/11/21 04:51 PHST- 2024/08/28 00:00 [received] PHST- 2024/11/01 00:00 [accepted] PHST- 2024/11/21 06:22 [medline] PHST- 2024/11/21 06:21 [pubmed] PHST- 2024/11/21 04:51 [entrez] PHST- 2024/11/16 00:00 [pmc-release] AID - 493478 [pii] AID - 10.2147/JHC.S493478 [doi] PST - epublish SO - J Hepatocell Carcinoma. 2024 Nov 16;11:2223-2239. doi: 10.2147/JHC.S493478. eCollection 2024. PMID- 34045964 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210530 IS - 1663-9812 (Print) IS - 1663-9812 (Electronic) IS - 1663-9812 (Linking) VI - 12 DP - 2021 TI - Integrated Strategy of Network Pharmacological Prediction and Experimental Validation Elucidate Possible Mechanism of Bu-Yang Herbs in Treating Postmenopausal Osteoporosis via ESR1. PG - 654714 LID - 10.3389/fphar.2021.654714 [doi] LID - 654714 AB - Postmenopausal osteoporosis (PMOP) is a type of bone metabolism disease-related to estrogen deficiency with an increasing incidence. Traditional Chinese (TCM) has always been used and showed effectiveness in treating PMOP. In the current study, Bu-Yang herbs were considered to be the most frequently used and efficient TCM herbs in PMOP treatment. However, chemical and pharmacological profiles were not elucidated. Network pharmacology was conducted on representative Bu-Yang herbs (Yin-Yang-Huo. Du-Zhong, Bu-Gu-Zhi, Tu-Si-Zi) to investigate the mechanism of Bu-Yang herbs on PMOP. Chemical compounds, potential targets, and disease related genes were available from the corresponding database. Results showed that Bu-Yang herbs could interact with ESR1 and estrogen signaling pathways. For further validation, the Bu-Yang decoction (BYD), formula consisted of the above-mentioned 4 Bu-Yang herbs was presented for experimental validation. In vivo, BYD significantly reversed ovariectomy (OVX)-induced osteoporosis progress in a dose-dependent manner by up-regulation of bone mineral density and amelioration of bone microarchitecture. In vitro, BYD dramatically improved the proliferation and mineral nodules formation of osteoblasts. Both in vitro and in vivo results illustrated that the phenotype change induced by BYD is correlated with up-regulated of ESR1 and activation of the β-catenin pathway. Meanwhile, inhibition of ESR1 by ICI182, 780 blocked the osteogenic phenotype and β-catenin pathway activation induced by BYD. In conclusion, the current study suggested that Bu-Yang herbs are the most useful TCM herbs in treating PMOP. Furthermore, the integrated strategy of network pharmacology prediction with experimental validation suggested that BYD exerted its anti-PMOP via ESR1 and the downstream mechanism might be activation of the β-catenin signaling pathway. CI - Copyright © 2021 Xia, Liu, Yang, Liu, Luo, Yang, Xie, Zeng, Xu, Ling, Zeng, Xu, Fang, Wang, Tong, Jin and Yang. FAU - Xia, Hanting AU - Xia H AD - The First Clinical College, Zhejiang Chinese Medical University, Hangzhou, China. AD - Institute of Orthopaedics and Traumatology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China. AD - Department of Orthopedics, Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, China. FAU - Liu, Jiangyuan AU - Liu J AD - Graduated School, Jiangxi University of Chinese Medicine, Nanchang, China. FAU - Yang, Wenlong AU - Yang W AD - Department of Orthopedics, Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, China. FAU - Liu, Min AU - Liu M AD - Department of Orthopedics, Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, China. FAU - Luo, Yunfeng AU - Luo Y AD - Graduated School, Jiangxi University of Chinese Medicine, Nanchang, China. FAU - Yang, Zhijun AU - Yang Z AD - Graduated School, Jiangxi University of Chinese Medicine, Nanchang, China. FAU - Xie, Jingbo AU - Xie J AD - Department of Orthopedics, People's Hospital of Fengcheng City, Fengcheng, China. FAU - Zeng, Huiliang AU - Zeng H AD - Department of Orthopedics, Foshan Hospital of Traditional Chinese Medicine, Foshan, China. FAU - Xu, Rui AU - Xu R AD - The First Clinical College, Zhejiang Chinese Medical University, Hangzhou, China. AD - Institute of Orthopaedics and Traumatology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China. FAU - Ling, Houfu AU - Ling H AD - The First Clinical College, Zhejiang Chinese Medical University, Hangzhou, China. AD - Institute of Orthopaedics and Traumatology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China. FAU - Zeng, Qinghe AU - Zeng Q AD - The First Clinical College, Zhejiang Chinese Medical University, Hangzhou, China. AD - Institute of Orthopaedics and Traumatology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China. FAU - Xu, Huihui AU - Xu H AD - The First Clinical College, Zhejiang Chinese Medical University, Hangzhou, China. AD - Institute of Orthopaedics and Traumatology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China. FAU - Fang, Liang AU - Fang L AD - The First Clinical College, Zhejiang Chinese Medical University, Hangzhou, China. AD - Institute of Orthopaedics and Traumatology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China. FAU - Wang, Hongyu AU - Wang H AD - Graduated School, Jiangxi University of Chinese Medicine, Nanchang, China. FAU - Tong, Peijian AU - Tong P AD - The First Clinical College, Zhejiang Chinese Medical University, Hangzhou, China. AD - Institute of Orthopaedics and Traumatology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China. AD - Department of Orthopaedic Surgery, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China. FAU - Jin, Hongting AU - Jin H AD - The First Clinical College, Zhejiang Chinese Medical University, Hangzhou, China. AD - Institute of Orthopaedics and Traumatology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China. AD - Department of Orthopaedic Surgery, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China. FAU - Yang, Fengyun AU - Yang F AD - Graduated School, Jiangxi University of Chinese Medicine, Nanchang, China. LA - eng PT - Journal Article DEP - 20210511 PL - Switzerland TA - Front Pharmacol JT - Frontiers in pharmacology JID - 101548923 PMC - PMC8144472 OTO - NOTNLM OT - Bu-Yang OT - estrogen receptor OT - network pharmacology OT - postmenopausal osteoporosis OT - traditional Chinese medicine COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/05/29 06:00 MHDA- 2021/05/29 06:01 PMCR- 2021/05/11 CRDT- 2021/05/28 07:23 PHST- 2021/01/17 00:00 [received] PHST- 2021/04/12 00:00 [accepted] PHST- 2021/05/28 07:23 [entrez] PHST- 2021/05/29 06:00 [pubmed] PHST- 2021/05/29 06:01 [medline] PHST- 2021/05/11 00:00 [pmc-release] AID - 654714 [pii] AID - 10.3389/fphar.2021.654714 [doi] PST - epublish SO - Front Pharmacol. 2021 May 11;12:654714. doi: 10.3389/fphar.2021.654714. eCollection 2021. PMID- 40792394 OWN - NLM STAT- MEDLINE DCOM- 20250812 LR - 20250814 IS - 2162-3279 (Electronic) VI - 15 IP - 8 DP - 2025 Aug TI - Immune Evasion Mechanism Mediated by ITPRIPL1 and Its Prognostic Implications in Glioma. PG - e70762 LID - 10.1002/brb3.70762 [doi] LID - e70762 AB - BACKGROUND: Glioma represent one of the most prevalent and lethal malignancies within the central nervous system. Recent studies have identified ITPRIPL1, a newly reported CD3ε-inhibitory ligand, as a suppressor of T cell activation, thereby facilitating tumor immune evasion and offering a novel avenue for immunotherapeutic intervention in glioma. METHODS: A comprehensive analysis was performed using datasets from The Cancer Genome Atlas (TCGA), the Chinese Glioma Genome Atlas (CGGA), and Gene Expression Omnibus (GEO). This included evaluating ITPRIPL1 expression levels in glioma, its association with clinicopathological features, prognostic significance, immune landscape, targeted drug sensitivity, and underlying biological functions. Ninety-eight machine learning algorithm combinations were screened to identify the optimal predictive model. A nomogram was subsequently constructed and validated to assess the integrated prognostic impact of ITPRIPL1 expression on glioma patients. RESULTS: Elevated ITPRIPL1 expression was positively correlated with higher tumor grade and poorer clinical outcomes. Immune infiltration profiling revealed that ITPRIPL1 expression was negatively associated with effector memory CD4⁺ T cells and type 17 T helper cells (Th17), but positively correlated with M2-polarized macrophages and several immune checkpoint molecules. Moreover, drug sensitivity analyses and molecular docking studies highlighted a potential therapeutic relationship between ITPRIPL1 and antitumor agents such as AZD8055. The SuperPC model emerged as the most robust predictor and was utilized to develop a prognostic nomogram capable of reliably forecasting survival in glioma patients. CONCLUSIONS: This study reveals that ITPRIPL1 plays a dual role in glioma: It suppresses T cell-mediated immune responses, contributing to an immunosuppressive microenvironment, and interferes with the efficacy of antitumor drugs, thereby promoting tumor progression and ultimately leading to poor patient prognosis. CI - © 2025 The Author(s). Brain and Behavior published by Wiley Periodicals LLC. FAU - Xiaoyun, Zou AU - Xiaoyun Z AUID- ORCID: 0009-0009-7958-0936 AD - Anhui Engineering Research Center for Neural Regeneration Technology and Medical New Materials, Bengbu Medical University, Bengbu, China. FAU - Wenhao, Ye AU - Wenhao Y AD - Anhui Engineering Research Center for Neural Regeneration Technology and Medical New Materials, Bengbu Medical University, Bengbu, China. FAU - Huan, Wu AU - Huan W AD - Anhui Engineering Research Center for Neural Regeneration Technology and Medical New Materials, Bengbu Medical University, Bengbu, China. FAU - Yuanyuan, Yang AU - Yuanyuan Y AD - Anhui Engineering Research Center for Neural Regeneration Technology and Medical New Materials, Bengbu Medical University, Bengbu, China. FAU - Changqing, Liu AU - Changqing L AD - Anhui Engineering Research Center for Neural Regeneration Technology and Medical New Materials, Bengbu Medical University, Bengbu, China. AD - School of Life Science, Bengbu Medical University, Bengbu, China. FAU - Hebao, Wen AU - Hebao W AD - Anhui Engineering Research Center for Neural Regeneration Technology and Medical New Materials, Bengbu Medical University, Bengbu, China. AD - Department of Physical Education and Arts, Bengbu Medical University, Bengbu, China. FAU - Caiyun, Ma AU - Caiyun M AD - Anhui Engineering Research Center for Neural Regeneration Technology and Medical New Materials, Bengbu Medical University, Bengbu, China. AD - School of Life Science, Bengbu Medical University, Bengbu, China. LA - eng GR - National Natural Science Foundation of China/ GR - Anhui Key Laboratory of Tissue Transplantation (Bengbu Medical University)/ GR - the Experimental Teaching and Teaching Laboratory Quality Engineering Project of Bengbu Medical University/ PT - Journal Article PL - United States TA - Brain Behav JT - Brain and behavior JID - 101570837 SB - IM MH - Humans MH - *Glioma/immunology/genetics/metabolism MH - Prognosis MH - *Brain Neoplasms/immunology/genetics/metabolism MH - *Immune Evasion MH - Male MH - Female PMC - PMC12340539 OTO - NOTNLM OT - ITPRIPL1 OT - glioma OT - immune infiltration OT - machine learning OT - prognostic biomarker COIS- The authors declare no conflicts of interest. EDAT- 2025/08/12 06:27 MHDA- 2025/08/12 06:28 PMCR- 2025/08/12 CRDT- 2025/08/12 05:43 PHST- 2025/07/14 00:00 [revised] PHST- 2025/05/09 00:00 [received] PHST- 2025/07/22 00:00 [accepted] PHST- 2025/08/12 06:28 [medline] PHST- 2025/08/12 06:27 [pubmed] PHST- 2025/08/12 05:43 [entrez] PHST- 2025/08/12 00:00 [pmc-release] AID - BRB370762 [pii] AID - 10.1002/brb3.70762 [doi] PST - ppublish SO - Brain Behav. 2025 Aug;15(8):e70762. doi: 10.1002/brb3.70762. PMID- 41282621 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251124 LR - 20251126 IS - 1663-9812 (Print) IS - 1663-9812 (Electronic) IS - 1663-9812 (Linking) VI - 16 DP - 2025 TI - Potential of herbal formulas and bioactive metabolites in treating atherosclerosis: targeted modulation of macrophage polarization. PG - 1631274 LID - 10.3389/fphar.2025.1631274 [doi] LID - 1631274 AB - Macrophage polarization plays a pivotal role in the pathogenesis and plaque stability of atherosclerosis (AS). In response to microenvironmental cues, macrophages differentiate into pro-inflammatory M1 or anti-inflammatory M2 phenotypes, which respectively exacerbate or mitigate inflammatory responses and influence plaque progression. Emerging evidence highlights the therapeutic potential of targeting macrophage polarization through signaling pathways such as Toll-like receptor 4 (TLR4)/nuclear factor-kappa B (NF-κB), peroxisome proliferator-activated receptor γ (PPAR-γ), Janus kinase (JAK)-signal transducer and activator of transcription (STAT), phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway, and mitogen-activated protein kinase (MAPK) pathway. Bioactive metabolites derived from traditional Chinese medicine (TCM)-including ginsenosides (e.g., Rb1, Rg3), berberine (BBR), curcumin (CUR), and tanshinone IIA (Tan IIA)-as well as herbal formulas like Bu Yang Huan Wu Decoction (BYHW) and Zhuyu Pill (ZYP), have demonstrated efficacy in promoting M2 polarization and suppressing M1 phenotypes, thereby attenuating AS. This review critically synthesizes the current body of evidence, with a primary focus on preclinical studies (in vitro and in vivo), which comprehensively synthesizes evidence on the targeted modulation of AS-associated macrophage polarization by bioactive metabolites and herbal formulas, with a unique emphasis on the role of TCM as a multi-target regulator of macrophage plasticity. This approach provides novel perspectives for the prevention and treatment of AS. CI - Copyright © 2025 Liu, Jing, Zhang, Sun and Zhu. FAU - Liu, Shixin AU - Liu S AD - Graduate School of Tianjin University of Traditional Chinese Medicine, Tianjin, China. FAU - Jing, Jinpeng AU - Jing J AD - Graduate School of Tianjin University of Traditional Chinese Medicine, Tianjin, China. FAU - Zhang, Yunsha AU - Zhang Y AD - Tianjin University of Traditional Chinese Medicine, Tianjin, China. AD - TCM Institute of Sore and Ulcer, Tianjin University of Traditional Chinese Medicine, Tianjin, China. FAU - Sun, Junchao AU - Sun J AD - TCM Institute of Sore and Ulcer, Tianjin University of Traditional Chinese Medicine, Tianjin, China. AD - Tianjin Institute of Traditional Chinese Medicine Surgery, Tianjin, China. AD - The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China. FAU - Zhu, Chaojun AU - Zhu C AD - TCM Institute of Sore and Ulcer, Tianjin University of Traditional Chinese Medicine, Tianjin, China. AD - Tianjin Institute of Traditional Chinese Medicine Surgery, Tianjin, China. AD - The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China. LA - eng PT - Journal Article PT - Review DEP - 20251106 PL - Switzerland TA - Front Pharmacol JT - Frontiers in pharmacology JID - 101548923 PMC - PMC12631451 OTO - NOTNLM OT - atherosclerosis OT - bioactive metabolites OT - herbal formulas OT - macrophage polarization OT - research progress OT - signaling pathways COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/11/24 18:21 MHDA- 2025/11/24 12:39 PMCR- 2025/11/06 CRDT- 2025/11/24 09:15 PHST- 2025/05/19 00:00 [received] PHST- 2025/10/14 00:00 [revised] PHST- 2025/10/17 00:00 [accepted] PHST- 2025/11/24 12:39 [medline] PHST- 2025/11/24 18:21 [pubmed] PHST- 2025/11/24 09:15 [entrez] PHST- 2025/11/06 00:00 [pmc-release] AID - 1631274 [pii] AID - 10.3389/fphar.2025.1631274 [doi] PST - epublish SO - Front Pharmacol. 2025 Nov 6;16:1631274. doi: 10.3389/fphar.2025.1631274. eCollection 2025. PMID- 8737474 OWN - NLM STAT- MEDLINE DCOM- 19961010 LR - 20131121 IS - 1001-5302 (Print) IS - 1001-5302 (Linking) VI - 20 IP - 11 DP - 1995 Nov TI - [Effects of buyang huan wu decoction on rat hyperlipemia model]. PG - 685-7, 704 AB - Buyang Huan Wu Decoction can obviously lower the blood-lipid in rat hyperlipemia model, as well as drop the cholesterol in the aortic wall. Moreover, the decoction can drop the rising specific viscosity of blood and plasma, raise SOD and lower LPO in the blood. FAU - Bian, H AU - Bian H AD - Nanjing College of TCM. FAU - Zhou, J AU - Zhou J LA - chi PT - English Abstract PT - Journal Article PL - China TA - Zhongguo Zhong Yao Za Zhi JT - Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica JID - 8913656 RN - 0 (Cholesterol, HDL) RN - 0 (Drugs, Chinese Herbal) RN - 0 (Lipid Peroxides) RN - 0 (Triglycerides) RN - 97C5T2UQ7J (Cholesterol) SB - IM MH - Animals MH - Aorta/metabolism MH - Blood Viscosity/drug effects MH - Cholesterol/*metabolism MH - Cholesterol, HDL/blood MH - Drugs, Chinese Herbal/*pharmacology MH - Hypercholesterolemia/*metabolism MH - Lipid Peroxides/blood MH - Male MH - Rats MH - Rats, Sprague-Dawley MH - Triglycerides/blood EDAT- 1995/11/01 00:00 MHDA- 1995/11/01 00:01 CRDT- 1995/11/01 00:00 PHST- 1995/11/01 00:00 [pubmed] PHST- 1995/11/01 00:01 [medline] PHST- 1995/11/01 00:00 [entrez] PST - ppublish SO - Zhongguo Zhong Yao Za Zhi. 1995 Nov;20(11):685-7, 704. PMID- 36724040 OWN - NLM STAT- MEDLINE DCOM- 20230321 LR - 20230423 IS - 1549-490X (Electronic) IS - 1083-7159 (Print) IS - 1083-7159 (Linking) VI - 28 IP - 3 DP - 2023 Mar 17 TI - Prevalence and Associations of Beta2-Microglobulin Mutations in MSI-H/dMMR Cancers. PG - e136-e144 LID - 10.1093/oncolo/oyac268 [doi] AB - Microsatellite instability (MSI) has emerged as an important predictor of sensitivity for immunotherapy-based strategies. β-2-Microglobulin (B2M) contains microsatellites within the coding regions and is prone to somatic changes in MSI/mismatch repair deficiency (MSI/dMMR) tumors. To delineate prevalence and associations of B2M mutations in MSI-H/dMMR cancers, we investigated the mutational profile of B2M and clinical and pathological features in gastric cancer (GC), colorectal cancer (CRC), and endometrial cancer (EC) with a high incidence of microsatellite instability-high (MSI-H)/dMMR. Formalin-fixed paraffin-embedded (FFPE) tumor tissues along with matched normal tissues were collected from 108 MSI/dMMR patients with GC, CRC, and EC. Genomic profiling of tissue and blood samples were assessed next-generation sequencing (NGS). Immunohistochemistry (IHC) was used to examine the presence or absence of B2M protein. Alternations in the exonic microsatellite regions of B2M were observed at various but high frequencies (57.5% in CRC, 23.9% in GC, and 13.6% in EC) and in different forms. NGS assay revealed that genes involved in chromatin regulation, the PI3K pathway, the WNT pathway, and mismatch repair were extensively altered in the MSI-H cohort. Signature 6 and 26, 2 of 4 mutational signatures associated with defective DNA mismatch repair, featured with high numbers of small insertion/deletions (INDEL) dominated in all 3 types of cancer. Alternations in the exonic microsatellite regions of B2M were observed at various but high frequencies (57.5% in CRC, 23.9% in GC, and 13.6% in EC) and in different forms. Tumor mutational burden (TMB) was significantly higher in the patients carrying MSI-H/dMMR tumors with B2M mutation than that in patients with wild-type B2M (P = .026).The frame shift alteration occurring at the exonic microsatellite sties caused loss of function of B2M gene. In addition, a case with CRC carrying indels in B2M gene resisted the ICI treatment was reported. In conclusion, patients carrying MSI-H/dMMR tumors with B2M mutation showed significantly higher TMB. Prescription of ICIs should be thoroughly evaluated for these patients. CI - © The Author(s) 2023. Published by Oxford University Press. FAU - Liu, Fangcen AU - Liu F AD - Department of Pathology, Affiliated Drum Tower Hospital to Medical School of Nanjing University, Nanjing, People's Republic of China. FAU - Zhong, Fangfang AU - Zhong F AD - Department of Pathology, Margaret Williamson Red House Hospital, Shanghai, People's Republic of China. FAU - Wu, Huan AU - Wu H AD - Department of R&D, OrigiMed, Shanghai, People's Republic of China. FAU - Che, Keying AU - Che K AD - The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School & Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China. FAU - Shi, Jiaochun AU - Shi J AD - Department of R&D, OrigiMed, Shanghai, People's Republic of China. FAU - Wu, Nandie AU - Wu N AD - The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School & Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China. FAU - Fu, Yao AU - Fu Y AD - Department of Pathology, Affiliated Drum Tower Hospital to Medical School of Nanjing University, Nanjing, People's Republic of China. FAU - Wang, Yue AU - Wang Y AD - The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School & Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China. FAU - Hu, Jing AU - Hu J AD - The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School & Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China. FAU - Qian, Xiaoping AU - Qian X AD - The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School & Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China. FAU - Fan, Xiangshan AU - Fan X AD - Department of Pathology, Affiliated Drum Tower Hospital to Medical School of Nanjing University, Nanjing, People's Republic of China. FAU - Wang, Weifeng AU - Wang W AD - Department of R&D, OrigiMed, Shanghai, People's Republic of China. FAU - Wei, Jia AU - Wei J AD - The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School & Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Oncologist JT - The oncologist JID - 9607837 RN - EC 2.7.1.- (Phosphatidylinositol 3-Kinases) RN - Turcot syndrome SB - IM MH - Brain Neoplasms MH - *Colorectal Neoplasms/genetics/pathology MH - Neoplastic Syndromes, Hereditary MH - *Endometrial Neoplasms MH - Female MH - Mutation MH - Humans MH - *Stomach Neoplasms/genetics MH - Prevalence MH - DNA Mismatch Repair MH - Microsatellite Instability MH - Phosphatidylinositol 3-Kinases/genetics PMC - PMC10020813 OTO - NOTNLM OT - B2M OT - MSI/dMMR OT - acquired resistance OT - immune checkpoint inhibitor therapy OT - primary resistance COIS- Huan Wu, Jiaochun Shi, and Weifeng Wang are employees of OrigiMed. The other authors indicated no financial relationships. EDAT- 2023/02/02 06:00 MHDA- 2023/03/22 06:00 PMCR- 2023/02/01 CRDT- 2023/02/01 12:02 PHST- 2022/07/10 00:00 [received] PHST- 2022/11/29 00:00 [accepted] PHST- 2023/02/02 06:00 [pubmed] PHST- 2023/03/22 06:00 [medline] PHST- 2023/02/01 12:02 [entrez] PHST- 2023/02/01 00:00 [pmc-release] AID - 7022155 [pii] AID - oyac268 [pii] AID - 10.1093/oncolo/oyac268 [doi] PST - ppublish SO - Oncologist. 2023 Mar 17;28(3):e136-e144. doi: 10.1093/oncolo/oyac268. PMID- 28771194 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20180223 LR - 20181113 IS - 1424-8220 (Electronic) IS - 1424-8220 (Linking) VI - 17 IP - 8 DP - 2017 Aug 3 TI - Monocular Vision-Based Underwater Object Detection. LID - 10.3390/s17081784 [doi] LID - 1784 AB - In this paper, we propose an underwater object detection method using monocular vision sensors. In addition to commonly used visual features such as color and intensity, we investigate the potential of underwater object detection using light transmission information. The global contrast of various features is used to initially identify the region of interest (ROI), which is then filtered by the image segmentation method, producing the final underwater object detection results. We test the performance of our method with diverse underwater datasets. Samples of the datasets are acquired by a monocular camera with different qualities (such as resolution and focal length) and setups (viewing distance, viewing angle, and optical environment). It is demonstrated that our ROI detection method is necessary and can largely remove the background noise and significantly increase the accuracy of our underwater object detection method. FAU - Chen, Zhe AU - Chen Z AD - College of Computer and Information, Hohai University, Nanjing 211100, Jiangsu, China. chenzhe@hhu.edu.cn. AD - Key Laboratory of Trusted Cloud Computing and Big Data Analysis, Nanjing Xiaozhuang University, Nanjing 211100, Jiangsu, China. chenzhe@hhu.edu.cn. FAU - Zhang, Zhen AU - Zhang Z AD - College of Computer and Information, Hohai University, Nanjing 211100, Jiangsu, China. zz_hhuc@hhu.edu.cn. FAU - Dai, Fengzhao AU - Dai F AD - Laboratory of Information Optics and Opto-Electronic Technology, Shanghai Institute of Optics and Fine Mechanics, Shanghai 201800, China. fzdai@siom.ac.cn. FAU - Bu, Yang AU - Bu Y AD - Laboratory of Information Optics and Opto-Electronic Technology, Shanghai Institute of Optics and Fine Mechanics, Shanghai 201800, China. buyang@siom.ac.cn. FAU - Wang, Huibin AU - Wang H AD - College of Computer and Information, Hohai University, Nanjing 211100, Jiangsu, China. hbwang@hhu.edu.cn. LA - eng PT - Journal Article DEP - 20170803 PL - Switzerland TA - Sensors (Basel) JT - Sensors (Basel, Switzerland) JID - 101204366 PMC - PMC5580077 OTO - NOTNLM OT - monocular vision OT - region of interest OT - transmission estimation OT - underwater object detection COIS- The authors declare no conflict of interest. EDAT- 2017/08/05 06:00 MHDA- 2017/08/05 06:01 PMCR- 2017/08/01 CRDT- 2017/08/04 06:00 PHST- 2017/05/24 00:00 [received] PHST- 2017/07/25 00:00 [revised] PHST- 2017/07/31 00:00 [accepted] PHST- 2017/08/04 06:00 [entrez] PHST- 2017/08/05 06:00 [pubmed] PHST- 2017/08/05 06:01 [medline] PHST- 2017/08/01 00:00 [pmc-release] AID - s17081784 [pii] AID - sensors-17-01784 [pii] AID - 10.3390/s17081784 [doi] PST - epublish SO - Sensors (Basel). 2017 Aug 3;17(8):1784. doi: 10.3390/s17081784. PMID- 36188612 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221004 IS - 1663-9812 (Print) IS - 1663-9812 (Electronic) IS - 1663-9812 (Linking) VI - 13 DP - 2022 TI - An Ethnopharmaceutical Study on the Hypolipidemic Formulae in Taiwan Issued by Traditional Chinese Medicine Pharmacies. PG - 900693 LID - 10.3389/fphar.2022.900693 [doi] LID - 900693 AB - Globally, approximately one-third of ischemic heart diseases are due to hyperlipidemia, which has been shown to cause various metabolic disorders. This study was aimed to disassemble and analyze hypolipidemic formulae sold by traditional Chinese medicine (TCM) pharmacies. Using commonly used statistical parameters in ethnopharmacology, we identified the core drug combination of the hypolipidemic formulae, thereby exploring the strategy by which the Taiwanese people select hypolipidemic drugs. Most important of all, we preserved the inherited knowledge of TCM. We visited 116 TCM pharmacies in Taiwan and collected 91 TCM formulae. The formulae were mainly disassembled by macroscopical identification, and the medicinal materials with a relative frequency of citation (RFC) >0.2 were defined as commonly used medicinal materials. Subsequently, we sorted the information of medicinal materials recorded in the Pharmacopeia, searched for modern pharmacological research on commonly used medicinal materials using PubMed database, and visualized data based on the statistical results. Finally, the core hypolipidemic medicinal materials used in folk medicine were obtained. Of the 91 TCM formulae collected in this study, 80 traditional Chinese medicinal materials were used, belonging to 43 families, predominantly Lamiaceae. Roots were the most commonly used part as a medicinal material. There were 17 commonly used medicinal materials. Based on medicinal records in Pharmacopeia, most flavors and properties were warm and pungent, the majority traditional effects were "tonifying and replenishing" and "blood-regulating." Besides, the targeted diseases searching from modern pharmacological studies were diabetes mellitus and dyslipidemia. The core medicinal materials consisted of Astragalus mongholicus Bunge and Crataegus pinnatifida Bunge, and the core formulae were Bu-Yang-Huan-Wu-Tang and Xie-Fu-Zhu-Yu-Tang. In addition, 7 groups of folk misused medicinal materials were found. Although these TCMs have been used for a long period of time, their hypolipidemic mechanisms remain unclear, and further studies are needed to validate their safety and efficacy. CI - Copyright © 2022 Chi, Chao, Ko and Huang. FAU - Chi, Min-Han AU - Chi MH AD - School of Pharmacy, China Medical University, Taichung, Taiwan. FAU - Chao, Jung AU - Chao J AD - Master Program for Food and Drug Safety, Chinese Medicine Research Center, Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung, Taiwan. FAU - Ko, Chien-Yu AU - Ko CY AD - School of Pharmacy, China Medical University, Taichung, Taiwan. FAU - Huang, Shyh-Shyun AU - Huang SS AD - School of Pharmacy, China Medical University, Taichung, Taiwan. AD - Department of Food Nutrition and Health Biotechnology, Asia University, Taichung, Taiwan. LA - eng PT - Journal Article DEP - 20220915 PL - Switzerland TA - Front Pharmacol JT - Frontiers in pharmacology JID - 101548923 PMC - PMC9520573 OTO - NOTNLM OT - drug combination OT - hyperlipidemia OT - hypolipidemic OT - pharmacies OT - traditional Chinese medicine COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/10/04 06:00 MHDA- 2022/10/04 06:01 PMCR- 2022/09/15 CRDT- 2022/10/03 05:10 PHST- 2022/03/21 00:00 [received] PHST- 2022/06/06 00:00 [accepted] PHST- 2022/10/03 05:10 [entrez] PHST- 2022/10/04 06:00 [pubmed] PHST- 2022/10/04 06:01 [medline] PHST- 2022/09/15 00:00 [pmc-release] AID - 900693 [pii] AID - 10.3389/fphar.2022.900693 [doi] PST - epublish SO - Front Pharmacol. 2022 Sep 15;13:900693. doi: 10.3389/fphar.2022.900693. eCollection 2022. PMID- 32884991 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231112 IS - 2352-3042 (Electronic) IS - 2352-4820 (Print) IS - 2352-3042 (Linking) VI - 7 IP - 3 DP - 2020 Sep TI - Traditional Chinese medicine as supportive care for the management of liver cancer: Past, present, and future. PG - 370-379 LID - 10.1016/j.gendis.2019.10.016 [doi] AB - Liver cancer is the sixth most commonly diagnosed cancer and the fourth leading cause of cancer death worldwide. Western medicine and therapies are the primary treatment strategies of hepatocellular carcinoma (HCC), but the general prognosis for HCC patients is still dismal. Under these circumstances, HCC prevention is particularly important. Traditional Chinese medicine (TCM) encompasses a wealth of documented therapeutic resources, and "preventative treatment" is the principle of TCM. In China, TCM has been used for HCC prevention for thousands of years, and has also been demonstrated to be effective for the treatment of HCC in modern China. However, the TCM theory for prevention and treatment of HCC is more widely accepted in China than abroad. In this review, we first summarize the herbs and ancient formulas with therapeutic effects on HCC. We also review the research status of TCM in modern medicine as well as the current obstacles in its development. Finally, we discuss the future of TCM in the context of precision and integrated medicine. After reviewing the literature, we believe that TCM, through ancient development, is an advanced method of cancer treatment with positive curative effects, despite its surrounding controversy. Furthermore, precise analyses and systematic research methods provides novel approaches to modernize TCM for the future. CI - © 2019 Chongqing Medical University. Production and hosting by Elsevier B.V. FAU - Liao, Xia AU - Liao X AD - Department of Nutrition, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China. FAU - Bu, Yang AU - Bu Y AD - Department of Hepatobiliary Surgery, General Hospital, Ningxia Medical University, Yinchuan, 750001, China. FAU - Jia, Qingan AU - Jia Q AD - Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China. LA - eng PT - Journal Article PT - Review DEP - 20191102 PL - Netherlands TA - Genes Dis JT - Genes & diseases JID - 101635967 PMC - PMC7452431 OTO - NOTNLM OT - Chinese herbal medicine OT - Hepatocellular carcinoma OT - Molecular mechanism OT - Network pharmacology OT - Traditional Chinese medicine EDAT- 2020/09/05 06:00 MHDA- 2020/09/05 06:01 PMCR- 2019/11/02 CRDT- 2020/09/05 06:00 PHST- 2019/09/27 00:00 [received] PHST- 2019/10/23 00:00 [revised] PHST- 2019/10/25 00:00 [accepted] PHST- 2020/09/05 06:00 [entrez] PHST- 2020/09/05 06:00 [pubmed] PHST- 2020/09/05 06:01 [medline] PHST- 2019/11/02 00:00 [pmc-release] AID - S2352-3042(19)30105-9 [pii] AID - 10.1016/j.gendis.2019.10.016 [doi] PST - epublish SO - Genes Dis. 2019 Nov 2;7(3):370-379. doi: 10.1016/j.gendis.2019.10.016. eCollection 2020 Sep. PMID- 23710223 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20130528 LR - 20211021 IS - 1741-427X (Print) IS - 1741-4288 (Electronic) IS - 1741-427X (Linking) VI - 2013 DP - 2013 TI - Effects of "Bu Shen Huo Xue Decoction" on the Endometrial Morphology and Expression of Leukaemia Inhibitory Factor in the Rat Uterus during the Oestrous Cycle. PG - 496036 LID - 10.1155/2013/496036 [doi] LID - 496036 AB - The purpose of this study was to explore the positive effects of Bu Shen Huo Xue Decoction (BSHXF) on assisted reproduction. The study aimed to evaluate whether BSHXD could improve endometrial morphology and increase the expression of LIF in a gonadotrophin-releasing hormone agonists (GnRHa) long protocol-induced rat model during metestrus, diestrus, proestrus, and oestrus. The BSHXD group presented significantly increased endometrium thickness and decreased MVD compared with the GnRHa long protocol group. In addition, the expression of LIF was significantly higher in the BSHXD group. There were no significant differences between the control group and the BSHXD group in terms of MVD and LIF expression. These results suggested that BSHXD can improve the endometrium development, reduce the abnormal angiogenesis, and increase the expression of receptivity markers in a GnRHa long protocol-induced rat model during the oestrous cycle, which might result in an endometrial environment better suited for female reproduction. FAU - Gong, Xin AU - Gong X AD - Reproductive Endocrinology Centre, Dongfang Hospital of Beijing University of Chinese Medicine, No. 6 Fangxingyuan 1 Qu, Fengtai District, Beijing 100078, China. FAU - Yu, Yanyan AU - Yu Y FAU - Tong, Qing AU - Tong Q FAU - Ren, Ying AU - Ren Y FAU - Jin, Zhe AU - Jin Z LA - eng PT - Journal Article DEP - 20130428 PL - United States TA - Evid Based Complement Alternat Med JT - Evidence-based complementary and alternative medicine : eCAM JID - 101215021 PMC - PMC3655613 EDAT- 2013/05/28 06:00 MHDA- 2013/05/28 06:01 PMCR- 2013/04/28 CRDT- 2013/05/28 06:00 PHST- 2013/02/15 00:00 [received] PHST- 2013/03/27 00:00 [revised] PHST- 2013/04/07 00:00 [accepted] PHST- 2013/05/28 06:00 [entrez] PHST- 2013/05/28 06:00 [pubmed] PHST- 2013/05/28 06:01 [medline] PHST- 2013/04/28 00:00 [pmc-release] AID - 10.1155/2013/496036 [doi] PST - ppublish SO - Evid Based Complement Alternat Med. 2013;2013:496036. doi: 10.1155/2013/496036. Epub 2013 Apr 28. PMID- 41189590 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251105 LR - 20251107 IS - 2048-7177 (Print) IS - 2048-7177 (Electronic) IS - 2048-7177 (Linking) VI - 13 IP - 11 DP - 2025 Nov TI - Mendelian Randomization and Bioinformatics Analysis Reveal the Potential Protective Role of Metformin in Primary Liver Cancer. PG - e71156 LID - 10.1002/fsn3.71156 [doi] LID - e71156 AB - Primary liver cancer (PLC) and metformin are not well understood to be associated. We conducted a Mendelian randomization (MR) analysis using genetic data from IEU OpenGWAS and FinnGen R10, with metformin as the exposure and PLC as the outcome. The inverse variance weighting (IVW) method was the primary analytical approach, with heterogeneity assessed by Cochran's Q test, pleiotropy by MR-Egger intercept, and outliers by MR-PRESSO. Bioinformatics analyses further explored potential mechanisms, including differential gene expression, protein-protein interactions (PPI), Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses, immune cell infiltration analysis, and drug sensitivity analysis. MR results demonstrated a significant association between metformin use and reduced risk of PLC (β = -5.6046, OR = 0.0037, p = 0.026), with a Benjamini-Hochberg false discovery rate (FDR) adjusted p value of 0.13. However, no causal effect was observed for hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC). By cross-referencing transcriptome data from the GEO database GSE241466 with metformin-related gene loci, 34 overlapping genes were identified. Differentially expressed genes (DEGs) were filtered using |log2FC| > 0 and p < 0.05, with five hub genes (DDX52, KIF11, GCDH, MRPL45, and TICRR) being particularly prominent. Functional enrichment analysis revealed involvement in cGMP-PKG signaling and fatty acid metabolism pathways. Further validation with GEPIA2, TIMER, and TISCH showed correlations between these genes and immune infiltration, while GSCA-based drug sensitivity analysis suggested therapeutic relevance. In summary, these findings indicate that metformin may reduce PLC risk by modulating metabolic and immune-related pathways, supporting its potential value as an adjunct therapeutic agent. However, further validation through large-scale clinical and basic research is warranted. CI - © 2025 The Author(s). Food Science & Nutrition published by Wiley Periodicals LLC. FAU - Ma, Yongxin AU - Ma Y AUID- ORCID: 0009-0008-1729-2501 AD - Department of Hepatobiliary Surgery General Hospital of Ningxia Medical University Yinchuan Ningxia China. AD - Ningxia Medical University Yinchuan Ningxia China. FAU - Qi, Jiaojiao AU - Qi J AD - Department of Obstetrics Function Center Inspection General Hospital of Ningxia Medical University Yinchuan Ningxia China. FAU - Chen, Zhiqiang AU - Chen Z AD - Ningxia Medical University Yinchuan Ningxia China. FAU - Zhang, Yubo AU - Zhang Y AD - Department of Hepatobiliary Surgery General Hospital of Ningxia Medical University Yinchuan Ningxia China. AD - Ningxia Medical University Yinchuan Ningxia China. FAU - Liu, Kejun AU - Liu K AD - Department of Hepatobiliary Surgery General Hospital of Ningxia Medical University Yinchuan Ningxia China. AD - Ningxia Medical University Yinchuan Ningxia China. FAU - Suo, Jiaxin AU - Suo J AD - Ningxia Medical University Yinchuan Ningxia China. FAU - Chen, Bendong AU - Chen B AD - Department of Hepatobiliary Surgery General Hospital of Ningxia Medical University Yinchuan Ningxia China. AD - Ningxia Medical University Yinchuan Ningxia China. FAU - Bu, Yang AU - Bu Y AD - Department of Hepatobiliary Surgery General Hospital of Ningxia Medical University Yinchuan Ningxia China. AD - Ningxia Medical University Yinchuan Ningxia China. LA - eng PT - Journal Article DEP - 20251102 PL - United States TA - Food Sci Nutr JT - Food science & nutrition JID - 101605473 PMC - PMC12580285 OTO - NOTNLM OT - bioinformatics OT - hepatocellular carcinoma OT - mendelian randomization OT - metformin OT - primary liver cancer COIS- The authors declare no conflicts of interest. EDAT- 2025/11/05 06:29 MHDA- 2025/11/05 06:30 PMCR- 2025/11/02 CRDT- 2025/11/05 04:13 PHST- 2025/06/22 00:00 [received] PHST- 2025/09/25 00:00 [revised] PHST- 2025/10/19 00:00 [accepted] PHST- 2025/11/05 06:30 [medline] PHST- 2025/11/05 06:29 [pubmed] PHST- 2025/11/05 04:13 [entrez] PHST- 2025/11/02 00:00 [pmc-release] AID - FSN371156 [pii] AID - 10.1002/fsn3.71156 [doi] PST - epublish SO - Food Sci Nutr. 2025 Nov 2;13(11):e71156. doi: 10.1002/fsn3.71156. eCollection 2025 Nov. PMID- 30151959 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20181010 LR - 20220201 IS - 1861-471X (Electronic) IS - 1861-471X (Linking) VI - 13 IP - 19 DP - 2018 Oct 4 TI - Enzyme-Embedded Metal-Organic Framework Colloidosomes via an Emulsion-Based Approach. PG - 2891-2896 LID - 10.1002/asia.201800976 [doi] AB - Improving the activity and stability of enzymes is significant in enzyme immobilization. Here a facile approach to prepare ring-like ZIF-8 colloidosomes and spherical catalase-embedded ZIF-8 colloidosomes is developed via one-step emulsion-based technique at the water/butanol interface. The influence of the concentrations of ZIF-8 nanocrystals and Pluronic F127 as well as the oil-water ratio was investigated. Compared with in situ biomineralization, the colloidosomes prepared via the pickering emulsion method show successful encapsulation of positively charged enzymes. By using catalase as an immobilized model, the immobilized catalase exhibits high biocatalytic activity, stability and recyclability compared with free catalase. CI - © 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. FAU - Zhu, Guixian AU - Zhu G AD - Beijing Key Laboratory for Optoelectronics Measurement Technology, Beijing Information Science and Technology University, No. 12, Xiaoying East Road, Beijing, 100016, China. FAU - Zhang, Mizhen AU - Zhang M AD - Beijing Key Laboratory for Optoelectronics Measurement Technology, Beijing Information Science and Technology University, No. 12, Xiaoying East Road, Beijing, 100016, China. FAU - Bu, Yang AU - Bu Y AD - College of Materials Sciences and Optoelectronics, University of Chinese Academy of Sciences, No. 19(A) Yuquan Road, Beijing, 100049, China. FAU - Lu, Lidan AU - Lu L AD - School of Precision Instrument and Opto-electronics Engineering, Tianjin University, No.92 Weijin Road, Tianjin, 300072, China. FAU - Lou, Xiaoping AU - Lou X AD - Beijing Key Laboratory for Optoelectronics Measurement Technology, Beijing Information Science and Technology University, No. 12, Xiaoying East Road, Beijing, 100016, China. FAU - Zhu, Lianqing AU - Zhu L AUID- ORCID: 0000-0002-5317-2645 AD - Beijing Key Laboratory for Optoelectronics Measurement Technology, Beijing Information Science and Technology University, No. 12, Xiaoying East Road, Beijing, 100016, China. AD - School of Instrument and Opto-electronics Engineering, Hefei University of Technology, No.193 Xitun Road, Anhui, 230009, China. LA - eng GR - 5221810911/Youth Foundation of Beijing Information Science and Technology University/ GR - 9141823205/The Open Research Project of Beijing Key Laboratory in 2018/ GR - 5211823208/Key Cultivation Projects of Beijing Information Science and Technology University/ PT - Journal Article DEP - 20180827 PL - Germany TA - Chem Asian J JT - Chemistry, an Asian journal JID - 101294643 EIN - Chem Asian J. 2022 Feb 1;17(3):e202101387. doi: 10.1002/asia.202101387. PMID: 35103403 OTO - NOTNLM OT - ZIF-8 nanocrystals OT - biocatalysis OT - colloidosomes OT - enzyme immobilization OT - pickering emulsion EDAT- 2018/08/29 06:00 MHDA- 2018/08/29 06:01 CRDT- 2018/08/29 06:00 PHST- 2018/06/20 00:00 [received] PHST- 2018/07/28 00:00 [revised] PHST- 2018/08/29 06:00 [pubmed] PHST- 2018/08/29 06:01 [medline] PHST- 2018/08/29 06:00 [entrez] AID - 10.1002/asia.201800976 [doi] PST - ppublish SO - Chem Asian J. 2018 Oct 4;13(19):2891-2896. doi: 10.1002/asia.201800976. Epub 2018 Aug 27. PMID- 36620084 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1942-0994 (Electronic) IS - 1942-0900 (Print) IS - 1942-0994 (Linking) VI - 2022 DP - 2022 TI - BYHW Decoction Improves Cognitive Impairments in Rats with Cerebral Microinfarcts via Activation of the PKA/CREB Pathway. PG - 4455654 LID - 10.1155/2022/4455654 [doi] LID - 4455654 AB - Cerebral microinfarcts (CMIs) are characterized by sporadic obstruction of small vessels leading to neurons death. They are associated with increased risk of cognitive impairments and may have different risk factors compared with macroinfarcts. CMIs have a high incidence and result in heavy social burden; thus, it is essential to provide reasonable treatment in clinical practice. However, there are relatively few researches on the mechanism and treatment of CMIs, and the literature is composed almost exclusively of community-or hospital based on autopsy or imageological studies focusing on elderly patients. The Bu Yang Huan Wu (BYHW) decoction, a traditional Chinese herbal formula, has long been used to treat stroke and stroke-related diseases, including cognitive impairments. We applied microsphere-induced CMI model in rats to investigate the behavioral and molecular consequences of CMIs and to determine how they were ameliorated by BYHW decoction treatment. We then used the Morris water maze, quantitative proteomics, immunohistochemistry, and other molecular assays and found that activation of the PKA/CREB pathway by BYHW decoction treatment may reverse mitochondrial dysfunction, inhibit apoptosis of hippocampal neurons, and ameliorate CMI-induced cognitive impairments in rats. Collectively, these findings confirmed the therapeutic potential of the BYHW decoction in treating cognitive impairments induced by CMIs and demonstrated a viable mechanism for its action. CI - Copyright © 2022 Bingjie Xue et al. FAU - Xue, Bingjie AU - Xue B AUID- ORCID: 0000-0002-8872-928X AD - Institute of Basic Medical Sciences, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China. AD - Institute for Brain Disorders, Beijing University of Chinese Medicine, Beijing, China. AD - Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China. AD - Chinese Medicine Key Research Room of Encephalopathy Syndrome and Treatment of the State Administration of TCM, Beijing, China. FAU - Ma, Bo AU - Ma B AD - Institute of Basic Medical Sciences, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China. AD - Institute of Materia Medica Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China. FAU - Yao, Yaoyao AU - Yao Y AD - Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China. AD - Chinese Medicine Key Research Room of Encephalopathy Syndrome and Treatment of the State Administration of TCM, Beijing, China. FAU - Zhao, Aimei AU - Zhao A AD - Institute of Basic Medical Sciences, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China. FAU - Gao, Ying AU - Gao Y AUID- ORCID: 0000-0001-6972-3846 AD - Institute for Brain Disorders, Beijing University of Chinese Medicine, Beijing, China. AD - Department of Neurology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China. FAU - Liu, Jianxun AU - Liu J AUID- ORCID: 0000-0002-7424-8282 AD - Institute of Basic Medical Sciences, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China. AD - NICM Health Research Institute, Western Sydney University, Locked Bag 1797, Penrith, NSW 2751, Australia. LA - eng PT - Journal Article DEP - 20221230 PL - United States TA - Oxid Med Cell Longev JT - Oxidative medicine and cellular longevity JID - 101479826 SB - IM MH - Rats MH - Animals MH - *Stroke/drug therapy MH - *Cognitive Dysfunction/drug therapy/metabolism MH - Hippocampus/metabolism MH - Apoptosis MH - Risk Factors PMC - PMC9822752 COIS- The authors declare that there is no conflict of interest regarding the publication of the study. EDAT- 2023/01/10 06:00 MHDA- 2023/01/11 06:00 PMCR- 2022/12/30 CRDT- 2023/01/09 04:05 PHST- 2022/05/23 00:00 [received] PHST- 2022/11/09 00:00 [revised] PHST- 2022/11/16 00:00 [accepted] PHST- 2023/01/09 04:05 [entrez] PHST- 2023/01/10 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/12/30 00:00 [pmc-release] AID - 10.1155/2022/4455654 [doi] PST - epublish SO - Oxid Med Cell Longev. 2022 Dec 30;2022:4455654. doi: 10.1155/2022/4455654. eCollection 2022. PMID- 36451469 OWN - NLM STAT- MEDLINE DCOM- 20221202 LR - 20240908 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 101 IP - 47 DP - 2022 Nov 25 TI - Efficacy and safety of Tonifying Qi and activating blood Chinese herbal prescriptions for myocardial infarction: Study protocol for a multi-centered RCT. PG - e31680 LID - 10.1097/MD.0000000000031680 [doi] LID - e31680 AB - INTRODUCTION: Acute myocardial infarction (AMI) is a common cause of death worldwide and heart failure (HF) is the main complication. Although the increase in percutaneous coronary intervention and drug treatment can reduce in-hospital mortality after AMI, the incidence of HF after AMI and the resulting risk of death are still rising, which causes difficulties in the rehabilitation of AMI patients after reperfusion. METHODS: In this prospective, multicenter, randomized, double-blind, double-dummy, placebo-controlled trial, we will assigned 673 eligible patients with AMI after reperfusion into 4 groups: receiving Nao-Xin-Tong capsule (NXT), Bu-Yang-Huan-Wu (BYHW) granule (BYHW), Yang-Yin-Tong-Nao granule (YYTN), or placebo. The course of treatment will be 3 months. The primary outcome is HF incidence within 180 days. Nao-Xin-Tong capsule, BYHW granule, and Yang-Yin-Tong-Nao granule are different traditional Chinese medicines used for tonifying Qi and activating blood (TQAB). RESULTS: Three months of TQAB combined with Western medicine may reduce the incidence of HF after reperfusion of AMI and improve patients' quality of life. DISCUSSION: This study will provide an important basis for the application of traditional Chinese medicine in patients with AMI after reperfusion and provide an evidence-based basis for the prevention and treatment strategy of HF after AMI. CI - Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Shang, Juju AU - Shang J AD - Department of Cardiology, Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, Beijing, China. FAU - Qiu, Shenglei AU - Qiu S AUID- ORCID: 0000-0003-1450-216 AD - Department of Cardiology, Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, Beijing, China. FAU - Zhou, Yingjie AU - Zhou Y AD - South of Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China. FAU - Liu, Sina AU - Liu S AD - Beijing University of Chinese Medicine, Beijing, China. FAU - Wang, Zi AU - Wang Z AD - Beijing University of Chinese Medicine, Beijing, China. FAU - Lai, Xiaolei AU - Lai X AD - Department of Cardiology, Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, Beijing, China. FAU - Liu, Hongxu AU - Liu H AD - Department of Cardiology, Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, Beijing, China. FAU - Zhou, Mingxue AU - Zhou M AD - Beijing Insititute of Traditional Chinese Medicine, Beijing, China. FAU - Zhang, Zhenmin AU - Zhang Z AD - Department of Cardiology, Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, Beijing, China. FAU - Liu, Pengyu AU - Liu P AD - Capital Medical University, Beijing, China. FAU - Zhang, Fangfang AU - Zhang F AD - Department of Cardiology, Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, Beijing, China. FAU - Meng, Xianghui AU - Meng X AD - Department of Cardiology, Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, Beijing, China. LA - eng PT - Clinical Trial Protocol PT - Journal Article PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R RN - G1LN9045DK (Busulfan) SB - IM MH - Humans MH - Qi MH - Quality of Life MH - Prospective Studies MH - *Myocardial Infarction/drug therapy MH - *Heart Failure/drug therapy MH - Prescriptions MH - Busulfan MH - China/epidemiology MH - Randomized Controlled Trials as Topic MH - Multicenter Studies as Topic PMC - PMC9704927 COIS- The authors have no conflicts of interest to disclose. EDAT- 2022/12/02 06:00 MHDA- 2022/12/03 06:00 PMCR- 2022/11/25 CRDT- 2022/12/01 01:05 PHST- 2022/12/01 01:05 [entrez] PHST- 2022/12/02 06:00 [pubmed] PHST- 2022/12/03 06:00 [medline] PHST- 2022/11/25 00:00 [pmc-release] AID - 00005792-202211250-00093 [pii] AID - 10.1097/MD.0000000000031680 [doi] PST - ppublish SO - Medicine (Baltimore). 2022 Nov 25;101(47):e31680. doi: 10.1097/MD.0000000000031680. PMID- 16970538 OWN - NLM STAT- MEDLINE DCOM- 20070109 LR - 20220408 IS - 1075-5535 (Print) IS - 1075-5535 (Linking) VI - 12 IP - 7 DP - 2006 Sep TI - Traditional chinese medicine treatment of epilepsy. PG - 673-7 AB - OBJECTIVES: To evaluate the effectiveness of traditional Chinese medicine, specifically the traditional herbal formulation Bu-yang-huan-wu-tang, for treating epilepsy stemming from cerebrovascular dysfunction. SUBJECTS: Three adult patients with epilepsy refractory to standard antiepileptic medications were involved. RESULTS: All three showed substantial improvement in the frequency and severity of seizures after Bu-yanghuan- wu-tang was added to conventional medical treatment. CONCLUSIONS: Decrease of seizure frequency and severity in three epileptic patients was achieved by adding Bu-yang-huan-wu-tang to conventional therapy according to the principles of Traditional Chinese Medicine (TCM) theory. This treatment mainly relied on the resolution of blood stagnation in cerebrovascular systems. Blood stagnation is an important underlying pathology of many disease processes according to TCM theory. FAU - Hijikata, Yasuyo AU - Hijikata Y AD - Toyodo Hijikata Clinic, ibaraki-shi, Osaka, Japan. Hijikata@osb.att.ne.jp FAU - Yasuhara, Akihiro AU - Yasuhara A FAU - Yoshida, Yuka AU - Yoshida Y FAU - Sento, Seishiro AU - Sento S LA - eng PT - Case Reports PT - Journal Article PL - United States TA - J Altern Complement Med JT - Journal of alternative and complementary medicine (New York, N.Y.) JID - 9508124 RN - 0 (Anticonvulsants) RN - 0 (Drugs, Chinese Herbal) SB - IM MH - Adult MH - Anticonvulsants/*administration & dosage MH - Drugs, Chinese Herbal/*administration & dosage MH - Epilepsies, Partial/*drug therapy MH - Female MH - Humans MH - Male MH - Medicine, Chinese Traditional/*methods MH - *Phytotherapy MH - Plants, Medicinal MH - Quality of Life MH - Treatment Outcome EDAT- 2006/09/15 09:00 MHDA- 2007/01/11 09:00 CRDT- 2006/09/15 09:00 PHST- 2006/09/15 09:00 [pubmed] PHST- 2007/01/11 09:00 [medline] PHST- 2006/09/15 09:00 [entrez] AID - 10.1089/acm.2006.12.673 [doi] PST - ppublish SO - J Altern Complement Med. 2006 Sep;12(7):673-7. doi: 10.1089/acm.2006.12.673. PMID- 36951129 OWN - NLM STAT- MEDLINE DCOM- 20230517 LR - 20230524 IS - 1473-0189 (Electronic) IS - 1473-0189 (Linking) VI - 23 IP - 10 DP - 2023 May 16 TI - Continuous-flow label-free size fractionation of extracellular vesicles through electrothermal fluid rolls and dielectrophoresis synergistically integrated in a microfluidic device. PG - 2421-2433 LID - 10.1039/d2lc01193j [doi] AB - Extracellular vesicles (EVs) are cell-derived bioparticles that play significant roles in various biological processes including cell-to-cell communication and intercellular delivery. Additionally, they hold great potential as liquid biopsy biomarkers for pre-diagnostic applications. However, the isolation of EV subpopulations, especially exosomes from a biological fluid remains a challenge due to their submicron range. Here, we demonstrate continuous-flow label-free size fractionation of EVs for the first time through a synergistic combination of electrothermal fluid rolls and dielectrophoresis in a microfluidic device. The device features three dimensional microelectrodes with unique sidewall contours that give rise to effective electrothermal fluid rolls in cooperation with dielectrophoretic forces for the electrokinetic manipulation and size separation of submicron particles. We first validate the device functionality by separating submicron polystyrene particles from binary mixtures with a cut-off size of ∼200 nm and then isolate intact exosomes from cell culture medium or blood serum with a high recovery rate and purity (∼80%). The device operation in a high-conductivity medium renders the method ideal for the purification of target bioparticles directly from physiological fluids, and may offer a robust and versatile platform for EV related diagnostic applications. FAU - Bu, Yang AU - Bu Y AD - Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong SAR, China. eelyobas@ust.hk. FAU - Wang, Jinhui AU - Wang J AD - Division of Life Sciences, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong SAR, China. FAU - Ni, Sheng AU - Ni S AUID- ORCID: 0000-0002-1786-7466 AD - Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong SAR, China. eelyobas@ust.hk. FAU - Guo, Yusong AU - Guo Y AD - Division of Life Sciences, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong SAR, China. FAU - Yobas, Levent AU - Yobas L AUID- ORCID: 0000-0003-3151-5616 AD - Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong SAR, China. eelyobas@ust.hk. AD - Department of Chemical and Biological Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, SAR, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230516 PL - England TA - Lab Chip JT - Lab on a chip JID - 101128948 SB - IM MH - *Microfluidic Analytical Techniques MH - *Extracellular Vesicles MH - Microelectrodes MH - *Exosomes MH - Lab-On-A-Chip Devices EDAT- 2023/03/24 06:00 MHDA- 2023/05/17 06:42 CRDT- 2023/03/23 05:23 PHST- 2023/05/17 06:42 [medline] PHST- 2023/03/24 06:00 [pubmed] PHST- 2023/03/23 05:23 [entrez] AID - 10.1039/d2lc01193j [doi] PST - epublish SO - Lab Chip. 2023 May 16;23(10):2421-2433. doi: 10.1039/d2lc01193j. PMID- 23983777 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20130828 LR - 20220330 IS - 1741-427X (Print) IS - 1741-4288 (Electronic) IS - 1741-427X (Linking) VI - 2013 DP - 2013 TI - Can medical herbs stimulate regeneration or neuroprotection and treat neuropathic pain in chemotherapy-induced peripheral neuropathy? PG - 423713 LID - 10.1155/2013/423713 [doi] LID - 423713 AB - Chemotherapy-induced neuropathy (CIPN) has a relevant impact on the quality of life of cancer patients. There are no curative conventional treatments, so further options have to be investigated. We conducted a systematic review in English and Chinese language databases to illuminate the role of medical herbs. 26 relevant studies on 5 single herbs, one extract, one receptor-agonist, and 8 combinations of herbs were identified focusing on the single herbs Acorus calamus rhizoma, Cannabis sativa fructus, Chamomilla matricaria, Ginkgo biloba, Salvia officinalis, Sweet bee venom, Fritillaria cirrhosae bulbus, and the herbal combinations Bu Yang Huan Wu, modified Bu Yang Huan Wu plus Liuwei Di Huang, modified Chai Hu Long Gu Mu Li Wan, Geranii herba plus Aconiti lateralis praeparata radix , Niu Che Sen Qi Wan (Goshajinkigan), Gui Zhi Jia Shu Fu Tang (Keishikajutsubuto), Huang Qi Wu Wu Tang (Ogikeishigomotsuto), and Shao Yao Gan Cao Tang (Shakuyakukanzoto). The knowledge of mechanism of action is still limited, the quality of clinical trials needs further improvement, and studies have not yielded enough evidence to establish a standard practice, but a lot of promising substances have been identified. While CIPN has multiple mechanisms of neuronal degeneration, a combination of herbs or substances might deal with multiple targets for the aim of neuroprotection or neuroregeneration in CIPN. FAU - Schröder, Sven AU - Schröder S AD - HanseMerkur Center for Traditional Chinese Medicine at the University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany ; ICBAS, University of Porto, Rua de Jorge Viterbo Ferreira No. 228, 4050-313 Porto, Portugal. FAU - Beckmann, Kathrin AU - Beckmann K FAU - Franconi, Giovanna AU - Franconi G FAU - Meyer-Hamme, Gesa AU - Meyer-Hamme G FAU - Friedemann, Thomas AU - Friedemann T FAU - Greten, Henry Johannes AU - Greten HJ FAU - Rostock, Matthias AU - Rostock M FAU - Efferth, Thomas AU - Efferth T LA - eng PT - Journal Article DEP - 20130731 PL - United States TA - Evid Based Complement Alternat Med JT - Evidence-based complementary and alternative medicine : eCAM JID - 101215021 PMC - PMC3747437 EDAT- 2013/08/29 06:00 MHDA- 2013/08/29 06:01 PMCR- 2013/07/31 CRDT- 2013/08/29 06:00 PHST- 2013/04/30 00:00 [received] PHST- 2013/06/05 00:00 [accepted] PHST- 2013/08/29 06:00 [entrez] PHST- 2013/08/29 06:00 [pubmed] PHST- 2013/08/29 06:01 [medline] PHST- 2013/07/31 00:00 [pmc-release] AID - 10.1155/2013/423713 [doi] PST - ppublish SO - Evid Based Complement Alternat Med. 2013;2013:423713. doi: 10.1155/2013/423713. Epub 2013 Jul 31. PMID- 39538887 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241114 IS - 1094-4087 (Electronic) IS - 1094-4087 (Linking) VI - 32 IP - 14 DP - 2024 Jul 1 TI - High precision wavefront correction method in interferometer testing. PG - 24480-24497 LID - 10.1364/OE.526063 [doi] AB - A wavefront correction method is proposed for high-precision optic surfacing, addressing the discrepancy between wavefront and real surface errors in Fizeau interferometer testing. We believe this to be a proposed novel method that encompasses optical surface function parameters fitting, lateral distortion correction, misalignment error removal, and sag surface error calculation. The method's error has been thoroughly analyzed, including aspects of function parameters fitting, ray tracing, and interpolation. The effectiveness of the method was demonstrated by correcting the wavefront of an off-axis parabolic mirror in null testing configurations, significantly reducing artificially created annular errors and improving off-axis direction errors from 0.23λ to 0.05λ (λ=632.8 nm), with the PV of aspheric departures exceeding 8.5 mm. FAU - Wu, Lunzhe AU - Wu L FAU - Zhao, Liangxiao AU - Zhao L FAU - Fang, Yuanyuan AU - Fang Y FAU - Walker, David AU - Walker D FAU - Yu, Guoyu AU - Yu G FAU - Li, Hongyu AU - Li H FAU - Bu, Yang AU - Bu Y LA - eng PT - Journal Article PL - United States TA - Opt Express JT - Optics express JID - 101137103 SB - IM EDAT- 2024/11/14 17:33 MHDA- 2024/11/14 17:34 CRDT- 2024/11/14 01:03 PHST- 2024/11/14 17:34 [medline] PHST- 2024/11/14 17:33 [pubmed] PHST- 2024/11/14 01:03 [entrez] AID - 552333 [pii] AID - 10.1364/OE.526063 [doi] PST - ppublish SO - Opt Express. 2024 Jul 1;32(14):24480-24497. doi: 10.1364/OE.526063. PMID- 37744321 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230926 IS - 1948-5190 (Print) IS - 1948-5190 (Electronic) VI - 15 IP - 9 DP - 2023 Sep 16 TI - Endoscopic Ruler for varix size measurement: A multicenter pilot study. PG - 564-573 LID - 10.4253/wjge.v15.i9.564 [doi] AB - BACKGROUND: We invented Endoscopic Ruler, a new endoscopic device to measure the size of varices in patients with cirrhosis and portal hypertension. AIM: To assess the feasibility and safety of Endoscopic Ruler, and evaluate the agreement on identifying large oesophageal varices (OV) between Endoscopic Ruler and the endoscopists, as well as the interobserver agreement on diagnosing large OV using Endoscopic Ruler. METHODS: We prospectively and consecutively enrolled patients with cirrhosis from 11 hospitals, all of whom got esophagogastroduodenoscopy (EGD) with Endoscopic Ruler. The primary study outcome was a successful measurement of the size of varices using Endoscopic Ruler. The secondary outcomes included adverse events, operation time, the agreement of identifying large OV between the objective measurement of Endoscopic Ruler and the empirical reading of endoscopists, together with the interobserver agreement on diagnosing large OV by Endoscopic Ruler. RESULTS: From November 2020 to April 2022, a total of 120 eligible patients with cirrhosis were recruited and all of them underwent EGD examinations with Endoscopic Ruler successfully without any adverse event. The median operation time of Endoscopic Ruler was 3.00 min [interquartile range (IQR): 3.00 min]. The kappa value between Endoscopic Ruler and the endoscopists while detecting large OV was 0.52, demonstrating a moderate agreement. The kappa value for diagnosing large OV using Endoscopic Ruler among the six independent observers was 0.77, demonstrating a substantial agreement. CONCLUSION: The data demonstrates that Endoscopic Ruler is feasible and safe for measuring the size of varices in patients with cirrhosis and portal hypertension. Endoscopic Ruler is potential to promote the clinical practice of the two-grade classification system of OV. CI - ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. FAU - Huang, Yi-Fei AU - Huang YF AD - Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China. FAU - Hu, Sheng-Juan AU - Hu SJ AD - Department of Gastroenterology, People's Hospital of Ningxia Hui Autonomous Region, Ningxia Medical University Affiliated People's Hospital of Autonomous Region, Yinchuan 750000, Ningxia Hui Autonomous Region, China. FAU - Bu, Yang AU - Bu Y AD - Department of Gastroenterology, People's Hospital of Ningxia Hui Autonomous Region, Ningxia Medical University Affiliated People's Hospital of Autonomous Region, Yinchuan 750000, Ningxia Hui Autonomous Region, China. FAU - Li, Yi-Ling AU - Li YL AD - Department of Gastroenterology, The First Affiliated Hospital of China Medical University, Shenyang 110000, Liaoning Province, China. FAU - Deng, Yan-Hong AU - Deng YH AD - Department of Gastroenterology, People's Hospital of Ningxia Hui Autonomous Region, Ningxia Medical University Affiliated People's Hospital of Autonomous Region, Yinchuan 750000, Ningxia Hui Autonomous Region, China. FAU - Hu, Jian-Ping AU - Hu JP AD - Department of Gastroenterology, Yinchuan First People's Hospital, Yinchuan 750000, Ningxia Hui Autonomous Region, China. FAU - Yang, Shao-Qi AU - Yang SQ AD - Department of Gastroenterology, Ningxia Medical University General Hospital, Yinchuan 750000, Ningxia Hui Autonomous Region, China. FAU - Shen, Qian AU - Shen Q AD - Department of Gastroenterology, Yinchuan Second People's Hospital, Yinchuan 750000, Ningxia Hui Autonomous Region, China. FAU - McAlindon, Mark AU - McAlindon M AD - Academic Department of Gastroenterology and Hepatology, Sheffield Teaching Hospitals NHS Trust, AL 35660, Sheffield, United Kingdom. FAU - Shi, Rui-Chun AU - Shi RC AD - Department of Gastroenterology, Wuzhong People's Hospital, Wuzhong 751100, Ningxia Hui Autonomous Region, China. FAU - Li, Xiao-Qin AU - Li XQ AD - Department of Gastroenterology, The Fifth People's Hospital of Ningxia Hui Autonomous Region, Shizuishan 753000, Ningxia Hui Autonomous Region, China. FAU - Song, Tie-Ying AU - Song TY AD - Department of Second Gastroenterology, The Sixth People's Hospital of Shenyang, Shenyang 110000, Liaoning Province, China. FAU - Qi, Hai-Long AU - Qi HL AD - Department of Gastroenterology, Shizuishan Second People's Hospital, Shizuishan 753000, Ningxia Hui Autonomous Region, China. FAU - Jiao, Tai-Wei AU - Jiao TW AD - Department of Gastroenterology, The First Affiliated Hospital of China Medical University, Shenyang 110000, Liaoning Province, China. FAU - Liu, Meng-Yuan AU - Liu MY AD - Department of Gastroenterology, The First Affiliated Hospital of China Medical University, Shenyang 110000, Liaoning Province, China. FAU - He, Fang AU - He F AD - Department of Gastroenterology, Ningxia Medical University General Hospital, Yinchuan 750000, Ningxia Hui Autonomous Region, China. FAU - Zhu, Jun AU - Zhu J AD - Department of Gastroenterology, The Fifth People's Hospital of Ningxia Hui Autonomous Region, Shizuishan 753000, Ningxia Hui Autonomous Region, China. FAU - Ma, Bin AU - Ma B AD - Department of Gastroenterology, Yinchuan First People's Hospital, Yinchuan 750000, Ningxia Hui Autonomous Region, China. FAU - Yu, Xiao-Bin AU - Yu XB AD - Department of Gastroenterology, People's Hospital of Ningxia Hui Autonomous Region, Ningxia Medical University Affiliated People's Hospital of Autonomous Region, Yinchuan 750000, Ningxia Hui Autonomous Region, China. FAU - Guo, Jian-Yang AU - Guo JY AD - Department of Gastroenterology, People's Hospital of Ningxia Hui Autonomous Region, Ningxia Medical University Affiliated People's Hospital of Autonomous Region, Yinchuan 750000, Ningxia Hui Autonomous Region, China. FAU - Yu, Yue-Hua AU - Yu YH AD - Department of Gastroenterology, Yinchuan First People's Hospital, Yinchuan 750000, Ningxia Hui Autonomous Region, China. FAU - Yong, Hai-Jiang AU - Yong HJ AD - Department of Gastroenterology, Wuzhong People's Hospital, Wuzhong 751100, Ningxia Hui Autonomous Region, China. FAU - Yao, Wen-Tun AU - Yao WT AD - Department of Gastroenterology, Yinchuan First People's Hospital, Yinchuan 750000, Ningxia Hui Autonomous Region, China. FAU - Ye, Ting AU - Ye T AD - Department of Gastroenterology, Yinchuan First People's Hospital, Yinchuan 750000, Ningxia Hui Autonomous Region, China. FAU - Wang, Hua AU - Wang H AD - Department of Gastroenterology, The Fifth People's Hospital of Ningxia Hui Autonomous Region, Shizuishan 753000, Ningxia Hui Autonomous Region, China. FAU - Dong, Wen-Fu AU - Dong WF AD - Department of Gastroenterology, The Fifth People's Hospital of Ningxia Hui Autonomous Region, Shizuishan 753000, Ningxia Hui Autonomous Region, China. FAU - Liu, Jian-Guo AU - Liu JG AD - Department of Gastroenterology, Zhongwei People's Hospital, Zhongwei 755000, Ningxia Hui Autonomous Region, China. FAU - Wei, Qiang AU - Wei Q AD - Department of Gastroenterology, Zhongwei People's Hospital, Zhongwei 755000, Ningxia Hui Autonomous Region, China. FAU - Tian, Jing AU - Tian J AD - Department of Gastroenterology, Zhongwei People's Hospital, Zhongwei 755000, Ningxia Hui Autonomous Region, China. FAU - Li, Xiao-Guo AU - Li XG AD - Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China. FAU - Dray, Xavier AU - Dray X AD - Department of Hepato-Gastroenterology, ETIS, ENSEA, CNRS, Sorbonne Université & APHP, Hôpital Saint Antoine, Université Paris-Seine, Université de Cergy-Pontoise, Paris 75012, Sélectionner, France. FAU - Qi, Xiao-Long AU - Qi XL AD - Center of Portal Hypertension, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing 210000, Jiangsu Province, China. qixiaolong@vip.163.com. LA - eng PT - Journal Article PL - United States TA - World J Gastrointest Endosc JT - World journal of gastrointestinal endoscopy JID - 101532474 PMC - PMC10514704 OTO - NOTNLM OT - Cirrhosis OT - Endoscopic ruler OT - Esophagogastroduodenoscopy OT - Oesophageal varices OT - Portal hypertension COIS- Conflict-of-interest statement: All authors declared no conflicts of interest related to this study. EDAT- 2023/09/25 06:42 MHDA- 2023/09/25 06:43 PMCR- 2023/09/16 CRDT- 2023/09/25 04:42 PHST- 2023/08/03 00:00 [received] PHST- 2023/08/18 00:00 [revised] PHST- 2023/09/01 00:00 [accepted] PHST- 2023/09/25 06:43 [medline] PHST- 2023/09/25 06:42 [pubmed] PHST- 2023/09/25 04:42 [entrez] PHST- 2023/09/16 00:00 [pmc-release] AID - 10.4253/wjge.v15.i9.564 [doi] PST - ppublish SO - World J Gastrointest Endosc. 2023 Sep 16;15(9):564-573. doi: 10.4253/wjge.v15.i9.564. PMID- 38364051 OWN - NLM STAT- MEDLINE DCOM- 20240228 LR - 20240731 IS - 1520-6882 (Electronic) IS - 0003-2700 (Linking) VI - 96 IP - 8 DP - 2024 Feb 27 TI - High-Performance Gel-Free and Label-Free Size Fractionation of Extracellular Vesicles with Two-Dimensional Electrophoresis in a Microfluidic Artificial Sieve. PG - 3508-3516 LID - 10.1021/acs.analchem.3c05290 [doi] AB - Extracellular vesicles (EVs) are cell-derived particles that exhibit diverse sizes, molecular contents, and clinical implications for various diseases depending on their specific subpopulations. However, fractionation of EV subpopulations with high resolution, efficiency, purity, and yield remains an elusive goal due to their diminutive sizes. In this study, we introduce a novel strategy that effectively separates EV subpopulations in a gel-free and label-free manner, using two-dimensional (2D) electrophoresis in a microfluidic artificial sieve. The microfabricated artificial sieve consists of periodically arranged micro-slit-well structures in a 2D array and generates an anisotropic electric field pattern to size fractionate EVs into discrete streams and steer the subpopulations into designated outlets for collection within a minute. Along with fractionating EV subpopulations, contaminants such as free proteins and short nucleic acids can be simultaneously directed to waste outlets, thus accomplishing both size fractionation and purification of EVs with high performance. Our platform offers a simple, rapid, and versatile solution for EV subpopulation isolation, which can potentially facilitate the discovery of biomarkers for specific EV subtypes and the development of EV-based therapeutics. FAU - Bu, Yang AU - Bu Y AD - Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong SAR 999077, P. R. China. FAU - Wang, Jinhui AU - Wang J AD - Division of Life Science, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong SAR 999077, P. R. China. FAU - Ni, Sheng AU - Ni S AD - Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong SAR 999077, P. R. China. FAU - Lu, Zechen AU - Lu Z AD - Division of Life Science, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong SAR 999077, P. R. China. FAU - Guo, Yusong AU - Guo Y AD - Division of Life Science, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong SAR 999077, P. R. China. FAU - Yobas, Levent AU - Yobas L AUID- ORCID: 0000-0003-3151-5616 AD - Department of Electronic and Computer Engineering, Department of Chemical and Biological Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong SAR 999077, P. R. China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240216 PL - United States TA - Anal Chem JT - Analytical chemistry JID - 0370536 RN - 0 (Proteins) RN - 0 (Biomarkers) SB - IM MH - *Microfluidics MH - *Extracellular Vesicles/chemistry MH - Proteins/analysis MH - Electrophoresis MH - Biomarkers/analysis EDAT- 2024/02/16 18:42 MHDA- 2024/02/28 06:45 CRDT- 2024/02/16 14:54 PHST- 2024/02/28 06:45 [medline] PHST- 2024/02/16 18:42 [pubmed] PHST- 2024/02/16 14:54 [entrez] AID - 10.1021/acs.analchem.3c05290 [doi] PST - ppublish SO - Anal Chem. 2024 Feb 27;96(8):3508-3516. doi: 10.1021/acs.analchem.3c05290. Epub 2024 Feb 16. PMID- 35991576 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220823 IS - 1664-8021 (Print) IS - 1664-8021 (Electronic) IS - 1664-8021 (Linking) VI - 13 DP - 2022 TI - Pan-cancer analysis of the prognostic and immunological role of ANLN: An onco-immunological biomarker. PG - 922472 LID - 10.3389/fgene.2022.922472 [doi] LID - 922472 AB - Anillin actin-binding protein (ANLN) is crucially involved in cell proliferation and migration. Moreover, ANLN is significantly in tumor progression in several types of human malignant tumors; however, it remains unclear whether ANLN acts through common molecular pathways within different tumor microenvironments, pathogeneses, prognoses and immunotherapy contexts. Therefore, this study aimed to perform bioinformatics analysis to examine the correlation of ANLN with tumor immune infiltration, immune evasion, tumor progression, immunotherapy, and tumor prognosis. We observed increased ANLN expression in multiple tumors, which could be involved in tumor cell proliferation, migration, infiltration, and prognosis. The level of ANLN methylation and genetic alteration was associated with prognosis in numerous tumors. ANLN facilitates tumor immune evasion through different mechanisms, which involve T-cell exclusion in different cancer types and tumor-infiltrating immune cells in colon adenocarcinoma, kidney renal clear cell carcinoma, liver hepatocellular carcinoma, and prostate adenocarcinoma. Additionally, ANLN is correlated with immune or chemotherapeutic outcomes in malignant cancers. Notably, ANLN expression may be a predictive biomarker for the response to immune checkpoint inhibitors. Taken together, our findings suggest that ANLN can be used as an onco-immunological biomarker and could serve as a hallmark for tumor screening, prognosis, individualized treatment design, and follow-up. CI - Copyright © 2022 Liu, Cui, Li, Tang, Niu, Hao, Bu and Chen. FAU - Liu, Kejun AU - Liu K AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, China. AD - Ningxia Hepatobiliary and Pancreatic Surgical Diseases Clinical Medical Research Center, Yinchuan, China. FAU - Cui, Lei AU - Cui L AD - School of Clinical Medicine, Ningxia Medical University, Yinchuan, China. FAU - Li, Cunquan AU - Li C AD - Ningxia Hepatobiliary and Pancreatic Surgical Diseases Clinical Medical Research Center, Yinchuan, China. FAU - Tang, Chaofeng AU - Tang C AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, China. AD - Ningxia Hepatobiliary and Pancreatic Surgical Diseases Clinical Medical Research Center, Yinchuan, China. FAU - Niu, Yiming AU - Niu Y AD - School of Clinical Medicine, Ningxia Medical University, Yinchuan, China. FAU - Hao, Ji AU - Hao J AD - School of Clinical Medicine, Ningxia Medical University, Yinchuan, China. FAU - Bu, Yang AU - Bu Y AD - School of Clinical Medicine, Ningxia Medical University, Yinchuan, China. AD - Department of Hepatobiliary Surgery, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, China. FAU - Chen, Bendong AU - Chen B AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, China. AD - Ningxia Hepatobiliary and Pancreatic Surgical Diseases Clinical Medical Research Center, Yinchuan, China. AD - School of Clinical Medicine, Ningxia Medical University, Yinchuan, China. LA - eng PT - Journal Article DEP - 20220805 PL - Switzerland TA - Front Genet JT - Frontiers in genetics JID - 101560621 PMC - PMC9390797 OTO - NOTNLM OT - anillin actin-binding protein (ANLN) OT - bioinformatics analysis OT - immunization OT - pan-cancer OT - prognosis COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/08/23 06:00 MHDA- 2022/08/23 06:01 PMCR- 2022/08/05 CRDT- 2022/08/22 04:13 PHST- 2022/04/18 00:00 [received] PHST- 2022/07/05 00:00 [accepted] PHST- 2022/08/22 04:13 [entrez] PHST- 2022/08/23 06:00 [pubmed] PHST- 2022/08/23 06:01 [medline] PHST- 2022/08/05 00:00 [pmc-release] AID - 922472 [pii] AID - 10.3389/fgene.2022.922472 [doi] PST - epublish SO - Front Genet. 2022 Aug 5;13:922472. doi: 10.3389/fgene.2022.922472. eCollection 2022. PMID- 37916921 OWN - NLM STAT- MEDLINE DCOM- 20231115 LR - 20231118 IS - 1520-6882 (Electronic) IS - 0003-2700 (Linking) VI - 95 IP - 45 DP - 2023 Nov 14 TI - Accelerated Electrophoretic Focusing and Purification of DNA Based on Synchronous Coefficient of Drag Alteration. PG - 16453-16458 LID - 10.1021/acs.analchem.3c03632 [doi] AB - Synchronous coefficient of drag alteration refers to a multidimensional transport mechanism where a net drift of molecules is achieved under a zero-time-average alternating motive force by perturbing their drag coefficient synchronously with the applied force. An electrophoretic form of the method is often applied to focus and purify nucleic acids in a gel under rotating electric fields. However, this method requires lengthy operation due to the use of limited field strengths. Here, using DNA as target molecules, we demonstrate that the operation time can be reduced from hours to minutes by replacing polymer gel with a microfabricated artificial sieve. We also describe an electrophoretic protocol that facilitates the collection of purified DNA from the sieve, which is shown to yield amplifiable DNA from crude samples including the lysates of cultured cells and whole blood. The sieve can be further equipped with nucleic acid amplification and detection functions for a point-of-care diagnostic application. FAU - Bu, Yang AU - Bu Y AD - Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, SAR 999077, P.R.China. FAU - Ni, Sheng AU - Ni S AD - Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, SAR 999077, P.R.China. FAU - Yobas, Levent AU - Yobas L AUID- ORCID: 0000-0003-3151-5616 AD - Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, SAR 999077, P.R.China. AD - Department of Chemical and Biological Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, SAR 999077, P.R.China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20231102 PL - United States TA - Anal Chem JT - Analytical chemistry JID - 0370536 RN - 9007-49-2 (DNA) RN - 0 (Nucleic Acids) RN - 0 (Polymers) SB - IM MH - *DNA MH - Electrophoresis/methods MH - *Nucleic Acids MH - Polymers MH - Nucleic Acid Amplification Techniques EDAT- 2023/11/02 12:42 MHDA- 2023/11/15 06:42 CRDT- 2023/11/02 09:54 PHST- 2023/11/15 06:42 [medline] PHST- 2023/11/02 12:42 [pubmed] PHST- 2023/11/02 09:54 [entrez] AID - 10.1021/acs.analchem.3c03632 [doi] PST - ppublish SO - Anal Chem. 2023 Nov 14;95(45):16453-16458. doi: 10.1021/acs.analchem.3c03632. Epub 2023 Nov 2. PMID- 33888645 OWN - NLM STAT- MEDLINE DCOM- 20210726 LR - 20210726 IS - 1945-4589 (Electronic) IS - 1945-4589 (Linking) VI - 13 IP - 8 DP - 2021 Apr 22 TI - LINC00514 promotes gastric cancer cell growth and EMT progression via miR-204-3p/KRAS. PG - 12007-12015 LID - 10.18632/aging.202905 [doi] AB - Long noncoding RNAs (LncRNAs) participate in tumor development and tumorigenesis. However, the mechanism, function and expression of LINC00514 in GC remain unknown. We showed that LINC00514 was upregulated in GC specimens compared with nontumor specimens. Overexpression of LINC00514 induced cell growth and EMT progression in GC cells. By using bioinformatics prediction, we found that miR-204-3p contained binding sequences for LINC00514. Luciferase reporter analysis noted that miR-204-3p overexpression decreased the luciferase expression under LINC00514-wild-type and KRAS-wild-type reporters but not that under mutant reporter. Ectopic LINC00514 expression decreased miR-204-3p expression. miR-204-3p expression was decreased in GC specimens compared with nontumor specimens and that LINC00514 was negatively correlated with miR-204-3p in GC specimens. Furthermore, KRAS was identified as a target gene for miR-204-3p according to TargetScan. Elevated miR-204-3p expression inhibited KRAS expression in HGC-27 cells, and ectopic expression of LINC00514 enhanced KRAS expression. Elevated LINC00514 expression enhanced cell growth and EMT progression by sponging KRAS. Our data indicated that LINC00514 may act as an oncogene and therapeutic target for GC. FAU - Yuan, Ling AU - Yuan L AD - Pharmacy College of Ningxia Medical University, Yinchuan 750004, China. AD - Ningxia Medical University Key Laboratory of Hui Ethnic Medicine Modernization Ministry of Education, Yinchuan 750004, China. FAU - Li, Jiaxin AU - Li J AD - Pharmacy College of Ningxia Medical University, Yinchuan 750004, China. FAU - Yang, Yi AU - Yang Y AD - Pharmacy College of Ningxia Medical University, Yinchuan 750004, China. FAU - Chen, Yan AU - Chen Y AD - Traditional Chinese Medicine College of Ningxia Medical University, Yinchuan 750004, China. FAU - Bu, Yang AU - Bu Y AD - Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan 750004, China. FAU - Ye, Mengyi AU - Ye M AD - Traditional Chinese Medicine College of Ningxia Medical University, Yinchuan 750004, China. FAU - Mao, Xiongjie AU - Mao X AD - Pharmacy College of Ningxia Medical University, Yinchuan 750004, China. FAU - Ma, Tingting AU - Ma T AD - Pharmacy College of Ningxia Medical University, Yinchuan 750004, China. FAU - Yu, Lei AU - Yu L AD - Department of Infectious Disease, The Fourth Hospital of Harbin Medical University, Harbin 150001, Heilongjiang, China. FAU - Nan, Yi AU - Nan Y AD - Ningxia Medical University Key Laboratory of Hui Ethnic Medicine Modernization Ministry of Education, Yinchuan 750004, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210422 PL - United States TA - Aging (Albany NY) JT - Aging JID - 101508617 RN - 0 (KRAS protein, human) RN - 0 (MIRN204 microRNA, human) RN - 0 (MicroRNAs) RN - 0 (RNA, Long Noncoding) RN - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras)) SB - IM MH - Carcinogenesis/genetics MH - Cell Line, Tumor MH - Cell Proliferation/genetics MH - Computational Biology MH - Epithelial-Mesenchymal Transition/genetics MH - Gene Expression Regulation, Neoplastic MH - Humans MH - MicroRNAs/*metabolism MH - Oncogenes MH - Proto-Oncogene Proteins p21(ras)/*genetics MH - RNA, Long Noncoding/genetics/*metabolism MH - Stomach/pathology MH - Stomach Neoplasms/*genetics/pathology MH - Up-Regulation PMC - PMC8109083 OTO - NOTNLM OT - KRAS OT - LINC00514 OT - gastric cancer OT - miR-204-3p COIS- CONFLICTS OF INTEREST: The authors declare that they have no conflicts of interest. EDAT- 2021/04/24 06:00 MHDA- 2021/07/27 06:00 PMCR- 2021/04/30 CRDT- 2021/04/23 05:46 PHST- 2020/10/09 00:00 [received] PHST- 2021/01/22 00:00 [accepted] PHST- 2021/04/24 06:00 [pubmed] PHST- 2021/07/27 06:00 [medline] PHST- 2021/04/23 05:46 [entrez] PHST- 2021/04/30 00:00 [pmc-release] AID - 202905 [pii] AID - 10.18632/aging.202905 [doi] PST - ppublish SO - Aging (Albany NY). 2021 Apr 22;13(8):12007-12015. doi: 10.18632/aging.202905. Epub 2021 Apr 22. PMID- 37090970 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230425 IS - 1664-2295 (Print) IS - 1664-2295 (Electronic) IS - 1664-2295 (Linking) VI - 14 DP - 2023 TI - Beneficial effects and safety of traditional Chinese medicine for chronic inflammatory demyelinating polyradiculoneuropathy: A case report and literature review. PG - 1126444 LID - 10.3389/fneur.2023.1126444 [doi] LID - 1126444 AB - Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated neuropathy. First-line treatments for CIDP include corticosteroids, intravenous immunoglobulin, and plasma exchange. However, the application is always limited by high costs, effectiveness, and adverse events. This study investigated a new potentially effective and safe therapeutic treatment to alleviate CIDP symptoms and improve the quality of life. In the present case, a 47-year-old rural woman presented with weakness and numbness of progressive extremities. She was diagnosed with CIDP based on abnormal cerebrospinal fluid and electromyography. The patient was treated with intravenous dexamethasone for 1 week and with Huangqi-Guizhi-Wuwu and Bu-Yang-Huan-Wu decoctions for 90 days. Surprisingly, after the treatment, the weakness and numbness were eliminated, and the quality of life improved. The varying INCAT, MRC, and BI scores also reflected the treatment effects. After 8 months of discharge, the symptoms did not relapse during the follow-up. We also searched "traditional Chinese medicine (TCM)" and "CIDP" in PubMed, EMBASE, the Web of Science, the Cochrane Library, the Chinese National Knowledge Infrastructure Databases, Wanfang Data, and the Chongqing Chinese Science and Technology Periodical Database. Finally, only ten studies were included in the literature review. Three studies were randomized controlled trials, and seven were case reports or case series. There were 419 CIDP patients, but all study sites were in China. Nine TCM formulas involving 44 herbs were reported, with Huang Qi (Astragalus membranaceus) being the most important herb. In conclusion, the case and literature demonstrated that TCM treatment might be a more effective, low-cost, and safe option for treating CIDP. Although these preliminary findings are promising, a larger sample size and higher-quality randomized clinical trials are urgently required to confirm our findings. CI - Copyright © 2023 Xie, Li, Xie, Jiang, Yao, Mao, Wang, Lin, Ge and Wu. FAU - Xie, Yao AU - Xie Y AD - Department of Neurology, Hunan Hospital of Integrated Traditional Chinese and Western Medicine, Changsha, China. FAU - Li, Lesang AU - Li L AD - Ophthalmology Department, Hunan Want Want Hospital, Changsha, China. FAU - Xie, Le AU - Xie L AD - Department of Neurology, Hunan Hospital of Integrated Traditional Chinese and Western Medicine, Changsha, China. FAU - Jiang, Junlin AU - Jiang J AD - Department of Neurology, Hunan Hospital of Integrated Traditional Chinese and Western Medicine, Changsha, China. FAU - Yao, Ting AU - Yao T AD - Department of Neurology, Hunan Hospital of Integrated Traditional Chinese and Western Medicine, Changsha, China. FAU - Mao, Guo AU - Mao G AD - Office of Academic Research, Hunan Hospital of Integrated Traditional Chinese and Western Medicine, Changsha, China. FAU - Wang, Shiliang AU - Wang S AD - Department of Neurology, Hunan Hospital of Integrated Traditional Chinese and Western Medicine, Changsha, China. FAU - Lin, Anchao AU - Lin A AD - Department of Neurology, Hunan Hospital of Integrated Traditional Chinese and Western Medicine, Changsha, China. FAU - Ge, Jinwen AU - Ge J AD - Department of Neurology, Hunan Hospital of Integrated Traditional Chinese and Western Medicine, Changsha, China. FAU - Wu, Dahua AU - Wu D AD - Department of Neurology, Hunan Hospital of Integrated Traditional Chinese and Western Medicine, Changsha, China. LA - eng PT - Case Reports PT - Journal Article DEP - 20230406 PL - Switzerland TA - Front Neurol JT - Frontiers in neurology JID - 101546899 PMC - PMC10115958 OTO - NOTNLM OT - Astragalus membranaceus OT - case report OT - chronic inflammatory demyelinating polyradiculoneuropathy OT - review OT - traditional Chinese medicine COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/04/24 06:42 MHDA- 2023/04/24 06:43 PMCR- 2023/04/06 CRDT- 2023/04/24 03:49 PHST- 2022/12/17 00:00 [received] PHST- 2023/03/09 00:00 [accepted] PHST- 2023/04/24 06:43 [medline] PHST- 2023/04/24 06:42 [pubmed] PHST- 2023/04/24 03:49 [entrez] PHST- 2023/04/06 00:00 [pmc-release] AID - 10.3389/fneur.2023.1126444 [doi] PST - epublish SO - Front Neurol. 2023 Apr 6;14:1126444. doi: 10.3389/fneur.2023.1126444. eCollection 2023. PMID- 35907496 OWN - NLM STAT- MEDLINE DCOM- 20220920 LR - 20220920 IS - 2468-7847 (Electronic) IS - 2468-7847 (Linking) VI - 51 IP - 8 DP - 2022 Oct TI - Second-stage cesarean delivery and preterm birth in subsequent pregnancy: A large multi-institutional cohort study. PG - 102447 LID - S2468-7847(22)00131-3 [pii] LID - 10.1016/j.jogoh.2022.102447 [doi] AB - OBJECTIVE: To estimate the risk of preterm birth associated with mode of delivery in a previous pregnancy. PATIENTS AND METHODS: This was a multicenter retrospective cohort study. Women who had two consecutive deliveries in the participating hospitals between January 2012 and January 2022 were included in this study. They were divided into three groups according to the mode of delivery in a previous pregnancy: vaginal birth (group A), cesarean section before the second stage of labor (group B), and second stage cesarean section (group C). Data were extracted from the medical records. The primary outcome was the risk of spontaneous preterm birth in the subsequent pregnancy. The secondary outcomes were the risk of early spontaneous preterm birth (< 34 weeks) and the medically indicated preterm birth in the subsequent pregnancy. The logistic regression was employed to estimate odds and adjust for confounders. RESULTS: 18,253 women were included. Among them, 10,951 women were in group A, 5111 women in group B, and 2191 women in group C. The rates of spontaneous preterm birth in groups A, B, and C were 5.5%, 7.3%, and 15.1%, respectively. The rates of early spontaneous preterm birth in groups A, B, and C were 2.3%, 3.4%, and 8.2%, respectively. When compared with vaginal birth, second-stage cesarean section significantly increased the risk of spontaneous preterm birth (aOR, 3.23; 95% CI, 2.02-5.17; P = 0.003) and early spontaneous preterm birth (aOR, 3.59; 95% CI, 2.01-5.19; P <0.001) in the subsequent pregnancy. The rates of medically indicated preterm birth in groups A, B, and C were 2.3%, 2.8%, and 2.2%, respectively. There was no statistical difference across the three groups. CONCLUSION: History of cesarean section at full dilation is independently associated with an increased risk of spontaneous preterm birth in the subsequent pregnancy. CI - Copyright © 2022 Elsevier Masson SAS. All rights reserved. FAU - Zhou, Hui AU - Zhou H AD - Department of Obstetrics and Gynecology, 363 Hospital, Chengdu, China; Department of Obstetrics and Gynecology, Chengdu 363 Hospital Affiliated of Southwest Medical University, Chengdu, China. Electronic address: huiz_swmu@163.com. FAU - Lai, Kai-Fa AU - Lai KF AD - Department of Obstetrics and Gynecology, 363 Hospital, Chengdu, China; Department of Obstetrics and Gynecology, Chengdu 363 Hospital Affiliated of Southwest Medical University, Chengdu, China. FAU - Xiang, Qian AU - Xiang Q AD - Department of Obstetrics and Gynecology, 363 Hospital, Chengdu, China; Department of Obstetrics and Gynecology, Chengdu 363 Hospital Affiliated of Southwest Medical University, Chengdu, China. FAU - Zhang, Lin-Lin AU - Zhang LL AD - Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China. FAU - Xu, You AU - Xu Y AD - Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China. FAU - Cheng, Chen AU - Cheng C AD - Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Chengdu Medical College, Chengdu, China. FAU - Huan, Wu AU - Huan W AD - Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Chengdu Medical College, Chengdu, China. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20220727 PL - France TA - J Gynecol Obstet Hum Reprod JT - Journal of gynecology obstetrics and human reproduction JID - 101701588 SB - IM MH - *Cesarean Section/adverse effects MH - Cohort Studies MH - Female MH - Humans MH - Infant, Newborn MH - Parturition MH - Pregnancy MH - *Premature Birth/epidemiology MH - Retrospective Studies MH - Risk Factors OTO - NOTNLM OT - Ccesarean delivery OT - Preterm birth OT - Second-stage COIS- Declaration of Competing Interest The authors have no conflict of interest to report. EDAT- 2022/07/31 06:00 MHDA- 2022/09/21 06:00 CRDT- 2022/07/30 19:13 PHST- 2022/05/30 00:00 [received] PHST- 2022/07/23 00:00 [revised] PHST- 2022/07/25 00:00 [accepted] PHST- 2022/07/31 06:00 [pubmed] PHST- 2022/09/21 06:00 [medline] PHST- 2022/07/30 19:13 [entrez] AID - S2468-7847(22)00131-3 [pii] AID - 10.1016/j.jogoh.2022.102447 [doi] PST - ppublish SO - J Gynecol Obstet Hum Reprod. 2022 Oct;51(8):102447. doi: 10.1016/j.jogoh.2022.102447. Epub 2022 Jul 27. PMID- 31724657 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20191209 LR - 20200108 IS - 1364-5528 (Electronic) IS - 0003-2654 (Linking) VI - 144 IP - 24 DP - 2019 Dec 2 TI - A nanofluidic memristor based on ion concentration polarization. PG - 7168-7172 LID - 10.1039/c9an01561b [doi] AB - This paper reports the very first nanofluidic memristor based on the principle of ion concentration polarization (ICP). ICP is induced through highly-ordered cylindrical nanochannels. These so-called nanocapillaries are formed within a glass layer on silicon through a thermal reflow process and low-resolution lithography. The current-voltage plots exhibit characteristic pinched-hysteresis loops and the concurrent tracking of fluorescent charged particles correlates the memristive behaviour to the ICP. The ICP-based nanofluidic memristor could have implications in emerging areas such as integrated fluid-based logic circuits. FAU - Bu, Yang AU - Bu Y AD - Dept. of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong SAR, China. eelyobas@ust.hk. FAU - Ahmed, Zisun AU - Ahmed Z FAU - Yobas, Levent AU - Yobas L LA - eng PT - Journal Article PL - England TA - Analyst JT - The Analyst JID - 0372652 SB - IM EDAT- 2019/11/15 06:00 MHDA- 2019/11/15 06:01 CRDT- 2019/11/15 06:00 PHST- 2019/11/15 06:00 [pubmed] PHST- 2019/11/15 06:01 [medline] PHST- 2019/11/15 06:00 [entrez] AID - 10.1039/c9an01561b [doi] PST - ppublish SO - Analyst. 2019 Dec 2;144(24):7168-7172. doi: 10.1039/c9an01561b. PMID- 31878460 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20200103 LR - 20200108 IS - 1094-4087 (Electronic) IS - 1094-4087 (Linking) VI - 27 IP - 23 DP - 2019 Nov 11 TI - Fast thermal aberration model for lithographic projection lenses. PG - 34038-34049 LID - 10.1364/OE.27.034038 [doi] AB - A novel fast thermal aberration model for lithographic projection lenses is proposed. In the model, optical intensity calculation is simplified by using pupil intensity mapping, and simplified formulas for temperature calculation are derived to realize fast simulation of thermal aberration. The simulation results using the proposed model are compared with that of experiments carried out on a commercial lithography tool. The R-square of the simulation is better than 0.99 and the simulation time is about 10 minutes. Experiments and simulations show that the model is capable of predicting the thermal aberration or the variation trend of the thermal aberration of lithographic projection lenses fast and accurately. The model is applicable in projection lens design, evaluating degree of production risk posed by thermal aberration, etc. FAU - Zhu, Boer AU - Zhu B FAU - Li, Sikun AU - Li S FAU - Mao, Yanjie AU - Mao Y FAU - Wang, Xiangzhao AU - Wang X FAU - Bu, Yang AU - Bu Y FAU - Wang, Jian AU - Wang J FAU - Sun, Gang AU - Sun G FAU - Duan, Lifeng AU - Duan L LA - eng PT - Journal Article PL - United States TA - Opt Express JT - Optics express JID - 101137103 SB - IM EDAT- 2019/12/28 06:00 MHDA- 2019/12/28 06:01 CRDT- 2019/12/28 06:00 PHST- 2019/12/28 06:00 [entrez] PHST- 2019/12/28 06:00 [pubmed] PHST- 2019/12/28 06:01 [medline] AID - 422958 [pii] AID - 10.1364/OE.27.034038 [doi] PST - ppublish SO - Opt Express. 2019 Nov 11;27(23):34038-34049. doi: 10.1364/OE.27.034038. PMID- 38044396 OWN - NLM STAT- MEDLINE DCOM- 20241114 LR - 20241117 IS - 1559-0305 (Electronic) IS - 1073-6085 (Print) IS - 1073-6085 (Linking) VI - 66 IP - 12 DP - 2024 Dec TI - SIRT1 Inhibition-Induced Mitochondrial Damage Promotes GSDME-Dependent Pyroptosis in Hepatocellular Carcinoma Cells. PG - 3628-3639 LID - 10.1007/s12033-023-00964-z [doi] AB - Hepatocellular carcinoma (HCC) is a malignant tumor that affects the liver and poses a significant threat to human health. Further investigation is necessary to fully understand the role of SIRT1, a protein linked to tumorigenesis, in HCC development. To investigate the effect of SIRT1 on HCC and elucidate the underlying mechanism. Eight pairs of HCC and paracancerous normal tissue specimens were collected. The levels of SIRT1 and GSDME in tissue samples were assessed using immunohistochemistry and western blotting. SIRT1 levels were determined in HCC (Huh7, HepG2, SNU-423, SNU-398, and HCCLM3) and L-02 cells using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blotting. SNU-423 and HCCLM3 cells were transfected with si-SIRT1 and/or si-GSDME to knock down SIRT1 or GSDME expression. RT-qPCR and western blotting were performed to measure the expression of SIRT1, pro-casp-3, cl-casp-3, GSDME, GSDME-N, PGC-1α, Bax, and cytochrome c (Cyto C). Cell proliferation, migration, invasion, and apoptosis were assessed using the cell counting kit-8 (CCK-8), wound healing assay, Transwell invasion assay, and flow cytometry, respectively. The release of lactate dehydrogenase (LDH) was evaluated using an LDH kit. SIRT1 was upregulated in HCC tissues and cells, and a negative correlation was observed between SIRT1 and GSDME-N. SIRT1 silencing suppressed the proliferation, migration, and invasion of HCC cells while also promoting apoptosis and inducing mitochondrial damage. Additionally, the silencing of SIRT1 resulted in the formation of large bubbles on the plasma membrane of HCC cells, leading to cellular swelling and aggravated GSDME-dependent pyroptosis, resulting in an increase in LDH release. Inhibition of GSDME reduced SIRT1 silencing-induced cell swelling, decreased LDH release rate, and promoted apoptosis. SIRT1 silencing promotes GSDME-dependent pyroptosis in HCC cells by damaging mitochondria. CI - © 2023. The Author(s). FAU - Liu, Di AU - Liu D AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, 804 Shengli Street, Xingqing District, Yinchuan City, Ningxia Hui Autonomous Region, China. FAU - Liu, Junhao AU - Liu J AD - School of Clinical Medicine, Ningxia Medical University, Yinchuan, China. FAU - Liu, Kejun AU - Liu K AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, 804 Shengli Street, Xingqing District, Yinchuan City, Ningxia Hui Autonomous Region, China. FAU - Hu, Yanchao AU - Hu Y AD - Department of Infectious Diseases, General Hospital of Ningxia Medical University, Yinchuan, China. FAU - Feng, Jinming AU - Feng J AD - Department of Surgery, Shapotou District People's Hospital, Zhongwei City, China. FAU - Bu, Yang AU - Bu Y AD - Department of Hepatobiliary Surgery, People's Hospital of Ningxia Hui Autonomous Region, No.301, Zhengyuan North Street, Jinfeng District, Yinchuan City, Ningxia Hui Autonomous Region, China. boyang1976@163.com. FAU - Wang, Qi AU - Wang Q AUID- ORCID: 0000-0003-2108-3266 AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, 804 Shengli Street, Xingqing District, Yinchuan City, Ningxia Hui Autonomous Region, China. wq-6562@163.com. LA - eng GR - 2020CXPT0007/the Innovation Platform Fund Project of the Ningxia Hui Autonomous Region Science and Technology Infrastructure Construction Plan/ GR - 2021GKLRLX04/the Ningxia Hui Autonomous Region Science and Technology Innovation Leading Talents/ GR - 2022AAC03558/the Ningxia Hui Autonomous Region Natural Science Foundation in 2022/ PT - Journal Article DEP - 20231203 PL - Switzerland TA - Mol Biotechnol JT - Molecular biotechnology JID - 9423533 RN - EC 3.5.1.- (Sirtuin 1) RN - EC 3.5.1.- (SIRT1 protein, human) SB - IM MH - Humans MH - *Sirtuin 1/metabolism/genetics MH - *Carcinoma, Hepatocellular/metabolism/pathology/genetics MH - *Liver Neoplasms/metabolism/pathology/genetics MH - *Pyroptosis MH - Cell Line, Tumor MH - *Mitochondria/metabolism/genetics MH - *Cell Proliferation MH - Cell Movement MH - Hep G2 Cells MH - Gene Expression Regulation, Neoplastic MH - Apoptosis MH - Male PMC - PMC11564359 OTO - NOTNLM OT - GSDME-dependent pyroptosis OT - Hepatocellular carcinoma (HCC) OT - Mitochondrial damage OT - SIRT1 COIS- Declarations Conflict of interest All authors declare that they have no competing interests. Ethical Approval Approval was obtained from the ethics committee of General Hospital of Ningxia Medical University. The procedures used in this study adhere to the tenets of the Declaration of Helsinki. Informed Consent Informed consent was obtained from all participating subjects. EDAT- 2023/12/04 00:42 MHDA- 2024/11/15 00:32 PMCR- 2023/12/03 CRDT- 2023/12/03 23:10 PHST- 2023/05/06 00:00 [received] PHST- 2023/10/24 00:00 [accepted] PHST- 2024/11/15 00:32 [medline] PHST- 2023/12/04 00:42 [pubmed] PHST- 2023/12/03 23:10 [entrez] PHST- 2023/12/03 00:00 [pmc-release] AID - 10.1007/s12033-023-00964-z [pii] AID - 964 [pii] AID - 10.1007/s12033-023-00964-z [doi] PST - ppublish SO - Mol Biotechnol. 2024 Dec;66(12):3628-3639. doi: 10.1007/s12033-023-00964-z. Epub 2023 Dec 3. PMID- 33583789 OWN - NLM STAT- MEDLINE DCOM- 20211013 LR - 20211013 IS - 1011-601X (Print) IS - 1011-601X (Linking) VI - 33 IP - 4 DP - 2020 Jul TI - Transport properties of paeoniflorin and amygdalin across caco-2 cell monolayer model and their modulation of cytochrome p450 metabolism. PG - 1569-1575 AB - Paeoniflorin and amygdalin are two major active saponins constituents in some Chinese herbal formulas used for cardio-cerebrovascular diseases. However, their intestinal absorption property and metabolic characteristics have not been clarified. The aim of this work was to study the absorption property of Paeoniflorin and Amygdalin across Caco-2 cell monolayer and their metabolic characteristics on the activity of cytochrome P450 (CYP450) enzyme. The results showed that the transport amount of Paeoniflorin and Amygdalin was positively correlated with the time and concentrations, and the transport amount from AP side to BL side was higher than that from BL to AP. The absorptions of Paeoniflorin and Amygdalin were reduced by P-glycoprotein, which provided the pharmacokinetic basis for their clinical application. Furthermore, we demonstrated that Paeoniflorin and Amygdalin had obvious inhibiting effects on CYP2C9 and CYP2E1. The transports of Paeoniflorin and Amygdalin across Caco-2 cell monolayer model were deduced as the passive transport, which indicated that the present bioassay system was appropriate and reliable for the evaluation of the transport characteristics and metabolic characteristics of active ingredient groups in Bu-yang-huan-wu decoction. Moreover, this research method may also be suitable for the appropriate bioactivity and metabolic characteristics analysis of other plant extracts. FAU - Zhou, Huifen AU - Zhou H AD - Zhejiang Chinese Medical University, Hangzhou, China. FAU - He, Yu AU - He Y AD - Zhejiang Chinese Medical University, Hangzhou, China. FAU - Yang, Jiehong AU - Yang J AD - Zhejiang Chinese Medical University, Hangzhou, China. FAU - Wan, Haofang AU - Wan H AD - Zhejiang Chinese Medical University, Hangzhou, China. FAU - Wang, Liqin AU - Wang L AD - The First Affiliated Hospital of Nanchang University, Nanchang, China. FAU - Wan, Haitong AU - Wan H AD - Zhejiang Chinese Medical University, Hangzhou, China. LA - eng PT - Journal Article PL - Pakistan TA - Pak J Pharm Sci JT - Pakistan journal of pharmaceutical sciences JID - 9426356 RN - 0 (Drugs, Chinese Herbal) RN - 0 (Glucosides) RN - 0 (Monoterpenes) RN - 0 (Saponins) RN - 214UUQ9N0H (Amygdalin) RN - 21AIQ4EV64 (peoniflorin) RN - 9035-51-2 (Cytochrome P-450 Enzyme System) SB - IM MH - Amygdalin/*metabolism MH - Biological Transport/*physiology MH - Caco-2 Cells MH - Cell Line, Tumor MH - Cytochrome P-450 Enzyme System/*metabolism MH - Drugs, Chinese Herbal/metabolism MH - Glucosides/*metabolism MH - Humans MH - Intestinal Absorption/physiology MH - Metabolic Clearance Rate/physiology MH - Monoterpenes/*metabolism MH - Oxidation-Reduction MH - Saponins/metabolism EDAT- 2021/02/16 06:00 MHDA- 2021/10/14 06:00 CRDT- 2021/02/15 06:05 PHST- 2021/02/15 06:05 [entrez] PHST- 2021/02/16 06:00 [pubmed] PHST- 2021/10/14 06:00 [medline] PST - ppublish SO - Pak J Pharm Sci. 2020 Jul;33(4):1569-1575. PMID- 38456951 OWN - NLM STAT- MEDLINE DCOM- 20240311 LR - 20240511 IS - 2359-4292 (Electronic) IS - 2359-3997 (Print) IS - 2359-3997 (Linking) VI - 68 DP - 2024 Mar 7 TI - Effect of fasting glucose levels on carotid intima-media thickness in premenopausal versus postmenopausal women. PG - e230110 LID - 2359-4292-2023-0110 [pii] LID - 10.20945/2359-4292-2023-0110 [doi] LID - e230110 AB - OBJECTIVE: To investigate the relationship between fasting blood glucose (FBG) and carotid intimamedia thickness (IMT) in premenopausal and postmenopausal women. SUBJECTS AND METHODS: The study enrolled 2,959 women seen at the Maanshan People's Hospital of Anhui Province from December 2013 to December 2018. Carotid IMT was measured using Doppler ultrasound. Linear regression and R smoothing curves were used to analyze the relationship between blood glucose level and carotid IMT in the premenopausal and postmenopausal groups. RESULTS: Postmenopausal compared with premenopausal women had higher mean IMT (mIMT; 0.81 ± 0.23 mm versus 0.70 ± 0.14 mm, respectively, p < 0.001) and maximum IMT (maxIMT; 0.86 ± 0.35 mm versus 0.74 ± 0.16 mm, respectively, p < 0.001) values. On linear regression analysis, mIMT values increased with increasing FBG values when FBG level was ≤ 7 mmol/L, but no significance was found between FBG and maxIMT. After stratification by menopausal status, mIMT and maxIMT increased with increasing FBG when FBG was ≤ 7 mmol/L in the premenopausal group. In the postmenopausal group, mIMT and maxIMT increased with increasing FBG. After adjustment for covariate factors, the relationship between FBG and mIMT remained the same as before the adjustment, but when FBG was ≤ 11 mmol/L, the maxIMT increased with increasing FBG. In the stratification analysis, maxIMT increased with increasing FBG when FBG was ≤ 7 mmol/L in the premenopausal group, while both mIMT and maxIMT increased with increasing FBG when FBG was > 10 mmol/L in the postmenopausal group. CONCLUSION: Levels of FBG contributed more to increased IMT in postmenopausal than premenopausal women. The influence of FBG was greater on maxIMT than mIMT. Additionally, FBG was helpful in assessing focal thickening of the carotid intima. FAU - Xia, Ren AU - Xia R AD - School of Public Health, Wannan Medical College, Wuhu, Anhui Province, China. FAU - Fan, Su AU - Fan S AD - School of Public Health, Wannan Medical College, Wuhu, Anhui Province, China. FAU - Jian, Hu AU - Jian H AD - School of Public Health, Wannan Medical College, Wuhu, Anhui Province, China. FAU - Lei, Cao AU - Lei C AD - School of Public Health, Wannan Medical College, Wuhu, Anhui Province, China. FAU - Wendan, Mei AU - Wendan M AD - School of Public Health, Wannan Medical College, Wuhu, Anhui Province, China. FAU - Chenxu, Wang AU - Chenxu W AD - School of Public Health, Wannan Medical College, Wuhu, Anhui Province, China. FAU - Yicheng, Fang AU - Yicheng F AD - School of Public Health, Wannan Medical College, Wuhu, Anhui Province, China. FAU - Tavengana, Grace AU - Tavengana G AD - School of Public Health, Wannan Medical College, Wuhu, Anhui Province, China. FAU - Mingfei, Jiang AU - Mingfei J AD - School of Clinical Medicine, Wannan Medical College, Wuhu, Anhui Province, China. FAU - Huan, Wu AU - Huan W AD - School of Laboratory Medicine, Wannan Medical College, Wuhu, Anhui Province, China. FAU - Wendan, Mei AU - Wendan M AD - School of Public Health, Wannan Medical College, Wuhu, Anhui Province, China. FAU - Yufeng, Wen AU - Yufeng W AD - School of Public Health, Wannan Medical College, Wuhu, Anhui Province, China, wyf2015w@sina.com. LA - eng PT - Journal Article PL - Brazil TA - Arch Endocrinol Metab JT - Archives of endocrinology and metabolism JID - 101652058 RN - 0 (Blood Glucose) SB - IM MH - Humans MH - Female MH - *Carotid Intima-Media Thickness MH - *Postmenopause MH - Blood Glucose MH - Premenopause MH - Carotid Arteries/diagnostic imaging MH - Fasting PMC - PMC11081054 OTO - NOTNLM OT - Postmenopause OT - carotid intima-media thickness OT - fasting blood glucose OT - premenopause COIS- Disclosure: no potential conflict of interest relevant to this article was reported. EDAT- 2024/03/08 12:41 MHDA- 2024/03/11 06:43 PMCR- 2024/03/15 CRDT- 2024/03/08 11:06 PHST- 2024/03/11 06:43 [medline] PHST- 2024/03/08 12:41 [pubmed] PHST- 2024/03/08 11:06 [entrez] PHST- 2024/03/15 00:00 [pmc-release] AID - 2359-4292-2023-0110 [pii] AID - 10.20945/2359-4292-2023-0110 [doi] PST - ppublish SO - Arch Endocrinol Metab. 2024 Mar 7;68:e230110. doi: 10.20945/2359-4292-2023-0110. PMID- 22465277 OWN - NLM STAT- MEDLINE DCOM- 20120719 LR - 20131121 IS - 1873-376X (Electronic) IS - 1570-0232 (Linking) VI - 895-896 DP - 2012 May 1 TI - Simultaneous determination and pharmacokinetics of protein unbound aspirin and salicylic acid in rat blood and brain by microdialysis: an application to herbal-drug interaction. PG - 31-8 LID - 10.1016/j.jchromb.2012.03.010 [doi] AB - Aspirin is commonly used for the prevention of myocardial infarction and ischemic stroke; whereas the Chinese people employ the bu-yang-huan-wu-tang (BYHWT) as a routine herbal formulation for the treatment and prevention of transient ischemic stroke. The current study develops a microdialysis technique coupled to a validated liquid chromatography system to measure free-form aspirin and salicylic acid for herbal-drug interaction in rat blood and brain. The intra- and inter-day precisions in biological dialysates were within 0.1-9.4% in the concentration ranges of 0.1-50 μg/mL and the accuracies ranged from -4.7 to 6.1%. The pharmacokinetic data demonstrate that the area under the concentration time curve (AUC) of the aspirin was 2031 ± 266 min μg/mL after aspirin administration (100mg/kg, i.v.). The AUC of salicylic acid was 12660 ± 1799 min μg/mL, which suggests that aspirin is quickly hydrolyzed to salicylic acid in blood and the metabolite can also be detected within 15 min in brain dialysate. The herbal-drug pharmacokinetic interaction showed no significant effect in blood and brain. The results of pharmacodynamics for the bleeding time suggested that there were no significant differences between the aspirin alone group and the BYHWT pretreated group. However, the bleeding time has been prolonged when compared aspirin alone or the group pretreated with BYHWT to the blank control. The conclusion provides practical information for clinical practice for the herbal formulation BYHWT and aspirin used concurrently. CI - Copyright © 2012 Elsevier B.V. All rights reserved. FAU - Shaw, Lee-Hsin AU - Shaw LH AD - Institute of Traditional Medicine, National Yang-Ming University, Taipei 112, Taiwan. FAU - Tsai, Tung-Hu AU - Tsai TH LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20120315 PL - Netherlands TA - J Chromatogr B Analyt Technol Biomed Life Sci JT - Journal of chromatography. B, Analytical technologies in the biomedical and life sciences JID - 101139554 RN - 0 (Drugs, Chinese Herbal) RN - O414PZ4LPZ (Salicylic Acid) RN - R16CO5Y76E (Aspirin) SB - IM MH - Animals MH - Area Under Curve MH - Aspirin/*analysis/blood/pharmacokinetics MH - Bleeding Time MH - Brain Chemistry MH - Drug Stability MH - Drugs, Chinese Herbal/*pharmacology MH - *Herb-Drug Interactions MH - Male MH - Microdialysis/*methods MH - Rats MH - Rats, Sprague-Dawley MH - Reproducibility of Results MH - Salicylic Acid/*analysis/blood/pharmacokinetics EDAT- 2012/04/03 06:00 MHDA- 2012/07/20 06:00 CRDT- 2012/04/03 06:00 PHST- 2011/11/08 00:00 [received] PHST- 2012/01/30 00:00 [revised] PHST- 2012/03/09 00:00 [accepted] PHST- 2012/04/03 06:00 [entrez] PHST- 2012/04/03 06:00 [pubmed] PHST- 2012/07/20 06:00 [medline] AID - S1570-0232(12)00159-6 [pii] AID - 10.1016/j.jchromb.2012.03.010 [doi] PST - ppublish SO - J Chromatogr B Analyt Technol Biomed Life Sci. 2012 May 1;895-896:31-8. doi: 10.1016/j.jchromb.2012.03.010. Epub 2012 Mar 15. PMID- 38793236 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240527 IS - 2072-666X (Print) IS - 2072-666X (Electronic) IS - 2072-666X (Linking) VI - 15 IP - 5 DP - 2024 May 19 TI - A Portable, Integrated, Sample-In Result-Out Nucleic Acid Diagnostic Device for Rapid and Sensitive Chikungunya Virus Detection. LID - 10.3390/mi15050663 [doi] LID - 663 AB - Chikungunya virus, a mosquito-borne virus that causes epidemics, is often misdiagnosed due to symptom similarities with other arboviruses. Here, a portable and integrated nucleic acid-based diagnostic device, which combines reverse transcription-loop-mediated isothermal amplification and lateral-flow detection, was developed. The device is simple to use, precise, equipment-free, and highly sensitive, enabling rapid chikungunya virus identification. The result can be obtained by the naked eye within 40 min. The assay can effectively distinguish chikungunya virus from dengue virus, Japanese encephalitis virus, Zika virus, and yellow fever virus with high specificity and sensitivity as low as 598.46 copies mL(-1). It has many benefits for the community screening and monitoring of chikungunya virus in resource-limited areas because of its effectiveness and simplicity. The platform has great potential for the rapid nucleic acid detection of other viruses. FAU - Xu, Changping AU - Xu C AD - Center for Public Health Research, Medical School of Nanjing University, Nanjing 210093, China. AD - Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, China. FAU - Chen, Yalin AU - Chen Y AD - School of Biomedical Engineering, Med-X Research Institute, Shanghai Jiao Tong University, Shanghai 200030, China. FAU - Zhu, Guiying AU - Zhu G AD - Shanghai Sci-Tech InnoCenter for Infection & Immunity, Shanghai 200030, China. FAU - Wu, Huan AU - Wu H AD - Ustar Biotechnologies (Hangzhou) Ltd., Hangzhou 310051, China. FAU - Jiang, Qi AU - Jiang Q AD - Ustar Biotechnologies (Hangzhou) Ltd., Hangzhou 310051, China. FAU - Zhang, Rui AU - Zhang R AD - Center for Public Health Research, Medical School of Nanjing University, Nanjing 210093, China. FAU - Yu, Beibei AU - Yu B AD - Department of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University College of Medicine, Hangzhou 310000, China. FAU - Fang, Lei AU - Fang L AUID- ORCID: 0000-0002-9916-5782 AD - Department of Critical Care Medicine, Sir Run Run Shaw Hospital, Zhejiang University College of Medicine, Hangzhou 310000, China. FAU - Wu, Zhiwei AU - Wu Z AD - Center for Public Health Research, Medical School of Nanjing University, Nanjing 210093, China. LA - eng GR - LGC22H200002; LGF22H300008/Basic Public Welfare Research Program of Zhejiang Province/ PT - Journal Article DEP - 20240519 PL - Switzerland TA - Micromachines (Basel) JT - Micromachines JID - 101640903 PMC - PMC11123350 OTO - NOTNLM OT - chikungunya virus OT - instrument-free nucleic acid-based detection OT - lateral-flow detection OT - loop-mediated isothermal amplification COIS- The authors declare no conflicts of interest. Huan Wu and Qi Jiang are employees of Ustar Biotechnologies (Hangzhou) Ltd. The paper reflects the views of the scientists, and not the company. EDAT- 2024/05/25 10:55 MHDA- 2024/05/25 10:56 PMCR- 2024/05/19 CRDT- 2024/05/25 01:20 PHST- 2024/04/01 00:00 [received] PHST- 2024/05/09 00:00 [revised] PHST- 2024/05/13 00:00 [accepted] PHST- 2024/05/25 10:56 [medline] PHST- 2024/05/25 10:55 [pubmed] PHST- 2024/05/25 01:20 [entrez] PHST- 2024/05/19 00:00 [pmc-release] AID - mi15050663 [pii] AID - micromachines-15-00663 [pii] AID - 10.3390/mi15050663 [doi] PST - epublish SO - Micromachines (Basel). 2024 May 19;15(5):663. doi: 10.3390/mi15050663. PMID- 25050339 OWN - NLM STAT- MEDLINE DCOM- 20150330 LR - 20211021 IS - 2314-6141 (Electronic) IS - 2314-6133 (Print) VI - 2014 DP - 2014 TI - Bioactivity-guided fractionation identifies amygdalin as a potent neurotrophic agent from herbal medicine Semen Persicae extract. PG - 306857 LID - 10.1155/2014/306857 [doi] LID - 306857 AB - Herbal medicine Semen Persicae is widely used to treat blood stasis in Chinese medicine and other oriental folk medicines. Although little is known about the effects of Semen Persicae and its active compounds on neuron differentiation, our pilot study showed that Semen Persicae extract promoted neurite outgrowth in rat dopaminergic PC12 cells. In the present study, we developed a bioactivity-guided fractionation procedure for the characterization of the neurotrophic activity of Semen Persicae extract. The resultant fractions were assayed for neurite outgrowth in PC12 cells based on microscopic assessment. Through liquid-liquid extraction and reverse phase HPLC separation, a botanical glycoside amygdalin was isolated as the active compound responsible for the neurotrophic activity of Semen Persicae extract. Moreover, we found that amygdalin rapidly induced the activation of extracellular-signal-regulated kinase 1/2 (ERK1/2). A specific ERK1/2 inhibitor PD98059 attenuated the stimulatory effect of amygdalin on neurite outgrowth. Taken together, amygdalin was identified as a potent neurotrophic agent from Semen Persicae extract through a bioactivity-guided fractional procedure. The neurotrophic activity of amygdalin may be mediated by the activation of ERK1/2 pathway. FAU - Yang, Chuanbin AU - Yang C AD - School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 10 Sassoon Road, Pokfulam, Hong Kong. FAU - Zhao, Jia AU - Zhao J AD - School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 10 Sassoon Road, Pokfulam, Hong Kong. FAU - Cheng, Yuanyuan AU - Cheng Y AD - School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 10 Sassoon Road, Pokfulam, Hong Kong. FAU - Li, Xuechen AU - Li X AD - Department of Chemistry, The University of Hong Kong, Pokfulam, Hong Kong. FAU - Rong, Jianhui AU - Rong J AD - School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 10 Sassoon Road, Pokfulam, Hong Kong. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140624 PL - United States TA - Biomed Res Int JT - BioMed research international JID - 101600173 RN - 0 (Drugs, Chinese Herbal) RN - 0 (Flavonoids) RN - 0 (Nerve Growth Factors) RN - 0 (bu-yang-huan-wu-tang) RN - 214UUQ9N0H (Amygdalin) RN - EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases) RN - SJE1IO5E3I (2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one) SB - IM MH - Amygdalin/*pharmacology MH - Animals MH - Chemical Fractionation MH - Chromatography, High Pressure Liquid MH - Drugs, Chinese Herbal/*pharmacology MH - Enzyme Activation/drug effects MH - Extracellular Signal-Regulated MAP Kinases/metabolism MH - Flavonoids/pharmacology MH - Nerve Growth Factors/*pharmacology MH - Neurites/drug effects/metabolism MH - PC12 Cells MH - Rats PMC - PMC4094722 EDAT- 2014/07/23 06:00 MHDA- 2015/03/31 06:00 PMCR- 2014/06/24 CRDT- 2014/07/23 06:00 PHST- 2014/03/23 00:00 [received] PHST- 2014/06/03 00:00 [revised] PHST- 2014/06/03 00:00 [accepted] PHST- 2014/07/23 06:00 [entrez] PHST- 2014/07/23 06:00 [pubmed] PHST- 2015/03/31 06:00 [medline] PHST- 2014/06/24 00:00 [pmc-release] AID - 10.1155/2014/306857 [doi] PST - ppublish SO - Biomed Res Int. 2014;2014:306857. doi: 10.1155/2014/306857. Epub 2014 Jun 24. PMID- 28468407 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20180207 LR - 20181023 IS - 1094-4087 (Electronic) IS - 1094-4087 (Linking) VI - 25 IP - 9 DP - 2017 May 1 TI - Depth-dependent dispersion compensation for full-depth OCT image. PG - 10345-10354 LID - 10.1364/OE.25.010345 [doi] AB - A depth-dependent dispersion compensation algorithm for enhancing the image quality of the Fourier-domain optical coherence tomography (OCT) is presented. The dispersion related with depth in the sample is considered. Using the iterative method, an analytical formula for compensating the depth-dependent dispersion in the sample is obtained. We apply depth-dependent dispersion compensation algorithm to process the phantom images and in vivo images. Using sharpness metric based on variation coefficient to compare the results processed with different dispersion compensation algorithms, we find that the depth-dependent dispersion compensation algorithm can improve image quality at full depth. FAU - Pan, Liuhua AU - Pan L FAU - Wang, Xiangzhao AU - Wang X FAU - Li, Zhongliang AU - Li Z FAU - Zhang, Xiangyang AU - Zhang X FAU - Bu, Yang AU - Bu Y FAU - Nan, Nan AU - Nan N FAU - Chen, Yan AU - Chen Y FAU - Wang, Xuan AU - Wang X LA - eng PT - Journal Article PL - United States TA - Opt Express JT - Optics express JID - 101137103 EDAT- 2017/05/05 06:00 MHDA- 2017/05/05 06:01 CRDT- 2017/05/05 06:00 PHST- 2017/05/05 06:00 [entrez] PHST- 2017/05/05 06:00 [pubmed] PHST- 2017/05/05 06:01 [medline] AID - 363477 [pii] AID - 10.1364/OE.25.010345 [doi] PST - ppublish SO - Opt Express. 2017 May 1;25(9):10345-10354. doi: 10.1364/OE.25.010345. PMID- 34539426 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210921 IS - 1664-042X (Print) IS - 1664-042X (Electronic) IS - 1664-042X (Linking) VI - 12 DP - 2021 TI - Effects of Lipid Deposition on Viscoelastic Response in Human Hepatic Cell Line HepG2. PG - 684121 LID - 10.3389/fphys.2021.684121 [doi] LID - 684121 AB - Hepatic steatosis is associated with various liver diseases. The main pathological feature of steatosis is the excessive lipid accumulation. Ultrasound has been extensively used for the diagnosis of hepatic steatosis. However, most ultrasound-based non-invasive methods are still not accurate enough for cases with light lipid infiltration. One important reason is that the extent to which lipid infiltration may affect mechanical properties of hepatocytes remains unknown. In this work, we used atomic force microscope and in vitro dose-dependent lipid deposition model to detect the quantitative changes of mechanical properties under different degrees of steatosis in a single-cell level. The results show that hepatic cells with lipid deposition can be treated as linear viscoelastic materials with the power law creep compliance and relaxation modulus. Further analysis showed that even slight accumulation of lipid can lead to measurable decrease of stiffness and increased fluidity in liver cells. The accurate detection of viscoelastic properties of hepatocytes and the analysis methods may provide novel insights into hepatic steatosis grading, especially in the very early stage with reversible liver lesion. The application of viscoelasticity index for grading fat deposition might be a new detection indicator in future clinical diagnosis. CI - Copyright © 2021 Li, Bu, Yang and Wang. FAU - Li, Rui AU - Li R AD - Key Laboratory of Mechanics on Disaster and Environment in Western China, Ministry of Education, College of Civil Engineering and Mechanics, Lanzhou University, Lanzhou, China. FAU - Bu, Yang AU - Bu Y AD - Key Laboratory of Mechanics on Disaster and Environment in Western China, Ministry of Education, College of Civil Engineering and Mechanics, Lanzhou University, Lanzhou, China. FAU - Yang, Chendong AU - Yang C AD - Key Laboratory of Mechanics on Disaster and Environment in Western China, Ministry of Education, College of Civil Engineering and Mechanics, Lanzhou University, Lanzhou, China. FAU - Wang, Jizeng AU - Wang J AD - Key Laboratory of Mechanics on Disaster and Environment in Western China, Ministry of Education, College of Civil Engineering and Mechanics, Lanzhou University, Lanzhou, China. LA - eng PT - Journal Article DEP - 20210901 PL - Switzerland TA - Front Physiol JT - Frontiers in physiology JID - 101549006 PMC - PMC8440969 OTO - NOTNLM OT - HepG2 cells OT - atomic force microscopy OT - liver steatosis OT - oleic acid OT - viscoelasticity COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/09/21 06:00 MHDA- 2021/09/21 06:01 PMCR- 2021/09/01 CRDT- 2021/09/20 06:01 PHST- 2021/03/22 00:00 [received] PHST- 2021/08/13 00:00 [accepted] PHST- 2021/09/20 06:01 [entrez] PHST- 2021/09/21 06:00 [pubmed] PHST- 2021/09/21 06:01 [medline] PHST- 2021/09/01 00:00 [pmc-release] AID - 10.3389/fphys.2021.684121 [doi] PST - epublish SO - Front Physiol. 2021 Sep 1;12:684121. doi: 10.3389/fphys.2021.684121. eCollection 2021. PMID- 24632571 OWN - NLM STAT- MEDLINE DCOM- 20141230 LR - 20250902 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 9 IP - 3 DP - 2014 TI - Maintenance of stemness in oxaliplatin-resistant hepatocellular carcinoma is associated with increased autocrine of IGF1. PG - e89686 LID - 10.1371/journal.pone.0089686 [doi] LID - e89686 AB - BACKGROUND: Evidence suggests that many types of cancers are composed of different cell types, including cancer stem cells (CSCs). We have previously shown that the chemotherapeutic agent oxaliplatin induced epithelial-mesenchymal transition, which is thought to be an important mechanism for generating CSCs. In the present study, we investigate whether oxaliplatin-treated cancer tissues possess characteristics of CSCs, and explore oxaliplatin resistance in these tissues. METHODS: Hepatocellular carcinoma cells (MHCC97H cells) were subcutaneously injected into mice to form tumors, and the mice were intravenously treated with either oxaliplatin or glucose. Five weeks later, the tumors were orthotopically xenografted into livers of other mice, and these mice were treated with either oxaliplatin or glucose. Metastatic potential, sensitivity to oxaliplatin, and expression of CSC-related markers in the xenografted tumor tissues were evaluated. DNA microarrays were used to measure changes in gene expression as a result of oxaliplatin treatment. Additionally, an oxaliplatin-resistant cell line (MHCC97H-OXA) was established to assess insulin-like growth factor 1 secretion, cell invasion, cell colony formation, oxaliplatin sensitivity, and expression of CSC-related markers. The effects of an insulin-like growth factor 1 receptor inhibitor were also assessed. RESULTS: Oxaliplatin treatment inhibited subcutaneous tumor growth. Tumors from oxaliplatin-treated mice that were subsequently xenografted into livers of other mice exhibited that decreasing sensitivity to oxaliplatin and increasing pulmonary metastatic potential. Among the expression of CSC-related proteins, the gene for insulin-like growth factor 1, was up-regulated expecially in these tumor tissues. Additionally, MHCC97H-OXA cells demonstrated that increasing cell invasion, colony formation, and expression of insulin-like growth factor 1 and CSC-related markers, whereas treatment with an inhibitor of the insulin-like growth factor 1 receptor suppressed these effects. CONCLUSION: Maintenance of stemness in oxaliplatin-resistant hepatocellular carcinoma cells is associated with increased autocrine of IGF1. FAU - Bu, Yang AU - Bu Y AD - Institutes of Biomedical Sciences, Fudan University, Shanghai, China; Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China. FAU - Jia, Qing-An AU - Jia QA AD - Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China; Hepatobiliary Surgery, Shanxi Provincial People's Hospital, Xi'an, China. FAU - Ren, Zheng-Gang AU - Ren ZG AD - Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China. FAU - Zhang, Ju-Bo AU - Zhang JB AD - Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China. FAU - Jiang, Xue-Mei AU - Jiang XM AD - Department of Gastroenterology, Haikou People's Hospital, Haikou, China. FAU - Liang, Lei AU - Liang L AD - Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China. FAU - Xue, Tong-Chun AU - Xue TC AD - Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China. FAU - Zhang, Quan-Bao AU - Zhang QB AD - Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China. FAU - Wang, Yan-Hong AU - Wang YH AD - Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China. FAU - Zhang, Lan AU - Zhang L AD - Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China. FAU - Xie, Xiao-Ying AU - Xie XY AD - Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China. FAU - Tang, Zhao-You AU - Tang ZY AD - Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Retracted Publication DEP - 20140314 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Antineoplastic Agents) RN - 0 (Organoplatinum Compounds) RN - 04ZR38536J (Oxaliplatin) RN - 67763-96-6 (Insulin-Like Growth Factor I) SB - IM RIN - PLoS One. 2025 Sep 2;20(9):e0331410. doi: 10.1371/journal.pone.0331410. PMID: 40892858 MH - Animals MH - Antineoplastic Agents/*therapeutic use MH - Carcinoma, Hepatocellular/drug therapy/*metabolism MH - Cell Line, Tumor MH - Drug Resistance, Neoplasm MH - Epithelial-Mesenchymal Transition/drug effects MH - Insulin-Like Growth Factor I/*metabolism MH - Liver Neoplasms/*drug therapy/*metabolism MH - Mice MH - Mice, Nude MH - Neoplastic Stem Cells/*drug effects MH - Organoplatinum Compounds/*therapeutic use MH - Oxaliplatin PMC - PMC3954560 COIS- Competing Interests: The authors have declared that no competing interests exist. EDAT- 2014/03/19 06:00 MHDA- 2014/12/31 06:00 PMCR- 2014/03/14 CRDT- 2014/03/18 06:00 PHST- 2013/08/19 00:00 [received] PHST- 2014/01/23 00:00 [accepted] PHST- 2014/03/18 06:00 [entrez] PHST- 2014/03/19 06:00 [pubmed] PHST- 2014/12/31 06:00 [medline] PHST- 2014/03/14 00:00 [pmc-release] AID - PONE-D-13-37186 [pii] AID - 10.1371/journal.pone.0089686 [doi] PST - epublish SO - PLoS One. 2014 Mar 14;9(3):e89686. doi: 10.1371/journal.pone.0089686. eCollection 2014. PMID- 31891124 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 2574-0970 (Electronic) IS - 2574-0970 (Linking) VI - 1 IP - 1 DP - 2018 Jan 26 TI - Silver-Nanoparticle-Embedded Porous Silicon Disks Enabled SERS Signal Amplification for Selective Glutathione Detection. PG - 410-417 LID - 10.1021/acsanm.7b00290 [doi] AB - As the major redox couple and nonprotein thiol source in human tissues, the level of glutathione (GSH) has been a concern for its relation with many diseases. However, the similar physical and chemical properties of interference molecules such as cysteine (Cys) and homocysteine (Hcy) make discriminative detection of GSH in complex biological fluids challenging. Here we report a novel surface-enhanced Raman scattering (SERS) platform, based on silver-nanoparticle-embedded porous silicon disks (PSDs/Ag) substrates for highly sensitive and selective detection of GSH in biofluids. Silver nanoparticles (AgNPs) were reductively synthesized and aggregated directly into pores of PSDs, achieving a SERS enhancement factor (EF) up to 2.59 × 10(7). Ellman's reagent 5,5'-ditho-bis (2-nitrobenzoic acid) (DTNB) was selected as the Raman reactive reporting agent, and the GSH quantification was determined using enzymatic recycling method, and allowed the detection limit of GSH to be down to 74.9 nM using a portable Raman spectrometer. Moreover, the significantly overwhelmed enhancement ratio of GSH over other substances enables the discrimination of GSH detection in complex biofluids. FAU - Bu, Yang AU - Bu Y AUID- ORCID: 0000-0003-2448-4743 AD - College of Materials Sciences and Optoelectronics, University of Chinese Academy of Sciences, Beijing 100049, China. AD - Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas 77030, United States. FAU - Zhu, Guixian AU - Zhu G AD - Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas 77030, United States. AD - School of Instrument Science and Optoelectronics Engineering, Beijing Information Science and Technology University, Beijing 100192, China. FAU - Li, Shengliang AU - Li S AUID- ORCID: 0000-0002-3890-8482 AD - Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas 77030, United States. FAU - Qi, Ruogu AU - Qi R AUID- ORCID: 0000-0001-9222-9272 AD - Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas 77030, United States. FAU - Bhave, Gauri AU - Bhave G AD - Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas 77030, United States. FAU - Zhang, Dechen AU - Zhang D AUID- ORCID: 0000-0003-3984-7674 AD - Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas 77030, United States. AD - Key Laboratory for Molecular Enzymology & Engineering, The Ministry of Education, College of Life Science, Jilin University, Jilin 130012, China. FAU - Han, Ruixuan AU - Han R AD - Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas 77030, United States. FAU - Sun, Dali AU - Sun D AD - Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas 77030, United States. FAU - Liu, Xiangfeng AU - Liu X AUID- ORCID: 0000-0001-9633-7721 AD - College of Materials Sciences and Optoelectronics, University of Chinese Academy of Sciences, Beijing 100049, China. FAU - Hu, Zhongbo AU - Hu Z AD - College of Materials Sciences and Optoelectronics, University of Chinese Academy of Sciences, Beijing 100049, China. FAU - Liu, Xuewu AU - Liu X AUID- ORCID: 0000-0002-8702-0295 AD - Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas 77030, United States. LA - eng GR - R21 CA190024/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20171218 PL - United States TA - ACS Appl Nano Mater JT - ACS applied nano materials JID - 101726750 PMC - PMC6936757 MID - NIHMS1022589 OTO - NOTNLM OT - SERS OT - biosensor OT - glutathione OT - porous silicon OT - signal amplification OT - silver nanoparticles COIS- Notes The authors declare no competing financial interest. EDAT- 2018/01/26 00:00 MHDA- 2018/01/26 00:01 PMCR- 2019/12/30 CRDT- 2020/01/01 06:00 PHST- 2020/01/01 06:00 [entrez] PHST- 2018/01/26 00:00 [pubmed] PHST- 2018/01/26 00:01 [medline] PHST- 2019/12/30 00:00 [pmc-release] AID - 10.1021/acsanm.7b00290 [doi] PST - ppublish SO - ACS Appl Nano Mater. 2018 Jan 26;1(1):410-417. doi: 10.1021/acsanm.7b00290. Epub 2017 Dec 18. PMID- 30906967 OWN - NLM STAT- MEDLINE DCOM- 20200106 LR - 20231011 IS - 1572-8781 (Electronic) IS - 1387-2176 (Print) IS - 1387-2176 (Linking) VI - 21 IP - 2 DP - 2019 Mar 25 TI - Microfluidic device for the analysis of MDR cancerous cell-derived exosomes' response to nanotherapy. PG - 35 LID - 10.1007/s10544-019-0381-1 [doi] AB - Exosomes are membrane-enclosed extracellular vesicles which have been indicated as important biomarkers of cancerous cell functionality, such as multiple drug resistance (MDR). Nanoparticles based chemotherapy is a promising strategy to overcome MDR by interfering the production and composition of exosomes. Therefore, tumor-derived exosomes post-treatment by nanotherapy are implied to play critical roles of biomarkers on cancer MDR analysis. However, the efficient isolation of such exosomes from extracellular environment for their therapeutic response analysis remains challenging. In this study, we presented a microfluidic device featured exosome specific anti-CD63 immobilized ciliated micropillars, which were capable to isolate cancer-derived exosomes from cell culture medium. The captured exosomes can be recovered intact by dissolving the cilia on the micropillars using PBS soaking. Owing to the immobilized antibody in the microfluidic device, nearly 70% of exosome from the biofluid could be isolated. So the secreted exosomes of the MDR and ordinary human breast cancer cells pre-treated by free drug or nanotherapy could be isolated with high purity. The drug contents of the isolated exosomes were measured to analysis of the exosomal pathway response of MDR cells to different chemotherapeutic formulations. Such analyses and further definition of the biomarkers of these exosomes could benefit the future investigations of accurately and reliably determine design principle, functional activity, and mechanisms of nanotherapy for MDR overcoming. FAU - Qi, Ruogu AU - Qi R AD - Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Ave, Houston, TX, 77030, USA. FAU - Zhu, Guixian AU - Zhu G AD - Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Ave, Houston, TX, 77030, USA. FAU - Wang, Yu AU - Wang Y AD - Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Ave, Houston, TX, 77030, USA. FAU - Wu, Suhong AU - Wu S AD - Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Ave, Houston, TX, 77030, USA. FAU - Li, Shengliang AU - Li S AD - Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Ave, Houston, TX, 77030, USA. FAU - Zhang, Dechen AU - Zhang D AD - Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Ave, Houston, TX, 77030, USA. FAU - Bu, Yang AU - Bu Y AD - Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Ave, Houston, TX, 77030, USA. FAU - Bhave, Gauri AU - Bhave G AD - Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Ave, Houston, TX, 77030, USA. FAU - Han, Ruixuan AU - Han R AD - Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Ave, Houston, TX, 77030, USA. FAU - Liu, Xuewu AU - Liu X AUID- ORCID: 0000-0002-8702-0295 AD - Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Ave, Houston, TX, 77030, USA. xliu@houstonmethodist.org. LA - eng GR - R01 GM127558/GM/NIGMS NIH HHS/United States GR - R21 CA190024/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20190325 PL - United States TA - Biomed Microdevices JT - Biomedical microdevices JID - 100887374 RN - 0 (Antineoplastic Agents) RN - 7631-86-9 (Silicon Dioxide) SB - IM MH - Antineoplastic Agents/*chemistry/*pharmacology MH - Cell Line, Tumor MH - Drug Resistance, Multiple/*drug effects MH - Exosomes/*drug effects MH - Humans MH - *Lab-On-A-Chip Devices MH - *Nanomedicine MH - Nanoparticles/chemistry MH - Porosity MH - Silicon Dioxide/chemistry PMC - PMC6532782 MID - NIHMS1022590 OTO - NOTNLM OT - Exosome OT - Isolation OT - Microfluidic device OT - Multiple drug resistance OT - Nanoparticles therapy EDAT- 2019/03/25 06:00 MHDA- 2020/01/07 06:00 PMCR- 2020/03/25 CRDT- 2019/03/26 06:00 PHST- 2019/03/26 06:00 [entrez] PHST- 2019/03/25 06:00 [pubmed] PHST- 2020/01/07 06:00 [medline] PHST- 2020/03/25 00:00 [pmc-release] AID - 10.1007/s10544-019-0381-1 [pii] AID - 10.1007/s10544-019-0381-1 [doi] PST - epublish SO - Biomed Microdevices. 2019 Mar 25;21(2):35. doi: 10.1007/s10544-019-0381-1. PMID- 40757347 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251002 LR - 20251002 IS - 2470-1343 (Electronic) IS - 2470-1343 (Linking) VI - 10 IP - 29 DP - 2025 Jul 29 TI - Numerical Investigation of Drop Impact on Immiscible Liquid-Liquid Interfaces. PG - 31954-31975 LID - 10.1021/acsomega.5c03506 [doi] AB - In this paper, we numerically investigate the levitation behaviors of a drop impacting an immiscible liquid-liquid interface, disregarding the influence of gravitational acceleration. Through energy budget analysis, we elucidate that the phenomenological model proposed by Sanjay et al. (J. Fluid Mech., 2023, vol. 958, p A25) and Jha et al. (Soft Matter. 2020, vol. 16, pp 7270-7273) is partially applicable to drop impact on liquid-liquid interfaces. Specifically, the magnitude of energy transferred from the impacting drop to the liquid film remains unchanged despite a two-orders-of-magnitude variation in the density of the surrounding liquid. Additionally, the normalized maximum film deflection exhibits a significant two-stage growth characteristic with increasing liquid film thickness under conditions of relatively high liquid film viscosity or an interfacial tension coefficient ratio. When the liquid film thickness is relatively low, the energy transfer from the impacting drop to the liquid film is also insensitive to changes in the interfacial tension coefficient ratio. CI - © 2025 The Authors. Published by American Chemical Society. FAU - Liao, Bin AU - Liao B AUID- ORCID: 0009-0009-1933-0839 AD - Key Laboratory of Mechanics, Anhui Polytechnic University, Wuhu, Anhui 241000, China. RINGGOLD: 162794 AD - Anhui Engineering Research Center of Green Building and Digital Construction, Anhui Polytechnic University, Wuhu, Anhui 241000, China. FAU - Ji, Weimin AU - Ji W AD - Key Laboratory of Mechanics, Anhui Polytechnic University, Wuhu, Anhui 241000, China. RINGGOLD: 162794 AD - Anhui Engineering Research Center of Green Building and Digital Construction, Anhui Polytechnic University, Wuhu, Anhui 241000, China. FAU - Bu, Yang AU - Bu Y AD - Key Laboratory of Mechanics, Anhui Polytechnic University, Wuhu, Anhui 241000, China. RINGGOLD: 162794 AD - Anhui Engineering Research Center of Green Building and Digital Construction, Anhui Polytechnic University, Wuhu, Anhui 241000, China. FAU - Du, Wangfang AU - Du W AD - CAS Key Laboratory of Microgravity, Institute of Mechanics, Chinese Academy of Science, Beijing 100190, China. RINGGOLD: 557087 FAU - Chen, Shanqun AU - Chen S AUID- ORCID: 0000-0002-3421-0546 AD - Key Laboratory of Mechanics, Anhui Polytechnic University, Wuhu, Anhui 241000, China. RINGGOLD: 162794 AD - Anhui Engineering Research Center of Green Building and Digital Construction, Anhui Polytechnic University, Wuhu, Anhui 241000, China. LA - eng PT - Journal Article DEP - 20250715 PL - United States TA - ACS Omega JT - ACS omega JID - 101691658 PMC - PMC12311746 EDAT- 2025/08/04 12:27 MHDA- 2025/08/04 12:28 PMCR- 2025/07/15 CRDT- 2025/08/04 06:26 PHST- 2025/04/16 00:00 [received] PHST- 2025/06/11 00:00 [revised] PHST- 2025/07/03 00:00 [accepted] PHST- 2025/08/04 12:27 [pubmed] PHST- 2025/08/04 12:28 [medline] PHST- 2025/08/04 06:26 [entrez] PHST- 2025/07/15 00:00 [pmc-release] AID - 10.1021/acsomega.5c03506 [doi] PST - epublish SO - ACS Omega. 2025 Jul 15;10(29):31954-31975. doi: 10.1021/acsomega.5c03506. eCollection 2025 Jul 29. PMID- 29061995 OWN - NLM STAT- MEDLINE DCOM- 20190716 LR - 20190816 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 7 IP - 1 DP - 2017 Oct 23 TI - CCN3 is a therapeutic target relating enhanced stemness and coagulation in hepatocellular carcinoma. PG - 13846 LID - 10.1038/s41598-017-14087-4 [doi] LID - 13846 AB - The general prognosis of patients with hepatocellular carcinoma (HCC) remains extremely dismal, due to the high frequency of metastasis. Since 2003, our research group has explored the gene expression profiles of metastasized HCC tissue samples and identified a significant upregulation of CCN3. However, the role and precise pathological function of CCN3 remains elusive. We showed that CCN3 is associated with the poor prognosis of patients with HCC, the malignant phenotype of HCC, and vascular thrombosis. We further evaluated the negative roles of CCN3 in vitro and in vivo, and identified osteopontin (OPN), and coagulation factors tissue factor (TF) and thrombin as the leading genes downstream of CCN3, that are positively associated with HCC cell stemness. We demonstrated that overexpressed CCN3 in HCC cells leads to enhanced survival and increased number of pulmonary metastases in vivo. The elevated levels of OPN and TF were associated with signal activation of nuclear factor κB (NFκB) and extracellular signal-regulated kinases (ERK). Our findings suggest CCN3 is a potential therapeutic target that would affect the upregulation of OPN and coagulation factors, which would lead to an enhanced stemness and blood coagulation microenvironment in HCC tissue. FAU - Jia, Qingan AU - Jia Q AD - Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China. FAU - Xue, Tongchun AU - Xue T AD - Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. FAU - Zhang, Qiangbo AU - Zhang Q AD - Department of General Surgery, Qilu Hospital, Shandong University, Jinan, 250012, China. FAU - Cheng, Wei AU - Cheng W AD - Department of Pharmacy and Medical Technology, Hanzhong Vocational and Technical College, Hanzhong, 723002, China. FAU - Zhang, Chun AU - Zhang C AD - Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China. AD - Department of General Surgery, Qilu Hospital, Shandong University, Jinan, 250012, China. FAU - Ma, Jingwei AU - Ma J AD - Department of Hepatobiliary Surgery, General Hospital, Ningxia Medical University, Yinchuan, 750001, China. FAU - Bu, Yang AU - Bu Y AD - Department of Hepatobiliary Surgery, General Hospital, Ningxia Medical University, Yinchuan, 750001, China. FAU - Yu, Songning AU - Yu S AD - Department of Hepatobiliary Surgery, General Hospital, Ningxia Medical University, Yinchuan, 750001, China. FAU - Liu, Qingguang AU - Liu Q AD - Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China. liuqingguang@vip.sina.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20171023 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (Biomarkers, Tumor) RN - 0 (CCN3 protein, human) RN - 0 (NF-kappa B) RN - 0 (Nephroblastoma Overexpressed Protein) RN - 0 (SPP1 protein, human) RN - 106441-73-0 (Osteopontin) RN - 9035-58-9 (Thromboplastin) SB - IM MH - Animals MH - Apoptosis MH - Biomarkers, Tumor/genetics/*metabolism MH - Blood Coagulation MH - Carcinoma, Hepatocellular/genetics/metabolism/*secondary/surgery MH - Cell Adhesion MH - Cell Movement MH - Cell Proliferation MH - Female MH - Follow-Up Studies MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Liver Neoplasms/genetics/metabolism/*pathology/surgery MH - Male MH - Mice MH - Mice, Inbred BALB C MH - Mice, Nude MH - Middle Aged MH - NF-kappa B/genetics/metabolism MH - Neoplasm Invasiveness MH - Neoplastic Stem Cells/metabolism/*pathology MH - Nephroblastoma Overexpressed Protein/genetics/*metabolism MH - Osteopontin/genetics/*metabolism MH - Prognosis MH - Survival Rate MH - Thromboplastin/genetics/*metabolism MH - Tumor Cells, Cultured MH - Tumor Microenvironment MH - Xenograft Model Antitumor Assays PMC - PMC5653869 COIS- The authors declare that they have no competing interests. EDAT- 2017/10/25 06:00 MHDA- 2019/07/17 06:00 PMCR- 2017/10/23 CRDT- 2017/10/25 06:00 PHST- 2017/02/21 00:00 [received] PHST- 2017/10/02 00:00 [accepted] PHST- 2017/10/25 06:00 [entrez] PHST- 2017/10/25 06:00 [pubmed] PHST- 2019/07/17 06:00 [medline] PHST- 2017/10/23 00:00 [pmc-release] AID - 10.1038/s41598-017-14087-4 [pii] AID - 14087 [pii] AID - 10.1038/s41598-017-14087-4 [doi] PST - epublish SO - Sci Rep. 2017 Oct 23;7(1):13846. doi: 10.1038/s41598-017-14087-4. PMID- 38749890 OWN - NLM STAT- MEDLINE DCOM- 20240604 LR - 20240604 IS - 1879-0003 (Electronic) IS - 0141-8130 (Linking) VI - 270 IP - Pt 1 DP - 2024 Jun TI - Ganoderma lucidum spores-derived particulate β-glucan treatment improves antitumor response by regulating myeloid-derived suppressor cells in triple-negative breast cancer. PG - 131949 LID - S0141-8130(24)02754-5 [pii] LID - 10.1016/j.ijbiomac.2024.131949 [doi] AB - Granular β-1,3-glucan extracted from the wall of Ganoderma lucidum spores, named GPG, is a bioregulator. In this study, we investigated the structural, thermal, and other physical properties of GPG. We determined whether GPG ameliorated immunosuppression caused by Gemcitabine (GEM) chemotherapy. Triple-negative breast cancer mice with GPG combined with GEM treatment had reduced tumor burdens. In addition, GEM treatment alone altered the tumor microenvironment(TME), including a reduction in antitumor T cells and a rise in myeloid-derived suppressor cells (MDSC) and regulatory T cells (Tregs). However, combined GPG treatment reversed the tumor immunosuppressive microenvironment induced by GEM. GPG inhibited bone marrow (BM)-derived MDSC differentiation and reversed MDSC expansion induced by conditioned medium (CM) in GEM-treated E0771 cells through a Dectin-1 pathway. In addition, GPG downgraded PD-L1 and IDO1 expression on MDSC while boosting MHC-II, CD86, TNF-α, and IL-6 expression. In conclusion, this study demonstrated that GPG could alleviate the adverse effects induced by GEM chemotherapy by regulating TME. CI - Copyright © 2024 Elsevier B.V. All rights reserved. FAU - Bu, Yang AU - Bu Y AD - Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, Jiangsu, PR China; Key Laboratory of New Drug Delivery Systems of Chinese Materia Medica, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing 210028, PR China. FAU - Liu, Qian AU - Liu Q AD - Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, Jiangsu, PR China; Key Laboratory of New Drug Delivery Systems of Chinese Materia Medica, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing 210028, PR China. FAU - Shang, Yongjie AU - Shang Y AD - Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, Jiangsu, PR China; Key Laboratory of New Drug Delivery Systems of Chinese Materia Medica, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing 210028, PR China. FAU - Zhao, Zhenzhen AU - Zhao Z AD - Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, Jiangsu, PR China; Key Laboratory of New Drug Delivery Systems of Chinese Materia Medica, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing 210028, PR China. FAU - Sun, Haonan AU - Sun H AD - Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, Jiangsu, PR China; Key Laboratory of New Drug Delivery Systems of Chinese Materia Medica, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing 210028, PR China. FAU - Chen, Feifei AU - Chen F AD - Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, Jiangsu, PR China; Key Laboratory of New Drug Delivery Systems of Chinese Materia Medica, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing 210028, PR China. FAU - Ma, Qian AU - Ma Q AD - Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, Jiangsu, PR China; Key Laboratory of New Drug Delivery Systems of Chinese Materia Medica, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing 210028, PR China. FAU - Song, Jie AU - Song J AD - Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, Jiangsu, PR China; Key Laboratory of New Drug Delivery Systems of Chinese Materia Medica, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing 210028, PR China. FAU - Cui, Li AU - Cui L AD - Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, Jiangsu, PR China; Key Laboratory of New Drug Delivery Systems of Chinese Materia Medica, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing 210028, PR China. FAU - Sun, E AU - Sun E AD - Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, Jiangsu, PR China; Key Laboratory of New Drug Delivery Systems of Chinese Materia Medica, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing 210028, PR China. FAU - Luo, Yi AU - Luo Y AD - Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, Jiangsu, PR China. FAU - Shu, Luan AU - Shu L AD - Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, Jiangsu, PR China; Key Laboratory of New Drug Delivery Systems of Chinese Materia Medica, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing 210028, PR China. FAU - Jing, Haibo AU - Jing H AD - Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, Jiangsu, PR China; Department of General Surgery, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, Jiangsu, PR China. Electronic address: jing860520@126.com. FAU - Tan, Xiaobin AU - Tan X AD - Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, Jiangsu, PR China; Key Laboratory of New Drug Delivery Systems of Chinese Materia Medica, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing 210028, PR China. Electronic address: njtxb@hotmail.com. LA - eng PT - Journal Article DEP - 20240515 PL - Netherlands TA - Int J Biol Macromol JT - International journal of biological macromolecules JID - 7909578 RN - 0 (beta-Glucans) RN - 0 (Antineoplastic Agents) RN - 0W860991D6 (Deoxycytidine) RN - 0 (dectin 1) RN - 0 (Lectins, C-Type) SB - IM MH - *Triple Negative Breast Neoplasms/drug therapy/pathology/metabolism MH - Animals MH - *Myeloid-Derived Suppressor Cells/drug effects/metabolism/immunology MH - Mice MH - *Spores, Fungal MH - *beta-Glucans/pharmacology/chemistry MH - *Reishi/chemistry MH - Female MH - *Tumor Microenvironment/drug effects MH - Cell Line, Tumor MH - Antineoplastic Agents/pharmacology/chemistry MH - Deoxycytidine/analogs & derivatives/pharmacology MH - Lectins, C-Type OTO - NOTNLM OT - Beta-glucan OT - Chemotherapy OT - Triple-negative breast cancer (TNBC) COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/05/16 00:43 MHDA- 2024/06/04 06:42 CRDT- 2024/05/15 22:03 PHST- 2023/09/14 00:00 [received] PHST- 2024/04/24 00:00 [revised] PHST- 2024/04/26 00:00 [accepted] PHST- 2024/06/04 06:42 [medline] PHST- 2024/05/16 00:43 [pubmed] PHST- 2024/05/15 22:03 [entrez] AID - S0141-8130(24)02754-5 [pii] AID - 10.1016/j.ijbiomac.2024.131949 [doi] PST - ppublish SO - Int J Biol Macromol. 2024 Jun;270(Pt 1):131949. doi: 10.1016/j.ijbiomac.2024.131949. Epub 2024 May 15. PMID- 34497155 OWN - NLM STAT- MEDLINE DCOM- 20220107 LR - 20220107 IS - 1945-4589 (Electronic) IS - 1945-4589 (Linking) VI - 13 IP - 17 DP - 2021 Sep 8 TI - Dual roles of WISP2 in the progression of hepatocellular carcinoma: implications of the fibroblast infiltration into the tumor microenvironment. PG - 21216-21231 LID - 10.18632/aging.203424 [doi] AB - The dismal outcome of hepatocellular carcinoma (HCC) patients is attributable to high frequency of metastasis and. Identification of effective biomarkers is a key strategy to inform prognosis and improve survival. Previous studies reported inconsistent roles of WISP2 in carcinogenesis, while the role of WISP2 in HCC progression also remains unclear. In this study, we confirmed that WISP2 was downregulated in HCC tissues, and WISP2 was acting as a protective factor, especially in patients without alcohol intake using multiple online datasets. In addition, we reported that upregulation of WISP2 in HCC was related to inhibition of the malignant phenotype in vitro, but these alterations were not observed in vivo. WISP2 also negatively correlated with tumour purity, and increased infiltration of fibroblasts promoted malignant progression in HCC tissues. The enhanced infiltration ability of fibroblasts was related to upregulated HMGB1 after overexpression of WISP2 in HCC. The findings shed light on the anticancer role of WISP2, and HMGB1 is one of the key factors involved in the inhibition of the efficiency of WISP2 through reducing the tumour purity with fibroblast infiltration. FAU - Jia, Qingan AU - Jia Q AD - Institute of Medical Research, Northwestern Polytechnical University, Xi'an 710072, China. FAU - Zhang, Yaoyao AU - Zhang Y AD - Institute of Medical Research, Northwestern Polytechnical University, Xi'an 710072, China. FAU - Xu, Binghui AU - Xu B AD - Institute of Medical Research, Northwestern Polytechnical University, Xi'an 710072, China. FAU - Liao, Xia AU - Liao X AD - Department of Nutrition, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China. FAU - Bu, Yang AU - Bu Y AD - Department of Hepatobiliary Surgery, General Hospital, Ningxia Medical University, Yinchuan 750001, China. FAU - Xu, Zihan AU - Xu Z AD - Department of Burns and Plastic Surgery, Affiliated Shaanxi Provincial People's Hospital, Northwestern Polytechnical University, Xi'an 710068, China. FAU - Duan, Xianglong AU - Duan X AD - Second Department of General Surgery, Shaanxi Provincial People's Hospital Affiliated Hospital of Northwestern Polytechnical University, Xi'an 710068, China. FAU - Zhang, Qiangbo AU - Zhang Q AD - Cheeloo College of Medicine, Shandong University, Jinan 250012, China. AD - Department of General Surgery, Qilu Hospital, Shandong University, Jinan 250012, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210908 PL - United States TA - Aging (Albany NY) JT - Aging JID - 101508617 RN - 0 (CCN Intercellular Signaling Proteins) RN - 0 (CCN5 protein, human) RN - 0 (HMGB1 Protein) RN - 0 (HMGB1 protein, human) RN - 0 (RNA, Messenger) RN - 0 (Repressor Proteins) SB - IM MH - CCN Intercellular Signaling Proteins/genetics/*metabolism MH - Carcinoma, Hepatocellular/*metabolism MH - Cell Line, Tumor MH - Fibroblasts/*physiology MH - Gene Expression Regulation, Neoplastic MH - HMGB1 Protein/genetics/*metabolism MH - Humans MH - Liver Neoplasms/*metabolism MH - RNA, Messenger/genetics/metabolism MH - Repressor Proteins/genetics/*metabolism MH - Transcriptome MH - *Tumor Microenvironment MH - Up-Regulation PMC - PMC8457598 OTO - NOTNLM OT - HCC OT - HMGB1 OT - WISP2 OT - fibroblast OT - prognosis COIS- CONFLICTS OF INTEREST: The authors declare no conflicts of interest related to this study. EDAT- 2021/09/10 06:00 MHDA- 2022/01/08 06:00 PMCR- 2021/09/15 CRDT- 2021/09/09 06:09 PHST- 2021/04/08 00:00 [received] PHST- 2021/07/08 00:00 [accepted] PHST- 2021/09/10 06:00 [pubmed] PHST- 2022/01/08 06:00 [medline] PHST- 2021/09/09 06:09 [entrez] PHST- 2021/09/15 00:00 [pmc-release] AID - 203424 [pii] AID - 10.18632/aging.203424 [doi] PST - ppublish SO - Aging (Albany NY). 2021 Sep 8;13(17):21216-21231. doi: 10.18632/aging.203424. Epub 2021 Sep 8. PMID- 27814372 OWN - NLM STAT- MEDLINE DCOM- 20170626 LR - 20201214 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 11 IP - 11 DP - 2016 TI - Decreased Expression of TMEM173 Predicts Poor Prognosis in Patients with Hepatocellular Carcinoma. PG - e0165681 LID - 10.1371/journal.pone.0165681 [doi] LID - e0165681 AB - Hepatocellular carcinoma (HCC) is one of the most lethal cancer types, and chronic infection with Hepatitis B Virus (HBV) is identified as the strongest risk factor for HCC. Transmembrane Protein 173 (TMEM173) is a pattern recognition receptor which functions as a major regulator of the innate immune response to viral and bacterial infections. However, the prognostic value of TMEM173 in HCC remains elusive. Thus, we aimed to evaluate the potential prognostic significance of TMEM173 expression in HCC patients following curative resection. Immunohistochemistry was used to detect TMEM173 expression in 96 HCC patients. We found that TMEM173 protein expression was remarkably decreased in tumor tissues compared to non-tumor tissues, and that TMEM173 staining intensity was inversely correlated with tumor size, tumor invasion TNM stage and overall survival (OS) in HCC patients. Multivariate analysis supported TMEM173 as an independent prognostic factor, and identified that combining TMEM173 expression with TNM stage showed better prognostic efficiency for OS in HCC patients. In summary, TMEM173 was discovered having an independent prognostic value and may serve as a potential immunotherapeutic target for HCC. FAU - Bu, Yang AU - Bu Y AUID- ORCID: 0000-0001-6240-8296 AD - Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, China. FAU - Liu, Fang AU - Liu F AD - Medical Examination Center, General Hospital of Ningxia Medical University, Yinchuan, China. FAU - Jia, Qing-An AU - Jia QA AD - Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an JiaoTong University, Xi'an, China. FAU - Yu, Song-Ning AU - Yu SN AD - Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, China. LA - eng PT - Journal Article DEP - 20161104 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Membrane Proteins) RN - 0 (STING1 protein, human) SB - IM MH - Carcinoma, Hepatocellular/*metabolism/*pathology MH - Cell Line, Tumor MH - Female MH - Gene Expression Regulation, Neoplastic/physiology MH - Humans MH - Immunohistochemistry/methods MH - Liver Neoplasms/*metabolism/*pathology MH - Male MH - Membrane Proteins/*metabolism MH - Middle Aged MH - Multivariate Analysis MH - Prognosis PMC - PMC5096716 COIS- The authors have declared that no competing interests exist. EDAT- 2016/11/05 06:00 MHDA- 2017/06/27 06:00 PMCR- 2016/11/04 CRDT- 2016/11/05 06:00 PHST- 2016/09/02 00:00 [received] PHST- 2016/10/14 00:00 [accepted] PHST- 2016/11/05 06:00 [entrez] PHST- 2016/11/05 06:00 [pubmed] PHST- 2017/06/27 06:00 [medline] PHST- 2016/11/04 00:00 [pmc-release] AID - PONE-D-16-33840 [pii] AID - 10.1371/journal.pone.0165681 [doi] PST - epublish SO - PLoS One. 2016 Nov 4;11(11):e0165681. doi: 10.1371/journal.pone.0165681. eCollection 2016. PMID- 38049741 OWN - NLM STAT- MEDLINE DCOM- 20231206 LR - 20231216 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 23 IP - 1 DP - 2023 Dec 4 TI - Identification of a Novel CD8(+) T cell exhaustion-related gene signature for predicting survival in hepatocellular carcinoma. PG - 1185 LID - 10.1186/s12885-023-11648-x [doi] LID - 1185 AB - BACKGROUND: Hepatocellular carcinoma (HCC) is a major health concern, necessitating a deeper understanding of its prognosis and underlying mechanisms. This study aimed to investigate the mechanism and prognostic value of CD8(+) T Cell exhaustion (CD8(+) TEX)-related genes in HCC and construct a survival prognosis prediction model for patients with HCC. METHODS: CD8(+) TEX-related genes associated with HCC prognosis were analysed and identified, and a prognostic prediction model was constructed using the 'least absolute shrinkage and selection operator' Cox regression model. Immunohistochemistry was used to verify the expression of the model genes in HCC tissues. A nomogram was constructed based on risk scores and clinical features, and its predictive efficacy was verified. The expression of STAM, ANXA5, and MAD2L2 in HCC cell lines was detected by western blotting; subsequently, these genes were knocked down in HCC cell lines by small interfering RNA, and their effects on the proliferation and migration of HCC cell lines were detected by colony formation assay, cck8, wound healing, and transwell assays. RESULTS: Six genes related to CD8(+) TEX were included in the risk-prediction model. The prognosis of patients with HCC in the low-risk group was significantly better than that of those in the high-risk group. Cox regression analysis revealed that the risk score was an independent risk factor for the prognosis of patients with HCC. The differentially expressed genes in patients with high-risk HCC were mainly enriched in the nucleotide-binding oligomerization domain-containing protein-like receptor, hypoxia-inducible factor-1, and tumour programmed cell death protein (PD)-1/PD-L1 immune checkpoint pathways. The CD8(+) TEX-related genes STAM, ANXA5, and MAD2L2 were knocked down in HCC cell lines to significantly inhibit cell proliferation and migration. The prediction results of the nomogram based on the risk score showed a good fit and application value. CONCLUSION: The prediction model based on CD8(+) TEX-related genes can predict the prognosis of HCC and provide a theoretical basis for the early identification of patients with poor HCC prognosis. CI - © 2023. The Author(s). FAU - Liu, Kejun AU - Liu K AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, 750004, China. AD - School of Clinical Medicine, Ningxia Medical University, Yinchuan, 750004, China. FAU - Liu, Junhao AU - Liu J AD - School of Clinical Medicine, Ningxia Medical University, Yinchuan, 750004, China. AD - Department of Hepatobiliary Surgery, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, 750002, China. FAU - Zhang, Xusheng AU - Zhang X AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, 750004, China. AD - School of Clinical Medicine, Ningxia Medical University, Yinchuan, 750004, China. FAU - Liu, Di AU - Liu D AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, 750004, China. AD - School of Clinical Medicine, Ningxia Medical University, Yinchuan, 750004, China. FAU - Yao, Weijie AU - Yao W AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, 750004, China. AD - School of Clinical Medicine, Ningxia Medical University, Yinchuan, 750004, China. FAU - Bu, Yang AU - Bu Y AD - School of Clinical Medicine, Ningxia Medical University, Yinchuan, 750004, China. buyang1976@163.com. AD - Department of Hepatobiliary Surgery, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, 750002, China. buyang1976@163.com. FAU - Chen, Bendong AU - Chen B AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, 750004, China. bendong8511@hotmail.com. AD - School of Clinical Medicine, Ningxia Medical University, Yinchuan, 750004, China. bendong8511@hotmail.com. LA - eng GR - No. YKDZY2022013/Newly recruited master's training project of the General Hospital of Ningxia Medical University/ GR - No. 2023AAC03606/Natural Science Foundation of Ningxia Hui Autonomous Region/ GR - XM2022041/Nature Foundation of Ningxia Medical University/ GR - 2021CMG03017/Technology Benefit Project of the Ningxia Hui Autonomous Region/ PT - Journal Article DEP - 20231204 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (Annexin A5) RN - 0 (MAD2L2 protein, human) RN - 0 (Mad2 Proteins) SB - IM MH - Humans MH - *Carcinoma, Hepatocellular/genetics MH - T-Cell Exhaustion MH - *Liver Neoplasms/genetics MH - Genes, cdc MH - Annexin A5 MH - CD8-Positive T-Lymphocytes MH - Prognosis MH - Mad2 Proteins PMC - PMC10694949 OTO - NOTNLM OT - CD8+ T Cell Exhaustion OT - Hepatocellular carcinoma OT - LASSO regression analysis OT - Prognosis COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/12/05 00:42 MHDA- 2023/12/06 06:42 PMCR- 2023/12/04 CRDT- 2023/12/04 23:45 PHST- 2023/08/31 00:00 [received] PHST- 2023/11/16 00:00 [accepted] PHST- 2023/12/06 06:42 [medline] PHST- 2023/12/05 00:42 [pubmed] PHST- 2023/12/04 23:45 [entrez] PHST- 2023/12/04 00:00 [pmc-release] AID - 10.1186/s12885-023-11648-x [pii] AID - 11648 [pii] AID - 10.1186/s12885-023-11648-x [doi] PST - epublish SO - BMC Cancer. 2023 Dec 4;23(1):1185. doi: 10.1186/s12885-023-11648-x. PMID- 38074914 OWN - NLM STAT- MEDLINE DCOM- 20231216 LR - 20231216 IS - 2219-2840 (Electronic) IS - 1007-9327 (Print) IS - 1007-9327 (Linking) VI - 29 IP - 43 DP - 2023 Nov 21 TI - Development of a machine learning-based model for predicting risk of early postoperative recurrence of hepatocellular carcinoma. PG - 5804-5817 LID - 10.3748/wjg.v29.i43.5804 [doi] AB - BACKGROUND: Surgical resection is the primary treatment for hepatocellular carcinoma (HCC). However, studies indicate that nearly 70% of patients experience HCC recurrence within five years following hepatectomy. The earlier the recurrence, the worse the prognosis. Current studies on postoperative recurrence primarily rely on postoperative pathology and patient clinical data, which are lagging. Hence, developing a new pre-operative prediction model for postoperative recurrence is crucial for guiding individualized treatment of HCC patients and enhancing their prognosis. AIM: To identify key variables in pre-operative clinical and imaging data using machine learning algorithms to construct multiple risk prediction models for early postoperative recurrence of HCC. METHODS: The demographic and clinical data of 371 HCC patients were collected for this retrospective study. These data were randomly divided into training and test sets at a ratio of 8:2. The training set was analyzed, and key feature variables with predictive value for early HCC recurrence were selected to construct six different machine learning prediction models. Each model was evaluated, and the best-performing model was selected for interpreting the importance of each variable. Finally, an online calculator based on the model was generated for daily clinical practice. RESULTS: Following machine learning analysis, eight key feature variables (age, intratumoral arteries, alpha-fetoprotein, pre-operative blood glucose, number of tumors, glucose-to-lymphocyte ratio, liver cirrhosis, and pre-operative platelets) were selected to construct six different prediction models. The XGBoost model outperformed other models, with the area under the receiver operating characteristic curve in the training, validation, and test datasets being 0.993 (95% confidence interval: 0.982-1.000), 0.734 (0.601-0.867), and 0.706 (0.585-0.827), respectively. Calibration curve and decision curve analysis indicated that the XGBoost model also had good predictive performance and clinical application value. CONCLUSION: The XGBoost model exhibits superior performance and is a reliable tool for predicting early postoperative HCC recurrence. This model may guide surgical strategies and postoperative individualized medicine. CI - ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. FAU - Zhang, Yu-Bo AU - Zhang YB AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan 750003, Ningxia Hui Autonomous Region, China. FAU - Yang, Gang AU - Yang G AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan 750003, Ningxia Hui Autonomous Region, China. FAU - Bu, Yang AU - Bu Y AD - Department of Hepatobiliary Surgery, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan 750003, Ningxia Hui Autonomous Region, China. FAU - Lei, Peng AU - Lei P AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan 750003, Ningxia Hui Autonomous Region, China. leipengnx@126.com. FAU - Zhang, Wei AU - Zhang W AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan 750003, Ningxia Hui Autonomous Region, China. FAU - Zhang, Dan-Yang AU - Zhang DY AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan 750003, Ningxia Hui Autonomous Region, China. LA - eng PT - Journal Article PL - United States TA - World J Gastroenterol JT - World journal of gastroenterology JID - 100883448 SB - IM MH - Humans MH - *Carcinoma, Hepatocellular/pathology MH - *Liver Neoplasms/pathology MH - Retrospective Studies MH - Risk Factors MH - Machine Learning PMC - PMC10701309 OTO - NOTNLM OT - Clinical features OT - Early recurrence OT - Hepatocellular carcinoma OT - Imaging features OT - Machine learning OT - Risk prediction models COIS- Conflict-of-interest statement: The authors declare no conflict of interest for this article. EDAT- 2023/12/11 06:45 MHDA- 2023/12/17 09:44 PMCR- 2023/11/21 CRDT- 2023/12/11 05:50 PHST- 2023/08/26 00:00 [received] PHST- 2023/10/07 00:00 [revised] PHST- 2023/11/03 00:00 [accepted] PHST- 2023/12/17 09:44 [medline] PHST- 2023/12/11 06:45 [pubmed] PHST- 2023/12/11 05:50 [entrez] PHST- 2023/11/21 00:00 [pmc-release] AID - 10.3748/wjg.v29.i43.5804 [doi] PST - ppublish SO - World J Gastroenterol. 2023 Nov 21;29(43):5804-5817. doi: 10.3748/wjg.v29.i43.5804. PMID- 36362831 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230308 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 11 IP - 21 DP - 2022 Nov 7 TI - Optimal Timing of Cholecystectomy for Patients with Concurrent Acute Cholecystitis and Acute Cholangitis after Successful Biliary Drainage by Interventional Endoscopic Retrograde Cholangiopancreatography. LID - 10.3390/jcm11216603 [doi] LID - 6603 AB - Background: Concurrent acute cholecystitis and acute cholangitis is a unique clinical situation. We tried to investigate the optimal timing of cholecystectomy after adequate biliary drainage under this condition. Methods: From January 2012 to November 2017, we retrospectively screened all in-hospitalized patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) and then identified patients with concurrent acute cholecystitis and acute cholangitis from the cohort. The selected patients were stratified into two groups: one-stage intervention (OSI) group (intended laparoscopic cholecystectomy at the same hospitalization) vs. two-stage intervention (TSI) group (interval intended laparoscopic cholecystectomy). Interrogated outcomes included recurrent biliary events, length of hospitalization, and surgical outcomes. Results: There were 147 patients ultimately enrolled for analysis (OSI vs. TSI, 96 vs. 51). Regarding surgical outcomes, there was no significant difference between the OSI group and TSI group, including intraoperative blood transfusion (1.0% vs. 2.0%, p = 1.000), conversion to open procedure (3.1% vs. 7.8%, p = 0.236), postoperative complication (6.3% vs. 11.8%, p = 0.342), operation time (118.0 min vs. 125.8 min, p = 0.869), and postoperative days until discharge (3.37 days vs. 4.02 days, p = 0.643). In the RBE analysis, the OSI group presented a significantly lower incidence of overall RBE (5.2% vs. 41.2%, p < 0.001) than the TSI group. Conclusions: Patients with an initial diagnosis of concurrent acute cholecystitis and cholangitis undergoing cholecystectomy after ERCP drainage during the same hospitalization period may receive some benefit in terms of clinical outcomes. FAU - Chang, Yau-Ren AU - Chang YR AD - Division of General Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan 333, Taiwan. FAU - Wu, Chi-Huan AU - Wu CH AUID- ORCID: 0000-0002-3913-8010 AD - Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Taoyuan 333, Taiwan. FAU - Chen, Huan-Wu AU - Chen HW AD - Division of Emergency and Critical Care Radiology, Department of Medical Imaging and Intervention, Linkou Chang Gung Memorial Hospital, Taoyuan 333, Taiwan. FAU - Hung, Yu-Liang AU - Hung YL AUID- ORCID: 0000-0002-9136-7224 AD - Division of General Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan 333, Taiwan. FAU - Hu, Chia-Hsiang AU - Hu CH AUID- ORCID: 0000-0003-3143-0292 AD - Department of General Surgery, Jen Ai Chang Gung Health, Dali Branch, Taichung 412224, Taiwan. FAU - Huang, Ruo-Yi AU - Huang RY AD - Department of General Surgery, Jen Ai Chang Gung Health, Dali Branch, Taichung 412224, Taiwan. FAU - Wu, Min-Jung AU - Wu MJ AUID- ORCID: 0000-0002-9197-8439 AD - School of Traditional Chinese Medicine, Chang Gung University, Taoyuan 333, Taiwan. FAU - Kou, Hao-Wei AU - Kou HW AUID- ORCID: 0000-0002-9360-908X AD - Division of General Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan 333, Taiwan. FAU - Chen, Ming-Yang AU - Chen MY AUID- ORCID: 0000-0002-6608-5436 AD - Division of General Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan 333, Taiwan. FAU - Tsai, Chun-Yi AU - Tsai CY AD - Division of General Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan 333, Taiwan. FAU - Wang, Shang-Yu AU - Wang SY AUID- ORCID: 0000-0003-1514-3015 AD - Division of General Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan 333, Taiwan. AD - School of Traditional Chinese Medicine, Chang Gung University, Taoyuan 333, Taiwan. FAU - Liu, Keng-Hao AU - Liu KH AD - Division of General Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan 333, Taiwan. FAU - Hsu, Jun-Te AU - Hsu JT AD - Division of General Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan 333, Taiwan. FAU - Yeh, Chun-Nan AU - Yeh CN AUID- ORCID: 0000-0003-1455-092X AD - Division of General Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan 333, Taiwan. FAU - Liu, Nai-Jen AU - Liu NJ AD - Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Taoyuan 333, Taiwan. FAU - Jan, Yi-Yin AU - Jan YY AD - Division of General Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan 333, Taiwan. LA - eng PT - Journal Article DEP - 20221107 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC9654930 OTO - NOTNLM OT - ERCP OT - cholangitis OT - cholecystectomy OT - cholecystitis OT - cholecystolithiasis OT - cholelithiasis OT - endoscopic retrograde cholangiopancreatography OT - gallbladder stones OT - laparoscopic cholecystectomy COIS- Yau-Ren Chang, Chi-Huan Wu, Huan-Wu Chen, Yu-Liang Hung, Hao-Wei Kou, Ming-Yang Chen, Chun-Yi Tsai, Chih-Yuan Fu, Shang-Yu Wang, Chun-Nan Yeh, Ta-Sen Yeh, Jun-Te Hsu, Nai-Jen Liu, and Yi-Yin Jan have no conflict of interest or financial ties to disclose. EDAT- 2022/11/12 06:00 MHDA- 2022/11/12 06:01 PMCR- 2022/11/07 CRDT- 2022/11/11 01:32 PHST- 2022/09/14 00:00 [received] PHST- 2022/10/28 00:00 [revised] PHST- 2022/11/03 00:00 [accepted] PHST- 2022/11/11 01:32 [entrez] PHST- 2022/11/12 06:00 [pubmed] PHST- 2022/11/12 06:01 [medline] PHST- 2022/11/07 00:00 [pmc-release] AID - jcm11216603 [pii] AID - jcm-11-06603 [pii] AID - 10.3390/jcm11216603 [doi] PST - epublish SO - J Clin Med. 2022 Nov 7;11(21):6603. doi: 10.3390/jcm11216603. PMID- 30581484 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231004 IS - 1741-427X (Print) IS - 1741-4288 (Electronic) IS - 1741-427X (Linking) VI - 2018 DP - 2018 TI - An Investigation of the Prescription Patterns of Chinese Herbal Products for Chronic Glomerulonephritis Patients: A Hospital-Based Cross-Sectional Study. PG - 5080764 LID - 10.1155/2018/5080764 [doi] LID - 5080764 AB - Chronic kidney disease (CKD) has a high incidence and prevalence worldwide, and chronic glomerulonephritis (CGN) is one of the main causes of CKD. Therefore, it is important to diagnose and treat CGN early. The purpose of this study is to analyze the prescription patterns and frequencies of Chinese herbal products (CHPs) for CGN by using a hospital-based database from the Chang Gung Memorial Hospital (CGMH), a large, tertiary hospital system in Taiwan, and to evaluate the safety and possible efficacy of CHPs by blood test. The International Classification of Disease Ninth Revision (ICD-9) code 582 was used to identify patients with CGN. From 2004 to 2015, a total of 54726 CHP prescriptions for CGN were provided. Association rule mining was used to analyze the prevalent of CHP combination patterns in treating CGN. Jia-Wei-Xiao-Yao-San (JWXYS) and Gorgon (Euryale feroxSalisb.) were the most frequently prescribed herbal formula (HF) and single herb (SH), respectively. The most frequently prescribed combination of CHPs was that of JWXYS with Bu-Yang-Huan-Wu-Tang (BYHWT) in CGMH. In statistical, the level of eGFR in Stage 3a and 3b group was increasing after treatment in 6 and 12 months and might not cause the renal function to worsen within 12-month treatments. To the best of our knowledge, this is the first pharmacoepidemiological study to review CHP treatments for CGN. However, additional studies and clinical trials are needed to provide data on the safety and efficacy of these CHPs. FAU - Chen, Wen AU - Chen W AD - Division of Chinese Internal Medicine, Center for Traditional Chinese Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan. AD - School of Chinese Medicine, China Medical University, Taichung, Taiwan. FAU - Chen, Hsing-Yu AU - Chen HY AD - Division of Chinese Internal Medicine, Center for Traditional Chinese Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan. AD - School of Traditional Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan. AD - Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan. FAU - Yang, Yao-Hsu AU - Yang YH AUID- ORCID: 0000-0002-8080-0504 AD - Department for Traditional Chinese Medicine, Chang Gung Memorial Hospital, Chia-Yi, Taiwan. AD - Institute of Occupational Medicine and Industrial Hygiene, National Taiwan University College of Public Health, Taipei, Taiwan. AD - Center of Excellence for Chang Gung Research Data link, Chang Gung Memorial Hospital, Chia-Yi, Taiwan. FAU - Yang, Sien-Hung AU - Yang SH AD - Division of Chinese Internal Medicine, Center for Traditional Chinese Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan. AD - School of Traditional Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan. AD - Chang Gung Immunology Consortium, Chang Gung Memorial Hospital and Chang Gung University, Gueishan, Taoyuan, Taiwan. FAU - Yang, Ching-Wei AU - Yang CW AD - Division of Chinese Internal Medicine, Center for Traditional Chinese Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan. AD - School of Traditional Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan. FAU - Wu, You-Hung AU - Wu YH AD - Graduate Institute of Acupuncture Science, College of Medicine, China Medical University, Taichung, Taiwan. FAU - Chen, Jiun-Liang AU - Chen JL AUID- ORCID: 0000-0002-9714-2771 AD - Division of Chinese Internal Medicine, Center for Traditional Chinese Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan. AD - School of Traditional Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan. LA - eng PT - Journal Article DEP - 20181115 PL - United States TA - Evid Based Complement Alternat Med JT - Evidence-based complementary and alternative medicine : eCAM JID - 101215021 PMC - PMC6276402 EDAT- 2018/12/26 06:00 MHDA- 2018/12/26 06:01 PMCR- 2018/11/15 CRDT- 2018/12/25 06:00 PHST- 2018/07/13 00:00 [received] PHST- 2018/09/28 00:00 [revised] PHST- 2018/10/23 00:00 [accepted] PHST- 2018/12/25 06:00 [entrez] PHST- 2018/12/26 06:00 [pubmed] PHST- 2018/12/26 06:01 [medline] PHST- 2018/11/15 00:00 [pmc-release] AID - 10.1155/2018/5080764 [doi] PST - epublish SO - Evid Based Complement Alternat Med. 2018 Nov 15;2018:5080764. doi: 10.1155/2018/5080764. eCollection 2018. PMID- 41573716 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260123 LR - 20260123 IS - 1663-9812 (Print) IS - 1663-9812 (Electronic) IS - 1663-9812 (Linking) VI - 16 DP - 2025 TI - Neuroprotective effects of traditional Chinese medicine formulas in animal models of retinal degenerative diseases: a systematic review and meta-analysis. PG - 1695150 LID - 10.3389/fphar.2025.1695150 [doi] LID - 1695150 AB - PURPOSE: Retinal degenerative diseases (RDDs) cause irreversible vision loss with limited treatment options. Traditional Chinese medicine (TCM) formulas have demonstrated neuroprotective effects, yet their overall efficacy lacks comprehensive meta-evidence. The aim of this study was to exploratively evaluate the neuroprotective effects of TCM formulas in animal RDD models. METHODS: A comprehensive literature search was conducted across eight electronic databases to identify animal studies that evaluated the neuroprotective effects of TCM formulas on RDDs. Pairwise meta-analysis and Bayesian network meta-analysis (NMA) were performed to synthesize evidence on key outcomes: neural growth, glial activation, oxidative stress, apoptosis factors, and ophthalmological parameters. Treatment rankings were assessed using the surface under the cumulative ranking curve (SUCRA). RESULTS: Twenty-four studies were included. The compositions and bioactive compounds of the TCM formulas have been defined and identified. Pairwise meta-analysis demonstrated that specific TCM formulas might exert neuroprotective effects on RDDs by regulating key biomarkers. Specifically, Zhen-Bao-Wan, Bu-Shen-Yi-Jing-Fang, and Qi-Shen-Yi-Qi pills modulated neural growth and glial activation by upregulating BDNF, CNTF, and reducing GFAP, respectively. Furthermore, Yi-Qi-Wen-Yang-Tong-Luo decoction, Zi-Yin-Ming-Mu decoction, and Yishi-Tablet suppressed oxidative stress and apoptosis by reducing SOD, retinal apoptotic cells and caspase-3, respectively. Additionally, Bu-Yang-Huan-Wu decoction improved retinal function by elevating ERG-a and ERG-b wave amplitudes. Subgroup analyses indicated that Bu-Yang-Huan-Wu decoction and Qu-Yu-Tong-Luo prescription exhibited superior efficacy in restoring retinal ganglion cell (RGC) counts and retinal thickness in specific RDD models. The NMA results indicated that the included TCM formulas exhibited target-specific and dose‒response trends, with different formulas showing preferential efficacy for distinct biomarkers. Given the limitations identified in this study, these findings should be interpreted as preliminary evidence to guide future research rather than as conclusive results. Future studies with rigorous experimental designs are needed to address these limitations and enhance translational relevance. CONCLUSION: This study provides preclinical and exploratory evidence that the included TCM formulas might exert neuroprotective effects on animal models of RDDs by modulating glial activation, promoting neuronal growth, and inhibiting oxidative stress and apoptosis. Additional high-quality preclinical studies are essential to validate these effects and inform future clinical translation. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251002491 identifier CRD420251002491. CI - Copyright © 2026 Xu, Mi, Yong, Xu, Zhao, Wang, Jiang, Yu and Ye. FAU - Xu, Yunxi AU - Xu Y AD - School of Ophthalmology, Chengdu University of Traditional Chinese Medicine, Chengdu, China. AD - Department of Ophthalmology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China. FAU - Mi, Qindong AU - Mi Q AD - Department of Traditional Chinese Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Yong, Qi AU - Yong Q AD - School of Ophthalmology, Chengdu University of Traditional Chinese Medicine, Chengdu, China. AD - Department of Ophthalmology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China. FAU - Xu, Chao AU - Xu C AD - School of Ophthalmology, Chengdu University of Traditional Chinese Medicine, Chengdu, China. AD - Department of Ophthalmology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China. FAU - Zhao, Dingmeng AU - Zhao D AD - School of Ophthalmology, Chengdu University of Traditional Chinese Medicine, Chengdu, China. AD - Department of Ophthalmology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China. FAU - Wang, Chuning AU - Wang C AD - School of Ophthalmology, Chengdu University of Traditional Chinese Medicine, Chengdu, China. AD - Department of Ophthalmology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China. FAU - Jiang, Zhongshan AU - Jiang Z AD - School of Ophthalmology, Chengdu University of Traditional Chinese Medicine, Chengdu, China. AD - Department of Ophthalmology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China. FAU - Yu, Chenghao AU - Yu C AD - School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China. FAU - Ye, Hejiang AU - Ye H AD - Department of Ophthalmology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China. LA - eng PT - Journal Article PT - Systematic Review DEP - 20260107 PL - Switzerland TA - Front Pharmacol JT - Frontiers in pharmacology JID - 101548923 PMC - PMC12819594 OTO - NOTNLM OT - apoptosis OT - meta-analysis OT - neuroprotection OT - oxidative stress OT - retinal degenerative diseases OT - traditional Chinese medicine COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/01/23 06:29 MHDA- 2026/01/23 06:30 PMCR- 2026/01/07 CRDT- 2026/01/23 04:57 PHST- 2025/08/29 00:00 [received] PHST- 2025/11/27 00:00 [revised] PHST- 2025/11/28 00:00 [accepted] PHST- 2026/01/23 06:30 [medline] PHST- 2026/01/23 06:29 [pubmed] PHST- 2026/01/23 04:57 [entrez] PHST- 2026/01/07 00:00 [pmc-release] AID - 1695150 [pii] AID - 10.3389/fphar.2025.1695150 [doi] PST - epublish SO - Front Pharmacol. 2026 Jan 7;16:1695150. doi: 10.3389/fphar.2025.1695150. eCollection 2025. PMID- 29348166 OWN - NLM STAT- MEDLINE DCOM- 20190930 LR - 20190930 IS - 1530-8561 (Electronic) IS - 0009-9147 (Print) IS - 0009-9147 (Linking) VI - 64 IP - 5 DP - 2018 May TI - Clinical Evaluation of a Blood Assay to Diagnose Paucibacillary Tuberculosis via Bacterial Antigens. PG - 791-800 LID - 10.1373/clinchem.2017.273698 [doi] AB - BACKGROUND: The diagnosis of active tuberculosis (TB) cases primarily relies on methods that detect Mycobacterium tuberculosis (Mtb) bacilli or their DNA in patient samples (e.g., mycobacterial culture and Xpert MTB/RIF assays), but these tests have low clinical sensitivity for patients with paucibacillary TB disease. Our goal was to evaluate the clinical performance of a newly developed assay that can rapidly diagnose active TB cases by direct detection of Mtb-derived antigens in patients' blood samples. METHODS: Nanoparticle (NanoDisk)-enriched peptides derived from the Mtb virulence factors CFP-10 (10-kDa culture factor protein) and ESAT-6 (6-kDa early secretory antigenic target) were analyzed by high-throughput mass spectrometry (MS). Serum from 294 prospectively enrolled Chinese adults were analyzed with this NanoDisk-MS method to evaluate the performance of direct serum Mtb antigen measurement as a means for rapid diagnosis of active TB cases. RESULTS: NanoDisk-MS diagnosed 174 (88.3%) of the study's TB cases, with 95.8% clinical specificity, and with 91.6% and 85.3% clinical sensitivity for culture-positive and culture-negative TB cases, respectively. NanoDisk-MS also exhibited 88% clinical sensitivity for pulmonary and 90% for extrapulmonary TB, exceeding the diagnostic performance of mycobacterial culture for these cases. CONCLUSIONS: Direct detection and quantification of serum Mtb antigens by NanoDisk-MS can rapidly and accurately diagnose active TB in adults, independent of disease site or culture status, and outperform Mycobacterium-based TB diagnostics. CI - © 2017 American Association for Clinical Chemistry. FAU - Liu, Chang AU - Liu C AD - Virginia G. Piper Biodesign Center for Personalized Diagnostics, The Biodesign Institute, Arizona State University, Tempe, AZ. AD - School of Biological and Health Systems Engineering, Arizona State University, Tempe, AZ. AD - Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX. FAU - Lyon, Christopher J AU - Lyon CJ AD - Virginia G. Piper Biodesign Center for Personalized Diagnostics, The Biodesign Institute, Arizona State University, Tempe, AZ. AD - Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX. FAU - Bu, Yang AU - Bu Y AD - Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX. AD - College of Materials Sciences and Opto-Electronics, University of Chinese Academy of Sciences, Beijing, China. FAU - Deng, Zaian AU - Deng Z AD - Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX. AD - School of Biomedical Engineering, School of Ophthalmology and Optometry, The Eye Hospital, Wenzhou Medical University, Wenzhou, China. FAU - Walters, Elisabetta AU - Walters E AD - Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. FAU - Li, Yan AU - Li Y AD - Institute of Biophysics, Chinese Academy of Sciences, Beijing, China. FAU - Zhang, Liqun AU - Zhang L AD - Department of Tuberculosis, Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing, China. FAU - Hesseling, Anneke C AU - Hesseling AC AD - Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. FAU - Graviss, Edward A AU - Graviss EA AD - Department of Pathology and Genomic Medicine, Houston Methodist Research Institute, Houston, TX. FAU - Hu, Ye AU - Hu Y AD - Virginia G. Piper Biodesign Center for Personalized Diagnostics, The Biodesign Institute, Arizona State University, Tempe, AZ; tyhu@asu.edu. AD - School of Biological and Health Systems Engineering, Arizona State University, Tempe, AZ. AD - Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX. LA - eng GR - R01 AI113725/AI/NIAID NIH HHS/United States GR - R01 AI122932/AI/NIAID NIH HHS/United States GR - R21 AI126361/AI/NIAID NIH HHS/United States GR - R01 HD090927/HD/NICHD NIH HHS/United States GR - UL1 TR000371/TR/NCATS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20180118 PL - England TA - Clin Chem JT - Clinical chemistry JID - 9421549 RN - 0 (Antigens, Bacterial) SB - IM CIN - Clin Chem. 2018 May;64(5):763-765. doi: 10.1373/clinchem.2017.285460. PMID: 29483104 MH - Antigens, Bacterial/*immunology MH - Female MH - Humans MH - Male MH - Mycobacterium tuberculosis/*immunology/*isolation & purification MH - Sensitivity and Specificity MH - Tuberculosis/*diagnosis/immunology/microbiology MH - Young Adult PMC - PMC5996152 MID - NIHMS955968 COIS- Authors’ Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or potential conflicts of interest: EDAT- 2018/01/20 06:00 MHDA- 2019/10/01 06:00 PMCR- 2018/06/12 CRDT- 2018/01/20 06:00 PHST- 2017/03/08 00:00 [received] PHST- 2017/12/08 00:00 [accepted] PHST- 2018/01/20 06:00 [pubmed] PHST- 2019/10/01 06:00 [medline] PHST- 2018/01/20 06:00 [entrez] PHST- 2018/06/12 00:00 [pmc-release] AID - clinchem.2017.273698 [pii] AID - 10.1373/clinchem.2017.273698 [doi] PST - ppublish SO - Clin Chem. 2018 May;64(5):791-800. doi: 10.1373/clinchem.2017.273698. Epub 2018 Jan 18. PMID- 25237385 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20140919 LR - 20220408 IS - 1749-8546 (Print) IS - 1749-8546 (Electronic) IS - 1749-8546 (Linking) VI - 9 DP - 2014 TI - Amygdalin isolated from Semen Persicae (Tao Ren) extracts induces the expression of follistatin in HepG2 and C2C12 cell lines. PG - 23 LID - 10.1186/1749-8546-9-23 [doi] AB - BACKGROUND: The Chinese medicine formulation ISF-1 (also known as Bu-Yang-Huan-Wu-Tang) for post-stroke rehabilitation could increase the expression of growth-regulating protein follistatin by approximately 4-fold. This study aims to identify the active compounds of ISF-1 for the induction of follistatin expression. METHODS: Active compounds in ISF-1 responsible for induction of follistatin were identified by a bioactivity-guided fractionation procedure involving liquid-liquid extraction, HPLC separation and RT-PCR detection. The aqueous extracts of seven ISF-1 ingredients including Semen Persicae (Tao Ren) and the S. Persicae-derived fractions were assayed for the induction of follistatin mRNA expression in human hepatocarcinoma HepG2 cells by RT-PCR. The concentrations of isolated compounds were proportionally normalized to the reported IC50 concentration (5.8 mg/mL) of the formulation ISF-1 in HepG2. The active fractions were characterized by reverse-phase HPLC on a C18 column and identified by mass spectrometry. RESULTS: Three ingredients of ISF-1, namely S. Persicae (Tao Ren), Pheretima (Di Long), and Flos Carthami (Hong Hua), induced the expression of follistatin mRNA. Among these, the ingredient S. Persicae were the most active, and amygdalin from S. Persicae extract was identified as a novel follistatin inducer. Amygdalin stimulated the growth of skeletal muscle cell line C2C12 cells in a concentration-dependent manner. CONCLUSIONS: Amygdalin isolated from S. Persicae extract in ISF-1 through a bioactivity-guided fractionation procedure induced the expression of follistatin in HepG2 and C2C12 cell lines. FAU - Yang, Chuanbin AU - Yang C AD - School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 10 Sassoon Road, Pokfulam, Hong Kong, China. FAU - Li, Xuechen AU - Li X AD - Department of Chemistry, The University of Hong Kong, Hong Kong, China. FAU - Rong, Jianhui AU - Rong J AD - School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 10 Sassoon Road, Pokfulam, Hong Kong, China. LA - eng PT - Journal Article DEP - 20140916 PL - England TA - Chin Med JT - Chinese medicine JID - 101265109 PMC - PMC4167460 EDAT- 2014/09/23 06:00 MHDA- 2014/09/23 06:01 PMCR- 2014/09/16 CRDT- 2014/09/20 06:00 PHST- 2014/04/03 00:00 [received] PHST- 2014/09/08 00:00 [accepted] PHST- 2014/09/20 06:00 [entrez] PHST- 2014/09/23 06:00 [pubmed] PHST- 2014/09/23 06:01 [medline] PHST- 2014/09/16 00:00 [pmc-release] AID - 1749-8546-9-23 [pii] AID - 10.1186/1749-8546-9-23 [doi] PST - epublish SO - Chin Med. 2014 Sep 16;9:23. doi: 10.1186/1749-8546-9-23. eCollection 2014. PMID- 34966645 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220429 IS - 2225-0719 (Print) IS - 2310-8819 (Electronic) IS - 2225-0719 (Linking) VI - 9 IP - 6 DP - 2021 Dec 28 TI - Noncontrast-enhanced MRI-based Noninvasive Score for Portal Hypertension (CHESS1802): An International Multicenter Study. PG - 818-827 LID - 10.14218/JCTH.2021.00177 [doi] AB - BACKGROUND AND AIMS: This study aimed to determine the performance of the non-invasive score using noncontrast-enhanced MRI (CHESS-DIS score) for detecting portal hypertension in cirrhosis. METHODS: In this international multicenter, diagnostic study (ClinicalTrials.gov, NCT03766880), patients with cirrhosis who had hepatic venous pressure gradient (HVPG) measurement and noncontrast-enhanced MRI were prospectively recruited from four university hospitals in China (n=4) and Turkey (n=1) between December 2018 and April 2019. A cohort of patients was retrospectively recruited from a university hospital in Italy between March 2015 and November 2017. After segmentation of the liver on fat-suppressed T1-weighted MRI maps, CHESS-DIS score was calculated automatically by an in-house developed code based on the quantification of liver surface nodularity. RESULTS: A total of 149 patients were included, of which 124 were from four Chinese hospitals (training cohort) and 25 were from two international hospitals (validation cohort). A positive correlation between CHESS-DIS score and HVPG was found with the correlation coefficients of 0.36 (p<0.0001) and 0.55 (p<0.01) for the training and validation cohorts, respectively. The area under the receiver operating characteristic curve of CHESS-DIS score in detection of clinically significant portal hypertension (CSPH) was 0.81 and 0.9 in the training and validation cohorts, respectively. The intraclass correlation coefficients for assessing the inter- and intra-observer agreement were 0.846 and 0.841, respectively. CONCLUSIONS: A non-invasive score using noncontrast-enhanced MRI was developed and proved to be significantly correlated with invasive HVPG. Besides, this score could be used to detect CSPH in patients with cirrhosis. CI - © 2021 Authors. FAU - Liu, Yanna AU - Liu Y AD - CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, Gansu, China. AD - CHESS Center, The Sixth People's Hospital of Shenyang, Shenyang, Liaoning, China. AD - Department of Infectious Disease, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China. AD - Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China. FAU - Tang, Tianyu AU - Tang T AD - Department of Radiology, Zhongda Hospital, Medical School of Southeast University, Nanjing, Jiangsu, China. FAU - Örmeci, Necati AU - Örmeci N AD - Istanbul Health and Technology University, Zytinburnu/İstanbul, Turkey. FAU - Huang, Yifei AU - Huang Y AD - CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, Gansu, China. FAU - Wang, Jitao AU - Wang J AD - CHESS Working Party, Xingtai People's Hospital, Xingtai, Hebei, China. FAU - Li, Xiaoguo AU - Li X AD - CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, Gansu, China. FAU - Li, Zhiwei AU - Li Z AD - Department of Hepatobiliary Surgery, The Third People's Hospital of Shenzhen, Shenzhen, Guangdong, China. FAU - An, Weimin AU - An W AD - Department of Radiology, Fifth Medical Center of PLA General Hospital, Beijing, China. FAU - Liu, Dengxiang AU - Liu D AD - CHESS Working Party, Xingtai People's Hospital, Xingtai, Hebei, China. FAU - Zhang, Chunqing AU - Zhang C AD - Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China. FAU - Liu, Changchun AU - Liu C AD - Department of Radiology, Fifth Medical Center of PLA General Hospital, Beijing, China. FAU - Liu, Jinqiang AU - Liu J AD - Department of Radiology, Zhongda Hospital, Medical School of Southeast University, Nanjing, Jiangsu, China. FAU - Liu, Chuan AU - Liu C AD - CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, Gansu, China. FAU - Wang, Guangchuan AU - Wang G AD - Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China. FAU - Mosconi, Cristina AU - Mosconi C AD - Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, University of Bologna, Italy. FAU - Cappelli, Alberta AU - Cappelli A AD - Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, University of Bologna, Italy. FAU - Bruno, Antonio AU - Bruno A AD - Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, University of Bologna, Italy. FAU - Akçalar, Seray AU - Akçalar S AD - Department of Radiology, Ankara University School of Medicine, Ankara, Turkey. FAU - Çelebioğlu, Emrecan AU - Çelebioğlu E AD - Department of Radiology, Ankara University School of Medicine, Ankara, Turkey. FAU - Üstüner, Evren AU - Üstüner E AD - Department of Radiology, Ankara University School of Medicine, Ankara, Turkey. FAU - Bilgiç, Sadık AU - Bilgiç S AD - Department of Radiology, Ankara University School of Medicine, Ankara, Turkey. FAU - Ellik, Zeynep AU - Ellik Z AD - Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey. FAU - Asiller, Özgün Ömer AU - Asiller ÖÖ AD - Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey. FAU - Li, Lei AU - Li L AD - CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, Gansu, China. FAU - Zhang, Haijun AU - Zhang H AD - CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, Gansu, China. FAU - Kang, Ning AU - Kang N AD - CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, Gansu, China. FAU - Xu, Dan AU - Xu D AD - CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, Gansu, China. FAU - He, Ruiling AU - He R AD - CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, Gansu, China. FAU - Wang, Yan AU - Wang Y AD - CHESS Center, The Sixth People's Hospital of Shenyang, Shenyang, Liaoning, China. FAU - Bu, Yang AU - Bu Y AD - Department of Hepatobiliary Surgery, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, Ningxia, China. FAU - Gu, Ye AU - Gu Y AD - CHESS Center, The Sixth People's Hospital of Shenyang, Shenyang, Liaoning, China. FAU - Ju, Shenghong AU - Ju S AUID- ORCID: 0000-0001-5041-7865 AD - Department of Radiology, Zhongda Hospital, Medical School of Southeast University, Nanjing, Jiangsu, China. FAU - Golfieri, Rita AU - Golfieri R AUID- ORCID: 0000-0001-8809-9989 AD - Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, University of Bologna, Italy. FAU - Qi, Xiaolong AU - Qi X AUID- ORCID: 0000-0002-3559-5855 AD - CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, Gansu, China. AD - CHESS Center, The Sixth People's Hospital of Shenyang, Shenyang, Liaoning, China. LA - eng SI - ClinicalTrials.gov/NCT03766880 PT - Journal Article DEP - 20210930 PL - United States TA - J Clin Transl Hepatol JT - Journal of clinical and translational hepatology JID - 101649815 PMC - PMC8666380 OTO - NOTNLM OT - Advanced chronic liver disease OT - Hepatic venous pressure gradient OT - Imaging OT - Liver cirrhosis OT - Liver surface nodularity COIS- The authors have no conflict of interests related to this publication. EDAT- 2021/12/31 06:00 MHDA- 2021/12/31 06:01 PMCR- 2021/09/30 CRDT- 2021/12/30 05:41 PHST- 2021/05/12 00:00 [received] PHST- 2021/08/10 00:00 [revised] PHST- 2021/08/29 00:00 [accepted] PHST- 2021/12/30 05:41 [entrez] PHST- 2021/12/31 06:00 [pubmed] PHST- 2021/12/31 06:01 [medline] PHST- 2021/09/30 00:00 [pmc-release] AID - JCTH.2021.00177 [pii] AID - 10.14218/JCTH.2021.00177 [doi] PST - ppublish SO - J Clin Transl Hepatol. 2021 Dec 28;9(6):818-827. doi: 10.14218/JCTH.2021.00177. Epub 2021 Sep 30. PMID- 25242412 OWN - NLM STAT- MEDLINE DCOM- 20150624 LR - 20220330 IS - 1791-2431 (Electronic) IS - 1021-335X (Linking) VI - 32 IP - 6 DP - 2014 Dec TI - CXCR7 correlates with the differentiation of hepatocellular carcinoma and suppresses HNF4α expression through the ERK pathway. PG - 2387-96 LID - 10.3892/or.2014.3501 [doi] AB - Hepatocellular carcinoma (HCC) is a malignancy with dysregulated differentiation. However, effective differentiation therapy for HCC is lacking. Previous evidence suggests that CXCR7 is associated with the differentiation of embryonic stem cells. Here, we evaluated the potential role of CXCR7 in the differentiation of HCC. In HCC cell lines, the expression of cancer stem cell-related markers was assessed by flow cytometry and confirmed by western blot and immunofluorescence analyses. Dimethyl sulfoxide, oncostatin M and dexamethasone were used to induce the differentiation of HCC. Immunohistochemical assay was performed on a tissue microarray based on 112 HCC cases that received hepatectomy. Ligand activation, inhibition assays and RNA interference were used to analyze the regulation of hepatocyte nuclear factor 4α (HNF4α) by the CXCR7 pathway. Huh7 and HCCLM3 cell lines were screened for differentiation induction based on biomarkers of hepatic cancer stem cells. CXCR7 was found to be closely associated with the differentiation of HCC, and an inverse expression trend between CXCR7 and HNF4α was found upon induced differentiation. Clinically, high CXCR7 expression was negatively correlated with HNF4α expression in patients with relatively well-differentiated HCC. Moreover, high CXCR7 expression was correlated with poor overall survival and accelerated post-resection metastasis in HCC with a low HNF4α level. Mechanistically, CXCR7 signaling inhibited HNF4α through extracellular regulated protein kinase (ERK) activation, which was inhibited by U0126, an inhibitor of MAPK/ERK kinases 1 and 2. Knockdown of CXCR7 further confirmed that CXCR7 signaling can regulate HNF4α expression. Taken together, our findings indicate that CXCR7 participates in the differentiation of HCC by regulating HNF4α. The CXCR7-ERK-HNF4α cascade represents a new target for the differentiation therapy of HCC. FAU - Xue, Tong-Chun AU - Xue TC AD - Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, P.R. China. FAU - Jia, Qing-An AU - Jia QA AD - Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, P.R. China. FAU - Bu, Yang AU - Bu Y AD - Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, P.R. China. FAU - Chen, Rong-Xin AU - Chen RX AD - Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, P.R. China. FAU - Cui, Jie-Feng AU - Cui JF AD - Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, P.R. China. FAU - Tang, Zhao-You AU - Tang ZY AD - Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, P.R. China. FAU - Ye, Sheng-Long AU - Ye SL AD - Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, P.R. China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140919 PL - Greece TA - Oncol Rep JT - Oncology reports JID - 9422756 RN - 0 (ACKR3 protein, human) RN - 0 (HNF4A protein, human) RN - 0 (Hepatocyte Nuclear Factor 4) RN - 0 (Receptors, CXCR) SB - IM MH - Carcinoma, Hepatocellular MH - Cell Differentiation MH - Cell Line, Tumor MH - Female MH - Gene Expression Regulation, Neoplastic MH - Hepatocyte Nuclear Factor 4/genetics/*metabolism MH - Humans MH - Liver Neoplasms MH - *MAP Kinase Signaling System MH - Male MH - Middle Aged MH - Prognosis MH - Receptors, CXCR/genetics/*metabolism EDAT- 2014/09/23 06:00 MHDA- 2015/06/25 06:00 CRDT- 2014/09/23 06:00 PHST- 2014/04/16 00:00 [received] PHST- 2014/06/12 00:00 [accepted] PHST- 2014/09/23 06:00 [entrez] PHST- 2014/09/23 06:00 [pubmed] PHST- 2015/06/25 06:00 [medline] AID - 10.3892/or.2014.3501 [doi] PST - ppublish SO - Oncol Rep. 2014 Dec;32(6):2387-96. doi: 10.3892/or.2014.3501. Epub 2014 Sep 19. PMID- 36890415 OWN - NLM STAT- MEDLINE DCOM- 20230605 LR - 20230608 IS - 1432-2218 (Electronic) IS - 0930-2794 (Print) IS - 0930-2794 (Linking) VI - 37 IP - 6 DP - 2023 Jun TI - Comparison of outcomes of proximal versus distal and combined splenic artery embolization in the management of blunt splenic injury: a report of 202 cases from a single trauma center. PG - 4689-4697 LID - 10.1007/s00464-023-09960-5 [doi] AB - BACKGROUND: To compare the outcomes of blunt splenic injuries (BSI) managed with proximal (P) versus distal (D) versus combined (C) splenic artery embolization (SAE). METHODS: This retrospective study included patients with BSI who demonstrated vascular injuries on angiograms and were managed with SAE between 2001 and 2015. The success rate and major complications (Clavien-Dindo classification ≥ III) were compared between the P, D, and C embolizations. RESULTS: In total, 202 patients were enrolled (P, n = 64, 31.7%; D, n = 84, 41.6%; C, n = 54, 26.7%). The median injury severity score was 25. The median times from injury to SAE were 8.3, 7.0, and 6.6 h for the P, D, and C embolization, respectively. The overall haemostasis success rates were 92.6%, 93.8%, 88.1%, and 98.1% in the P, D, and C embolizations, respectively, with no significant difference (p = 0.079). Additionally, the outcomes were not significantly different between the different types of vascular injuries on angiograms or the materials used in the location of embolization. Splenic abscess occurred in six patients (P, n = 0; D, n = 5; C, n = 1), although it occurred more commonly in those who underwent D embolization with no significant difference (p = 0.092). CONCLUSIONS: The success rate and major complications of SAE were not significantly different regardless of the location of embolization. The different types of vascular injuries on angiograms and agents used in different embolization locations also did not affect the outcomes. CI - © 2023. The Author(s). FAU - Lin, Being-Chuan AU - Lin BC AUID- ORCID: 0000-0002-5391-0900 AD - Division of Trauma & Emergency Surgery, Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, 5, Fu-Hsing Street, Kwei-Shan, Tao-Yuan City, 333, Taiwan. linbc@cgmh.org.tw. FAU - Wu, Cheng-Hsien AU - Wu CH AD - Division of Emergency and Critical Care Radiology, Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital, Chang Gung University, Tao-Yuan City, Taiwan. FAU - Wong, Yon-Cheong AU - Wong YC AD - Division of Emergency and Critical Care Radiology, Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital, Chang Gung University, Tao-Yuan City, Taiwan. FAU - Chen, Huan-Wu AU - Chen HW AD - Division of Emergency and Critical Care Radiology, Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital, Chang Gung University, Tao-Yuan City, Taiwan. FAU - Fu, Chen-Ju AU - Fu CJ AD - Division of Emergency and Critical Care Radiology, Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital, Chang Gung University, Tao-Yuan City, Taiwan. FAU - Huang, Chen-Chih AU - Huang CC AD - Department of Medical Imaging and Intervention, New Taipei Municipal Tucheng Hospital, Chang Gung Medical Foundation, New Taipei City, Taiwan. FAU - Wu, Chen-Te AU - Wu CT AD - Division of Emergency and Critical Care Radiology, Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital, Chang Gung University, Tao-Yuan City, Taiwan. FAU - Ku, Yi-Kang AU - Ku YK AD - Division of Emergency and Critical Care Radiology, Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital, Chang Gung University, Tao-Yuan City, Taiwan. FAU - Chen, Chien-Cheng AU - Chen CC AD - Division of Emergency and Critical Care Radiology, Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital, Chang Gung University, Tao-Yuan City, Taiwan. FAU - Sheng, Ting-Wen AU - Sheng TW AD - Division of Emergency and Critical Care Radiology, Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital, Chang Gung University, Tao-Yuan City, Taiwan. FAU - Chang, Chun-Bi AU - Chang CB AD - Division of Emergency and Critical Care Radiology, Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital, Chang Gung University, Tao-Yuan City, Taiwan. LA - eng PT - Journal Article DEP - 20230308 PL - Germany TA - Surg Endosc JT - Surgical endoscopy JID - 8806653 SB - IM MH - Humans MH - Retrospective Studies MH - *Splenic Diseases MH - Splenic Artery MH - Trauma Centers MH - *Vascular System Injuries MH - Treatment Outcome MH - *Embolization, Therapeutic/adverse effects MH - *Abdominal Injuries MH - *Wounds, Nonpenetrating/diagnostic imaging/therapy PMC - PMC10234934 OTO - NOTNLM OT - Blunt splenic injury OT - Contrast extravasation OT - Location of embolization OT - Pseudoaneurysm OT - Splenic artery embolization COIS- Drs. Being-Chuan Lin, Cheng-Hsien Wu, Yon-Cheong Wong, Huan-Wu Chen, Chen-Ju Fu, Chen-Chih Huang, Chen-Te Wu, Yi-Kang Ku, Chien-Cheng Chen, Ting-Wen Sheng, and Chun-Bi, Chang have no conflicts of interest or financial ties to disclose. EDAT- 2023/03/09 06:00 MHDA- 2023/06/05 06:42 PMCR- 2023/03/08 CRDT- 2023/03/08 23:25 PHST- 2022/10/19 00:00 [received] PHST- 2023/02/12 00:00 [accepted] PHST- 2023/06/05 06:42 [medline] PHST- 2023/03/09 06:00 [pubmed] PHST- 2023/03/08 23:25 [entrez] PHST- 2023/03/08 00:00 [pmc-release] AID - 10.1007/s00464-023-09960-5 [pii] AID - 9960 [pii] AID - 10.1007/s00464-023-09960-5 [doi] PST - ppublish SO - Surg Endosc. 2023 Jun;37(6):4689-4697. doi: 10.1007/s00464-023-09960-5. Epub 2023 Mar 8. PMID- 34263847 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210715 IS - 1539-4522 (Electronic) IS - 1559-128X (Linking) VI - 60 IP - 19 DP - 2021 Jul 1 TI - Measurement algorithm for wafer alignment based on principal component analysis. PG - 5569-5580 LID - 10.1364/AO.425767 [doi] AB - We propose a novel measurement algorithm for wafer alignment technology based on principal component analysis (PCA) of a mark image. The waveform of the mark is extracted from the enlarged mark image, which is collected by CCD. The position of the mark center on the CCD can be calculated based on the extracted waveform. By applying PCA to the mark image, the first principal component containing position information of the mark can be obtained. Therefore PCA can be used to extract the waveform from the mark image. Compared with the typical waveform extraction method (the summed projection (SP) method), the proposed PCA method can use the position information contained in the mark image more effectively. Through simulation and experiment, it is proved that the proposed PCA method can improve the contrast of the normalized waveform, and then improve the alignment accuracy. FAU - Shu, Ting AU - Shu T FAU - Wang, Shaoqing AU - Wang S FAU - Xu, Jinghao AU - Xu J FAU - Fan, Lili AU - Fan L FAU - Yuan, Fenghua AU - Yuan F FAU - Pan, Songyong AU - Pan S FAU - Dai, Fengzhao AU - Dai F FAU - Bu, Yang AU - Bu Y FAU - Wang, Xiangzhao AU - Wang X LA - eng PT - Journal Article PL - United States TA - Appl Opt JT - Applied optics JID - 0247660 SB - IM EDAT- 2021/07/16 06:00 MHDA- 2021/07/16 06:01 CRDT- 2021/07/15 09:06 PHST- 2021/07/15 09:06 [entrez] PHST- 2021/07/16 06:00 [pubmed] PHST- 2021/07/16 06:01 [medline] AID - 452682 [pii] AID - 10.1364/AO.425767 [doi] PST - ppublish SO - Appl Opt. 2021 Jul 1;60(19):5569-5580. doi: 10.1364/AO.425767. PMID- 34093786 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210608 IS - 1837-9664 (Print) IS - 1837-9664 (Electronic) IS - 1837-9664 (Linking) VI - 12 IP - 13 DP - 2021 TI - OSCAR facilitates malignancy with enhanced metastasis correlating to inhibitory immune microenvironment in multiple cancer types. PG - 3769-3780 LID - 10.7150/jca.51964 [doi] AB - Cross talk between tumors and the immune microenvironment play a critical role in the malignant progression. The osteoclast-associated receptor (OSCAR) is a regulator of lymphocyte differentiation and maturation, but little is known about the role of OSCAR in multiple cancer types. We comprehensively analyzed OSCAR expression and explored its correlation with prognosis in multiple cancer types using Oncomine, TIMER, Gene GEPIA2 and CCLE. We examined OSCAR expression correlations with lymph node metastasis and pathological stage across tumor samples using UALCAN and GEPIA2. We analyzed the effects of OSCAR on survival using the Kaplan Meier plotter. We explored genes co-expressed with OSCAR using the LinkedOmics database and analyzed associated gene ontologies using Metascape. Further, we examined the correlation between OSCAR expression and immunocyte infiltration, markers of epithelial-mesenchymal transition, and lymphocyte subtypes using TIMER. OSCAR mRNA levels were upregulated in most cancer types compared with adjacent normal tissues. Higher expression of OSCAR correlated with lymph node metastasis or advanced stage subgroups. High expression of OSCAR was related to low tumor purity, with increased levels of M2 macrophage polarization, T cells exhaustion, and mesenchymal phenotype in most cancer types. We also showed that the strength of OSCAR expression influence in malignant progression and inhibitory immune microenvironment is mitigated by the infiltration of natural killer cells. These findings shed light on the pro-carcinogenic role of OSCAR in most cancer types and indicate OSCAR could be targeted in future therapeutics to reverse the inhibitory immune microenvironment. CI - © The author(s). FAU - Liao, Xia AU - Liao X AD - Department of Nutrition, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China. FAU - Bu, Yang AU - Bu Y AD - Department of Hepatobiliary Surgery, People' hospital of Ningxia Hui Autonomous Region, Yinchuan 750001, China. FAU - Zhang, Yaoyao AU - Zhang Y AD - Institute of Medical Research, Northwestern Polytechnical University, Xi'an 710072, China. FAU - Xu, Binghui AU - Xu B AD - Institute of Medical Research, Northwestern Polytechnical University, Xi'an 710072, China. FAU - Liang, Junrong AU - Liang J AD - State Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an 710032, China. FAU - Jia, Qingan AU - Jia Q AD - Institute of Medical Research, Northwestern Polytechnical University, Xi'an 710072, China. FAU - Zhang, Chun AU - Zhang C AD - Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China. LA - eng PT - Journal Article DEP - 20210505 PL - Australia TA - J Cancer JT - Journal of Cancer JID - 101535920 PMC - PMC8176254 OTO - NOTNLM OT - OSCAR OT - immune microenvironment OT - macrophage OT - metastasis OT - prognosis COIS- Competing Interests: The authors have declared that no competing interest exists. EDAT- 2021/06/08 06:00 MHDA- 2021/06/08 06:01 PMCR- 2021/01/01 CRDT- 2021/06/07 05:52 PHST- 2020/08/14 00:00 [received] PHST- 2021/04/25 00:00 [accepted] PHST- 2021/06/07 05:52 [entrez] PHST- 2021/06/08 06:00 [pubmed] PHST- 2021/06/08 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - jcav12p3769 [pii] AID - 10.7150/jca.51964 [doi] PST - epublish SO - J Cancer. 2021 May 5;12(13):3769-3780. doi: 10.7150/jca.51964. eCollection 2021. PMID- 40500057 OWN - NLM STAT- MEDLINE DCOM- 20250611 LR - 20250611 IS - 1095-9939 (Electronic) IS - 0048-3575 (Linking) VI - 212 DP - 2025 Aug TI - Risk assessment and resistant mechanism of Fusarium graminearum to fluopyram. PG - 106449 LID - S0048-3575(25)00162-2 [pii] LID - 10.1016/j.pestbp.2025.106449 [doi] AB - Fusarium head blight (FHB), caused by the Fusarium graminearum species complex, poses a significant threat to global wheat production and human health due to its high virulence and the ability to produce harmful secondary metabolites. Although various fungicides have been extensively used to control FHB, there is a critical need for more comprehensive information on the resistance of F. graminearum to fluopyram in China. This study evaluated the sensitivity of F. graminearum strains collected from five distinct regions to fluopyram. The EC(50) values for fluopyram ranged from 1.20 to 6.42 μg/mL, with an average value of 3.30 μg/mL. Additionally, fluopyram-resistant mutants were generated in the laboratory by chemical taming, with a resistance frequency of 8.3 × 10-(-3). Furthermore, no significant differences were observed in conidiation, growth rate, and temperature sensitivity between the resistant mutants and the parental strains. It was also determined that fluopyram exhibits positive cross-resistance with pydiflumetofen but no cross-resistance with carbendazim, tebuconazole, and pyraclostrobin. The mutations associated with fluopyram resistance in F. graminearum were identified as SDHB-H248L, SDHC2-A83V, and SDHC2-R86K. Based on these findings, the risk of resistance development in F. graminearum to fluopyram was assessed as moderate. Additionally, it was found that the combination of prothioconazole and fluopyram is more effective than their individual use in field trials. Considering the role of fluopyram in inhibiting DON produced by F. graminearum, it is recommended that fluopyram be used in conjunction with other highly effective fungicides to control FHB, thereby achieving both disease control and mycotoxin reduction. CI - Copyright © 2024. Published by Elsevier Inc. FAU - Jie, Zhang AU - Jie Z AD - State Key Laboratory of Agricultural and Forestry Biosecurity, College of Plant Protection, Nanjing Agricultural University, Nanjing 210095, China. FAU - SiYu, Sun AU - SiYu S AD - State Key Laboratory of Agricultural and Forestry Biosecurity, College of Plant Protection, Nanjing Agricultural University, Nanjing 210095, China. FAU - Yu, Guo AU - Yu G AD - State Key Laboratory of Agricultural and Forestry Biosecurity, College of Plant Protection, Nanjing Agricultural University, Nanjing 210095, China. FAU - Fuhao, Ren AU - Fuhao R AD - State Key Laboratory of Agricultural and Forestry Biosecurity, College of Plant Protection, Nanjing Agricultural University, Nanjing 210095, China. FAU - Guilin, Sheng AU - Guilin S AD - Institute for the Control of Agrochemicals Jiangsu Province, Nanjing 210036, China. FAU - Huan, Wu AU - Huan W AD - State Key Laboratory of Agricultural and Forestry Biosecurity, College of Plant Protection, Nanjing Agricultural University, Nanjing 210095, China. FAU - Baoquan, Zhao AU - Baoquan Z AD - State Key Laboratory of Agricultural and Forestry Biosecurity, College of Plant Protection, Nanjing Agricultural University, Nanjing 210095, China. FAU - Yiqiang, Cai AU - Yiqiang C AD - State Key Laboratory of Agricultural and Forestry Biosecurity, College of Plant Protection, Nanjing Agricultural University, Nanjing 210095, China. FAU - Chunyan, Gu AU - Chunyan G AD - Anhui Province Key Laboratory of Pesticide Resistance Management on Grain and Vegetable Pests, Anhui Academy of Agricultural Sciences, Hefei 230041, China. Electronic address: guchunyan0408@163.com. FAU - Yabing, Duan AU - Yabing D AD - State Key Laboratory of Agricultural and Forestry Biosecurity, College of Plant Protection, Nanjing Agricultural University, Nanjing 210095, China. Electronic address: dyb@njau.edu.cn. LA - eng PT - Journal Article DEP - 20250508 PL - United States TA - Pestic Biochem Physiol JT - Pesticide biochemistry and physiology JID - 1301573 RN - 0 (Fungicides, Industrial) RN - 0 (Pyridines) RN - F0VT7K5302 (N-(2-(3-chloro-5-(trifluoromethyl)-2-pyridyl)ethyl)-alpha,alpha,alpha-trifluoro-o-toluamide) RN - 0 (Benzamides) RN - Fusarium graminearum SB - IM MH - *Fusarium/drug effects/genetics MH - *Fungicides, Industrial/pharmacology MH - *Drug Resistance, Fungal/genetics MH - Risk Assessment MH - Plant Diseases/microbiology MH - *Pyridines/pharmacology MH - Triticum/microbiology MH - China MH - Benzamides OTO - NOTNLM OT - Fluopyram OT - Fusarium head blight OT - Resistance mechanism OT - Resistance risk EDAT- 2025/06/12 00:38 MHDA- 2025/06/12 00:39 CRDT- 2025/06/11 20:55 PHST- 2025/02/05 00:00 [received] PHST- 2025/02/25 00:00 [revised] PHST- 2025/05/07 00:00 [accepted] PHST- 2025/06/12 00:39 [medline] PHST- 2025/06/12 00:38 [pubmed] PHST- 2025/06/11 20:55 [entrez] AID - S0048-3575(25)00162-2 [pii] AID - 10.1016/j.pestbp.2025.106449 [doi] PST - ppublish SO - Pestic Biochem Physiol. 2025 Aug;212:106449. doi: 10.1016/j.pestbp.2025.106449. Epub 2025 May 8. PMID- 31006299 OWN - NLM STAT- MEDLINE DCOM- 20191218 LR - 20200225 IS - 1473-2300 (Electronic) IS - 0300-0605 (Print) IS - 0300-0605 (Linking) VI - 47 IP - 6 DP - 2019 Jun TI - Therapeutic strategy of central vein perforation accompanied by a mediastinal lesion after catheterization. PG - 2702-2708 LID - 10.1177/0300060519843686 [doi] AB - Central vein perforation associated with a mediastinal lesion is a rare complication of catheterization. A 50-year-old woman was diagnosed with chronic kidney disease and required hemodialysis treatment. The patient developed central vein injury during attempted placement of a double-channel catheter. A computed tomographic scan and venography showed that the catheter had punctured the mediastinum from the central vein. After comprehensive assessment and multidisciplinary consultation, percutaneous catheter thrombin injection with follow-up balloon dilatation under fluoroscopy guidance successfully fixed the perforation. We summarize the therapeutic strategy of this complication and other treatment options, and discuss the related literature of central vein injury. FAU - Li, Chi-Chang AU - Li CC AD - Cardiovascular Department, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China. FAU - Zhang, Wei AU - Zhang W AUID- ORCID: 0000-0001-5574-622X AD - Cardiovascular Department, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China. FAU - Wu, Xing-Jie AU - Wu XJ AD - Cardiovascular Department, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China. FAU - Bu, Yang AU - Bu Y AD - Cardiovascular Department, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China. FAU - Zheng, Zhi-Peng AU - Zheng ZP AD - Cardiovascular Department, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China. LA - eng PT - Case Reports PT - Journal Article DEP - 20190421 PL - England TA - J Int Med Res JT - The Journal of international medical research JID - 0346411 SB - IM MH - Catheterization/*adverse effects MH - Central Venous Catheters/*adverse effects MH - Female MH - Humans MH - Mediastinum/blood supply/*pathology MH - Middle Aged MH - Prognosis MH - Renal Dialysis MH - Renal Insufficiency, Chronic/*therapy MH - Vascular System Injuries/diagnosis/etiology/*therapy PMC - PMC6567695 OTO - NOTNLM OT - Catheterization OT - central vein injury OT - hemodialysis OT - hemorrhage OT - kidney disease OT - mediastinum OT - thrombin EDAT- 2019/04/23 06:00 MHDA- 2019/12/19 06:00 PMCR- 2019/06/01 CRDT- 2019/04/23 06:00 PHST- 2019/04/23 06:00 [pubmed] PHST- 2019/12/19 06:00 [medline] PHST- 2019/04/23 06:00 [entrez] PHST- 2019/06/01 00:00 [pmc-release] AID - 10.1177_0300060519843686 [pii] AID - 10.1177/0300060519843686 [doi] PST - ppublish SO - J Int Med Res. 2019 Jun;47(6):2702-2708. doi: 10.1177/0300060519843686. Epub 2019 Apr 21. PMID- 31931755 OWN - NLM STAT- MEDLINE DCOM- 20200908 LR - 20200908 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 20 IP - 1 DP - 2020 Jan 13 TI - Oxaliplatin resistance is enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in hepatocellular carcinoma. PG - 31 LID - 10.1186/s12885-019-6480-9 [doi] LID - 31 AB - BACKGROUND: Chemo-resistance in hepatocellular carcinoma (HCC) is a major problem, and acquired drug resistance prevents cancer therapies from achieving complete responses. Molecular targeting therapy presents an opportunity to impede tumor through combination or sequential therapy, while the accurate effect is vague. METHODS: The efficacy of combinations between oxaliplatin and anti-cancer molecular targeting drugs was screened. Strangely, the combined chemotherapy with oxaliplatin and saracatinib induced significantly antagonistic effects. Then the antitumor effects of combined treatment with saracatinib and oxaliplatin were confirmed in wide type HCC as well as in saracatinib- and oxaliplatin-resistant HCC. RNA sequencing was used to explore the resistance mechanism, and the roles of ATP-binding cassette transporter G1 (ABCG1) and Wnt signaling in oxaliplatin resistance were confirmed. RESULTS: Chemotherapy with oxaliplatin and saracatinib individually induced strong anti-HCC effects, while combined or sequential treatment of HCC cells with these two drugs exhibited reduced efficacy compared to treatment with the single drugs. And it was saracatinib treatment caused oxaliplatin resistance. RNA sequencing revealed 458 genes that were altered by treatment with saracatinib and oxaliplatin. Of these, the gene encoding ABCG1 and Wnt-associated genes were significantly upregulated. Upregulation of ABCG1 and oxaliplatin resistance were associated with activation of Wnt signaling. Interference with ABCG1 expression or inhibition of Wnt signaling resulted in reversal of the saracatinib-induced oxaliplatin resistance in HCC. CONCLUSIONS: These studies demonstrated that combined or sequential chemotherapy with oxaliplatin and saracatinib reduced antitumor efficacy, and this antagonism was attributed to the activation of Wnt signaling and upregulation of ABCG1 by saracatinib. FAU - Liao, Xia AU - Liao X AD - Department of Nutrition, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China. FAU - Song, Ge AU - Song G AD - Department of Nutrition, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China. FAU - Xu, Zihan AU - Xu Z AD - Department of Burns and Plastic Surgery, Shaanxi Provincial People's Hospital, Xi'an, 710068, China. FAU - Bu, Yang AU - Bu Y AD - Department of Hepatobiliary Surgery, General Hospital, Ningxia Medical University, Yinchuan, 750001, China. FAU - Chang, Fan AU - Chang F AD - Metabolite Research Center, Shaanxi Institute of Microbiology, Xi'an, 710043, China. FAU - Jia, Fengan AU - Jia F AD - Metabolite Research Center, Shaanxi Institute of Microbiology, Xi'an, 710043, China. FAU - Xiao, Xuelian AU - Xiao X AD - Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi'an Jiaotong University, 277 West Yanta Road, Xi'an, 710061, China. FAU - Ren, Xuejiao AU - Ren X AD - Medical College of Yan'an University, Yan'an, 716000, China. FAU - Zhang, Mei AU - Zhang M AD - Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi'an Jiaotong University, 277 West Yanta Road, Xi'an, 710061, China. FAU - Jia, Qingan AU - Jia Q AUID- ORCID: 0000-0002-3256-7197 AD - Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi'an Jiaotong University, 277 West Yanta Road, Xi'an, 710061, China. qajia66@163.com. LA - eng GR - 81502694/National Natural Science Foundation of China/ GR - 1191329835/Fundamental Research Funds for the Central Universities/ GR - 2015M570330/Postdoctoral Science Foundation of China/ GR - NZ15130/Key projects of Ningxia Natural Science Foundation/ PT - Journal Article DEP - 20200113 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (ABCG1 protein, human) RN - 0 (ATP Binding Cassette Transporter, Subfamily G, Member 1) RN - 0 (Benzodioxoles) RN - 0 (Quinazolines) RN - 0 (Wnt Proteins) RN - 04ZR38536J (Oxaliplatin) RN - 9KD24QGH76 (saracatinib) SB - IM MH - ATP Binding Cassette Transporter, Subfamily G, Member 1/genetics/*metabolism MH - Animals MH - Benzodioxoles/*pharmacology MH - Carcinoma, Hepatocellular/drug therapy/genetics/*metabolism/pathology MH - Cell Line, Tumor MH - Computational Biology/methods MH - Disease Models, Animal MH - Drug Antagonism MH - *Drug Resistance, Neoplasm MH - Gene Expression Profiling MH - Gene Expression Regulation/drug effects MH - Humans MH - Liver Neoplasms/drug therapy/*metabolism/pathology MH - Mice MH - Oxaliplatin/*pharmacology MH - Quinazolines/*pharmacology MH - Signal Transduction/*drug effects MH - Wnt Proteins/*metabolism MH - Xenograft Model Antitumor Assays PMC - PMC6958774 OTO - NOTNLM OT - ABCG1 OT - Hepatocellular carcinoma OT - Oxaliplatin resistance OT - Saracatinib OT - Wnt signaling COIS- The authors declare that they have no competing interests. EDAT- 2020/01/15 06:00 MHDA- 2020/09/09 06:00 PMCR- 2020/01/13 CRDT- 2020/01/15 06:00 PHST- 2019/05/30 00:00 [received] PHST- 2019/12/18 00:00 [accepted] PHST- 2020/01/15 06:00 [entrez] PHST- 2020/01/15 06:00 [pubmed] PHST- 2020/09/09 06:00 [medline] PHST- 2020/01/13 00:00 [pmc-release] AID - 10.1186/s12885-019-6480-9 [pii] AID - 6480 [pii] AID - 10.1186/s12885-019-6480-9 [doi] PST - epublish SO - BMC Cancer. 2020 Jan 13;20(1):31. doi: 10.1186/s12885-019-6480-9. PMID- 23409093 OWN - NLM STAT- MEDLINE DCOM- 20130805 LR - 20220321 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 8 IP - 2 DP - 2013 TI - Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma. PG - e55945 LID - 10.1371/journal.pone.0055945 [doi] LID - e55945 AB - Sorafenib, a multi-tyrosine kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC). The present study was undertaken to determine whether the growth and metastasis of HCC were influenced in mice receiving sorafenib prior to implantation with tumors, and to investigate the in-vivo and in-vitro effect of sorafenib on natural killer (NK) cells. In sorafenib-pretreated BALB/c nu/nu mice and C57BL/6 mice, tumor growth was accelerated, mouse survival was decreased, and lung metastasis was increased. However, the depletion of NK1.1(+) cells in C57BL/6 mice eliminated sorafenib-mediated pro-metastatic effects. Sorafenib significantly reduced the number of NK cells and inhibited reactivity of NK cells against tumor cells, in both tumor-bearing and tumor-free C57BL/6 mice. Sorafenib down-regulated the stimulatory receptor CD69 in NK cells of tumor-bearing mice, but not in tumor-free mice, and inhibited proliferation of NK92-MI cells, which is associated with the blocking of the PI3K/AKT pathway, and inhibited cytotoxicity of NK cells in response to tumor targets, which was due to impaired ERK phosphorylation. These results suggest immunotherapeutic approaches activating NK cells may enhance the therapeutic efficacy of sorafenib in HCC patients. FAU - Zhang, Qiang-Bo AU - Zhang QB AD - Liver Cancer Institute and Zhongshan Hospital, Fudan University, Key Laboratory for Carcinogenesis and Cancer Invasion, The Chinese Ministry of Education, Shanghai, PR China. FAU - Sun, Hui-Chuan AU - Sun HC FAU - Zhang, Ke-Zhi AU - Zhang KZ FAU - Jia, Qing-An AU - Jia QA FAU - Bu, Yang AU - Bu Y FAU - Wang, Miao AU - Wang M FAU - Chai, Zong-Tao AU - Chai ZT FAU - Zhang, Quan-Bao AU - Zhang QB FAU - Wang, Wen-Quan AU - Wang WQ FAU - Kong, Ling-Qun AU - Kong LQ FAU - Zhu, Xiao-dong AU - Zhu XD FAU - Lu, Lu AU - Lu L FAU - Wu, Wei-Zhong AU - Wu WZ FAU - Wang, Lu AU - Wang L FAU - Tang, Zhao-You AU - Tang ZY LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20130208 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Antigens, CD) RN - 0 (Antigens, Differentiation, T-Lymphocyte) RN - 0 (Antineoplastic Agents) RN - 0 (CD69 antigen) RN - 0 (Immunosuppressive Agents) RN - 0 (Lectins, C-Type) RN - 0 (Phenylurea Compounds) RN - 25X51I8RD4 (Niacinamide) RN - 9ZOQ3TZI87 (Sorafenib) RN - EC 2.7.1.- (Phosphatidylinositol 3-Kinases) RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-raf) SB - IM MH - Animals MH - Antigens, CD/metabolism MH - Antigens, Differentiation, T-Lymphocyte/metabolism MH - Antineoplastic Agents/administration & dosage/*pharmacology/toxicity MH - Carcinoma, Hepatocellular/*immunology/mortality/*pathology MH - Cell Line, Tumor MH - Cell Proliferation/drug effects MH - Disease Models, Animal MH - Humans MH - Immunocompromised Host MH - Immunosuppressive Agents/administration & dosage/pharmacology/toxicity MH - K562 Cells MH - Killer Cells, Natural/*drug effects/immunology MH - Lectins, C-Type/metabolism MH - Liver Neoplasms/*immunology/mortality/*pathology MH - Lung Neoplasms/pathology/secondary MH - MAP Kinase Signaling System/drug effects MH - Male MH - Mice MH - Neoplasm Metastasis MH - Niacinamide/administration & dosage/*analogs & derivatives/pharmacology MH - Phenylurea Compounds/administration & dosage/*pharmacology MH - Phosphatidylinositol 3-Kinases/metabolism MH - Proto-Oncogene Proteins c-akt/metabolism MH - Proto-Oncogene Proteins c-raf/metabolism MH - Signal Transduction/drug effects MH - Sorafenib MH - Tumor Burden/drug effects MH - Xenograft Model Antitumor Assays PMC - PMC3568028 COIS- Competing Interests: The authors have declared that no competing interests exist. EDAT- 2013/02/15 06:00 MHDA- 2013/08/06 06:00 PMCR- 2013/02/08 CRDT- 2013/02/15 06:00 PHST- 2012/11/26 00:00 [received] PHST- 2013/01/03 00:00 [accepted] PHST- 2013/02/15 06:00 [entrez] PHST- 2013/02/15 06:00 [pubmed] PHST- 2013/08/06 06:00 [medline] PHST- 2013/02/08 00:00 [pmc-release] AID - PONE-D-12-37237 [pii] AID - 10.1371/journal.pone.0055945 [doi] PST - ppublish SO - PLoS One. 2013;8(2):e55945. doi: 10.1371/journal.pone.0055945. Epub 2013 Feb 8. PMID- 28177210 OWN - NLM STAT- MEDLINE DCOM- 20180813 LR - 20231112 IS - 1520-6882 (Electronic) IS - 0003-2700 (Print) IS - 0003-2700 (Linking) VI - 88 IP - 24 DP - 2016 Dec 20 TI - Noise Reduction Method for Quantifying Nanoparticle Light Scattering in Low Magnification Dark-Field Microscope Far-Field Images. PG - 12001-12005 LID - 10.1021/acs.analchem.6b03661 [doi] AB - Nanoparticles have become a powerful tool for cell imaging and biomolecule, cell and protein interaction studies, but are difficult to rapidly and accurately measure in most assays. Dark-field microscope (DFM) image analysis approaches used to quantify nanoparticles require high-magnification near-field (HN) images that are labor intensive due to a requirement for manual image selection and focal adjustments needed when identifying and capturing new regions of interest. Low-magnification far-field (LF) DFM imagery is technically simpler to perform but cannot be used as an alternate to HN-DFM quantification, since it is highly sensitive to surface artifacts and debris that can easily mask nanoparticle signal. We now describe a new noise reduction approach that markedly reduces LF-DFM image artifacts to allow sensitive and accurate nanoparticle signal quantification from LF-DFM images. We have used this approach to develop a "Dark Scatter Master" (DSM) algorithm for the popular NIH image analysis program ImageJ, which can be readily adapted for use with automated high-throughput assay analyses. This method demonstrated robust performance quantifying nanoparticles in different assay formats, including a novel method that quantified extracellular vesicles in patient blood sample to detect pancreatic cancer cases. Based on these results, we believe our LF-DFM quantification method can markedly decrease the analysis time of most nanoparticle-based assays to impact both basic research and clinical analyses. FAU - Sun, Dali AU - Sun D AD - Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, TX 77030, United States. FAU - Fan, Jia AU - Fan J AD - Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, TX 77030, United States. FAU - Liu, Chang AU - Liu C AD - Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, TX 77030, United States. FAU - Liu, Yang AU - Liu Y AD - Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, TX 77030, United States. FAU - Bu, Yang AU - Bu Y AD - Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, TX 77030, United States. FAU - Lyon, Christopher J AU - Lyon CJ AD - Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, TX 77030, United States. FAU - Hu, Ye AU - Hu Y AD - School of Biological and Health Systems Engineering, Virginia G. Piper Biodesign Center for Personalized Diagnostics, The Biodesign Institute, Arizona State University, 727 E. Tyler St. B 130-B, Tempe, AZ 85287, United States. LA - eng GR - R01 AI113725/AI/NIAID NIH HHS/United States GR - R01 AI122932/AI/NIAID NIH HHS/United States GR - R01 HD090927/HD/NICHD NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20161128 PL - United States TA - Anal Chem JT - Analytical chemistry JID - 0370536 RN - 0 (Antibodies, Immobilized) RN - 0 (Bacterial Proteins) RN - 0 (IgG Fc-binding protein, Streptococcus) RN - 0 (Staphylococcal Protein A) RN - 7440-57-5 (Gold) SB - IM MH - Algorithms MH - Antibodies, Immobilized/chemistry/metabolism MH - Artifacts MH - Bacterial Proteins/metabolism MH - Gold/chemistry MH - Humans MH - Immunoassay MH - Metal Nanoparticles/*chemistry MH - Microscopy/*methods MH - Staphylococcal Protein A/metabolism PMC - PMC5300049 MID - NIHMS833346 EDAT- 2017/02/09 06:00 MHDA- 2018/08/14 06:00 PMCR- 2017/02/09 CRDT- 2017/02/09 06:00 PHST- 2017/02/09 06:00 [entrez] PHST- 2017/02/09 06:00 [pubmed] PHST- 2018/08/14 06:00 [medline] PHST- 2017/02/09 00:00 [pmc-release] AID - 10.1021/acs.analchem.6b03661 [doi] PST - ppublish SO - Anal Chem. 2016 Dec 20;88(24):12001-12005. doi: 10.1021/acs.analchem.6b03661. Epub 2016 Nov 28. PMID- 23326293 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20130118 LR - 20211021 IS - 1741-4288 (Electronic) IS - 1741-427X (Print) IS - 1741-427X (Linking) VI - 2012 DP - 2012 TI - Herbal Compound "Songyou Yin" Renders Hepatocellular Carcinoma Sensitive to Oxaliplatin through Inhibition of Stemness. PG - 908601 LID - 10.1155/2012/908601 [doi] LID - 908601 AB - We investigated the effect of Chinese herbal compound Song-you Yin on HCC stemness. MHCC97H and Hep3B cell lines were pretreated with SYY for 4 weeks, and their chemosensitivity to oxaliplatin was evaluated. The expression of CSC-related markers, cell invasion and migration, and colony formation were also examined. SYY-treated orthotopic nude mouse models of human HCC were developed to explore the effect of oxaliplatin on tumor growth, metastasis, and survival. The CSC-related molecular changes in vivo were also evaluated. The result showed that MHCC97H and Hep3B cells pretreated with SYY showed significantly increased chemosensitivity to oxaliplatin and the downregulation of CSC-related markers CD90, CD24, and EPCAM. SYY also attenuated cell motility, invasion, and colony formation in MHCC97H and Hep3B cell lines. The reduced tumorigenicity and pulmonary metastasis were observed in SYY-pretreated cell lines. Combination treatment with oxaliplatin and SYY significantly reduced tumor volume and pulmonary metastasis and prolonged survival compared with oxaliplatin treatment alone. Immunohistochemical analysis showed reduced expression of CD90, ABCG2, ALDH, CD44, EPCAM, vimentin, and MMP-9 and increased the expression of E-cadherin, in HCC cells following combination treatment. These data clearly demonstrate that SYY renders hepatocellular carcinoma sensitive to oxaliplatin through the inhibition of stemness. FAU - Jia, Qing-An AU - Jia QA AD - Liver Cancer Institute, Zhongshan Hospital, Fudan University and Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, 180 Fenglin Road, Shanghai 200032, China. FAU - Ren, Zheng-Gang AU - Ren ZG FAU - Bu, Yang AU - Bu Y FAU - Wang, Zhi-Ming AU - Wang ZM FAU - Zhang, Qiang-Bo AU - Zhang QB FAU - Liang, Lei AU - Liang L FAU - Jiang, Xue-Mei AU - Jiang XM FAU - Zhang, Quan-Bao AU - Zhang QB FAU - Tang, Zhao-You AU - Tang ZY LA - eng PT - Journal Article DEP - 20121220 PL - United States TA - Evid Based Complement Alternat Med JT - Evidence-based complementary and alternative medicine : eCAM JID - 101215021 PMC - PMC3541605 EDAT- 2013/01/18 06:00 MHDA- 2013/01/18 06:01 PMCR- 2012/12/20 CRDT- 2013/01/18 06:00 PHST- 2012/10/12 00:00 [received] PHST- 2012/11/12 00:00 [accepted] PHST- 2013/01/18 06:00 [entrez] PHST- 2013/01/18 06:00 [pubmed] PHST- 2013/01/18 06:01 [medline] PHST- 2012/12/20 00:00 [pmc-release] AID - 10.1155/2012/908601 [doi] PST - ppublish SO - Evid Based Complement Alternat Med. 2012;2012:908601. doi: 10.1155/2012/908601. Epub 2012 Dec 20. PMID- 30462016 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20181126 LR - 20190115 IS - 1539-4522 (Electronic) IS - 1559-128X (Linking) VI - 57 IP - 33 DP - 2018 Nov 20 TI - Calibration method of overlay measurement error caused by asymmetric mark. PG - 9814-9821 LID - 10.1364/AO.57.009814 [doi] AB - With the process nodes extending to sub-10-nm in advanced semiconductor manufacturing, the overlay requirements keep progressively scaling down, which makes it very important to measure overlay precisely for monitoring on-product performance. The overlay mark being asymmetrical when generated via the lithography process, this asymmetry will be slightly variated even in the same process or same lot, and it will bring overlay measurement error. In general, the wafer alignment data are used for correcting this overlay measurement error, utilizing its wavelengths and polarizations dependence. However, there is a residual error that cannot be removed because the structures of the wafer alignment mark and overlay mark are different and are affected by the process differently. In this paper, a new method is proposed for calibrating the overlay measurement error introduced by the asymmetric mark, which is based on the relationship between measurement data of the overlay mark and the single layer mark. The validity is verified by simulation with different types of asymmetric mark. It is very useful for improving overlay measurement accuracy and for understanding how the overlay measurement error is affected by the asymmetric mark. FAU - Du, Juyou AU - Du J FAU - Dai, Fengzhao AU - Dai F FAU - Bu, Yang AU - Bu Y FAU - Wang, Xiangzhao AU - Wang X LA - eng PT - Journal Article PL - United States TA - Appl Opt JT - Applied optics JID - 0247660 EDAT- 2018/11/22 06:00 MHDA- 2018/11/22 06:01 CRDT- 2018/11/22 06:00 PHST- 2018/11/22 06:00 [entrez] PHST- 2018/11/22 06:00 [pubmed] PHST- 2018/11/22 06:01 [medline] AID - 401353 [pii] AID - 10.1364/AO.57.009814 [doi] PST - ppublish SO - Appl Opt. 2018 Nov 20;57(33):9814-9821. doi: 10.1364/AO.57.009814. PMID- 31250351 OWN - NLM STAT- MEDLINE DCOM- 20200127 LR - 20200225 IS - 1936-0541 (Electronic) IS - 1936-0533 (Print) IS - 1936-0533 (Linking) VI - 13 IP - 4 DP - 2019 Jul TI - CCN2-MAPK-Id-1 loop feedback amplification is involved in maintaining stemness in oxaliplatin-resistant hepatocellular carcinoma. PG - 440-453 LID - 10.1007/s12072-019-09960-5 [doi] AB - BACKGROUND: Hepatocellular carcinoma (HCC) is the second leading cause of cancer death worldwide. Chemotherapy is an alternative treatment for advanced HCCs, but chemo-resistance prevents cancer therapies from achieving stable and complete responses. Understanding the underlying mechanisms in chemo-resistance is critical to improve the efficacy of HCC. METHODS: The expression levels of Id-1 and CCN2 were detected in large cohorts of HCCs, and functional analyses of Id-1 and CCN2 were performed both in vitro and in vivo. cDNA microarrays were performed to evaluate the alterations of expression profiling of HCC cells with overexpression of CCN2. Finally, the role of downstream signaling of MAPK/Id-1 signaling pathway in oxaliplatin resistance were also explored. RESULTS: The increased expression of Id-1 and CCN2 were closely related to oxaliplatin resistance in HCC. Upregulation of CCN2 and Id-1 was independently associated with shorter survival and increased recurrence in HCC patients, and significantly enhanced oxaliplatin resistance and promoted lung metastasis in vivo, whereas knock-down of their expression significantly reversed the chemo-resistance and inhibited HCC cell stemness. cDNA microarrays and PCR revealed that Id-1 and MAPK pathway were the downstream signaling of CCN2. CCN2 significantly enhanced oxaliplatin resistance by activating the MAPK/Id-1 signaling pathway, and Id-1 could upregulate CCN2 in a positive feedback manner. CONCLUSIONS: CCN2/MAPK/Id-1 loop feedback amplification is involved in oxaliplatin resistance, and the combination of oxaliplatin with inhibitor of CCN2 or MAPK signaling could provide a promising approach to ameliorating oxaliplatin resistance in HCC. FAU - Liao, Xia AU - Liao X AD - Department of Nutrition, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China. FAU - Bu, Yang AU - Bu Y AD - Department of Hepatobiliary Surgery, General Hospital, Ningxia Medical University, Yinchuan, 750001, China. FAU - Jiang, Shanshan AU - Jiang S AD - Institute of Hematological Research, Shaanxi Provincial People's Hospital, Xi'an, 710068, China. FAU - Chang, Fan AU - Chang F AD - Metabolite Research Center, Shaanxi Institute of Microbiology, Xi'an, 710043, China. FAU - Jia, Fengan AU - Jia F AD - Metabolite Research Center, Shaanxi Institute of Microbiology, Xi'an, 710043, China. FAU - Xiao, Xuelian AU - Xiao X AD - Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi'an Jiaotong University, 277 West Yanta Road, Xi'an, 710061, China. FAU - Song, Ge AU - Song G AD - Department of Nutrition, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China. FAU - Zhang, Mei AU - Zhang M AD - Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi'an Jiaotong University, 277 West Yanta Road, Xi'an, 710061, China. FAU - Ning, Pengbo AU - Ning P AD - School of Life Science and Technology, Xidian University, Xi'an, Shaanxi, China. FAU - Jia, Qingan AU - Jia Q AD - Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi'an Jiaotong University, 277 West Yanta Road, Xi'an, 710061, China. qajia66@163.com. LA - eng GR - 81502694/National Natural Science Foundation of China/ GR - 1191329835/Fundamental Research Funds for the Central Universities/ GR - 2015M570330/Postdoctoral Research Foundation of China/ GR - NZ15130/Natural Science Foundation of Ningxia Province/ PT - Journal Article DEP - 20190627 PL - United States TA - Hepatol Int JT - Hepatology international JID - 101304009 RN - 0 (Antineoplastic Agents) RN - 0 (Biomarkers, Tumor) RN - 0 (Butadienes) RN - 0 (CCN2 protein, human) RN - 0 (Nitriles) RN - 0 (Protein Kinase Inhibitors) RN - 0 (RNA, Messenger) RN - 0 (U 0126) RN - 04ZR38536J (Oxaliplatin) RN - 139568-91-5 (Connective Tissue Growth Factor) RN - 9ZOQ3TZI87 (Sorafenib) RN - EC 2.7.11.24 (MAPK1 protein, human) RN - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 1) SB - IM MH - Adult MH - Aged MH - Animals MH - Antineoplastic Agents/*therapeutic use MH - Biomarkers, Tumor/metabolism MH - Butadienes/pharmacology MH - Carcinoma, Hepatocellular/*drug therapy MH - Cell Line, Tumor MH - Connective Tissue Growth Factor/*metabolism MH - Down-Regulation/drug effects MH - Drug Resistance, Neoplasm MH - Feedback/drug effects MH - Female MH - Gene Expression Regulation, Neoplastic/drug effects/physiology MH - Heterografts MH - Humans MH - Liver Neoplasms/*drug therapy MH - MAP Kinase Signaling System/drug effects MH - Male MH - Mice, Nude MH - Middle Aged MH - Mitogen-Activated Protein Kinase 1/metabolism MH - Neoplasm Recurrence, Local MH - Neoplasm Transplantation MH - Neoplastic Stem Cells/drug effects MH - Nitriles/pharmacology MH - Oxaliplatin/*therapeutic use MH - Protein Kinase Inhibitors/pharmacology MH - RNA, Messenger/metabolism MH - Sorafenib/pharmacology MH - Up-Regulation/drug effects PMC - PMC6661033 OTO - NOTNLM OT - CCN2 OT - Hepatocellular carcinoma OT - Id-1 OT - MAPK signaling OT - Oxaliplatin COIS- Xia Liao, Yang Bu, Shanshan Jiang, Fan Chang, Fengan Jia, Xuelian Xiao, Ge Song, Mei Zhang, Pengbo Ning, Qingan Jia declare that they have no competing interests. EDAT- 2019/06/30 06:00 MHDA- 2020/01/28 06:00 PMCR- 2019/06/27 CRDT- 2019/06/29 06:00 PHST- 2019/02/21 00:00 [received] PHST- 2019/06/11 00:00 [accepted] PHST- 2019/06/30 06:00 [pubmed] PHST- 2020/01/28 06:00 [medline] PHST- 2019/06/29 06:00 [entrez] PHST- 2019/06/27 00:00 [pmc-release] AID - 10.1007/s12072-019-09960-5 [pii] AID - 9960 [pii] AID - 10.1007/s12072-019-09960-5 [doi] PST - ppublish SO - Hepatol Int. 2019 Jul;13(4):440-453. doi: 10.1007/s12072-019-09960-5. Epub 2019 Jun 27. PMID- 33967557 OWN - NLM STAT- MEDLINE DCOM- 20210514 LR - 20210514 IS - 2219-2840 (Electronic) IS - 1007-9327 (Print) IS - 1007-9327 (Linking) VI - 27 IP - 16 DP - 2021 Apr 28 TI - Depletion of MRPL35 inhibits gastric carcinoma cell proliferation by regulating downstream signaling proteins. PG - 1785-1804 LID - 10.3748/wjg.v27.i16.1785 [doi] AB - BACKGROUND: Gastric carcinoma (GC) is a digestive system disease with high morbidity and mortality. However, early clinical detection is difficult, and the therapeutic effect for advanced disease is not satisfactory. Thus, finding new tumor markers and therapeutic targets conducive to the treatment of GC is imperative. MRPL35 is a member of the large subunit family of mitochondrial ribosomal protein. MRPL35 shows the characteristic of oncogene in colorectal cancer and esophageal cancer, which promotes the exploration of the correlation between MRPL35 and GC. We proposed that the expression of MRPL35 might be critical in GC. AIM: To study the effect of MRPL35 knockdown on GC cell proliferation. METHODS: The expression of MRPL35 in GC was evaluated based on data from the public tumor database UALCAN (www.ualcan.path.uab.edu). The effect of the expression of MRPL35 on the prognosis was evaluated with KMplot (www.kmplot.com). The expression of MRPL35 was assessed on the tissue microarray by immunohistochemistry and the level of MRPL35 mRNA in 25 pairs of clinical GC tissues and matched adjacent tissues was detected by quantitative reverse transcription-polymerase chain reaction. Celigo cell count assay, colony formation assay, and flow cytometry were used to assess the role of MRPL35 in GC cell proliferation and apoptosis in vitro. Additionally, tumor formation experiment in BALB/c nude mice was utilized to determine the effect of MRPL35 on GC cell proliferation. After knockdown of MRPL35, related proteins were identified by isobaric tags for relative and absolute quantification analysis, and the expression of related proteins was detected by Western blot. RESULTS: The expression of MRPL35 was up-regulated in GC (P = 1.77 × 10(-4)). The Kaplan-Meier plots of the overall survival indicated that high expression of MRPL35 was associated with a poor survival in GC. Compared with adjacent tissues, the expression of MRPL35 in GC tissues was increased, which was related to age (P = 0.03), lymph node metastasis (P = 0.007), and pathological tumor-node-metastasis stage (P = 0.024). Knockdown of MRPL35 inhibited GC cell proliferation and colony formation and induced apoptosis. Animal experiment results showed that knockdown of MRPL35 inhibited tumor formation in BALB/c nude mice. Western blotting analysis showed that after knockdown of MRPL35, the expression of PICK1 and BCL-XL proteins decreased, and that of AGR2 protein increased. CONCLUSION: Collectively, our findings demonstrate that knockdown of MRPL35 inhibits GC cell proliferation through related proteins including PICK1, BCL-XL, and AGR2. CI - ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. FAU - Yuan, Ling AU - Yuan L AD - Pharmacy College of Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China. FAU - Li, Jia-Xin AU - Li JX AD - Pharmacy College of Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China. FAU - Yang, Yi AU - Yang Y AD - Pharmacy College of Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China. FAU - Chen, Yan AU - Chen Y AD - Traditional Chinese Medicine College, Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China. FAU - Ma, Ting-Ting AU - Ma TT AD - Pharmacy College of Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China. FAU - Liang, Shuang AU - Liang S AD - Department of Oncology and Endocrinology, Yinchuan Hospital of Traditional Chinese Medicine Affiliated to Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China. FAU - Bu, Yang AU - Bu Y AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China. FAU - Yu, Lei AU - Yu L AD - Department of Infectious Diseases, The Fourth Hospital of Harbin Medical University, Harbin 150001, Heilongjiang Province, China. FAU - Nan, Yi AU - Nan Y AD - Key Laboratory of Hui Ethnic Medicine Modernization of Ministry of Education, Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China. 20080011@nxmu.edu.cn. LA - eng PT - Journal Article PL - United States TA - World J Gastroenterol JT - World journal of gastroenterology JID - 100883448 SB - IM MH - Animals MH - Apoptosis MH - Cell Line, Tumor MH - Cell Proliferation MH - *Gene Expression Regulation, Neoplastic MH - Mice MH - Mice, Inbred BALB C MH - Mice, Nude MH - Prognosis MH - *Stomach Neoplasms/genetics PMC - PMC8072187 OTO - NOTNLM OT - Apoptosis OT - Gastric carcinoma OT - Isobaric tags for relative and absolute quantification OT - MRPL35 OT - Proliferation OT - Tissue microarray COIS- Conflict-of-interest statement: All authors declare no financial or commercial conflict of interest. EDAT- 2021/05/11 06:00 MHDA- 2021/05/15 06:00 PMCR- 2021/04/28 CRDT- 2021/05/10 06:17 PHST- 2020/12/22 00:00 [received] PHST- 2021/02/04 00:00 [revised] PHST- 2021/03/11 00:00 [accepted] PHST- 2021/05/10 06:17 [entrez] PHST- 2021/05/11 06:00 [pubmed] PHST- 2021/05/15 06:00 [medline] PHST- 2021/04/28 00:00 [pmc-release] AID - 10.3748/wjg.v27.i16.1785 [doi] PST - ppublish SO - World J Gastroenterol. 2021 Apr 28;27(16):1785-1804. doi: 10.3748/wjg.v27.i16.1785. PMID- 41195842 OWN - NLM STAT- MEDLINE DCOM- 20251205 LR - 20251205 IS - 1473-0189 (Electronic) IS - 1473-0189 (Linking) VI - 25 IP - 24 DP - 2025 Dec 2 TI - Multiscale microfluidic platform with vacuum-driven chambers for automated high-volume ssDNA generation. PG - 6662-6672 LID - 10.1039/d5lc00785b [doi] AB - We present a multiscale microfluidic platform for automated high-volume single-stranded DNA (ssDNA) generation through plasmonic bead-based PCR. Central to the system are vacuum-driven chambers capable of handling fluid volumes in the tens of microliters-at least an order of magnitude larger than conventional microfluidic chambers. These chambers are seamlessly integrated with microfluidic components such as micromixers and pneumatically actuated microvalves, enabling precise fluidic transport in processing high volumes. This architecture overcomes limitations of pressure-driven flow in exchanging fluids in deep geometries. Direct vacuum access to these chambers improves fluid handling efficiency while reducing hardware complexity. We demonstrate the platform's capabilities through automated ssDNA preparation where plasmonic thermocycling is achieved via volumetric heating using gold nanorods dispersed in the reaction mixture. Magnetic beads functionalized with reverse primers facilitate selective amplification and effective strand separation. Despite the large reaction volume (20 μL), 20 PCR cycles are completed within 12 minutes. Fluorescence-based assays confirm 66% recovery of ssDNA from the beads, with 92% retention of complementary strands, indicating minimal contamination by double-stranded DNA (dsDNA). This multiscale integration of vacuum-driven chambers with microfluidic control offers a scalable and automated platform for preparative applications where high-volume processing is essential. FAU - Hu, Anni AU - Hu A AD - Department of Chemical and Biological Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, SAR, China. eelyobas@ust.hk. FAU - Bu, Yang AU - Bu Y AD - Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, SAR, China. FAU - Liu, Yuze AU - Liu Y AD - Department of Chemical and Biological Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, SAR, China. eelyobas@ust.hk. FAU - Lee, Yung Ching AU - Lee YC AUID- ORCID: 0009-0002-1968-1005 AD - Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, SAR, China. FAU - Ni, Sheng AU - Ni S AUID- ORCID: 0000-0002-1786-7466 AD - Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, SAR, China. FAU - Yobas, Levent AU - Yobas L AUID- ORCID: 0000-0003-3151-5616 AD - Department of Chemical and Biological Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, SAR, China. eelyobas@ust.hk. AD - Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, SAR, China. LA - eng PT - Journal Article DEP - 20251202 PL - England TA - Lab Chip JT - Lab on a chip JID - 101128948 RN - 0 (DNA, Single-Stranded) RN - 7440-57-5 (Gold) SB - IM MH - *DNA, Single-Stranded/chemistry MH - Vacuum MH - *Microfluidic Analytical Techniques/instrumentation MH - Gold/chemistry MH - Polymerase Chain Reaction/instrumentation MH - Automation MH - Equipment Design MH - *Lab-On-A-Chip Devices EDAT- 2025/11/06 12:32 MHDA- 2025/12/05 06:27 CRDT- 2025/11/06 07:43 PHST- 2025/12/05 06:27 [medline] PHST- 2025/11/06 12:32 [pubmed] PHST- 2025/11/06 07:43 [entrez] AID - 10.1039/d5lc00785b [doi] PST - epublish SO - Lab Chip. 2025 Dec 2;25(24):6662-6672. doi: 10.1039/d5lc00785b. PMID- 29581592 OWN - NLM STAT- MEDLINE DCOM- 20191025 LR - 20191025 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 8 IP - 1 DP - 2018 Mar 26 TI - Passively Driven Probe Based on Miniaturized Propeller for Intravascular Optical Coherence Tomography. PG - 5150 LID - 10.1038/s41598-018-23547-4 [doi] LID - 5150 AB - Optical coherent tomography (OCT) has enabled clinical applications ranging from ophthalmology to cardiology that revolutionized in vivo medical diagnostics in the last few decades, and a variety of endoscopic probes have been developed in order to meet the needs of various endoscopic OCT imaging. We propose a passive driven intravascular optical coherent tomography (IV-OCT) probe in this paper. Instead of using any electrically driven scanning device, the probe makes use of the kinetic energy of the fluid that flushes away the blood during the intravascular optical coherence tomography imaging. The probe converts it into the rotational kinetic energy of the propeller, and the rotation of the rectangular prism mounted on the propeller shaft enables the scanning of the beam. The probe is low cost, and enables unobstructed stable circumferential scanning over 360 deg. The experimental results show that the probe scanning speed can exceed 100 rotations per second (rps). Spectral-domain OCT imaging of a phantom and porcine cardiac artery are demonstrated with axial resolution of 13.6 μm, lateral resolution of 22 μm, and sensitivity of 101.7 dB. We present technically the passively driven IV-OCT probe in full detail and discuss how to optimize the probe in further. FAU - Lu, Yu AU - Lu Y AD - Laboratory of Information Optics and Opto-Electronic Technology, Shanghai Institute of Optics and Fine Mechanics, Chinese Academy of Sciences, Shanghai, 201800, China. AD - University of Chinese Academy of Sciences, Beijing, 100049, China. FAU - Li, Zhongliang AU - Li Z AD - Laboratory of Information Optics and Opto-Electronic Technology, Shanghai Institute of Optics and Fine Mechanics, Chinese Academy of Sciences, Shanghai, 201800, China. lizhongliang@siom.ac.cn. AD - University of Chinese Academy of Sciences, Beijing, 100049, China. lizhongliang@siom.ac.cn. FAU - Nan, Nan AU - Nan N AD - Laboratory of Information Optics and Opto-Electronic Technology, Shanghai Institute of Optics and Fine Mechanics, Chinese Academy of Sciences, Shanghai, 201800, China. FAU - Bu, Yang AU - Bu Y AD - Laboratory of Information Optics and Opto-Electronic Technology, Shanghai Institute of Optics and Fine Mechanics, Chinese Academy of Sciences, Shanghai, 201800, China. AD - University of Chinese Academy of Sciences, Beijing, 100049, China. FAU - Liu, Xuebo AU - Liu X AD - Department of Cardiology, Tongji Hospital, Tongji University, Shanghai, 200065, China. FAU - Xu, Xiangdong AU - Xu X AD - Cardiovascular department, Central hospital of Jiading District, Hospital affiliated to shanghai university of medicine and health sciences, Shanghai, 201800, China. FAU - Wang, Xuan AU - Wang X AD - Laboratory of Information Optics and Opto-Electronic Technology, Shanghai Institute of Optics and Fine Mechanics, Chinese Academy of Sciences, Shanghai, 201800, China. AD - University of Chinese Academy of Sciences, Beijing, 100049, China. FAU - Sasaki, Osami AU - Sasaki O AD - Faculty of Engineering, Niigata University, Niigata-shi, 9502181, Japan. FAU - Wang, Xiangzhao AU - Wang X AD - Laboratory of Information Optics and Opto-Electronic Technology, Shanghai Institute of Optics and Fine Mechanics, Chinese Academy of Sciences, Shanghai, 201800, China. wxz26267@siom.ac.cn. AD - University of Chinese Academy of Sciences, Beijing, 100049, China. wxz26267@siom.ac.cn. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20180326 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Abattoirs MH - Angioscopy/*methods MH - Animals MH - Coronary Vessels/diagnostic imaging MH - Equipment Design/*methods MH - Heart MH - Kinetics MH - Phantoms, Imaging MH - Rotation MH - Swine MH - Tomography, Optical Coherence/economics/*instrumentation/*methods PMC - PMC5980104 COIS- The authors declare no competing interests. EDAT- 2018/03/28 06:00 MHDA- 2019/10/28 06:00 PMCR- 2018/03/26 CRDT- 2018/03/28 06:00 PHST- 2017/10/02 00:00 [received] PHST- 2018/02/21 00:00 [accepted] PHST- 2018/03/28 06:00 [entrez] PHST- 2018/03/28 06:00 [pubmed] PHST- 2019/10/28 06:00 [medline] PHST- 2018/03/26 00:00 [pmc-release] AID - 10.1038/s41598-018-23547-4 [pii] AID - 23547 [pii] AID - 10.1038/s41598-018-23547-4 [doi] PST - epublish SO - Sci Rep. 2018 Mar 26;8(1):5150. doi: 10.1038/s41598-018-23547-4. PMID- 32400477 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200513 IS - 1539-4522 (Electronic) IS - 1559-128X (Linking) VI - 59 IP - 12 DP - 2020 Apr 20 TI - Micromirror array allocation algorithm based on deconvolution. PG - 3582-3588 LID - 10.1364/AO.389891 [doi] AB - Freeform illumination is one of the necessary techniques in 28 nm technology nodes and beyond. The micromirror array (MMA) has been widely used in lithography freeform illumination systems due to its programmability and high free degree. The MMA allocation algorithm is the key to generate the target freeform illumination source. Its computational speed and precision affect the generation speed and precision of the target illumination source as well as the process window size of the generated illumination pupil directly. In this paper, an MMA allocation method based on deconvolution is proposed. The target freeform illumination source can be obtained directly with the deconvolution and quantization processes. Without the iterative optimization process, the computational speed of the proposed method is much faster than that of the traditional method. The numerical simulation results show that the difference between the target source and the MMA source generated using the proposed method is less than 0.2%. Compared with the process window loss of the target source, the process window loss of the MMA source generated by the proposed deconvolution method is less than 0.5%. Compared with the traditional allocation method, the runtime of the proposed method is less than 0.05 s and has improved by 1463 times. FAU - Liu, Zhifan AU - Liu Z FAU - Yang, Chaoxing AU - Yang C FAU - Bu, Yang AU - Bu Y FAU - Li, Sikun AU - Li S FAU - Zhang, Jianhua AU - Zhang J FAU - Wang, Xiangzhao AU - Wang X FAU - Sun, Gang AU - Sun G LA - eng PT - Journal Article PL - United States TA - Appl Opt JT - Applied optics JID - 0247660 SB - IM EDAT- 2020/05/14 06:00 MHDA- 2020/05/14 06:01 CRDT- 2020/05/14 06:00 PHST- 2020/05/14 06:00 [entrez] PHST- 2020/05/14 06:00 [pubmed] PHST- 2020/05/14 06:01 [medline] AID - 430118 [pii] AID - 10.1364/AO.389891 [doi] PST - ppublish SO - Appl Opt. 2020 Apr 20;59(12):3582-3588. doi: 10.1364/AO.389891. PMID- 26517671 OWN - NLM STAT- MEDLINE DCOM- 20160920 LR - 20181113 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 6 IP - 37 DP - 2015 Nov 24 TI - The herbal compound Songyou Yin (SYY) inhibits hepatocellular carcinoma growth and improves survival in models of chronic fibrosis via paracrine inhibition of activated hepatic stellate cells. PG - 40068-80 LID - 10.18632/oncotarget.5313 [doi] AB - Chronic fibrosis is a major risk factor for the development of hepatocellular carcinoma (HCC). The pathological progression of hepatic fibrosis has been linked to cellular processes that promote tumor growth and metastasis. Several recent studies have highlighted the cross-talk between tumor cells and activated hepatic stellate cells (aHSCs) in HCC. The herbal compound Songyou Yin (SYY) is known to attenuate hepatoma cell invasion and metastasis via down-regulation of cytokine secretion by aHSCs. However the underlying mechanism of SYY treatment in reversal of hepatic fibrosis and metastasis of liver cancers is not known. In the current study, a nude mouse model with liver fibrosis bearing orthotopic xenograft was established and we found that SYY could reduce associated fibrosis, inhibit tumor growth and improve survival. In the subcutaneous tumor model with fibrosis, we found that SYY could inhibit liver cancer. In vitro, hepatoma cells incubated with conditioned media (CM) from SYY treated aHSCs showed reduced proliferation, decrease in colony formation and invasive potential. SYY treated group showed altered gene expression, with 1205 genes up-regulated and 1323 genes down-regulated. Gene cluster analysis indicated that phosphatidylinositol-3-kinase (PI3K) was one of the key genes altered in the expression profiles. PI3K related markers were all significantly down-regulated. ELISA also indicated decreased secretion of cytokines which were regulated by PI3K/AKT signaling after SYY treatment in the hepatic stellate cell line, LX2. These data clearly demonstrate that SYY therapy inhibits HCC invasive and metastatic potential and improves survival in nude mice models with chronic fibrosis background via inhibition of cytokine secretion by activated hepatic stellate cells. FAU - Bu, Yang AU - Bu Y AD - Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan 750001, China. AD - Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai 200032, China. FAU - Jia, Qing-An AU - Jia QA AD - Cancer Center, Institutes of Biomedical Sciences, General Surgery, Huashan Hospital, Fudan University, Shanghai 200032, China. FAU - Ren, Zheng-Gang AU - Ren ZG AD - Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai 200032, China. FAU - Xue, Tong-Chun AU - Xue TC AD - Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai 200032, China. FAU - Zhang, Quan-Bao AU - Zhang QB AD - Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai 200032, China. FAU - Zhang, Ke-Zhi AU - Zhang KZ AD - Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai 200032, China. FAU - Zhang, Qiang-Bo AU - Zhang QB AD - Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai 200032, China. FAU - You, Yang AU - You Y AD - Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai 200032, China. FAU - Tian, Hui AU - Tian H AD - Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai 200032, China. FAU - Qin, Lun-Xiu AU - Qin LX AD - Cancer Center, Institutes of Biomedical Sciences, General Surgery, Huashan Hospital, Fudan University, Shanghai 200032, China. FAU - Tang, Zhao-You AU - Tang ZY AD - Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai 200032, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 RN - 0 (Cytokines) RN - 0 (Drugs, Chinese Herbal) RN - 0 (songyou yin) RN - EC 2.7.1.- (Phosphatidylinositol 3-Kinases) RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) SB - IM MH - Animals MH - Blotting, Western MH - Carcinoma, Hepatocellular/genetics/metabolism/*prevention & control MH - Cell Line MH - Cell Line, Tumor MH - Chronic Disease MH - Cytokines/genetics/metabolism MH - Drugs, Chinese Herbal/*pharmacology MH - Gene Expression Regulation, Neoplastic/drug effects MH - Hepatic Stellate Cells/*drug effects/metabolism MH - Humans MH - Liver Cirrhosis/*drug therapy/genetics/metabolism MH - Liver Neoplasms/genetics/metabolism/*prevention & control MH - Male MH - Mice, Inbred BALB C MH - Mice, Nude MH - Paracrine Communication/drug effects/genetics MH - Phosphatidylinositol 3-Kinases/genetics/metabolism MH - Phytotherapy/methods MH - Proto-Oncogene Proteins c-akt/genetics/metabolism MH - Reverse Transcriptase Polymerase Chain Reaction MH - Signal Transduction/drug effects/genetics MH - Survival Analysis MH - Tumor Burden/drug effects/genetics MH - Xenograft Model Antitumor Assays PMC - PMC4741880 OTO - NOTNLM OT - Songyou Yin OT - activated hepatic stellate cells OT - chronic fibrosis OT - hepatocellular carcinoma COIS- CONFLICTS OF INTERESTS The authors declare that they have no competing interests. EDAT- 2015/10/31 06:00 MHDA- 2016/09/22 06:00 PMCR- 2015/11/24 CRDT- 2015/10/31 06:00 PHST- 2014/04/08 00:00 [received] PHST- 2015/10/09 00:00 [accepted] PHST- 2015/10/31 06:00 [entrez] PHST- 2015/10/31 06:00 [pubmed] PHST- 2016/09/22 06:00 [medline] PHST- 2015/11/24 00:00 [pmc-release] AID - 5313 [pii] AID - 10.18632/oncotarget.5313 [doi] PST - ppublish SO - Oncotarget. 2015 Nov 24;6(37):40068-80. doi: 10.18632/oncotarget.5313. PMID- 33235099 OWN - NLM STAT- MEDLINE DCOM- 20201210 LR - 20201214 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 99 IP - 48 DP - 2020 Nov 25 TI - Prognostic value of γ-glutamyl transpeptidase to albumin ratio combined with aspartate aminotransferase to lymphocyte ratio in patients with hepatocellular carcinoma after hepatectomy. PG - e23339 LID - 10.1097/MD.0000000000023339 [doi] LID - e23339 AB - Hepatocellular carcinoma (HCC) is a malignant tumor associated with a high recurrence rate after hepatectomy. Recently, preoperative inflammatory and liver function reserve indices were found to predict increased risk of recurrence and decreased survival in HCC patients. This study aims to evaluate the ability of the γ-glutamyl transpeptidase-to-albumin ratio (GAR) and aspartate aminotransferase-to-lymphocyte ratio (ALRI), individually and in combination, to predict the prognosis of HCC patients after hepatectomy.We retrospectively reviewed 206 HCC patients who underwent radical resection at the General Hospital of Ningxia Medical University from January 2011 to November 2016. Receiver operating characteristic (ROC) curve analysis was performed to determine the optimal cut-off value for GAR and ALRI. The Pearson Chi-Squared test was used to analyze the correlations between GAR, ALRI and clinicopathological characteristics. Univariate and multivariate analyses were used to determine the predictive value of these factors for disease-free survival (DFS) and overall survival (OS). Survival rates were drawn according to the Kaplan-Meier method and differences between subgroups were compared by the log-rank statistics.GAR and ALRI were significantly correlated with gender, history of smoking, prothrombin time, tumor diameter, T stage and early intrahepatic recurrence by the Pearson Chi-Squared test (all P < .05). Univariate analysis indicated that T stage, GAR and ALRI were significantly correlated with DFS and OS in HCC patients after hepatectomy. Multivariate analysis illustrated that GAR and ALRI were independently related to DFS and OS in HCC patients. Preoperative GAR > 0.946 or ALRI > 18.734 predicted poor prognosis in HCC patients after hepatectomy. Additionally, the predictive scope of GAR combined with ALRI was more sensitive than that of either individual measurement alone.Our data indicate that there is a close association between the clinicopathological characteristics in HCC patients and increased GAR or ALRI. Higher levels of GAR and ALRI could sensitively and specifically predict a poor prognosis in HCC patients after hepatectomy. Furthermore, combined usage of GAR and ALRI could improve the accuracy of this prediction. FAU - Liu, Ke-Jun AU - Liu KJ AD - School of Clinical Medicine, Ningxia Medical University. FAU - Lv, Yong-Xue AU - Lv YX AD - School of Basic Medicine, Ningxia Medical University. FAU - Niu, Yi-Ming AU - Niu YM AD - School of Clinical Medicine, Ningxia Medical University. FAU - Bu, Yang AU - Bu Y AD - School of Clinical Medicine, Ningxia Medical University. AD - Department of Hepatobiliary Surgery, People's Hospital of Ningxia Hui Autonomous Region, Ningxia, China. LA - eng PT - Journal Article PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R RN - 0 (Biomarkers) RN - 0 (Serum Albumin) RN - EC 2.3.2.2 (gamma-Glutamyltransferase) RN - EC 2.6.1.1 (Aspartate Aminotransferases) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Alcohol Drinking/epidemiology MH - Aspartate Aminotransferases/blood MH - Biomarkers MH - Carcinoma, Hepatocellular/*blood/epidemiology/mortality/*surgery MH - Female MH - Hepatectomy MH - Humans MH - Kaplan-Meier Estimate MH - Liver Neoplasms/*blood/epidemiology/mortality/*surgery MH - Lymphocytes/metabolism MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/epidemiology MH - Prognosis MH - ROC Curve MH - Retrospective Studies MH - Serum Albumin/analysis MH - Sex Factors MH - Smoking/epidemiology MH - gamma-Glutamyltransferase/blood PMC - PMC7710195 COIS- The authors declare no conflicts of interest. EDAT- 2020/11/26 06:00 MHDA- 2020/12/15 06:00 PMCR- 2020/11/25 CRDT- 2020/11/25 05:39 PHST- 2020/11/25 05:39 [entrez] PHST- 2020/11/26 06:00 [pubmed] PHST- 2020/12/15 06:00 [medline] PHST- 2020/11/25 00:00 [pmc-release] AID - 00005792-202011250-00047 [pii] AID - MD-D-20-04424 [pii] AID - 10.1097/MD.0000000000023339 [doi] PST - ppublish SO - Medicine (Baltimore). 2020 Nov 25;99(48):e23339. doi: 10.1097/MD.0000000000023339. PMID- 31805888 OWN - NLM STAT- MEDLINE DCOM- 20200402 LR - 20200402 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 19 IP - 1 DP - 2019 Dec 5 TI - Remodeling of hepatic stellate cells orchestrated the stroma-derived oxaliplatin-resistance through CCN3 paracrine in hepatocellular carcinoma. PG - 1192 LID - 10.1186/s12885-019-6362-1 [doi] LID - 1192 AB - BACKGROUND: Hepatic stellate cells (HSCs) have a key role in fibrogenesis and in the filtrates of the hepatocellular carcinoma (HCC) stroma, in which they are remodeled and play a critical role in HCC progression. However, the precise role of HSCs trending, infiltration and paracrine in orchestrating the stroma-derived oxaliplatin-resistance in HCC is still vague. METHODS: The chemo-resistant models were established to explore the correlation between HSC cells and the condition of chemoresistance. The HCC clinical samples were collected to confirm this phenomenon. Then, the relationship between secretory CCN3 from oxaliplatin-resistant HCC and the infiltration of HSCs in associated HCC microenvironment was evaluated. Finally, the role and mechanism of HSCs remodeling in the orchestration of oxaliplatin-resistant HCC were explored. RESULTS: The increased infiltration of HSCs and collagen accumulation were found in the microenvironment of oxaliplatin-resistant HCC. The cDNA profiles of the oxaliplatin-resistant HCC was reanalyzed, and CCN3 was one of the significantly increased genes. In HCC clinical samples, the levels of CCN3 and α-SMA are positively correlated, and high expression of CCN3 and α-SMA are positively associated with malignant phenotype and poor prognosis. Then the enhanced abilities of migration and proliferation of HSCs, and elevation of the cytokines paracrine from HSCs relating to HCC malignancy were proved in vitro and in vivo, and which were related to CCN3-ERK signaling pathway activation. CONCLUSIONS: HSCs remodeling are positively related to CCN3 paracrine in hepatocellular carcinoma, which orchestrated the stroma-derived resistance to chemotherapy in HCC. FAU - Liao, Xia AU - Liao X AD - Department of Nutrition, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China. FAU - Bu, Yang AU - Bu Y AD - Department of Hepatobiliary Surgery, General Hospital, Ningxia Medical University, Yinchuan, 750001, China. FAU - Chang, Fan AU - Chang F AD - Metabolite Research Center, Shaanxi Institute of Microbiology, Xi'an, 710043, China. FAU - Jia, Fengan AU - Jia F AD - Metabolite Research Center, Shaanxi Institute of Microbiology, Xi'an, 710043, China. FAU - Song, Ge AU - Song G AD - Department of Nutrition, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China. FAU - Xiao, Xuelian AU - Xiao X AD - Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi'an Jiaotong University, 277 West Yanta Road, Xi'an, 710061, China. FAU - Zhang, Mei AU - Zhang M AD - Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi'an Jiaotong University, 277 West Yanta Road, Xi'an, 710061, China. FAU - Ning, Pengbo AU - Ning P AD - School of Life Science and Technology, Xidian University, Xi'an, Shaanxi, China. FAU - Jia, Qingan AU - Jia Q AUID- ORCID: 0000-0002-3256-7197 AD - Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi'an Jiaotong University, 277 West Yanta Road, Xi'an, 710061, China. qajia66@163.com. LA - eng GR - 81502694/National Natural Science Foundation of China/ GR - 1191329835/Fundamental Research Funds for the Central Universities/ GR - 2015M570330/Postdoctoral Science Foundation of China/ GR - NZ15130/Key projects of Ningxia Natural Science Foundation/ PT - Journal Article DEP - 20191205 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (ACTA2 protein, human) RN - 0 (Actins) RN - 0 (CCN3 protein, human) RN - 0 (Nephroblastoma Overexpressed Protein) RN - 04ZR38536J (Oxaliplatin) RN - 9007-34-5 (Collagen) SB - IM MH - Actins/genetics MH - Animals MH - Carcinoma, Hepatocellular/genetics/metabolism/*pathology MH - Cell Line, Tumor MH - Cell Movement MH - Cell Proliferation MH - Collagen/metabolism MH - Disease Progression MH - *Drug Resistance, Neoplasm MH - Female MH - Gene Expression Regulation, Neoplastic MH - Hepatic Stellate Cells/metabolism/*pathology MH - Humans MH - Liver Neoplasms/genetics/metabolism/*pathology MH - Male MH - Mice MH - Neoplasm Transplantation MH - Nephroblastoma Overexpressed Protein/*genetics/*metabolism MH - Oxaliplatin MH - Paracrine Communication MH - Prognosis MH - Tumor Microenvironment MH - Up-Regulation PMC - PMC6896671 OTO - NOTNLM OT - CCN3 OT - Hepatic stellate cells OT - Hepatocellular carcinoma OT - Microenvironment OT - Oxaliplatin resistance COIS- The authors declare that they have no competing interests. EDAT- 2019/12/07 06:00 MHDA- 2020/04/03 06:00 PMCR- 2019/12/05 CRDT- 2019/12/07 06:00 PHST- 2019/04/24 00:00 [received] PHST- 2019/11/14 00:00 [accepted] PHST- 2019/12/07 06:00 [entrez] PHST- 2019/12/07 06:00 [pubmed] PHST- 2020/04/03 06:00 [medline] PHST- 2019/12/05 00:00 [pmc-release] AID - 10.1186/s12885-019-6362-1 [pii] AID - 6362 [pii] AID - 10.1186/s12885-019-6362-1 [doi] PST - epublish SO - BMC Cancer. 2019 Dec 5;19(1):1192. doi: 10.1186/s12885-019-6362-1. PMID- 23549843 OWN - NLM STAT- MEDLINE DCOM- 20130930 LR - 20240318 IS - 1862-1783 (Electronic) IS - 1673-1581 (Print) IS - 1673-1581 (Linking) VI - 14 IP - 4 DP - 2013 Apr TI - Organic nitrogen components in soils from southeast China. PG - 259-69 LID - 10.1631/jzus.B1200104 [doi] AB - OBJECTIVE: To investigate the amounts of extractable organic nitrogen (EON), and the relationships between EON and total extractable nitrogen (TEN), especially the amino acids (AAs) adsorbed by soils, and a series of other hydrolyzed soil nitrogen indices in typical land use soil types from southeast China. Under traditional agricultural planting conditions, the functions of EON, especially AAs in the rhizosphere and in bulk soil zones were also investigated. METHODS: Pot experiments were conducted using plants of pakchoi (Brassica chinensis L.) and rice (Oryza sativa L.). In the rhizosphere and bulk soil zone studies, organic nitrogen components were extracted with either distilled water, 0.5 mol/L K2SO4 or acid hydrolysis. RESULTS: K2SO4-EON constituted more than 30% of TEN pools. K2SO4-extractable AAs accounted for 25% of EON pools and nearly 10% of TEN pools in rhizosphere soils. Overall, both K2SO4-EON and extractable AAs contents had positive correlations with TEN pools. CONCLUSIONS: EON represented a major component of TEN pools in garden and paddy soils under traditional planting conditions. Although only a small proportion of the EON was present in the form of water-extractable and K2SO4-extractable AAs, the release of AAs from soil exchangeable sites might be an important source of organic nitrogen (N) for plant growth. Our findings suggest that the content of most organic forms of N was significantly greater in rhizosphere than in bulk soil zone samples. However, it was also apparent that the TEN pool content was lower in rhizosphere than in bulk soil samples without added N. FAU - Chen, Xian-you AU - Chen XY AD - Ministry of Education Key Laboratory of Environmental Remediation and Ecosystem Health, College of Environmental and Resource Sciences, Zhejiang University, Hangzhou 310058, China. FAU - Wu, Liang-huan AU - Wu LH FAU - Cao, Xiao-chuang AU - Cao XC FAU - Zhu, Yuan-hong AU - Zhu YH LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - China TA - J Zhejiang Univ Sci B JT - Journal of Zhejiang University. Science. B JID - 101236535 RN - 0 (Amino Acids) RN - 0 (Organic Chemicals) RN - 0 (Soil) RN - N762921K75 (Nitrogen) SB - IM MH - Amino Acids/*analysis MH - China MH - Nitrogen/*analysis MH - Organic Chemicals/*analysis MH - Rhizome/*chemistry MH - Soil/*analysis/*chemistry PMC - PMC3625522 COIS- Compliance with ethics guidelines: Xian-you CHEN, Liang-huan WU, Xiao-chuang CAO, and Yuan-hong ZHU declare that they have no conflict of interest. This article does not contain any studies with human or animal subjects performed by any of the authors. EDAT- 2013/04/04 06:00 MHDA- 2013/10/01 06:00 PMCR- 2013/04/01 CRDT- 2013/04/04 06:00 PHST- 2013/04/04 06:00 [entrez] PHST- 2013/04/04 06:00 [pubmed] PHST- 2013/10/01 06:00 [medline] PHST- 2013/04/01 00:00 [pmc-release] AID - 10.1631/jzus.B1200104 [doi] PST - ppublish SO - J Zhejiang Univ Sci B. 2013 Apr;14(4):259-69. doi: 10.1631/jzus.B1200104. PMID- 30069985 OWN - NLM STAT- MEDLINE DCOM- 20181001 LR - 20210109 IS - 1365-2184 (Electronic) IS - 0960-7722 (Print) IS - 0960-7722 (Linking) VI - 51 IP - 5 DP - 2018 Oct TI - Roflumilast enhances cisplatin-sensitivity and reverses cisplatin-resistance of ovarian cancer cells via cAMP/PKA/CREB-FtMt signalling axis. PG - e12474 LID - 10.1111/cpr.12474 [doi] LID - e12474 AB - OBJECTIVE: We previously demonstrated the roflumilast inhibited cell proliferation and increased cell apoptosis in ovarian cancer. In this study, we aimed to investigate the roles of roflumilast in development of cisplatin (DDP)-sensitive and -resistant ovarian cancer. METHODS: OVCAR3 and SKOV3 were selected and the corresponding DDP-resistant cells were constructed. Cell viability, proliferation, apoptosis, cycle were performed. Expression cAMP, PKA, CREB, phosphorylation of CREB and FtMt were detected. The roles of roflumilast in development of DDP-sensitive and -resistant ovarian cancer were confirmed by xenograft model. RESULTS: Roflumilast + DDP inhibited cell proliferation, and induced cell apoptosis and G0/G1 arrest in OVCAR3 and SKOV3 cells, roflumilast induced expression of FtMt, the activity of cAMP and PKA and phosphorylation of CREB in ovarian cancer cells and the above-effect were inhibited by H89. Downregulation of CREB inhibited the roflumilast-increased DDP sensitivity of ovarian cancer cells, and the roflumilast-induced FtMt expression and phosphorylation of CREB. Also, roflumilast reversed cisplatin-resistance, and induced expression of FtMt and activation of cAMP/PKA/CREB in DDP-resistant ovarian cancer cells. Similarly, treated with H89 or downregulation of CREB inhibited the changes induced by roflumilast. In vivo, roflumilast inhibited the development of SKOV3 or SKOV3-DDP-R xenograft models. CONCLUSIONS: Roflumilast enhanced DDP sensitivity and reversed the DDP resistance of ovarian cancer cells via activation of cAMP/PKA/CREB pathway and upregulation of the downstream FtMt expression, which has great promise in clinical treatment. CI - © 2018 John Wiley & Sons Ltd. FAU - Gong, Shipeng AU - Gong S AUID- ORCID: 0000-0003-2620-221X AD - Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China. FAU - Chen, Yongning AU - Chen Y AD - Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China. FAU - Meng, Fanliang AU - Meng F AD - Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China. FAU - Zhang, Yadi AU - Zhang Y AD - Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China. FAU - Li, Chanyuan AU - Li C AD - Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China. FAU - Zhang, Guangping AU - Zhang G AD - Department of Gynecology, People's Hospital of Huadu District, Guangzhou, China. FAU - Huan, Wu AU - Huan W AD - Department of Obstetrics and Gynecology, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. FAU - Wu, Fei AU - Wu F AD - Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China. LA - eng SI - GENBANK/ab66111 SI - GENBANK/ab124889 SI - GENBANK/ab32096 SI - GENBANK/BS12478 SI - GENBANK/BS13278 GR - HD15CXY006/Science and Technology Bureau of Huadu District/ GR - 201604KW010/Science and Technology Bureau of Tianhe District/ GR - 81402127/National Natural Science Foundation of China/ GR - 2016A020215115/Guangdong Science and Technology Department/ PT - Journal Article DEP - 20180802 PL - England TA - Cell Prolif JT - Cell proliferation JID - 9105195 RN - 0 (Aminopyridines) RN - 0 (Antineoplastic Agents) RN - 0 (Benzamides) RN - 0 (CREB1 protein, human) RN - 0 (Cyclic AMP Response Element-Binding Protein) RN - 0 (Cyclopropanes) RN - 0 (Mitochondrial Proteins) RN - 0 (mitochondrial ferritin, human) RN - 0P6C6ZOP5U (Roflumilast) RN - 9007-73-2 (Ferritins) RN - E0399OZS9N (Cyclic AMP) RN - EC 2.7.11.11 (Cyclic AMP-Dependent Protein Kinases) RN - Q20Q21Q62J (Cisplatin) SB - IM MH - Aminopyridines/*pharmacology MH - Antineoplastic Agents/pharmacology MH - Apoptosis/drug effects MH - Benzamides/*pharmacology MH - Cell Cycle Checkpoints/drug effects MH - Cell Line, Tumor MH - Cell Proliferation/drug effects MH - Cisplatin/*pharmacology MH - Cyclic AMP/*metabolism MH - Cyclic AMP Response Element-Binding Protein/*metabolism MH - Cyclic AMP-Dependent Protein Kinases/*metabolism MH - Cyclopropanes/pharmacology MH - Down-Regulation/drug effects MH - Drug Resistance, Neoplasm/*drug effects MH - Female MH - Ferritins/*metabolism MH - G1 Phase/drug effects MH - Humans MH - Mitochondrial Proteins/*metabolism MH - Ovarian Neoplasms/*drug therapy/metabolism MH - Resting Phase, Cell Cycle/drug effects MH - Signal Transduction/drug effects PMC - PMC6528923 COIS- No competing financial interests exist. EDAT- 2018/08/03 06:00 MHDA- 2018/10/03 06:00 PMCR- 2018/08/02 CRDT- 2018/08/03 06:00 PHST- 2017/12/26 00:00 [received] PHST- 2018/03/30 00:00 [accepted] PHST- 2018/08/03 06:00 [pubmed] PHST- 2018/10/03 06:00 [medline] PHST- 2018/08/03 06:00 [entrez] PHST- 2018/08/02 00:00 [pmc-release] AID - CPR12474 [pii] AID - 10.1111/cpr.12474 [doi] PST - ppublish SO - Cell Prolif. 2018 Oct;51(5):e12474. doi: 10.1111/cpr.12474. Epub 2018 Aug 2. PMID- 31029128 OWN - NLM STAT- MEDLINE DCOM- 20190826 LR - 20200225 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 19 IP - 1 DP - 2019 Apr 27 TI - Paracrine effects of CCN3 from non-cancerous hepatic cells increase signaling and progression of hepatocellular carcinoma. PG - 395 LID - 10.1186/s12885-019-5603-7 [doi] LID - 395 AB - BACKGROUND: The liver microenvironment plays a key role in the progression and metastasis of hepatocellular carcinoma (HCC). Gene expression profiling of non-cancerous hepatic tissues obtained from patients with metastatic HCC exhibit a unique immune response signature, including upregulation of CCN3. However, the role of CCN3 secreted from non-cancerous hepatic tissues in the progression of HCC remains unclear. METHODS: Using tissue microarrays, we examined CCN3 in non-cancerous hepatic tissues of patients with HCC and correlated expression with clinical and pathological features. In addition, CCN3 localization and mechanisms of HCC progression were investigated in tissues and cell lines. Finally, correlations between CCN3 and cirrhosis were explored in patients. RESULTS: CCN3 was primarily localized to hepatic cells of non-cancerous hepatic tissues and was associated with vascular invasion and poor prognosis in patients with HCC. CCN3 expression in non-cancerous hepatic tissues also correlated with the degree of liver fibrosis. Compared with conditioned media from wild-type LO2 cells, conditioned media from hepatic cell line LO2 activated by LX2 (aLO2-CM) induced CCN3 expression and HCC cell proliferation and metastasis. Further, aLO2-CM activated MAPK signaling and epithelial-mesenchymal transition in HCC cells. Finally, CCN3 was inversely related to cirrhosis in the prognosis of HCC and negatively regulated hepatic stellate cells (HSCs) in vitro with downregulation of α-SMA, TGF-β, and collagens. CONCLUSIONS: CCN3 was secreted from hepatic cells activated by HSCs and increased MAPK signaling, EMT, proliferation and metastasis of HCC cells. CCN3 was also inversely related to cirrhosis, regulating HSCs through a negative feedback loop. FAU - Li, Weimin AU - Li W AD - Department of Nutrition, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China. FAU - Liao, Xia AU - Liao X AD - Department of Nutrition, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China. FAU - Ning, Pengbo AU - Ning P AD - School of Life Science and Technology, Xidian University, Xi'an, Shaanxi, China. FAU - Cao, Yu AU - Cao Y AD - Department of pediatrics, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China. FAU - Zhang, Mei AU - Zhang M AD - Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi'an Jiaotong University, 277 West Yanta Road, Xi'an, 710061, China. FAU - Bu, Yang AU - Bu Y AD - Department of Hepatobiliary Surgery, General Hospital, Ningxia Medical University, Yinchuan, 750001, China. FAU - Lv, Jun AU - Lv J AD - Clinical Research Center of Xi'an Jiaotong University, Xi'an, 710061, China. FAU - Jia, Qingan AU - Jia Q AD - Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi'an Jiaotong University, 277 West Yanta Road, Xi'an, 710061, China. qajia66@163.com. LA - eng GR - 81502694/National Natural Science Foundation of China/ GR - 2015M570330/Postdoctoral Research Foundation of China/ GR - 1191329835/Research Funds for the Central Universities/ GR - NZ15130/Key projects of Ningxia Natural Science Foundation/ PT - Journal Article DEP - 20190427 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (Nephroblastoma Overexpressed Protein) MH - Carcinoma, Hepatocellular/*genetics/metabolism/pathology MH - Cell Line, Tumor MH - Disease Progression MH - Female MH - Gene Expression Profiling MH - Gene Expression Regulation, Neoplastic MH - Hepatocytes/*metabolism/pathology MH - Humans MH - Liver Cirrhosis/genetics/metabolism/pathology MH - Liver Neoplasms/*genetics/metabolism/pathology MH - Male MH - Middle Aged MH - Nephroblastoma Overexpressed Protein/*genetics/metabolism MH - Paracrine Communication/genetics MH - Signal Transduction/genetics MH - Tumor Microenvironment/genetics PMC - PMC6486990 OTO - NOTNLM OT - CCN3 OT - Cirrhosis OT - Hepatic cell OT - Hepatocellular carcinoma COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Ethical approval was obtained from the Research Ethics Committee of Fudan University and written consent was obtained from each patient. CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. EDAT- 2019/04/29 06:00 MHDA- 2019/08/27 06:00 PMCR- 2019/04/27 CRDT- 2019/04/29 06:00 PHST- 2018/10/30 00:00 [received] PHST- 2019/04/12 00:00 [accepted] PHST- 2019/04/29 06:00 [entrez] PHST- 2019/04/29 06:00 [pubmed] PHST- 2019/08/27 06:00 [medline] PHST- 2019/04/27 00:00 [pmc-release] AID - 10.1186/s12885-019-5603-7 [pii] AID - 5603 [pii] AID - 10.1186/s12885-019-5603-7 [doi] PST - epublish SO - BMC Cancer. 2019 Apr 27;19(1):395. doi: 10.1186/s12885-019-5603-7. PMID- 24351817 OWN - NLM STAT- MEDLINE DCOM- 20140715 LR - 20211021 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 14 IP - 12 DP - 2013 Dec 13 TI - Effect of the GLP-1 analog exendin-4 and oxaliplatin on intrahepatic cholangiocarcinoma cell line and mouse model. PG - 24293-304 LID - 10.3390/ijms141224293 [doi] AB - The influence of Glucagon-like peptide-1 (GLP-1) and Exendin-4 on development of intrahepatic cholangiocarcinoma (ICC) is evaluated in the study. In vitro tests, including acute toxicity test, cell colony formation assays, cells proliferation and apoptosis, transwell assay, were performed. An ICC in situ tumor animal model was established. Then, animals were randomly divided into four groups (n = 6): control, Exendin-4 treatment, oxaliplatin treatment and Exendin-4-oxaliplatin treatment. Animals in the Exendin-4 treatment and Exendin-4-oxaliplatin treatment groups received a subcutaneous injection of Exendin-4 (100 μg/kg/day) for 1 week, and then received oxaliplatin (10 mg/kg/week) by tail vein injection. Animals in the control group received PBS. Immunohistochemistry tests were used for PCNA, Ki67, Caspase 3 expression in tumor tissue. Results show that that, after incubation of human cholangiocarcinoma cell lines, HuCCTI and GLP-1, or HuCCTI and Exendin-4, colony formation number was sharply decreased. However, GLP-1, HuCCTI or Exendin-4 did not affect the colony of normal cells. Combination treatment with oxaliplatin and Exendin-4 can significantly inhibit tumor cells' proliferation and promote apoptosis. The combined effect is stronger than that of oxaliplatin or Exendin-4. Combination treatment with oxaliplatin and Exendin4 can significantly decrease Ki67 and PCNA proteins' expression in subcutaneous tumors of nude mice. The inhibitory effect of Combination treatment with oxaliplatin and Exendin4 is clearly stronger than that of oxaliplatin. In addition, Combination treatment with oxaliplatin and Exendin4 can significantly increase Caspase3 protein positive expression. In short, these results show that combination treatment with oxaliplatin and Exendin4 can inhibit tumor cells' proliferation, and promote apoptosis. FAU - Chen, Ben-Dong AU - Chen BD FAU - Zhao, Wen-Chao AU - Zhao WC FAU - Jia, Qing-An AU - Jia QA FAU - Zhou, Wen-Yan AU - Zhou WY FAU - Bu, Yang AU - Bu Y FAU - Wang, Zuo-Zheng AU - Wang ZZ FAU - Wang, Feng AU - Wang F FAU - Wu, Wu-Jun AU - Wu WJ FAU - Wang, Qi AU - Wang Q AD - Department of Hepatobiliary Surgery, Ningxia Medical University, Yinchuan 750004, Ningxia, China. wangqnxmed@163.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20131213 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Ki-67 Antigen) RN - 0 (Organoplatinum Compounds) RN - 0 (Peptides) RN - 0 (Proliferating Cell Nuclear Antigen) RN - 0 (Venoms) RN - 04ZR38536J (Oxaliplatin) RN - 89750-14-1 (Glucagon-Like Peptide 1) RN - 9P1872D4OL (Exenatide) RN - EC 3.4.22.- (Caspase 3) SB - IM MH - Animals MH - Apoptosis/*drug effects MH - Bile Duct Neoplasms MH - Bile Ducts, Intrahepatic MH - Caspase 3/metabolism MH - Cell Line, Tumor MH - Cell Proliferation/*drug effects MH - Cholangiocarcinoma/drug therapy/metabolism/pathology MH - Disease Models, Animal MH - Exenatide MH - Glucagon-Like Peptide 1/analogs & derivatives/pharmacology/therapeutic use MH - Humans MH - Ki-67 Antigen/metabolism MH - Liver Neoplasms/drug therapy/metabolism/pathology MH - Male MH - Mice MH - Mice, Inbred BALB C MH - Mice, Nude MH - Organoplatinum Compounds/*pharmacology/therapeutic use MH - Oxaliplatin MH - Peptides/*pharmacology/therapeutic use MH - Proliferating Cell Nuclear Antigen/metabolism MH - Toxicity Tests, Acute MH - Transplantation, Heterologous MH - Venoms/*pharmacology/therapeutic use PMC - PMC3876111 EDAT- 2013/12/20 06:00 MHDA- 2014/07/16 06:00 PMCR- 2013/12/01 CRDT- 2013/12/20 06:00 PHST- 2013/09/09 00:00 [received] PHST- 2013/11/04 00:00 [revised] PHST- 2013/11/13 00:00 [accepted] PHST- 2013/12/20 06:00 [entrez] PHST- 2013/12/20 06:00 [pubmed] PHST- 2014/07/16 06:00 [medline] PHST- 2013/12/01 00:00 [pmc-release] AID - ijms141224293 [pii] AID - ijms-14-24293 [pii] AID - 10.3390/ijms141224293 [doi] PST - epublish SO - Int J Mol Sci. 2013 Dec 13;14(12):24293-304. doi: 10.3390/ijms141224293. PMID- 32523603 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200928 IS - 1664-8021 (Print) IS - 1664-8021 (Electronic) IS - 1664-8021 (Linking) VI - 11 DP - 2020 TI - WISP1 Predicts Clinical Prognosis and Is Associated With Tumor Purity, Immunocyte Infiltration, and Macrophage M2 Polarization in Pan-Cancer. PG - 502 LID - 10.3389/fgene.2020.00502 [doi] LID - 502 AB - Cancer is becoming the leading cause of death and a major public health problem. Although many advanced treatment strategies are currently in use, the general prognosis of cancer patients remains dismal due to the high frequency of recurrence, metastasis. The identification of effective biomarkers is important for predicting survival of cancer patients and improving treatment efficacy. In this study, we comprehensively analyzed WNT1-inducible-signaling pathway protein 1 (WISP1) expression and explored its correlation with prognosis in pan-cancer using tumor IMmune Estimation Resource (TIMER) and Gene Expression Profiling Interactive Analysis 2 (GEPIA2). We also examined correlations between WISP1 and immunocyte infiltration using TIMER. We identified genes co-expressed with WISP1 using the LinkedOmics database and analyzed associated gene ontology using Metascape. Finally, we constructed protein-protein interaction networks and examined correlations between genes co-expressed with WISP1 and immunocyte infiltration in pan-cancer. WISP1 level differed between human pan-cancer tissues and normal tissues, indicating its potential as a prognostic biomarker. WISP1 expression was correlated with tumor purity and immunocyte infiltration, especially monocyte-macrophage trafficking and M2 polarization. Genes co-expressed with WISP1 were mainly associated with extracellular matrix organization, with collagen members COL6A3, COL5A1, and COL8A1 being key genes correlated with macrophage infiltration and M2 polarization in pan-cancer. Conversely, in certain types of cancer with better prognoses, WISP1 was associated with low M2 macrophage infiltration. These results suggest that WISP1 affect clinical prognosis through associations with tumor purity, immune cell infiltration, and macrophage M2 polarization in pan-cancer, with collagen member proteins may serving as effector molecules of WISP1. CI - Copyright © 2020 Liao, Bu, Xu, Jia, Chang, Liang, Jia and Lv. FAU - Liao, Xia AU - Liao X AD - Department of Nutrition, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Bu, Yang AU - Bu Y AD - Department of Hepatobiliary Surgery, General Hospital, Ningxia Medical University, Yinchuan, China. FAU - Xu, Zihan AU - Xu Z AD - Department of Burns and Plastic Surgery, Shaanxi Provincial People's Hospital, Xi'an, China. FAU - Jia, Fengan AU - Jia F AD - Metabolite Research Center, Shaanxi Institute of Microbiology, Xi'an, China. FAU - Chang, Fan AU - Chang F AD - Metabolite Research Center, Shaanxi Institute of Microbiology, Xi'an, China. FAU - Liang, Junrong AU - Liang J AD - State Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China. FAU - Jia, Qingan AU - Jia Q AD - Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Lv, Yi AU - Lv Y AD - Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. LA - eng PT - Journal Article DEP - 20200525 PL - Switzerland TA - Front Genet JT - Frontiers in genetics JID - 101560621 PMC - PMC7261883 OTO - NOTNLM OT - WISP1 OT - macrophage OT - pan-cancer OT - prognosis OT - tumor purity EDAT- 2020/06/12 06:00 MHDA- 2020/06/12 06:01 PMCR- 2020/05/25 CRDT- 2020/06/12 06:00 PHST- 2019/09/12 00:00 [received] PHST- 2020/04/23 00:00 [accepted] PHST- 2020/06/12 06:00 [entrez] PHST- 2020/06/12 06:00 [pubmed] PHST- 2020/06/12 06:01 [medline] PHST- 2020/05/25 00:00 [pmc-release] AID - 10.3389/fgene.2020.00502 [doi] PST - epublish SO - Front Genet. 2020 May 25;11:502. doi: 10.3389/fgene.2020.00502. eCollection 2020. PMID- 36132126 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220924 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 12 DP - 2022 TI - Survival after laparoscopy versus laparotomy for apparent early-stage uterine clear cell carcinoma: Results of a large multicenter cohort study. PG - 975485 LID - 10.3389/fonc.2022.975485 [doi] LID - 975485 AB - OBJECTIVE: To compare the long-term survival between laparoscopic surgery and open surgery in patients with apparent early-stage uterine clear cell carcinoma (UCCC). PATIENTS AND METHODS: 254 patients with apparent early-stage UCCC were reviewed. Comparisons were made between patients who underwent laparoscopic surgery versus those who underwent open surgery. Baseline data, clinicopathological data, and oncological outcomes were analyzed. 5-year disease-free survival (DFS) rate and 5-year overall survival (OS) rate were estimated and compared using the Kaplan-Meier method and the Log-rank test. The Cox proportional hazard regression model was employed to control the confounding factors. RESULTS: 147 patients underwent laparoscopic surgery, and 107 patients were managed by open surgery. No differences in terms of recurrence rate (laparoscopy versus laparotomy: 10.9% versus 12.9%, P=0.842) and recurrence pattern were observed. For patients who underwent open surgery and patients who underwent laparoscopic surgery, the 5-year DFS rates and 5-year OS rate were 75.8% (95% CI: 65.8%-83.2%) and 69.1% (95% CI: 58.8%-77.4%), 66.0% (95% CI: 57.1%-73.5%) and 60.8% (95% CI: 52.0%-68.5%), respectively. The Cox proportional hazards regression model shown that for apparent early-stage UCCC, the approach of surgical staging was not an independent predictor for survival (laparoscopy versus laparotomy: for DFS, aHR=1.06, 95% CI=0.64-1.75, P=0.826; for OS, aHR=1.10, 95% CI=0.72-1.68, P=0.671). CONCLUSION: For apparent early-stage UCCC, in terms of oncological survival, laparoscopic surgery was as safe as open surgery. CI - Copyright © 2022 Shui, Ran, Tian, Qin, Gu, Xu, Hu, Zhang, Xu, Cheng and Huan. FAU - Shui, Chengyu AU - Shui C AD - Department of Obstetrics and Gynecology, Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi Clinical College of Wuhan University, Enshi, China. FAU - Ran, Lin AU - Ran L AD - Department of Obstetrics and Gynecology, Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi Clinical College of Wuhan University, Enshi, China. FAU - Tian, Yong AU - Tian Y AD - Department of Obstetrics and Gynecology, Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi Clinical College of Wuhan University, Enshi, China. FAU - Qin, Li AU - Qin L AD - Department of Obstetrics and Gynecology, Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi Clinical College of Wuhan University, Enshi, China. FAU - Gu, Xin AU - Gu X AD - Department of Obstetrics and Gynecology, Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi Clinical College of Wuhan University, Enshi, China. FAU - Xu, Hui AU - Xu H AD - Department of Obstetrics and Gynecology, Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi Clinical College of Wuhan University, Enshi, China. FAU - Hu, Cui AU - Hu C AD - Department of Obstetrics and Gynecology, Mianzhu City People's Hospital, Mianzhu, China. AD - Department of Obstetrics and Gynecology, Sichuan University West China Hospital (Mianzhu Hospital), Mianzhu, China. FAU - Zhang, Lin-Lin AU - Zhang LL AD - Department of Obstetrics and Gynecology, Mianzhu City People's Hospital, Mianzhu, China. AD - Department of Obstetrics and Gynecology, Sichuan University West China Hospital (Mianzhu Hospital), Mianzhu, China. FAU - Xu, You AU - Xu Y AD - Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China. FAU - Cheng, Chen AU - Cheng C AD - Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Chengdu Medical College, Chengdu, China. FAU - Huan, Wu AU - Huan W AD - Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Chengdu Medical College, Chengdu, China. LA - eng PT - Journal Article DEP - 20220905 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC9483121 OTO - NOTNLM OT - disease-free survival OT - laparoscopy OT - overall survival OT - surgical staging OT - uterine clear cell carcinoma COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/09/23 06:00 MHDA- 2022/09/23 06:01 PMCR- 2022/01/01 CRDT- 2022/09/22 03:33 PHST- 2022/06/22 00:00 [received] PHST- 2022/08/16 00:00 [accepted] PHST- 2022/09/22 03:33 [entrez] PHST- 2022/09/23 06:00 [pubmed] PHST- 2022/09/23 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2022.975485 [doi] PST - epublish SO - Front Oncol. 2022 Sep 5;12:975485. doi: 10.3389/fonc.2022.975485. eCollection 2022. PMID- 26699805 OWN - NLM STAT- MEDLINE DCOM- 20171012 LR - 20181113 IS - 1552-695X (Electronic) IS - 1534-7354 (Print) IS - 1534-7354 (Linking) VI - 15 IP - 3 DP - 2016 Sep TI - Herbal Compound Songyou Yin and Moderate Swimming Suppress Growth and Metastasis of Liver Cancer by Enhancing Immune Function. PG - 368-75 LID - 10.1177/1534735415622011 [doi] AB - Objective Both the Chinese herbal compound Songyou Yin (SYY) and swimming exercise have been shown to have protective effects against liver cancer in animal models. In this study, we investigated whether SYY and moderate swimming (MS) have enhanced effect on suppressing progression of liver cancer by immunomodulation. Methods C57BL/6 mice were transplanted with Hepa1-6 murine liver cancer cell lines and received treatment with SYY alone or SYY combined with MS. The green fluorescent protein (GFP)-positive metastatic foci in lungs were imaged with a stereoscopic fluorescence microscope. Flow cytometry was used to test the proportion of CD4 +, CD8 + T cells in peripheral blood and the proportions of CD4 + CD25 + Foxp3 + Treg cells in peripheral blood, spleen, and tumor tissues. Cytokine transforming growth factor (TGF)-β1 level in serum was detected by ELISA. Results SYY plus MS significantly suppressed the growth and lung metastasis of liver cancer and prolonged survival in tumor-burdened mice. SYY plus MS markedly raised the CD4 to CD8 ratio in peripheral blood and lowered the serum TGF-β1 level and the proportions of Treg cells in peripheral blood, spleen, and tumor tissue. The effects of the combined intervention were significantly superior to SYY or MS alone. Conclusion The combined application of SYY and MS exerted an enhanced effect on suppressing growth and metastasis of liver cancer by strengthening immunity. CI - © The Author(s) 2015. FAU - Zhang, Quan-Bao AU - Zhang QB AD - Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China Cancer Metastasis Institute, Huashan Hospital, Fudan University, Shanghai, China. FAU - Meng, Xiang-Ting AU - Meng XT AD - School of Anesthesiology, Xuzhou Medical College, Xuzhou, China. FAU - Jia, Qing-An AU - Jia QA AD - Institute of Biomedical Sciences, Fudan University, Shanghai, China. FAU - Bu, Yang AU - Bu Y AD - Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China. FAU - Ren, Zheng-Gang AU - Ren ZG AD - Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China. FAU - Zhang, Bo-Heng AU - Zhang BH AD - Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China. FAU - Tang, Zhao-You AU - Tang ZY AD - Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China zytang88@163.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20151222 PL - United States TA - Integr Cancer Ther JT - Integrative cancer therapies JID - 101128834 RN - 0 (Cytokines) RN - 0 (Drugs, Chinese Herbal) RN - 0 (Transforming Growth Factor beta1) RN - 0 (songyou yin) SB - IM MH - Animals MH - Carcinoma, Hepatocellular/*drug therapy/*immunology/metabolism MH - Cell Line, Tumor MH - Cytokines/immunology/metabolism MH - Drugs, Chinese Herbal/*pharmacology MH - Flow Cytometry/methods MH - Liver Neoplasms/*drug therapy/*immunology/metabolism MH - Male MH - Mice MH - Mice, Inbred C57BL MH - Swimming/*physiology MH - T-Lymphocytes, Regulatory/drug effects/immunology/metabolism MH - Transforming Growth Factor beta1/immunology/metabolism MH - Tumor Burden/drug effects/immunology PMC - PMC5739186 OTO - NOTNLM OT - herbal medicine OT - immunity OT - liver cancer OT - metastasis OT - swimming COIS- Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2015/12/25 06:00 MHDA- 2017/10/13 06:00 PMCR- 2015/12/22 CRDT- 2015/12/25 06:00 PHST- 2015/12/25 06:00 [entrez] PHST- 2015/12/25 06:00 [pubmed] PHST- 2017/10/13 06:00 [medline] PHST- 2015/12/22 00:00 [pmc-release] AID - 1534735415622011 [pii] AID - 10.1177_1534735415622011 [pii] AID - 10.1177/1534735415622011 [doi] PST - ppublish SO - Integr Cancer Ther. 2016 Sep;15(3):368-75. doi: 10.1177/1534735415622011. Epub 2015 Dec 22. PMID- 25634760 OWN - NLM STAT- MEDLINE DCOM- 20151013 LR - 20211203 IS - 1421-9778 (Electronic) IS - 1015-8987 (Linking) VI - 35 IP - 2 DP - 2015 TI - Advanced oxidation protein products induce hypertrophy and epithelial-to-mesenchymal transition in human proximal tubular cells through induction of endoplasmic reticulum stress. PG - 816-28 LID - 10.1159/000369740 [doi] AB - BACKGROUND: In chronic kidney disease (CKD), the accumulation of advanced oxidation protein products (AOPPs) is prevalent. Hypertrophy and epithelial-to-mesenchymal transition (EMT) of tubular cells are associated with the pathogenesis of CKD. However, whether AOPPs induce tubular-cell hypertrophy and EMT is unclear. In this study, we investigated the effect of AOPPs on human proximal tubular cells (HK-2 cells) and the mechanisms underlying tubular-cell hypertrophy and EMT in vitro. METHODS: The mRNA and protein expression of CCAAT/enhancer-binding protein-homologous protein (CHOP), glucose-regulated protein (GRP) 78, p27, α-smooth muscle actin (α-SMA) and E-cadherin were evaluated by quantitative real-time PCR and western blot, respectively. Cell cycle was detected by flow cytometry. Bicinchoninic acid method was performed to measure total protein content. RESULTS: AOPP treatment upregulated total protein expression, caused an increase in the percentage of G1-phase cells, and induced the overexpression of p27 and α-SMA, lowered the expression of E-cadherin. Furthermore, AOPP treatment induced the overexpression of GRP78 and CHOP. Moreover, the aforementioned effects were reversed following the treatment of cells with an NADPH oxidase inhibitor, a reactive oxygen species (ROS) scavenger, or salubrinal, which is an inhibitor of ER stress, whereas these effects were produced after exposure to thapsigargin, an inducer of ER stress. CONCLUSION: Our results suggest that AOPPs induced HK-2-cell hypertrophy and EMT by inducing ER stress, which was likely mediated by ROS. These findings could facilitate the development of novel therapeutic strategies for suppressing the progression of CKD. CI - © 2015 S. Karger AG, Basel. FAU - Tang, Xun AU - Tang X AD - Department of Nephrology, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China. FAU - Rong, Guang AU - Rong G FAU - Bu, Yang AU - Bu Y FAU - Zhang, Shaojie AU - Zhang S FAU - Zhang, Min AU - Zhang M FAU - Zhang, Jun AU - Zhang J FAU - Liang, Xiujie AU - Liang X LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150130 PL - Germany TA - Cell Physiol Biochem JT - Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology JID - 9113221 RN - 0 (ACTA2 protein, human) RN - 0 (Actins) RN - 0 (Advanced Oxidation Protein Products) RN - 0 (Cadherins) RN - 0 (DDIT3 protein, human) RN - 0 (Endoplasmic Reticulum Chaperone BiP) RN - 0 (HSPA5 protein, human) RN - 0 (Heat-Shock Proteins) RN - 147336-12-7 (Transcription Factor CHOP) SB - IM MH - Actins/genetics/metabolism MH - Advanced Oxidation Protein Products/*pharmacology MH - Cadherins/genetics/metabolism MH - Cell Cycle/drug effects MH - Cells, Cultured MH - Endoplasmic Reticulum Chaperone BiP MH - Endoplasmic Reticulum Stress/*drug effects MH - Epithelial-Mesenchymal Transition/*drug effects MH - Gene Expression Regulation/drug effects MH - Heat-Shock Proteins/genetics/metabolism MH - Humans MH - Hypertrophy/*chemically induced/metabolism MH - In Vitro Techniques MH - Kidney Tubules, Proximal/cytology/*drug effects/pathology MH - Transcription Factor CHOP/genetics/metabolism EDAT- 2015/01/31 06:00 MHDA- 2015/10/16 06:00 CRDT- 2015/01/31 06:00 PHST- 2014/12/10 00:00 [accepted] PHST- 2015/01/31 06:00 [entrez] PHST- 2015/01/31 06:00 [pubmed] PHST- 2015/10/16 06:00 [medline] AID - 000369740 [pii] AID - 10.1159/000369740 [doi] PST - ppublish SO - Cell Physiol Biochem. 2015;35(2):816-28. doi: 10.1159/000369740. Epub 2015 Jan 30. PMID- 35103403 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220201 IS - 1861-471X (Electronic) IS - 1861-471X (Linking) VI - 17 IP - 3 DP - 2022 Feb 1 TI - Corrigendum: Enzyme-Embedded Metal-Organic Framework Colloidosomes via an Emulsion-Based Approach. PG - e202101387 LID - 10.1002/asia.202101387 [doi] FAU - Zhu, Guixian AU - Zhu G FAU - Zhang, Mizhen AU - Zhang M FAU - Bu, Yang AU - Bu Y FAU - Lu, Lidan AU - Lu L FAU - Lou, Xiaoping AU - Lou X FAU - Zhu, Lianqing AU - Zhu L LA - eng PT - Published Erratum PL - Germany TA - Chem Asian J JT - Chemistry, an Asian journal JID - 101294643 SB - IM EFR - Chem Asian J. 2018 Oct 4;13(19):2891-2896. doi: 10.1002/asia.201800976. PMID: 30151959 OTO - NOTNLM OT - ZIF-8 nanocrystals OT - biocatalysis OT - colloidosomes OT - enzyme immobilization OT - pickering emulsion EDAT- 2022/02/02 06:00 MHDA- 2022/02/02 06:01 CRDT- 2022/02/01 08:45 PHST- 2022/02/01 08:45 [entrez] PHST- 2022/02/02 06:00 [pubmed] PHST- 2022/02/02 06:01 [medline] AID - 10.1002/asia.202101387 [doi] PST - ppublish SO - Chem Asian J. 2022 Feb 1;17(3):e202101387. doi: 10.1002/asia.202101387. PMID- 29462594 OWN - NLM STAT- MEDLINE DCOM- 20180906 LR - 20180906 IS - 1879-0712 (Electronic) IS - 0014-2999 (Linking) VI - 825 DP - 2018 Apr 15 TI - Melatonin promotes neuroprotection of induced pluripotent stem cells-derived neural stem cells subjected to H(2)O(2)-induced injury in vitro. PG - 143-150 LID - S0014-2999(18)30104-3 [pii] LID - 10.1016/j.ejphar.2018.02.027 [doi] AB - Melatonin is a neurohormone mainly extracted from the pineal gland with neuroprotective effects. It has antioxidant, anti-inflammatory, and antiapoptotic functions. However, the mechanism of melatonin against reactive oxygen species is unclear. Here, we explore the potential proliferative and neuroprotective mechanism of melatonin on induced pluripotent stem cells (iPSC)-derived neural stem cells (NSCs) exposed to hydrogen peroxide (H(2)O(2)). NSCs were induced from iPSCs, then pretreated with 500 μM H(2)O(2), 1 μM melatonin, 1 μM melatonin receptor antagonist (Luzindole), or 10 μM Phosphatidylinositide 3 kinase (PI3K) inhibitor (LY294002). The results showed that melatonin stimulated proliferation of iPSC-derived NSCs on H(2)O(2) exposure. Melatonin also markedly improved stabilization of the mitochondrial membrane potential and reduced the rate of apoptosis. Treatment with Luzindole or LY294002 inhibited the increasing proliferative and neuroprotective effects of melatonin on iPSC-derived NSCs with H(2)O(2) treatment. Our results further demonstrated that these promotional effects of melatonin were related with the activity of phosphorylation of AKT. Therefore, these outcomes propose that melatonin protects iPSC-derived NSCs from H(2)O(2)-induced injury through the mediation of melatonin receptor and PI3K/AKT signaling pathway. CI - Copyright © 2018 Elsevier B.V. All rights reserved. FAU - Shu, Tao AU - Shu T AD - Department of Spine Surgery, The 3rd Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, China. FAU - Fan, Lei AU - Fan L AD - Department of Spine Surgery, The 3rd Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, China. FAU - Wu, Tao AU - Wu T AD - Department of Emergency, Guangdong Provincial Corps Hospital of Chinese People's Armed Police Forces, Guangzhou Medical University, Guangzhou, Guangdong 510000, China. FAU - Liu, Chang AU - Liu C AD - Department of Spine Surgery, The 3rd Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, China. FAU - He, Lei AU - He L AD - Department of Spine Surgery, The 3rd Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, China. FAU - Pang, Mao AU - Pang M AD - Department of Spine Surgery, The 3rd Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, China. FAU - Bu, Yang AU - Bu Y AD - Department of Spine Surgery, The 3rd Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, China. FAU - Wang, Xuan AU - Wang X AD - Department of Spine Surgery, The 3rd Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, China. FAU - Wang, Juan AU - Wang J AD - Department of Gynaecology, Common Splendor International Health Management, Guangzhou, Guangdong 510000, China. FAU - Rong, Limin AU - Rong L AD - Department of Spine Surgery, The 3rd Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, China. Electronic address: ronglm21@163.com. FAU - Liu, Bin AU - Liu B AD - Department of Spine Surgery, The 3rd Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, China. Electronic address: johnliu2001@sina.com. LA - eng PT - Journal Article DEP - 20180217 PL - Netherlands TA - Eur J Pharmacol JT - European journal of pharmacology JID - 1254354 RN - 0 (Chromones) RN - 0 (Morpholines) RN - 0 (Neuroprotective Agents) RN - 0 (Receptors, Melatonin) RN - 0 (Tryptamines) RN - 117946-91-5 (luzindole) RN - 31M2U1DVID (2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one) RN - BBX060AN9V (Hydrogen Peroxide) RN - EC 2.7.1.- (Phosphatidylinositol 3-Kinases) RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) RN - JL5DK93RCL (Melatonin) SB - IM MH - Animals MH - Apoptosis/drug effects MH - Cell Proliferation/drug effects MH - Cells, Cultured MH - Chromones/pharmacology MH - Hydrogen Peroxide/*pharmacology MH - Induced Pluripotent Stem Cells/*drug effects/metabolism MH - Melatonin/*pharmacology MH - Membrane Potential, Mitochondrial/drug effects MH - Mice MH - Morpholines/pharmacology MH - Neural Stem Cells/drug effects MH - Neuroprotection/*drug effects MH - Neuroprotective Agents/*pharmacology MH - Phosphatidylinositol 3-Kinases/metabolism MH - Proto-Oncogene Proteins c-akt/metabolism MH - Receptors, Melatonin/metabolism MH - Signal Transduction/drug effects MH - Tryptamines/pharmacology OTO - NOTNLM OT - AKT OT - Induced pluripotent stem cells OT - Melatonin OT - Neural stem cells OT - Reactive oxygen species EDAT- 2018/02/21 06:00 MHDA- 2018/09/07 06:00 CRDT- 2018/02/21 06:00 PHST- 2017/07/23 00:00 [received] PHST- 2018/01/31 00:00 [revised] PHST- 2018/02/16 00:00 [accepted] PHST- 2018/02/21 06:00 [pubmed] PHST- 2018/09/07 06:00 [medline] PHST- 2018/02/21 06:00 [entrez] AID - S0014-2999(18)30104-3 [pii] AID - 10.1016/j.ejphar.2018.02.027 [doi] PST - ppublish SO - Eur J Pharmacol. 2018 Apr 15;825:143-150. doi: 10.1016/j.ejphar.2018.02.027. Epub 2018 Feb 17. PMID- 23773050 OWN - NLM STAT- MEDLINE DCOM- 20140203 LR - 20130905 IS - 1520-510X (Electronic) IS - 0020-1669 (Linking) VI - 52 IP - 13 DP - 2013 Jul 1 TI - Photophysical studies of europium coordination polymers based on a tetracarboxylate ligand. PG - 7658-65 LID - 10.1021/ic400777c [doi] AB - Reaction of europium sulfate octahydrate with p-terphenyl-3,3″,5,5″-tetracarboxylic acid (H4ptptc) in a mixed solvent system has afforded three new coordination polymers formulated as {[Eu(ptptc)0.75(H2O)2]·0.5DMF·1.5H2O}n (1), {[Me2H2N]2 [Eu2(ptptc)2(H2O)(DMF)]·1.5DMF·7H2O}n (2), and {[Eu(Hptptc)(H2O)4]·0.5DMF·H2O}n (3). Complex 1 exhibits a three-dimensional (3D) metal-organic framework based on {Eu2(μ2-COO)2(COO)4}n chains, complex 2 shows a 3D metal-organic framework constructed by [Eu2(μ2-COO)2(COO)6](2-) dimetallic subunits, and complex 3 features a 2D layer architecture assembling to 3D framework through π···π interactions. All complexes exhibit the characteristic red luminescence of Eu(III) ion. The triplet state of ligand H4ptptc matches well with the emission level of Eu(III) ion, which allows the preparation of new optical materials with enhanced luminescence properties. The luminescence properties of these complexes are further studied in terms of their emission quantum yields, emission lifetimes, and the radiative/nonradiative rates. FAU - Gai, Yan-Li AU - Gai YL AD - State Key Laboratory of Structure Chemistry, Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou, 350002, People's Republic of China. FAU - Jiang, Fei-Long AU - Jiang FL FAU - Chen, Lian AU - Chen L FAU - Bu, Yang AU - Bu Y FAU - Su, Kong-Zhao AU - Su KZ FAU - Al-Thabaiti, Shaeel A AU - Al-Thabaiti SA FAU - Hong, Mao-Chun AU - Hong MC LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20130617 PL - United States TA - Inorg Chem JT - Inorganic chemistry JID - 0366543 RN - 0 (Carboxylic Acids) RN - 0 (Coordination Complexes) RN - 0 (Polymers) RN - 444W947O8O (Europium) SB - IM MH - Carboxylic Acids/*chemistry MH - Coordination Complexes/*chemistry MH - Europium/*chemistry MH - Luminescence MH - Models, Molecular MH - Polymers/*chemistry EDAT- 2013/06/19 06:00 MHDA- 2014/02/04 06:00 CRDT- 2013/06/19 06:00 PHST- 2013/06/19 06:00 [entrez] PHST- 2013/06/19 06:00 [pubmed] PHST- 2014/02/04 06:00 [medline] AID - 10.1021/ic400777c [doi] PST - ppublish SO - Inorg Chem. 2013 Jul 1;52(13):7658-65. doi: 10.1021/ic400777c. Epub 2013 Jun 17. PMID- 24678763 OWN - NLM STAT- MEDLINE DCOM- 20150102 LR - 20211021 IS - 1756-8722 (Electronic) IS - 1756-8722 (Linking) VI - 7 DP - 2014 Mar 30 TI - Arsenic trioxide induces differentiation of CD133+ hepatocellular carcinoma cells and prolongs posthepatectomy survival by targeting GLI1 expression in a mouse model. PG - 28 LID - 10.1186/1756-8722-7-28 [doi] AB - BACKGROUND: Cancer stem cells (CSCs) play a key role in the posthepatectomy recurrence of hepatocellular carcinoma (HCC). CD133+ HCC cells exhibit liver CSC-like properties, and CSC differentiation-inducing therapy may lead these cells to lose their self-renewal ability and may induce terminal differentiation, which may in turn allow their malignant potential to be controlled. Because arsenic trioxide (As₂O₃) increases remission rates and prolongs survival among patients with acute promyelocytic leukemia by inducing differentiation and apoptosis of leukemic cells, we hypothesized that As₂O₃ might also inhibit HCC recurrence and prolong survival time after hepatectomy by inducing differentiation of HCC CSCs. METHODS: We evaluated the As₂O₃ induced differentiation of human HCC CSCs and its mechanism in vitro, and we investigated the effects of treatment with As₂O₃ on recurrence rates and median survival in a mouse xenograft model. RESULTS: We found that As₂O₃ induced HCC CSC differentiation by down-regulating the expression of CD133 and some stemness genes, thus inhibiting the cells' self-renewal ability and tumorigenic capacity without inhibiting their proliferation in vitro. In vivo experiments indicated that As₂O₃ decreased recurrence rates after radical resection and prolonged survival in a mouse model. As₂O₃, which shows no apparent toxicity, may induce HCC CSC differentiation by down-regulating the expression of GLI1. CONCLUSIONS: We found that As₂O₃ induced HCC CSC differentiation, inhibited recurrence, and prolonged survival after hepatectomy by targeting GLI1expression. Our results suggest that the clinical safety and utility of As₂O₃ should be further evaluated. FAU - Zhang, Ke-Zhi AU - Zhang KZ FAU - Zhang, Qiang-Bo AU - Zhang QB FAU - Zhang, Quan-Bao AU - Zhang QB FAU - Sun, Hui-Chuan AU - Sun HC FAU - Ao, Jian-Yang AU - Ao JY FAU - Chai, Zong-Tao AU - Chai ZT FAU - Zhu, Xiao-Dong AU - Zhu XD FAU - Lu, Lu AU - Lu L FAU - Zhang, Yuan-Yuan AU - Zhang YY FAU - Bu, Yang AU - Bu Y FAU - Kong, Ling-Qun AU - Kong LQ FAU - Tang, Zhao-You AU - Tang ZY AD - Liver Cancer Institute and Zhongshan Hospital, Fudan University, Key Laboratory for Carcinogenesis and Cancer Invasion, The Chinese Ministry of Education, 136 Yi Xue Yuan Road, Shanghai 200032, P R China. zytang88@163.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140330 PL - England TA - J Hematol Oncol JT - Journal of hematology & oncology JID - 101468937 RN - 0 (AC133 Antigen) RN - 0 (Antigens, CD) RN - 0 (Arsenicals) RN - 0 (GLI1 protein, human) RN - 0 (Glycoproteins) RN - 0 (Oxides) RN - 0 (PROM1 protein, human) RN - 0 (Peptides) RN - 0 (Prom1 protein, mouse) RN - 0 (Transcription Factors) RN - 0 (Zinc Finger Protein GLI1) RN - S7V92P67HO (Arsenic Trioxide) SB - IM MH - AC133 Antigen MH - Animals MH - Antigens, CD/*metabolism MH - Arsenic Trioxide MH - Arsenicals/*pharmacology MH - Carcinoma, Hepatocellular/*drug therapy/metabolism/pathology/surgery MH - Cell Differentiation/drug effects MH - Cell Line, Tumor MH - Disease Models, Animal MH - Down-Regulation MH - Glycoproteins/*metabolism MH - Humans MH - Liver Neoplasms/*drug therapy/metabolism/pathology/surgery MH - Male MH - Mice MH - Mice, Inbred NOD MH - Mice, SCID MH - Neoplasm Recurrence, Local/metabolism/pathology MH - Neoplastic Stem Cells/pathology MH - Oxides/*pharmacology MH - Peptides/*metabolism MH - Random Allocation MH - Signal Transduction MH - Survival Analysis MH - Transcription Factors/*biosynthesis/genetics MH - Xenograft Model Antitumor Assays MH - Zinc Finger Protein GLI1 PMC - PMC4022144 EDAT- 2014/04/01 06:00 MHDA- 2015/01/03 06:00 PMCR- 2014/03/30 CRDT- 2014/04/01 06:00 PHST- 2013/12/29 00:00 [received] PHST- 2014/03/20 00:00 [accepted] PHST- 2014/04/01 06:00 [entrez] PHST- 2014/04/01 06:00 [pubmed] PHST- 2015/01/03 06:00 [medline] PHST- 2014/03/30 00:00 [pmc-release] AID - 1756-8722-7-28 [pii] AID - 10.1186/1756-8722-7-28 [doi] PST - epublish SO - J Hematol Oncol. 2014 Mar 30;7:28. doi: 10.1186/1756-8722-7-28. PMID- 34807141 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211123 IS - 1539-4522 (Electronic) IS - 1559-128X (Linking) VI - 60 IP - 31 DP - 2021 Nov 1 TI - Sub-pixel position estimation algorithm based on Gaussian fitting and sampling theorem interpolation for wafer alignment. PG - 9607-9618 LID - 10.1364/AO.437440 [doi] AB - Wafer alignment is the core technique of lithographic tools. Image-processing-based wafer alignment techniques are commonly used in lithographic tools. An alignment algorithm is used to analyze the alignment mark image for obtaining the mark position. The accuracy and speed of the alignment algorithm are very important for guaranteeing the overlay and throughput of lithographic tools. The most commonly used algorithm in image-processing-based alignment techniques is the self-correlation method. This method has a high accuracy, but the calculation is complex, and the calculation speed is slow. In this paper, we propose a sub-pixel position estimation algorithm based on Gaussian fitting and sampling theorem interpolation. The algorithm first reconstructs the alignment signal by sampling theorem interpolation and then obtains the sub-pixel position of the mark by Gaussian fitting. The accuracy and robustness of the algorithm are verified by testing the simulated marks and experimentally captured marks. The repeat accuracy can reach 1/100 pixels, which is in the same level with the self-correlation method. The calculation speed is highly improved compared with the self-correlation method, which needs only about 1/3 of even short calculation time. FAU - Pan, Songyong AU - Pan S FAU - Wang, Shaoqing AU - Wang S FAU - Xu, Jinghao AU - Xu J FAU - Fan, Lili AU - Fan L FAU - Yuan, Fenghua AU - Yuan F FAU - Shu, Ting AU - Shu T FAU - Dai, Fengzhao AU - Dai F FAU - Yan, Xiaona AU - Yan X FAU - Bu, Yang AU - Bu Y FAU - Wang, Xiangzhao AU - Wang X LA - eng PT - Journal Article PL - United States TA - Appl Opt JT - Applied optics JID - 0247660 SB - IM EDAT- 2021/11/23 06:00 MHDA- 2021/11/23 06:01 CRDT- 2021/11/22 12:18 PHST- 2021/11/22 12:18 [entrez] PHST- 2021/11/23 06:00 [pubmed] PHST- 2021/11/23 06:01 [medline] AID - 461931 [pii] AID - 10.1364/AO.437440 [doi] PST - ppublish SO - Appl Opt. 2021 Nov 1;60(31):9607-9618. doi: 10.1364/AO.437440. PMID- 35962229 OWN - NLM STAT- MEDLINE DCOM- 20230117 LR - 20250312 IS - 1432-2218 (Electronic) IS - 0930-2794 (Print) IS - 0930-2794 (Linking) VI - 37 IP - 1 DP - 2023 Jan TI - Splenic artery embolization changes the management of blunt splenic injury: an observational analysis of 680 patients graded by the revised 2018 AAST-OIS. PG - 371-381 LID - 10.1007/s00464-022-09531-0 [doi] AB - BACKGROUND: This study aimed to evaluate the management of blunt splenic injury (BSI) and highlight the role of splenic artery embolization (SAE). METHODS: We conducted a retrospective review of all patients with BSI over 15 years. Splenic injuries were graded by the 2018 revision of the American Association for the Surgery of Trauma-Organ Injury Scale (AAST-OIS). Our hospital provide 24/7 in-house surgeries and 24/7 in-house interventional radiology facility. Patients with BSI who arrived hypotensive and were refractory to resuscitation required surgery and patients with vascular injury on abdominal computed tomography were considered for SAE. RESULTS: In total, 680 patients with BSI, the number of patients who underwent nonoperative management with observation (NOM-obs), SAE, and surgery was 294, 234, and 152, respectively. The number of SAEs increased from 4 (8.3%) in 2001 to 23 (60.5%) in 2015 (p < 0.0001); conversely, the number of surgeries decreased from 21 (43.8%) in 2001 to 4 (10.5%) in 2015 (p = 0.001). The spleen-related mortality rate of NOM-obs, SAEs, and surgery was 0%, 0.4%, and 7.2%, respectively. In the SAE subgroup, according to the 2018 AAST-OIS, 234 patients were classified as grade II, n = 3; III, n = 21; IV, n = 111; and V, n = 99, respectively.; and compared with 1994 AST-OIS, 150 patients received a higher grade and the total number of grade IV and V injuries ranged from 96 (41.0%) to 210 (89.7%) (p < 0.0001). On angiography, 202 patients who demonstrated vascular injury and 187 achieved hemostasis after SAE with a 92.6% success rate. Six of the 15 patients failed to SAE preserved the spleen after second embolization with a 95.5% salvage rate. CONCLUSIONS: Our data confirm the superiority of the 2018 AAST-OIS and support the role of SAE in changing the trend of management of BSI. CI - © 2022. The Author(s). FAU - Lin, Being-Chuan AU - Lin BC AUID- ORCID: 0000-0002-5391-0900 AD - Division of Trauma and Emergency Surgery, Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, 5, Fu-Hsing Street, Kwei-Shan, Tao-Yuan City, 333, Taiwan. linbc@cgmh.org.tw. FAU - Wu, Cheng-Hsien AU - Wu CH AD - Division of Emergency and Critical Care Radiology, Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital, Chang Gung University, Tao-Yuan City, Taiwan. FAU - Wong, Yon-Cheong AU - Wong YC AD - Division of Emergency and Critical Care Radiology, Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital, Chang Gung University, Tao-Yuan City, Taiwan. FAU - Chen, Huan-Wu AU - Chen HW AD - Division of Emergency and Critical Care Radiology, Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital, Chang Gung University, Tao-Yuan City, Taiwan. FAU - Fu, Chen-Ju AU - Fu CJ AD - Division of Emergency and Critical Care Radiology, Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital, Chang Gung University, Tao-Yuan City, Taiwan. FAU - Huang, Chen-Chih AU - Huang CC AD - Department of Medical Imaging and Intervention, New Taipei Municipal Tucheng Hospital, Chang Gung Medical Foundation, New Taipei City, Taiwan. FAU - Wu, Chen-Te AU - Wu CT AD - Division of Emergency and Critical Care Radiology, Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital, Chang Gung University, Tao-Yuan City, Taiwan. FAU - Hsieh, Chi-Hsun AU - Hsieh CH AD - Division of Trauma and Emergency Surgery, Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, 5, Fu-Hsing Street, Kwei-Shan, Tao-Yuan City, 333, Taiwan. LA - eng PT - Journal Article PT - Observational Study DEP - 20220812 PL - Germany TA - Surg Endosc JT - Surgical endoscopy JID - 8806653 SB - IM MH - Humans MH - Spleen/diagnostic imaging MH - Splenic Artery/diagnostic imaging MH - *Vascular System Injuries MH - *Embolization, Therapeutic MH - *Wounds, Nonpenetrating/diagnostic imaging/therapy MH - Retrospective Studies MH - Treatment Outcome PMC - PMC9839812 OTO - NOTNLM OT - Blunt splenic injury OT - Contrast extravasation OT - Pseudoaneurysm OT - Splenic artery embolization OT - Splenic salvage rate COIS- Drs Being-Chuan Lin, Cheng-Hsien Wu, Yon-Cheong Wong, Huan-Wu Chen, Chen-Ju Fu, Chen-Chih Huang, Chen-Te Wu, and Chi-Hsun Hsieh have no conflicts of interest or financial ties to disclose. EDAT- 2022/08/13 06:00 MHDA- 2023/01/18 06:00 PMCR- 2022/08/12 CRDT- 2022/08/12 23:32 PHST- 2022/04/17 00:00 [received] PHST- 2022/07/31 00:00 [accepted] PHST- 2022/08/13 06:00 [pubmed] PHST- 2023/01/18 06:00 [medline] PHST- 2022/08/12 23:32 [entrez] PHST- 2022/08/12 00:00 [pmc-release] AID - 10.1007/s00464-022-09531-0 [pii] AID - 9531 [pii] AID - 10.1007/s00464-022-09531-0 [doi] PST - ppublish SO - Surg Endosc. 2023 Jan;37(1):371-381. doi: 10.1007/s00464-022-09531-0. Epub 2022 Aug 12. PMID- 23622143 OWN - NLM STAT- MEDLINE DCOM- 20130923 LR - 20211021 IS - 1472-6882 (Electronic) IS - 1472-6882 (Linking) VI - 13 DP - 2013 Apr 27 TI - Herbal compound "Songyou Yin" attenuates hepatoma cell invasiveness and metastasis through downregulation of cytokines secreted by activated hepatic stellate cells. PG - 89 LID - 10.1186/1472-6882-13-89 [doi] AB - BACKGROUND: Activated hepatic stellate cells (aHSCs) play an important role in the progression of hepatocellular carcinoma (HCC). Here, we determined if cytokines secreted in response to the herbal compound "Songyou Yin" (SYY) treatment of aHSCs could influence invasiveness and metastatic capabilities of hepatoma cells. METHODS: Primary rat hepatic stellate cells (HSCs) were isolated, activated, divided into SYY treated and untreated (nSYY) groups, and conditioned media (CM-SYY and CM-nSYY, respectively) were collected. The hepatoma cell line, McA-RH7777 was cultured for 4 weeks with SYY, CM-SYY, and CM-nSYY, designated McA-SYY, McA-SYYCM and McA-nSYYCM. The invasiveness and metastatic capabilities were evaluated using Matrigel invasion assay in vitro and pulmonary metastasis in vivo. Matrix metalloproteinase-2 (MMP-2), MMP-9, E-cadherin, N-cadherin, and vimentin protein levels in McA-SYYCM and McA-nSYYCM were evaluated by Western blot. Cytokine levels in conditioned media were tested using enzyme-linked immunosorbent assay (ELISA). RESULTS: Matrigel invasion assay indicated that the number of McA-SYYCM cells passing through the basement membrane was less than in McA-nSYYCM cells (P < 0.01). Similar results were also observed in vivo for lung metastasis. McA-SYYCM cells showed less pulmonary metastasis capabilities than McA-nSYYCM cells (P < 0.001). The reduced expression of MMP-2 and reversed epithelial to mesenchymal transition with E-cadherin upregulation, and N-cadherin and vimentin downregulation were also found in McA-SYYCM compared to McA-nSYYCM. Metastasis-promoting cytokines hepatocyte growth factor, interleukin-6, transforming growth factor-β1, and vascular endothelial growth factor were markedly decreased in CM-SYY compared to CM-nSYY. CONCLUSIONS: SYY attenuates hepatoma cell invasiveness and metastasis capabilities through downregulating cytokines secreted by activated hepatic stellate cells. FAU - Jia, Qing-An AU - Jia QA AD - Liver Cancer Institute, Zhongshan Hospital, Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai 200032, China. FAU - Wang, Zhi-Ming AU - Wang ZM FAU - Ren, Zheng-Gang AU - Ren ZG FAU - Bu, Yang AU - Bu Y FAU - Xie, Xiao-Ying AU - Xie XY FAU - Wang, Yan-Hong AU - Wang YH FAU - Zhang, Lan AU - Zhang L FAU - Zhang, Qiang-Bo AU - Zhang QB FAU - Xue, Tong-Chun AU - Xue TC FAU - Deng, Li-Fen AU - Deng LF FAU - Tang, Zhao-You AU - Tang ZY LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20130427 PL - England TA - BMC Complement Altern Med JT - BMC complementary and alternative medicine JID - 101088661 RN - 0 (Cadherins) RN - 0 (Cytokines) RN - 0 (Drugs, Chinese Herbal) RN - 0 (Transforming Growth Factor beta1) RN - EC 3.4.24.24 (Matrix Metalloproteinase 2) RN - EC 3.4.24.35 (Matrix Metalloproteinase 9) SB - IM MH - Animals MH - Cadherins/metabolism MH - Carcinoma, Hepatocellular/*drug therapy/genetics/metabolism/pathology MH - Cells, Cultured MH - Cytokines/*metabolism MH - Down-Regulation/*drug effects MH - Drugs, Chinese Herbal/*pharmacology MH - Hepatic Stellate Cells/*metabolism MH - Humans MH - Liver Neoplasms/*drug therapy/genetics/metabolism/pathology MH - Male MH - Matrix Metalloproteinase 2/metabolism MH - Matrix Metalloproteinase 9/metabolism MH - Neoplasm Invasiveness MH - Neoplasm Metastasis MH - Rats MH - Rats, Inbred BUF MH - Transforming Growth Factor beta1/metabolism PMC - PMC3639812 EDAT- 2013/04/30 06:00 MHDA- 2013/09/24 06:00 PMCR- 2013/04/27 CRDT- 2013/04/30 06:00 PHST- 2012/10/05 00:00 [received] PHST- 2013/04/17 00:00 [accepted] PHST- 2013/04/30 06:00 [entrez] PHST- 2013/04/30 06:00 [pubmed] PHST- 2013/09/24 06:00 [medline] PHST- 2013/04/27 00:00 [pmc-release] AID - 1472-6882-13-89 [pii] AID - 10.1186/1472-6882-13-89 [doi] PST - epublish SO - BMC Complement Altern Med. 2013 Apr 27;13:89. doi: 10.1186/1472-6882-13-89. PMID- 41198556 OWN - NLM STAT- MEDLINE DCOM- 20251106 LR - 20251106 IS - 2768-6698 (Electronic) IS - 2768-6698 (Linking) VI - 30 IP - 10 DP - 2025 Oct 31 TI - Study on the Mechanism of CCN2 Promoting Sorafenib Resistance in HCC and Its Combined Intervention Strategy. PG - 45454 LID - 10.31083/FBL45454 [doi] AB - BACKGROUND: Since its introduction in 2008, sorafenib has remained the standard first-line systemic treatment for advanced hepatocellular carcinoma (HCC). Nevertheless, its clinical benefits are often compromised by the rapid emergence of drug resistance. This study explores the molecular mechanisms underlying sorafenib resistance, with particular emphasis on the involvement of connective tissue growth factor (CCN2/CTGF) in the regulation of c-Met signaling pathways. METHODS: We began by evaluating CCN2 expression levels in HCC tissue samples via immunohistochemistry and analyzing their correlation with clinicopathological characteristics. To functionally characterize CCN2, we established stable HCC cell lines with either knockdown or overexpression of the gene using lentiviral transduction. The effects of CCN2 on cellular proliferation and drug resistance were evaluated using cell counting kit-8 (CCK-8) and colony formation assays. To elucidate the downstream signaling mechanisms, a tyrosine kinase PCR array was employed to identify expression changes within the tyrosine kinase superfamily after CCN2 knockdown. Further investigation into the molecular mechanism by which CCN2 promotes sorafenib resistance was conducted using real-time quantitative PCR (RT-qPCR), western blotting, and immunofluorescence. Finally, the therapeutic potential of co-targeting CCN2 and sorafenib was validated in a nude mouse xenograft tumor model. RESULTS: Our results establish that CCN2 overexpression significantly enhances HCC proliferation, while also inducing resistance to sorafenib. Mechanistically, we identified that CCN2 binds to integrin αV, triggering focal adhesion kinase (FAK) phosphorylation, which in turn promotes yes-associated protein (YAP) nuclear translocation and leads to the transcriptional upregulation of c-Met. This proposed signaling axis was consistently supported by tyrosine kinase PCR array, co-immunoprecipitation, and western blot analyses. Ultimately, in vivo experiments confirmed that simultaneously targeting CCN2 and administering sorafenib produces a synergistic effect, markedly inhibiting tumor growth and restoring therapeutic sensitivity. CONCLUSION: These results not only elucidate a novel CCN2/FAK/YAP/c-Met axis in sorafenib resistance but also provide a mechanistic rationale for dual-targeting strategies to improve outcomes in advanced HCC. CI - © 2025 The Author(s). Published by IMR Press. FAU - Cui, Lei AU - Cui L AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, 750004 Yinchuan, Ningxia, China. AD - School of Clinical Medicine, Ningxia Medical University, 750004 Yinchuan, Ningxia, China. FAU - Liu, Junhao AU - Liu J AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, 750004 Yinchuan, Ningxia, China. AD - School of Clinical Medicine, Ningxia Medical University, 750004 Yinchuan, Ningxia, China. FAU - Lv, Yongxue AU - Lv Y AD - School of Basic Medicine, Ningxia Medical University, 750004 Yinchuan, Ningxia, China. FAU - Chen, Bendong AU - Chen B AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, 750004 Yinchuan, Ningxia, China. AD - School of Clinical Medicine, Ningxia Medical University, 750004 Yinchuan, Ningxia, China. FAU - Liu, Kejun AU - Liu K AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, 750004 Yinchuan, Ningxia, China. AD - School of Clinical Medicine, Ningxia Medical University, 750004 Yinchuan, Ningxia, China. FAU - Bu, Yang AU - Bu Y AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, 750004 Yinchuan, Ningxia, China. AD - School of Clinical Medicine, Ningxia Medical University, 750004 Yinchuan, Ningxia, China. LA - eng GR - 81960533/National Natural Science Foundation/ GR - 2023AAC03507/Natural Science Foundation of Ningxia Hui Autonomous Region/ GR - 2023AAC03606/Natural Science Foundation of Ningxia Hui Autonomous Region/ GR - 2024BEH04154/Key R&D Program of Ningxia Hui Autonomous Region for High-level Talents Introduction/ PT - Journal Article PL - Singapore TA - Front Biosci (Landmark Ed) JT - Frontiers in bioscience (Landmark edition) JID - 101612996 RN - 9ZOQ3TZI87 (Sorafenib) RN - 139568-91-5 (Connective Tissue Growth Factor) RN - 0 (CCN2 protein, human) RN - 0 (Antineoplastic Agents) RN - EC 2.7.10.1 (Proto-Oncogene Proteins c-met) RN - 0 (YAP-Signaling Proteins) SB - IM MH - *Sorafenib/pharmacology/therapeutic use MH - Humans MH - *Connective Tissue Growth Factor/metabolism/genetics MH - *Drug Resistance, Neoplasm/genetics MH - *Liver Neoplasms/drug therapy/pathology/metabolism/genetics MH - *Carcinoma, Hepatocellular/drug therapy/pathology/metabolism/genetics MH - Animals MH - Mice MH - Cell Line, Tumor MH - Cell Proliferation/drug effects MH - Signal Transduction/drug effects MH - *Antineoplastic Agents/pharmacology/therapeutic use MH - Male MH - Female MH - Gene Expression Regulation, Neoplastic/drug effects MH - Xenograft Model Antitumor Assays MH - Mice, Nude MH - Proto-Oncogene Proteins c-met/metabolism MH - Middle Aged MH - YAP-Signaling Proteins OTO - NOTNLM OT - c-Met OT - connective tissue growth factor OT - drug resistance OT - hepatocellular carcinoma OT - sorafenib EDAT- 2025/11/07 00:27 MHDA- 2025/11/07 00:28 CRDT- 2025/11/06 22:02 PHST- 2025/07/31 00:00 [received] PHST- 2025/10/12 00:00 [revised] PHST- 2025/10/15 00:00 [accepted] PHST- 2025/11/07 00:28 [medline] PHST- 2025/11/07 00:27 [pubmed] PHST- 2025/11/06 22:02 [entrez] AID - S2768-6701(25)01873-8 [pii] AID - 10.31083/FBL45454 [doi] PST - ppublish SO - Front Biosci (Landmark Ed). 2025 Oct 31;30(10):45454. doi: 10.31083/FBL45454. PMID- 39566034 OWN - NLM STAT- MEDLINE DCOM- 20250426 LR - 20250517 IS - 1208-6002 (Electronic) IS - 0829-8211 (Linking) VI - 103 DP - 2025 Jan 1 TI - TMCO1 regulates energy metabolism and mitochondrial function of hepatocellular carcinoma cells through TOMM20, affecting the growth of subcutaneous graft tumors and infiltration of CAFs. PG - 1-15 LID - 10.1139/bcb-2024-0091 [doi] AB - This study mainly shows the role of endoplasmic reticulum transmembrane and coiled coil domains 1 (TMCO1) in the regulatory mechanism of hepatocellular carcinoma (HCC). Invasion and migration capacity were detected by Transwell and wound healing after TMCO1 and TOMM20 overexpression and knockdown, and mitochondrial function was detected through reactive oxygen species (ROS), mitochondrial permeability transition pore (mPTP), mitochondrial membrane potential (MMP), and ATP production. A model of subcutaneous tumor formation in nude mice was established to detect the effect of TMCO1 on tumor formation. The results showed that overexpression of TMCO1 significantly promoted HCC cell metastasis, promoted cell proliferation and ATP production, inhibited cell apoptosis, mPTP opening and ROS production, mediated the increase of MMP level and cytoskeletal remodeling. However, knocking down TMCO1 can have the opposite effect. More importantly, knocking down TOMM20 can block the regulation effect of TMCO1, and TOMM20 overexpression can alleviate the inhibitory effect of knocking down TMCO1 on the development of liver cancer cells. In animal models, knockdown of TMCO1 expression significantly inhibited the growth of subcutaneous implant tumors. This suggests that TMCO1 may be a potential and valuable therapeutic target for liver cancer. CI - © 2024 The Author(s). Permission for reuse (free in most cases) can be obtained from copyright.com. FAU - Wang, Genwang AU - Wang G AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan 750004, Ningxia, China. FAU - Liu, Di AU - Liu D AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan 750004, Ningxia, China. FAU - Leng, Junzhi AU - Leng J AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan 750004, Ningxia, China. FAU - Jin, Dong AU - Jin D AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan 750004, Ningxia, China. FAU - Wang, Qi AU - Wang Q AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan 750004, Ningxia, China. FAU - Wang, Hao AU - Wang H AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan 750004, Ningxia, China. FAU - Bu, Yang AU - Bu Y AD - Department of Hepatobiliary Surgery, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan 750002, Ningxia, China. FAU - Wang, Feng AU - Wang F AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan 750004, Ningxia, China. FAU - Hui, Yongfeng AU - Hui Y AUID- ORCID: 0009-0001-1309-7767 AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan 750004, Ningxia, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20241120 PL - Canada TA - Biochem Cell Biol JT - Biochemistry and cell biology = Biochimie et biologie cellulaire JID - 8606068 RN - 0 (Mitochondrial Precursor Protein Import Complex Proteins) RN - 0 (TOMM20 protein, human) RN - 0 (Receptors, Cell Surface) RN - 0 (Reactive Oxygen Species) RN - 0 (Membrane Transport Proteins) RN - 0 (Mitochondrial Membrane Transport Proteins) SB - IM MH - *Liver Neoplasms/metabolism/pathology MH - *Carcinoma, Hepatocellular/metabolism/pathology MH - Animals MH - Humans MH - Mitochondrial Precursor Protein Import Complex Proteins MH - Mice MH - Mice, Nude MH - *Energy Metabolism MH - Cell Proliferation MH - *Mitochondria/metabolism/pathology MH - Mice, Inbred BALB C MH - *Receptors, Cell Surface/metabolism/genetics MH - Reactive Oxygen Species/metabolism MH - Apoptosis MH - Cell Line, Tumor MH - Male MH - *Membrane Transport Proteins/metabolism/genetics MH - Mitochondrial Membrane Transport Proteins/metabolism OTO - NOTNLM OT - TMCO1 OT - TOMM20 OT - cancer-associated fibroblasts (CAFs) OT - energy metabolism OT - hepatoma carcinoma COIS- The authors declare there are no competing interests. EDAT- 2024/11/20 18:22 MHDA- 2025/01/20 22:54 CRDT- 2024/11/20 16:43 PHST- 2025/01/20 22:54 [medline] PHST- 2024/11/20 18:22 [pubmed] PHST- 2024/11/20 16:43 [entrez] AID - 10.1139/bcb-2024-0091 [doi] PST - ppublish SO - Biochem Cell Biol. 2025 Jan 1;103:1-15. doi: 10.1139/bcb-2024-0091. Epub 2024 Nov 20. PMID- 29329245 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20180222 LR - 20181113 IS - 1424-8220 (Electronic) IS - 1424-8220 (Linking) VI - 18 IP - 1 DP - 2018 Jan 12 TI - Underwater Object Segmentation Based on Optical Features. LID - 10.3390/s18010196 [doi] LID - 196 AB - Underwater optical environments are seriously affected by various optical inputs, such as artificial light, sky light, and ambient scattered light. The latter two can block underwater object segmentation tasks, since they inhibit the emergence of objects of interest and distort image information, while artificial light can contribute to segmentation. Artificial light often focuses on the object of interest, and, therefore, we can initially identify the region of target objects if the collimation of artificial light is recognized. Based on this concept, we propose an optical feature extraction, calculation, and decision method to identify the collimated region of artificial light as a candidate object region. Then, the second phase employs a level set method to segment the objects of interest within the candidate region. This two-phase structure largely removes background noise and highlights the outline of underwater objects. We test the performance of the method with diverse underwater datasets, demonstrating that it outperforms previous methods. FAU - Chen, Zhe AU - Chen Z AUID- ORCID: 0000-0002-2250-5371 AD - College of Computer and Information, Hohai University, Nanjing 211100, China. chenzhe@hhu.edu.cn. FAU - Zhang, Zhen AU - Zhang Z AD - College of Computer and Information, Hohai University, Nanjing 211100, China. zz_hhuc@hhu.edu.cn. FAU - Bu, Yang AU - Bu Y AD - Laboratory of Information Optics and Opto-Electronic Technology, Shanghai Institute of Optics and Fine Mechanics, Shanghai 201800, China. buyang@siom.ac.cn. FAU - Dai, Fengzhao AU - Dai F AD - Laboratory of Information Optics and Opto-Electronic Technology, Shanghai Institute of Optics and Fine Mechanics, Shanghai 201800, China. fzdai@siom.ac.cn. FAU - Fan, Tanghuai AU - Fan T AD - School of Information Engineering, Nanchang Institute of Technology, Nanchang 330099, China. fantanghuai@nit.edu.cn. FAU - Wang, Huibin AU - Wang H AD - College of Computer and Information, Hohai University, Nanjing 211100, China. hbwang@hhu.edu.cn. LA - eng PT - Journal Article DEP - 20180112 PL - Switzerland TA - Sensors (Basel) JT - Sensors (Basel, Switzerland) JID - 101204366 PMC - PMC5795476 OTO - NOTNLM OT - artificial light guidance OT - level-set-based object segmentation OT - optical features OT - underwater object segmentation COIS- The authors declare no conflict of interest. EDAT- 2018/01/13 06:00 MHDA- 2018/01/13 06:01 PMCR- 2018/01/01 CRDT- 2018/01/13 06:00 PHST- 2017/12/01 00:00 [received] PHST- 2018/01/09 00:00 [revised] PHST- 2018/01/09 00:00 [accepted] PHST- 2018/01/13 06:00 [entrez] PHST- 2018/01/13 06:00 [pubmed] PHST- 2018/01/13 06:01 [medline] PHST- 2018/01/01 00:00 [pmc-release] AID - s18010196 [pii] AID - sensors-18-00196 [pii] AID - 10.3390/s18010196 [doi] PST - epublish SO - Sensors (Basel). 2018 Jan 12;18(1):196. doi: 10.3390/s18010196. PMID- 41427790 OWN - NLM STAT- MEDLINE DCOM- 20251222 LR - 20251224 IS - 1530-6860 (Electronic) IS - 0892-6638 (Print) IS - 0892-6638 (Linking) VI - 39 IP - 24 DP - 2025 Dec 31 TI - Single-Cell Multi-Omics Reveals B2M-Mediated Myeloid Reprogramming and Constructs a Predictive Model for Early Hepatocellular Carcinoma Recurrence. PG - e71362 LID - 10.1096/fj.202503144R [doi] LID - e71362 AB - Early recurrence remains a major challenge in the management of hepatocellular carcinoma (HCC), yet its molecular mechanisms are not fully understood. In this study, we applied an integrative multi-omics strategy at single-cell resolution to explore potential drivers of early HCC recurrence (recurrence time < 2 years) and to develop a predictive framework. By combining single-cell RNA sequencing, proteomics, transcriptomics, and clinical feature analysis, we identified 14 relapse-associated proteins, including CD274, B2M, MYC, and CASP3, as candidate risk factors. Transcriptomic profiling suggested the enrichment of pathways such as MYC-TARGETS-V2 and INTERFERON-GAMMA-RESPONSE. Single-cell analysis indicated reduced immune cell infiltration in recurrent tumors, with myeloid cells (particularly cDC2 and macrophages) showing B2M-associated reprogramming characterized by HLA downregulation and altered GAS6/PROS1 signaling, consistent with tumor-associated macrophage-like phenotypes. A LASSO regression model based on cDC2 and macrophage signature genes demonstrated moderate predictive performance in both the training and validation cohorts (AUC > 0.65). Drug sensitivity analyses further suggested that vandetanib may have the potential to inhibit recurrence by targeting B2M-related pathways. These findings provide evidence that B2M may contribute to remodeling of the immune microenvironment in recurrent HCC. Our integrative single-cell multi-omics approach highlights a possible mechanism of early recurrence and offers a preliminary predictive tool with therapeutic implications. CI - © 2025 The Author(s). The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology. FAU - Tan, Zhenyao AU - Tan Z AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, China. AD - School of Clinical Medicine, Ningxia Medical University, Yinchuan, China. FAU - Tang, Yezhen AU - Tang Y AD - School of Basic Medicine, Ningxia Medical University, Yinchuan, China. FAU - Chen, Bendong AU - Chen B AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, China. AD - School of Clinical Medicine, Ningxia Medical University, Yinchuan, China. FAU - Lv, Yongxue AU - Lv Y AUID- ORCID: 0000-0002-9095-0469 AD - School of Basic Medicine, Ningxia Medical University, Yinchuan, China. FAU - Zhang, Bozhi AU - Zhang B AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, China. AD - School of Clinical Medicine, Ningxia Medical University, Yinchuan, China. FAU - Liu, Kejun AU - Liu K AUID- ORCID: 0000-0001-5770-7865 AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, China. AD - School of Clinical Medicine, Ningxia Medical University, Yinchuan, China. FAU - Bu, Yang AU - Bu Y AUID- ORCID: 0000-0003-1219-997X AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, China. AD - School of Clinical Medicine, Ningxia Medical University, Yinchuan, China. LA - eng GR - 81960533/National Natural Science Foundation/ GR - 2023AAC02073/Natural Science Foundation of Ningxia Hui Autonomous Region/ GR - 2025AAC030642/Natural Science Foundation of Ningxia Hui Autonomous Region/ GR - 2024FRD05095/Central Guidance on Local Science and Technology Development Foundation of Ningxia Province/ GR - 2024BEH04154/Key R&D Program of Ningxia Hui Autonomous Region/ GR - 2022(46)/Ningxia Overseas Returnees' Innovation and Entrepreneurship Project/ PT - Journal Article PL - United States TA - FASEB J JT - FASEB journal : official publication of the Federation of American Societies for Experimental Biology JID - 8804484 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Carcinoma, Hepatocellular/metabolism/pathology/genetics MH - *Liver Neoplasms/metabolism/pathology/genetics MH - *Neoplasm Recurrence, Local/metabolism/pathology/genetics MH - Single-Cell Analysis/methods MH - *Myeloid Cells/metabolism/pathology MH - Male MH - Transcriptome MH - Female MH - Gene Expression Regulation, Neoplastic MH - Proteomics/methods MH - Middle Aged MH - Gene Expression Profiling MH - Biomarkers, Tumor/genetics/metabolism MH - *Cellular Reprogramming MH - Multiomics PMC - PMC12721209 OTO - NOTNLM OT - B2M OT - early recurrence OT - hepatocellular carcinoma OT - macrophages OT - predictors COIS- The authors declare no conflicts of interest. EDAT- 2025/12/22 12:56 MHDA- 2025/12/22 12:57 PMCR- 2025/12/22 CRDT- 2025/12/22 09:43 PHST- 2025/11/29 00:00 [revised] PHST- 2025/08/29 00:00 [received] PHST- 2025/12/08 00:00 [accepted] PHST- 2025/12/22 12:57 [medline] PHST- 2025/12/22 12:56 [pubmed] PHST- 2025/12/22 09:43 [entrez] PHST- 2025/12/22 00:00 [pmc-release] AID - FSB271362 [pii] AID - 10.1096/fj.202503144R [doi] PST - ppublish SO - FASEB J. 2025 Dec 31;39(24):e71362. doi: 10.1096/fj.202503144R. PMID- 29041312 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20180207 LR - 20181023 IS - 1094-4087 (Electronic) IS - 1094-4087 (Linking) VI - 25 IP - 20 DP - 2017 Oct 2 TI - Automatic spectral calibration for polarization-sensitive optical coherence tomography. PG - 23605-23618 LID - 10.1364/OE.25.023605 [doi] AB - Accurate wavelength assignment is important for Fourier domain polarization-sensitive optical coherence tomography. Incorrect wavelength mapping between the orthogonal horizontal (H) and vertical (V) polarization channels leads to broadening the axial point spread function and generating polarization artifacts. To solve the problem, we propose an automatic spectral calibration method by seeking the optimal calibration coefficient between wavenumber kH and kV. The method first performs a rough calibration to get the relationship between the wavelength λ and the pixel number x of the CCD for each channel. And then a precise calibration is taken to bring both polarization interferograms in the same k range through the optimal calibration coefficient. The optimal coefficient is automatically obtained by evaluating the cross-correlation of A-line signals. Simulations and experiments are implemented to demonstrate the performance of the proposed method. The results show that, compared to the peaks method, the proposed method is suitable in both Gaussian and non-Gaussian spectrums with a higher calibration accuracy. FAU - Chen, Yan AU - Chen Y FAU - Li, Zhongliang AU - Li Z FAU - Nan, Nan AU - Nan N FAU - Bu, Yang AU - Bu Y FAU - Wang, Xuan AU - Wang X FAU - Pan, Liuhua AU - Pan L FAU - Wang, Xiangzhao AU - Wang X LA - eng PT - Journal Article PL - United States TA - Opt Express JT - Optics express JID - 101137103 EDAT- 2017/10/19 06:00 MHDA- 2017/10/19 06:01 CRDT- 2017/10/19 06:00 PHST- 2017/10/19 06:00 [entrez] PHST- 2017/10/19 06:00 [pubmed] PHST- 2017/10/19 06:01 [medline] AID - 372925 [pii] AID - 10.1364/OE.25.023605 [doi] PST - ppublish SO - Opt Express. 2017 Oct 2;25(20):23605-23618. doi: 10.1364/OE.25.023605. PMID- 28870205 OWN - NLM STAT- MEDLINE DCOM- 20180510 LR - 20191023 IS - 1756-9966 (Electronic) IS - 0392-9078 (Print) IS - 0392-9078 (Linking) VI - 36 IP - 1 DP - 2017 Sep 4 TI - Maintenance of stemness is associated with the interation of LRP6 and heparin-binding protein CCN2 autocrined by hepatocellular carcinoma. PG - 117 LID - 10.1186/s13046-017-0576-3 [doi] LID - 117 AB - BACKGROUND: The overall response rate of hepatocellular carcinoma (HCC) to chemotherapy is poor. In our previous study, oxaliplatin-resistant HCC is found to exhibit an enhanced stemness, and increased levels of CCN2 and LRP6, while the role of CCN2 and LRP6 in the prognosis of HCC patients, and the interaction regulation mechanism between CCN2 and LRP6 are still unclear. METHODS: The expression levels of CCN2 and LRP6 were detected in large cohorts of HCCs, and functional analyses of CCN2 and LRP6 were performed both in vitro and in vivo. The roles of cell surface heparin sulfate proteoglycans (HSPGs) in the mutual regulatory between CCN2 and LRP6 were verified in HCC, and the interventions of low molecular weight heparin sodium (LMWH) were explored. RESULTS: CCN2 and LRP6 were overexpressed in HCCs, and the CCN2 and LRP6 levels were positively associated with the malignant phenotypes and poor prognosis of HCCs. LRP6 could significantly upregulate the expression of CCN2. Meanwhile, CCN2 was able to enhance malignant phenotype of HCC cells in a dose-dependent manner through binding with LRP6; and knock-down of LRP6 expression, perturbation of HSPGs, co-incubation of CCN2 with LMWH could significantly block the adhesion of CCN2 to LRP6. LMWH enhanced the therapeutic effect of oxaliplatin on HCC with a high CCN2 expression. CONCLUSIONS: CCN2 plays a promoting role in HCC progression through activating LRP6 in a HSPGs-dependent manner. Heparin in combination with chemotherapy has a synergic effect and could be a treatment choice for HCCs with a high CCN2 expression. FAU - Jia, Qingan AU - Jia Q AD - Department of Hepatobiliary Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, 277 West Yanta Road, Xi'an, 710061, China. FAU - Bu, Yang AU - Bu Y AD - Department of Hepatobiliary Surgery, General Hospital, Ningxia Medical University, Yinchuan, 750001, China. FAU - Wang, Zhiming AU - Wang Z AD - Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. FAU - Chen, Bendong AU - Chen B AD - Department of Hepatobiliary Surgery, General Hospital, Ningxia Medical University, Yinchuan, 750001, China. FAU - Zhang, Qiangbo AU - Zhang Q AD - Department of General Surgery, Qilu Hospital, Shandong University, Jinan, 250012, China. FAU - Yu, Songning AU - Yu S AD - Department of Hepatobiliary Surgery, General Hospital, Ningxia Medical University, Yinchuan, 750001, China. FAU - Liu, Qingguang AU - Liu Q AD - Department of Hepatobiliary Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, 277 West Yanta Road, Xi'an, 710061, China. liuqingguang@vip.sina.com. LA - eng PT - Journal Article DEP - 20170904 PL - England TA - J Exp Clin Cancer Res JT - Journal of experimental & clinical cancer research : CR JID - 8308647 RN - 0 (CCN2 protein, human) RN - 0 (Heparin, Low-Molecular-Weight) RN - 0 (LRP6 protein, human) RN - 0 (Low Density Lipoprotein Receptor-Related Protein-6) RN - 0 (Organoplatinum Compounds) RN - 04ZR38536J (Oxaliplatin) RN - 139568-91-5 (Connective Tissue Growth Factor) SB - IM MH - Adult MH - Aged MH - Autocrine Communication/genetics MH - Carcinoma, Hepatocellular/*drug therapy/genetics/pathology MH - Cell Line, Tumor MH - Cell Proliferation/drug effects MH - Connective Tissue Growth Factor/*genetics MH - Drug Resistance, Neoplasm/genetics MH - Female MH - Gene Expression Regulation, Neoplastic/drug effects MH - Heparin, Low-Molecular-Weight/genetics MH - Humans MH - Liver Neoplasms/*drug therapy/genetics/pathology MH - Low Density Lipoprotein Receptor-Related Protein-6/*genetics MH - Male MH - Middle Aged MH - Neoplastic Stem Cells/drug effects MH - Organoplatinum Compounds/administration & dosage MH - Oxaliplatin MH - Prognosis PMC - PMC5584530 OTO - NOTNLM OT - CCN2 OT - Combination therapy OT - Hepatocellular carcinoma OT - LRP6 OT - Wnt COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Not applicable. CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. EDAT- 2017/09/06 06:00 MHDA- 2018/05/11 06:00 PMCR- 2017/09/04 CRDT- 2017/09/06 06:00 PHST- 2017/06/27 00:00 [received] PHST- 2017/08/02 00:00 [accepted] PHST- 2017/09/06 06:00 [entrez] PHST- 2017/09/06 06:00 [pubmed] PHST- 2018/05/11 06:00 [medline] PHST- 2017/09/04 00:00 [pmc-release] AID - 10.1186/s13046-017-0576-3 [pii] AID - 576 [pii] AID - 10.1186/s13046-017-0576-3 [doi] PST - epublish SO - J Exp Clin Cancer Res. 2017 Sep 4;36(1):117. doi: 10.1186/s13046-017-0576-3. PMID- 23698195 OWN - NLM STAT- MEDLINE DCOM- 20140123 LR - 20130619 IS - 1477-9234 (Electronic) IS - 1477-9226 (Linking) VI - 42 IP - 27 DP - 2013 Jul 21 TI - A series of novel zinc(II) entangled coordination polymers based on carboxyphenyl-terpyridine ligands. PG - 9954-65 LID - 10.1039/c3dt50532d [doi] AB - Hydrothermal synthesis has afforded five divalent zinc coordination polymers containing 4-(4-carboxyphenyl)-2,2':6',2''-terpyridine (HL1) or its isomer 4-(4-carboxyphenyl)-2,2':4',4''-terpyridine (HL2), with or without the addition of auxiliary ligands, 1,3,5-benzenetricarboxylic acid (H3btc) and 1,4-benzenedicarboxylic acid (H2bdc). Their structures have been characterized by single crystal X-ray analyses and further characterized by infrared spectra, elemental analyses, powder X-ray diffraction, thermogravimetric analyses and photoluminescent spectra. Across this series, the π···π interactions have a dramatic impact on the self-assembly of these entanglement structures, in either case it can exert an important structure-directing role. In addition, the disposition of pyridine nitrogen atoms in ligands also plays a large role in structure direction in this system. Complex 1 is a 2D + 2D→3D inclined polycatenated coordination polymer based on the resulting array of 2D (6,3) layers constructed by 1D→2D π···π directed self-assembly. Complex 2 is assembled into a 3D framework by means of 1D + 1D→3D mutual interdigitation based on 1D→1D self-assembly driven by π···π stacking interactions. Complex 3 shows a 2D + 2D→3D interdigital network involving 2D + 2D→2D parallel interpenetrated and 2D + 2D→2D interdigital (4,4) layer motifs. Complex 4 displays a 2D + 2D→3D polythreaded framework based on a 2D (4,4) network comprised of alternating rings and rods. Complex 5 is a (3,4)-connected 3D framework with topology (4.8(2).10(3))(4.8(2)). In comparison with covalently connected entanglements, such π···π directing self-assembly of entanglements are far less explored, especially, polycatenane based on 1D chain motifs and polythread based on 2D layer motifs are rarely reported. Furthermore, the luminescent properties of complexes 1-5 at room temperature have also been studied in detail herein. FAU - Gai, Yan-Li AU - Gai YL AD - State Key Laboratory of Structure Chemistry, Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou, 350002, China. FAU - Jiang, Fei-Long AU - Jiang FL FAU - Chen, Lian AU - Chen L FAU - Bu, Yang AU - Bu Y FAU - Wu, Ming-Yan AU - Wu MY FAU - Zhou, Kang AU - Zhou K FAU - Pan, Jie AU - Pan J FAU - Hong, Mao-Chun AU - Hong MC LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20130523 PL - England TA - Dalton Trans JT - Dalton transactions (Cambridge, England : 2003) JID - 101176026 RN - 0 (Ligands) RN - 0 (Organometallic Compounds) RN - 0 (Polymers) RN - 0 (Pyridines) RN - J41CSQ7QDS (Zinc) SB - IM MH - Ligands MH - Luminescent Measurements MH - Models, Molecular MH - Organometallic Compounds/*chemical synthesis/chemistry MH - Polymers/*chemistry MH - Pyridines/*chemistry MH - Zinc/*chemistry EDAT- 2013/05/24 06:00 MHDA- 2014/01/24 06:00 CRDT- 2013/05/24 06:00 PHST- 2013/05/24 06:00 [entrez] PHST- 2013/05/24 06:00 [pubmed] PHST- 2014/01/24 06:00 [medline] AID - 10.1039/c3dt50532d [doi] PST - ppublish SO - Dalton Trans. 2013 Jul 21;42(27):9954-65. doi: 10.1039/c3dt50532d. Epub 2013 May 23. PMID- 30876077 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20190318 LR - 20190318 IS - 1094-4087 (Electronic) IS - 1094-4087 (Linking) VI - 27 IP - 4 DP - 2019 Feb 18 TI - Jones pupil metrology of lithographic projection lens and its optimal configuration in the presence of error sources. PG - 4629-4647 LID - 10.1364/OE.27.004629 [doi] AB - Mueller matrix imaging polarimeter (MMIP) can be used to measure the polarization aberration (PA) of a lithographic projector in the form of the Mueller pupil, while the Jones pupil is required for lithographic imaging simulations, projection lens design and PA evaluation. In this paper, a Jones pupil measurement method of lithographic projection lens is proposed. The measurement device of the method is the same as an MMIP, but a new polarimetric measurement equation is derived to solve the Jones pupil directly from the Kronecker product of the Jones matrix and the measured intensities. Two new polarimeter configurations with the minimum condition number are designed to further improve the accuracy in the presence of error sources. The performance of the method is evaluated by measurement errors of a typical Jones pupil in the presence of error sources. Comparisons between the proposed method and the conventional method, in which the Jones pupil is converted from the Mueller pupil measured by MMIP, are given. The results validate that the measurement accuracy of the Jones pupil is significantly improved without increasing the complexity of existing measurement systems. FAU - Meng, Zejiang AU - Meng Z FAU - Li, Sikun AU - Li S FAU - Wang, Xiangzhao AU - Wang X FAU - Bu, Yang AU - Bu Y FAU - Wang, Jian AU - Wang J FAU - Ni, Sheng AU - Ni S FAU - Yang, Chaoxing AU - Yang C FAU - Mao, Yanjie AU - Mao Y LA - eng PT - Journal Article PL - United States TA - Opt Express JT - Optics express JID - 101137103 EDAT- 2019/03/17 06:00 MHDA- 2019/03/17 06:01 CRDT- 2019/03/17 06:00 PHST- 2019/03/17 06:00 [entrez] PHST- 2019/03/17 06:00 [pubmed] PHST- 2019/03/17 06:01 [medline] AID - 404809 [pii] AID - 10.1364/OE.27.004629 [doi] PST - ppublish SO - Opt Express. 2019 Feb 18;27(4):4629-4647. doi: 10.1364/OE.27.004629. PMID- 40917057 OWN - NLM STAT- MEDLINE DCOM- 20250911 LR - 20250911 IS - 2768-6698 (Electronic) IS - 2768-6698 (Linking) VI - 30 IP - 8 DP - 2025 Aug 29 TI - MED10 as a Novel Oncogenic Driver in HCC: Promoting Cell Cycle Progression and Proliferation Through RAF1 Activation. PG - 39944 LID - 10.31083/FBL39944 [doi] AB - BACKGROUND: Mediator complex subunit 10 (MED10) serves as a critical regulator of eukaryotic gene expression by facilitating RNA polymerase II activity. Our investigation aims to characterize MED10's functional contributions and underlying molecular pathways in hepatocellular carcinoma (HCC) development. METHODS: MED10 expression patterns in HCC and their correlation with clinicopathological parameters and patient outcomes were examined using bioinformatics databases and immunohistochemistry. Subsequently, we systematically investigated the biological functions of MED10 in the malignant progression of HCC through comprehensive in vitro experiments, including assessments of cell migration (transwell and wound healing assays), proliferative capacity (cell counting kit-8, colony formation, and 5-Ethynyl-2'-deoxyuridine assays), and cell cycle progression (flow cytometry analysis). Furthermore, we elucidated the underlying molecular mechanisms using real-time quantitative PCR (RT-qPCR), western blotting, immunofluorescence staining, and public database analyses. Furthermore, an in vivo subcutaneous xenograft model was employed to validate MED10's impact on tumor growth. RESULTS: The results revealed a marked increase in MED10 expression levels within HCC tissues, showing a strong association with unfavorable clinical outcomes. Mechanistically, MED10 induced the epithelial-mesenchymal transition (EMT) and enhanced HCC cell migration. Moreover, MED10 overexpression drives HCC cell cycle progression and proliferation by activating rapidly accelerated fibrosarcoma 1 (RAF1), a process potentially mediated through the mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK)/cellular myelocytomatosis oncogene (c-Myc) signaling axis. CONCLUSION: MED10 promotes HCC cell migration and EMT but, more importantly, also drives cell cycle progression and proliferation via RAF1 activation, and is related to the MEK/ERK/c-Myc axis. CI - © 2025 The Author(s). Published by IMR Press. FAU - Liu, Junhao AU - Liu J AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, 750004 Yinchuan, Ningxia Hui Autonomous Region, China. AD - School of Clinical Medicine, Ningxia Medical University, 750004 Yinchuan, Ningxia Hui Autonomous Region, China. FAU - Lv, Yongxue AU - Lv Y AD - School of Basic Medicine, Ningxia Medical University, 750004 Yinchuan, Ningxia Hui Autonomous Region, China. FAU - Liu, Kejun AU - Liu K AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, 750004 Yinchuan, Ningxia Hui Autonomous Region, China. AD - School of Clinical Medicine, Ningxia Medical University, 750004 Yinchuan, Ningxia Hui Autonomous Region, China. FAU - Li, Zhengquan AU - Li Z AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, 750004 Yinchuan, Ningxia Hui Autonomous Region, China. AD - School of Clinical Medicine, Ningxia Medical University, 750004 Yinchuan, Ningxia Hui Autonomous Region, China. FAU - Chen, Bendong AU - Chen B AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, 750004 Yinchuan, Ningxia Hui Autonomous Region, China. AD - School of Clinical Medicine, Ningxia Medical University, 750004 Yinchuan, Ningxia Hui Autonomous Region, China. FAU - Bu, Yang AU - Bu Y AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, 750004 Yinchuan, Ningxia Hui Autonomous Region, China. AD - School of Clinical Medicine, Ningxia Medical University, 750004 Yinchuan, Ningxia Hui Autonomous Region, China. LA - eng GR - 81960533/National Natural Science Foundation of China/ GR - 2023AAC03606/Ningxia natural science foundation/ GR - 2023AAC03507/Ningxia natural science foundation/ GR - XM2022041/School-level scientific research project of Ningxia Medical University/ GR - 4301240006/2024 First-class Discipline Funding of Ningxia Medical University (Third Clinical College of Medicine)/ GR - 2024BEH04154/Key R&D Program Talent Introduction Special Project of Ningxia Hui Autonomous Region/ PT - Journal Article PL - Singapore TA - Front Biosci (Landmark Ed) JT - Frontiers in bioscience (Landmark edition) JID - 101612996 RN - 0 (MED10 protein, human) RN - EC 2.7.11.1 (Raf1 protein, human) RN - 0 (Mediator Complex) RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-raf) SB - IM MH - *Carcinoma, Hepatocellular/genetics MH - Carcinogenesis MH - *Cell Cycle MH - Cell Proliferation MH - *Mediator Complex/genetics MH - *Proto-Oncogene Proteins c-raf/genetics MH - Humans MH - Animals MH - Epithelial-Mesenchymal Transition MH - MAP Kinase Signaling System MH - Cell Line, Tumor MH - Female MH - Mice MH - Mice, Inbred BALB C MH - Mice, Nude MH - Neoplasms, Experimental/genetics MH - Male MH - Middle Aged MH - Adult MH - Aged OTO - NOTNLM OT - MAPK signaling pathway OT - cell cycle OT - hepatocellular carcinoma OT - mediator complex subunit 10 OT - prognosis OT - proliferation EDAT- 2025/09/08 12:42 MHDA- 2025/09/08 12:43 CRDT- 2025/09/08 06:53 PHST- 2025/04/24 00:00 [received] PHST- 2025/07/13 00:00 [revised] PHST- 2025/07/28 00:00 [accepted] PHST- 2025/09/08 12:43 [medline] PHST- 2025/09/08 12:42 [pubmed] PHST- 2025/09/08 06:53 [entrez] AID - S2768-6701(25)01798-8 [pii] AID - 10.31083/FBL39944 [doi] PST - ppublish SO - Front Biosci (Landmark Ed). 2025 Aug 29;30(8):39944. doi: 10.31083/FBL39944. PMID- 32261812 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200408 IS - 2050-7518 (Electronic) IS - 2050-750X (Linking) VI - 2 IP - 38 DP - 2014 Oct 14 TI - Er(3+)-doped YbPO(4) up-conversion porous nanospheres for UCL/CT bimodal imaging in vivo and chemotherapy. PG - 6508-6516 LID - 10.1039/c4tb00880d [doi] AB - The combined use nanotechnology and medical technologies holds great promise for the development and improvement of various theranostic media. Here, based on a facile hydrothermal method, polyethyleneimine (PEI) functionalized YbPO(4):Er up-conversion porous nanospheres (UCPSs) were fabricated, which combined the capabilities of up-conversion luminescence (UCL)/X-ray computed tomography (CT) bimodal imaging and drug delivery. The resulting hydrophilic PEI functionalized YbPO(4):Er UCPSs (PEI-UCPSs) showed uniform morphology and high crystallinity. Moreover, PEI-UCPSs possessed high drug loading capacity because of their large specific surface area, which was confirmed by the Brunauer-Emmett-Teller (BET) experiment. Cellular experiments indicated that the PEI-UCPSs had low cytotoxicity and confirmed the performance of the pH-mediated cancer targeting of PEI-UCPSs@DOX. Importantly, because of the ideal UCL property and high CT contrast both in vitro and in vivo, YbPO(4):Er PEI-UCPSs could be used as an optical probe and a contrast agent for optical and CT imaging, forming a promising platform for simultaneous bioimaging and drug delivery. FAU - Zheng, Xiaopeng AU - Zheng X AD - Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing, 100049, P. R. China. zhoulj@ihep.ac.cn zjgu@ihep.ac.cn zhaoyuliang@ihep.ac.cn. FAU - Zhou, Liangjun AU - Zhou L FAU - Bu, Yang AU - Bu Y FAU - Yin, Wenyan AU - Yin W FAU - Hu, Zhongbo AU - Hu Z FAU - Li, Meng AU - Li M FAU - Gu, Zhanjun AU - Gu Z FAU - Zhao, Yuliang AU - Zhao Y LA - eng PT - Journal Article DEP - 20140820 PL - England TA - J Mater Chem B JT - Journal of materials chemistry. B JID - 101598493 SB - IM EDAT- 2014/10/14 00:00 MHDA- 2014/10/14 00:01 CRDT- 2020/04/09 06:00 PHST- 2020/04/09 06:00 [entrez] PHST- 2014/10/14 00:00 [pubmed] PHST- 2014/10/14 00:01 [medline] AID - 10.1039/c4tb00880d [doi] PST - ppublish SO - J Mater Chem B. 2014 Oct 14;2(38):6508-6516. doi: 10.1039/c4tb00880d. Epub 2014 Aug 20. PMID- 31804063 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20200414 LR - 20200414 IS - 1520-6882 (Electronic) IS - 0003-2700 (Linking) VI - 92 IP - 1 DP - 2020 Jan 7 TI - Conductance Interplay in Ion Concentration Polarization across 1D Nanochannels: Microchannel Surface Shunt and Nanochannel Conductance. PG - 1252-1259 LID - 10.1021/acs.analchem.9b04417 [doi] AB - Ion concentration polarization has received much interest in the past decade for lab-on-a-chip applications, primarily preconcentration of biomolecules and water desalination. Studying the basic phenomenon in microfluidics has also generated new knowledge, which could be pivotal in the design of novel devices. Many studies, however, have focused on designs featuring nanoslits/slots or surface-patterned ion-selective membranes whereas the characteristics of 1D nanochannels are still lacking. Here, we report on ion concentration polarization across highly ordered 1D nanochannels in isolation as well as in array formation. Intriguingly, the nanochannels in isolation exhibit a linear current-voltage characteristic at low salt concentrations despite the confirmed presence of ion-depletion zone, which is associated with the diffusion-limited transport and the consequent nonlinearity in the classical sense. The characteristic in array formation breaks away from the linearity with a peculiar dip in current for a critical salt concentration in the dilute limit. We describe these findings based on the interplay between the nanochannel conductance and the conductance of the neighboring microchannel walls (the so-called surface shunt). Also, the nanochannel transport is identified with the mobility of protons more closely than that of salt cations. We attribute fast transport to phosphorus-doped silicate glass, the nanochannel material known to have very fine pores likely to be populated with protons as a result of moisture and carbon dioxide adsorption from the air. The nanochannels possess a tubular profile 70 nm in nominal diameter and fabricated through thermal reflow of doped glass on silicon without using advanced lithography. FAU - Ahmed, Zisun AU - Ahmed Z AUID- ORCID: 0000-0001-9125-4193 FAU - Bu, Yang AU - Bu Y FAU - Yobas, Levent AU - Yobas L AUID- ORCID: 0000-0003-3151-5616 LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20191216 PL - United States TA - Anal Chem JT - Analytical chemistry JID - 0370536 SB - IM EDAT- 2019/12/06 06:00 MHDA- 2019/12/06 06:01 CRDT- 2019/12/06 06:00 PHST- 2019/12/06 06:00 [pubmed] PHST- 2019/12/06 06:01 [medline] PHST- 2019/12/06 06:00 [entrez] AID - 10.1021/acs.analchem.9b04417 [doi] PST - ppublish SO - Anal Chem. 2020 Jan 7;92(1):1252-1259. doi: 10.1021/acs.analchem.9b04417. Epub 2019 Dec 16. PMID- 26145146 OWN - NLM STAT- MEDLINE DCOM- 20160617 LR - 20161125 IS - 2040-3372 (Electronic) IS - 2040-3364 (Linking) VI - 7 IP - 29 DP - 2015 Aug 7 TI - Silica-coated bismuth sulfide nanorods as multimodal contrast agents for a non-invasive visualization of the gastrointestinal tract. PG - 12581-91 LID - 10.1039/c5nr03068d [doi] AB - Non-invasive and real-time imaging of the gastrointestinal (GI) tract is particularly desirable for research and clinical studies of patients with symptoms arising from gastrointestinal diseases. Here, we designed and fabricated silica-coated bismuth sulfide nanorods (Bi2S3@SiO2 NRs) for a non-invasive spatial-temporally imaging of the GI tract. The Bi2S3 NRs were synthesized by a facile solvothermal method and then coated with a SiO2 layer to improve their biocompatibility and stability in the harsh environments of the GI tract, such as the stomach and the small intestine. Due to their strong X-ray- and near infrared-absorption abilities, we demonstrate that, following oral administration in mice, the Bi2S3@SiO2 NRs can be used as a dual-modal contrast agent for the real-time and non-invasive visualization of NRs distribution and the GI tract via both X-ray computed tomography (CT) and photoacoustic tomography (PAT) techniques. Importantly, integration of PAT with CT provides complementary information on anatomical details with high spatial resolution. In addition, we use Caenorhabditis Elegans (C. Elegans) as a simple model organism to investigate the biological response of Bi2S3@SiO2 NRs by oral administration. The results indicate that these NRs can pass through the GI tract of C. Elegans without inducing notable toxicological effects. The above results suggest that Bi2S3@SiO2 NRs pave an alternative way for the fabrication of multi-modal contrast agents which integrate CT and PAT modalities for a direct and non-invasive visualization of the GI tract with low toxicity. FAU - Zheng, Xiaopeng AU - Zheng X AD - CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, P. R. China. yanliang@ihep.ac.cn zjgu@ihep.ac.cn zhaoyuliang@ihep.ac.cn. FAU - Shi, Junxin AU - Shi J FAU - Bu, Yang AU - Bu Y FAU - Tian, Gan AU - Tian G FAU - Zhang, Xiao AU - Zhang X FAU - Yin, Wenyan AU - Yin W FAU - Gao, Bifen AU - Gao B FAU - Yang, Zhiyong AU - Yang Z FAU - Hu, Zhongbo AU - Hu Z FAU - Liu, Xiangfeng AU - Liu X FAU - Yan, Liang AU - Yan L FAU - Gu, Zhanjun AU - Gu Z FAU - Zhao, Yuliang AU - Zhao Y LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150706 PL - England TA - Nanoscale JT - Nanoscale JID - 101525249 RN - 0 (Contrast Media) RN - 0 (Sulfides) RN - 7631-86-9 (Silicon Dioxide) RN - U015TT5I8H (Bismuth) RN - XZC47M60X8 (bismuth sulfide) SB - IM MH - Administration, Oral MH - Animals MH - Bismuth/chemistry MH - Caenorhabditis elegans/growth & development/metabolism MH - Cell Line MH - Cell Survival/drug effects MH - Contrast Media/*chemistry MH - Female MH - Gastrointestinal Tract/diagnostic imaging/*pathology MH - Humans MH - Mice MH - Mice, Inbred BALB C MH - Mice, Nude MH - Microscopy, Fluorescence MH - Nanotubes/*chemistry/toxicity MH - *Photoacoustic Techniques MH - Silicon Dioxide/chemistry MH - Sulfides/chemistry MH - *Tomography, X-Ray Computed EDAT- 2015/07/07 06:00 MHDA- 2016/06/18 06:00 CRDT- 2015/07/07 06:00 PHST- 2015/07/07 06:00 [entrez] PHST- 2015/07/07 06:00 [pubmed] PHST- 2016/06/18 06:00 [medline] AID - 10.1039/c5nr03068d [doi] PST - ppublish SO - Nanoscale. 2015 Aug 7;7(29):12581-91. doi: 10.1039/c5nr03068d. Epub 2015 Jul 6. PMID- 23205639 OWN - NLM STAT- MEDLINE DCOM- 20130530 LR - 20161125 IS - 1520-510X (Electronic) IS - 0020-1669 (Linking) VI - 51 IP - 24 DP - 2012 Dec 17 TI - Visible and NIR photoluminescence properties of a series of novel lanthanide-organic coordination polymers based on hydroxyquinoline-carboxylate ligands. PG - 13128-37 LID - 10.1021/ic301261g [doi] AB - A series of novel two-dimensional (2D) lanthanide coordination polymers with 4-hydroxyquinoline-2-carboxylate (H(2)hqc) ligands, [Ln(Hhqc)(3)(H(2)O)](n)·3nH(2)O (Ln = Eu (1), Tb (2), Sm (3), Nd (4), and Gd (5)) and [Ln(Hhqc)(ox)(H(2)O)(2)](n) (Ln = Eu (6), Tb (7), Sm (8), Tm (9), Dy (10), Nd (11), Yb (12), and Gd (13); H(2)ox = oxalic acid), have been synthesized under hydrothermal conditions. Complexes 1-5 are isomorphous, which can be described as a two-dimensional (2D) hxl/Shubnikov network based on Ln(2)(CO(2))(4) paddle-wheel units, and the isomorphous complexes 6-13 feature a 2D decker layer architecture constructed by Ln-ox infinite chains cross-linked alternatively by bridging Hhqc(-) ligands. The room-temperature photoluminescence spectra of complexes Eu(III) (1 and 6), Tb(III) (2 and 7), and Sm(III) (3 and 8) exhibit strong characteristic emissions in the visible region, whereas Nd(III) (4 and 11) and Yb(III) (12) complexes display NIR luminescence upon irradiation at the ligand band. Moreover, the triplet state of H(2)hqc matches well with the emission level of Eu(III), Tb(III), and Sm(III) ions, which allows the preparation of new optical materials with enhanced luminescence properties. FAU - Gai, Yan-Li AU - Gai YL AD - State Key Laboratory of Structure Chemistry, Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou, 350002, China. FAU - Xiong, Ke-Cai AU - Xiong KC FAU - Chen, Lian AU - Chen L FAU - Bu, Yang AU - Bu Y FAU - Li, Xing-Jun AU - Li XJ FAU - Jiang, Fei-Long AU - Jiang FL FAU - Hong, Mao-Chun AU - Hong MC LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20121203 PL - United States TA - Inorg Chem JT - Inorganic chemistry JID - 0366543 RN - 0 (Carboxylic Acids) RN - 0 (Hydroxyquinolines) RN - 0 (Lanthanoid Series Elements) RN - 0 (Ligands) RN - 0 (Organometallic Compounds) RN - 0 (Polymers) RN - M1O131WXFO (4-hydroxyquinoline) SB - IM MH - Carboxylic Acids/*chemistry MH - Crystallography, X-Ray MH - Drug Stability MH - Hydroxyquinolines/*chemistry MH - Lanthanoid Series Elements/*chemistry MH - Ligands MH - Light MH - Luminescence MH - Organometallic Compounds/*chemistry MH - Photochemical Processes MH - Polymers/*chemistry MH - Temperature EDAT- 2012/12/05 06:00 MHDA- 2013/06/01 06:00 CRDT- 2012/12/05 06:00 PHST- 2012/12/05 06:00 [entrez] PHST- 2012/12/05 06:00 [pubmed] PHST- 2013/06/01 06:00 [medline] AID - 10.1021/ic301261g [doi] PST - ppublish SO - Inorg Chem. 2012 Dec 17;51(24):13128-37. doi: 10.1021/ic301261g. Epub 2012 Dec 3. PMID- 24752108 OWN - NLM STAT- MEDLINE DCOM- 20141222 LR - 20221207 IS - 1673-4254 (Print) IS - 1673-4254 (Linking) VI - 34 IP - 4 DP - 2014 Apr TI - [Correlation between TMEM39A gene polymorphism and systemic lupus erythematosus in Chinese Han patients]. PG - 556-9 AB - OBJECTIVE: To investigate the association between single nucleotide polymorphisms (SNPs) of the transmembrane protein 39A (TMEM39A) at the loci 1880G/A, 2442T/G, and 2456A/T and systemic lupus erythematosus (SLE) in Chinese Han patients. METHODS: TMEM39A gene polymorphisms at 3 loci (1880G/A, 2442T/G, 2456 A/T) were analyzed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in 110 Chinese Han patients with SLE and 80 normal control subjects, and the allele and genotype frequencies were compared by Chi-square test between the two groups. RESULTS: Both the genotype frequencies (AA, GA and GG) and allele frequencies (A and G) at 1880G/A differed significantly between SLE cases and the normal controls (P=0.002 and P=0.044, respectively). The two groups also showed significant differences in the genotype frequencies (GG, TG and TT) (P=0.001) and allele frequencies (G and T) (P=0.041) at 2442T/G. No significant differences were found in the genotype frequencies (TT, AT and AA) or allele frequencies (T and A) at 2456A/T between the two groups (P>0.05). The allele and genotype frequencies of the 3 SNPs showed no significant differences between lupus nephritis (LN) patients and non-LN patients. CONCLUSION: The TMEM39A polymorphisms at 1880G/A and 2442T/G, but not at 2456 A/T gene, may be associated with the susceptibility to SLE in Chinese Han population. The genotype or allele frequencies of the 3 SNPs have no effect on the incidence of lupus nephritis. FAU - Zhang, Jun AU - Zhang J AD - Department of Nephrology, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China.E-mail: gz163@fimmu.com. FAU - Ma, Yaqiong AU - Ma Y FAU - Qiu, Minzi AU - Qiu M FAU - Yang, Lei AU - Yang L FAU - Bu, Yang AU - Bu Y FAU - Tang, Xun AU - Tang X LA - chi PT - Journal Article PL - China TA - Nan Fang Yi Ke Da Xue Xue Bao JT - Nan fang yi ke da xue xue bao = Journal of Southern Medical University JID - 101266132 RN - 0 (Membrane Proteins) RN - 0 (TMEM39A protein, human) SB - IM MH - Adult MH - Alleles MH - Asian People/genetics MH - Case-Control Studies MH - Female MH - Gene Frequency MH - Genotype MH - Humans MH - Lupus Erythematosus, Systemic/*genetics MH - Male MH - Membrane Proteins/*genetics MH - Middle Aged MH - *Polymorphism, Single Nucleotide MH - Young Adult EDAT- 2014/04/23 06:00 MHDA- 2014/12/23 06:00 CRDT- 2014/04/23 06:00 PHST- 2014/04/23 06:00 [entrez] PHST- 2014/04/23 06:00 [pubmed] PHST- 2014/12/23 06:00 [medline] PST - ppublish SO - Nan Fang Yi Ke Da Xue Xue Bao. 2014 Apr;34(4):556-9. PMID- 33514991 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20210302 LR - 20210302 IS - 1473-0189 (Electronic) IS - 1473-0189 (Linking) VI - 21 IP - 4 DP - 2021 Feb 23 TI - Ordered surface crack patterns in situ formed under confinement on fluidic microchannel boundaries in polydimethylsiloxane. PG - 668-673 LID - 10.1039/d0lc01131b [doi] AB - We present ordered surface crack patterns discovered in microfluidic channels/chambers in polydimethylsiloxane (PDMS). The cracks are formed in situ under confinement due to compression applied following an oxygen plasma step in a soft lithography process. The crack patterns are noticeable only after fluorescent labeling and vary with fluidic layout as well as material compliance. FAU - Bu, Yang AU - Bu Y AD - Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong SAR, China. eelyobas@ust.hk. FAU - Ni, Sheng AU - Ni S AD - Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong SAR, China. eelyobas@ust.hk. FAU - Yobas, Levent AU - Yobas L AUID- ORCID: 0000-0003-3151-5616 AD - Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong SAR, China. eelyobas@ust.hk and Division of Biomedical Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong SAR, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Lab Chip JT - Lab on a chip JID - 101128948 SB - IM EDAT- 2021/01/31 06:00 MHDA- 2021/01/31 06:01 CRDT- 2021/01/30 05:33 PHST- 2021/01/31 06:00 [pubmed] PHST- 2021/01/31 06:01 [medline] PHST- 2021/01/30 05:33 [entrez] AID - 10.1039/d0lc01131b [doi] PST - ppublish SO - Lab Chip. 2021 Feb 23;21(4):668-673. doi: 10.1039/d0lc01131b. PMID- 24849431 OWN - NLM STAT- MEDLINE DCOM- 20150909 LR - 20220408 IS - 1673-4254 (Print) IS - 1673-4254 (Linking) VI - 34 IP - 5 DP - 2014 May TI - [Advanced oxidation protein products induce epithelial-to-mesenchymal transition in cultured human proximal tubular epithelial cells via oxidative stress]. PG - 659-63 AB - OBJECTIVE: To investigate the effects of advanced oxidation protein products (AOPP) on epithelial-to-mesenchymal transition (EMT) in cultured human proximal tubular epithelial cells (HK-2) and explore the mechanism. METHODS: HK-2 cells treated with 50, 100, 200, and 400 µg/ml AOPP or 50 µg/m bovine serum albumin (BSA) for 24 h, or with 200 µg/ml AOPP for 0.5, 1, 3, 6, 12, and 24 h were examined for the protein expression of α-SMA and E-cadherin. In cells pretreated with diphenyleneiodonium (DPI) or cytoplasmic superoxide dismutase (C-SOD), the effects of 50 µg/ml BSA and 200 µg/ml AOPP were assessed on the expressions of α-SMA and E-cadherin, malondialdehyde (MDA) level, superoxide dismutase (SOD) activity, catalase (CAT) activity, and glutathione peroxidase (GSH-px) activity. RESULTS: AOPP treatment up-regulated α-SMA expression and down-regulated E-cadherin expression in a dose- and time-dependent fashion. AOPP exposure of the cells resulted in increased MDA level and lowered activities of SOD, CAT and GSH-PX. DPI and C-SOD partially attenuated the effects of AOPP on α-SMA, E-cadherin, MDA, SOD, CAT and GSH-px. CONCLUSION: AOPP can induce EMT in cultured HK-2 cells via oxidative stress, and this effect can be attenuated by inhibiting the activation of NADPH oxidase and using antioxidants to delay the progression of renal interstitial fibrosis. FAU - Zhang, Jun AU - Zhang J AD - Department of Nephrology, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China. E-mail: gzh_zj@qq.com. FAU - Qiu, Minzi AU - Qiu M FAU - Ma, Yaqiong AU - Ma Y FAU - Bu, Yang AU - Bu Y FAU - Yang, Lei AU - Yang L FAU - Tang, Xun AU - Tang X LA - chi PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - China TA - Nan Fang Yi Ke Da Xue Xue Bao JT - Nan fang yi ke da xue xue bao = Journal of Southern Medical University JID - 101266132 RN - 0 (Actins) RN - 0 (Advanced Oxidation Protein Products) RN - 0 (Antigens, CD) RN - 0 (Antioxidants) RN - 0 (CDH1 protein, human) RN - 0 (Cadherins) RN - 4Y8F71G49Q (Malondialdehyde) RN - EC 1.11.1.6 (Catalase) RN - EC 1.11.1.9 (Glutathione Peroxidase) RN - EC 1.15.1.1 (Superoxide Dismutase) RN - EC 1.6.3.- (NADPH Oxidases) SB - IM MH - Actins/metabolism MH - *Advanced Oxidation Protein Products MH - Antigens, CD MH - Antioxidants/metabolism MH - Cadherins/metabolism MH - Catalase/metabolism MH - Cell Line MH - Cells, Cultured MH - Down-Regulation MH - Epithelial Cells/*cytology MH - *Epithelial-Mesenchymal Transition MH - Glutathione Peroxidase/metabolism MH - Humans MH - Malondialdehyde/metabolism MH - NADPH Oxidases/metabolism MH - *Oxidative Stress MH - Superoxide Dismutase/metabolism MH - Up-Regulation EDAT- 2014/05/23 06:00 MHDA- 2015/09/10 06:00 CRDT- 2014/05/23 06:00 PHST- 2014/05/23 06:00 [entrez] PHST- 2014/05/23 06:00 [pubmed] PHST- 2015/09/10 06:00 [medline] PST - ppublish SO - Nan Fang Yi Ke Da Xue Xue Bao. 2014 May;34(5):659-63. PMID- 27505367 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20180129 LR - 20181023 IS - 1539-4522 (Electronic) IS - 1559-128X (Linking) VI - 55 IP - 22 DP - 2016 Aug 1 TI - Zernike polynomials as a basis for modal fitting in lateral shearing interferometry: a discrete domain matrix transformation method. PG - 5884-91 LID - 10.1364/AO.55.005884 [doi] AB - A Zernike-polynomials-based wavefront reconstruction method for lateral shearing interferometry is proposed. Shear matrices are calculated using matrix transformation instead of mathematical derivation. Simulation results show that the shear matrices calculated using the proposed method are the same as those obtained from mathematical derivation. The advantage of the proposed method is that high order shear matrices can be obtained easily; thus, wavefront reconstruction can be extended to higher order Zernike terms, and reconstruction accuracy can be improved. FAU - Dai, Fengzhao AU - Dai F FAU - Zheng, Yazhong AU - Zheng Y FAU - Bu, Yang AU - Bu Y FAU - Wang, Xiangzhao AU - Wang X LA - eng PT - Journal Article PL - United States TA - Appl Opt JT - Applied optics JID - 0247660 EDAT- 2016/08/10 06:00 MHDA- 2016/08/10 06:01 CRDT- 2016/08/10 06:00 PHST- 2016/08/10 06:00 [entrez] PHST- 2016/08/10 06:00 [pubmed] PHST- 2016/08/10 06:01 [medline] AID - 347966 [pii] AID - 10.1364/AO.55.005884 [doi] PST - ppublish SO - Appl Opt. 2016 Aug 1;55(22):5884-91. doi: 10.1364/AO.55.005884. PMID- 40166368 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250402 IS - 1792-1082 (Electronic) IS - 1792-1074 (Print) IS - 1792-1074 (Linking) VI - 29 IP - 5 DP - 2025 May TI - Development and application of an early warning model for predicting early mortality following stent placement in malignant biliary obstruction: A comparative analysis of logistic regression and artificial neural network approaches. PG - 237 LID - 10.3892/ol.2025.14983 [doi] LID - 237 AB - Patients with malignant biliary obstruction (MBO) are often treated with endoscopic retrograde cholangiopancreatography (ERCP) combined with biliary stent placement for tumor progression. However, certain patients die within 30 days after the procedure, increasing healthcare resource consumption and patient burden. Therefore, the development of early mortality prediction models is important for optimizing treatment decisions. The present study retrospectively analyzed the clinical data of 285 patients with MBO, including demographic information, laboratory indicators and tumor-related factors. Logistic regression and artificial neural network (ANN) models were used to construct a prediction tool, and the model performance was evaluated using area under the curve (AUC), accuracy, sensitivity and specificity. The logistic regression model, which identified the cancer antigen 19-9 (CA19-9) level and a history of previous ERCP surgery as independent risk factors, had an AUC of 0.727 and an accuracy of 65.0%. The ANN model, which combined five variables, namely CA19-9, history of previous ERCP surgery, neutrophil-lymphocyte ratio (NLR), liver metastasis and carcinoembryonic antigen, demonstrated that NLR was the most weighted predictor. Furthermore, the ANN model had an AUC of 0.813, an accuracy of 88.2% and a specificity that was markedly higher than that of the logistic regression model (95.5 vs. 83.3%). However, the ANN model was revealed to be slightly less sensitive compared with the logistic regression model (61.1 vs. 61.2%). In conclusion, compared with logistic regression, the ANN model had a greater performance level in terms of predictive power and specificity, and is suitable for capturing complex non-linear relationships. However, its complexity and risk of overfitting need to be further optimized. The present study provides a new tool for the accurate prediction of the risk of early death after ERCP in patients with MBO, which could help improve individualized treatment strategies. CI - Copyright: © 2025 Ma et al. FAU - Ma, Yongxin AU - Ma Y AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China. AD - Department of Hepatobiliary Surgery, First Clinical College of Medicine, Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China. FAU - Qi, Jiaojiao AU - Qi J AD - Department of Obstetrics Function Center Inspection, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China. FAU - Zhang, Xusheng AU - Zhang X AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China. AD - Department of Hepatobiliary Surgery, First Clinical College of Medicine, Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China. FAU - Liu, Kejun AU - Liu K AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China. AD - Department of Hepatobiliary Surgery, First Clinical College of Medicine, Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China. FAU - Liu, Yimin AU - Liu Y AD - Department of Hepatobiliary Surgery, First Clinical College of Medicine, Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China. FAU - Yu, Xuehai AU - Yu X AD - Department of Pediatric Surgery, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China. FAU - Bu, Yang AU - Bu Y AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China. AD - Department of Hepatobiliary Surgery, First Clinical College of Medicine, Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China. FAU - Chen, Bendong AU - Chen B AD - Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China. AD - Department of Hepatobiliary Surgery, First Clinical College of Medicine, Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China. LA - eng PT - Journal Article DEP - 20250320 PL - Greece TA - Oncol Lett JT - Oncology letters JID - 101531236 PMC - PMC11956143 OTO - NOTNLM OT - artificial neural networks OT - early mortality OT - endoscopic retrograde cholangiopancreatography OT - logistic regression models OT - malignant biliary obstruction COIS- The authors declare that they have no competing interests. EDAT- 2025/04/01 06:26 MHDA- 2025/04/01 06:27 PMCR- 2025/03/20 CRDT- 2025/04/01 05:01 PHST- 2024/10/15 00:00 [received] PHST- 2025/02/28 00:00 [accepted] PHST- 2025/04/01 06:27 [medline] PHST- 2025/04/01 06:26 [pubmed] PHST- 2025/04/01 05:01 [entrez] PHST- 2025/03/20 00:00 [pmc-release] AID - OL-29-5-14983 [pii] AID - 10.3892/ol.2025.14983 [doi] PST - epublish SO - Oncol Lett. 2025 Mar 20;29(5):237. doi: 10.3892/ol.2025.14983. eCollection 2025 May. PMID- 40827580 OWN - NLM STAT- MEDLINE DCOM- 20250923 LR - 20250923 IS - 1473-0189 (Electronic) IS - 1473-0189 (Linking) VI - 25 IP - 19 DP - 2025 Sep 23 TI - A compact sample-to-answer system for rapid MRSA detection in serum based on reagent-free electrophoretic purification of nucleic acids and colorimetric LAMP. PG - 5019-5029 LID - 10.1039/d5lc00152h [doi] AB - Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant threat as a leading cause of nosocomial infections, inflicting severe complications and fatalities worldwide. Its rising prevalence has become a major public health concern as its resistance to common antibiotics complicates treatments, placing additional burden on healthcare systems. Microbial culture is the "gold standard" for diagnosing MRSA; however, this method is time-consuming and labor-intensive, often leading to prolonged delays in diagnosis and treatment. In contrast, nucleic acid amplification tests (NAATs) dramatically reduce diagnostic times to mere hours, while maintaining high sensitivity and specificity. Bringing NAATs to the point of care can facilitate timely treatment decisions and yet requires a compact "sample-to-answer" system whose development has long been hindered by the required sample preparation for these tests. Here, we present such a system detecting MRSA in human serum through a simple microfluidic chip, achieving a limit of detection of 1 CFU per reaction and a turnaround time of just 45 min. The chip effectively overcomes the sample preparation challenge with an innovative use of a sieve, a dense array of micropillars with submicrometer gaps. Along with associated reservoirs, this sieve integrates bacterial lysis, reagent-free electrophoretic purification and loop-mediated isothermal amplification (LAMP) of nucleic acids with colorimetric detection visible to the naked eye. Within the sieve, nucleic acids are selectively driven by rotating electric fields and focused near the sieve center while steady electric fields remove all contaminants, without the need for reagents. The system shows great potential for point-of-care diagnostics. FAU - Lee, Yung Ching AU - Lee YC AUID- ORCID: 0009-0002-1968-1005 AD - Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, SAR, China. eelyobas@ust.hk. FAU - Bu, Yang AU - Bu Y AD - Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, SAR, China. eelyobas@ust.hk. FAU - Ni, Sheng AU - Ni S AUID- ORCID: 0000-0002-1786-7466 AD - Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, SAR, China. eelyobas@ust.hk. FAU - Liu, Yuze AU - Liu Y AD - Department of Chemical and Biological Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, SAR, China. FAU - Hu, Anni AU - Hu A AD - Department of Chemical and Biological Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, SAR, China. FAU - Yobas, Levent AU - Yobas L AUID- ORCID: 0000-0003-3151-5616 AD - Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, SAR, China. eelyobas@ust.hk. AD - Department of Chemical and Biological Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, SAR, China. LA - eng PT - Journal Article DEP - 20250923 PL - England TA - Lab Chip JT - Lab on a chip JID - 101128948 RN - 0 (DNA, Bacterial) RN - LAMP assay SB - IM MH - *Methicillin-Resistant Staphylococcus aureus/isolation & purification/genetics MH - *Nucleic Acid Amplification Techniques/instrumentation/methods MH - Humans MH - *Colorimetry/instrumentation MH - *Lab-On-A-Chip Devices MH - *Molecular Diagnostic Techniques/instrumentation MH - *DNA, Bacterial/isolation & purification/blood/genetics MH - Staphylococcal Infections/diagnosis/microbiology/blood MH - Electrophoresis/instrumentation MH - Limit of Detection EDAT- 2025/08/19 12:33 MHDA- 2025/09/23 12:46 CRDT- 2025/08/19 06:23 PHST- 2025/09/23 12:46 [medline] PHST- 2025/08/19 12:33 [pubmed] PHST- 2025/08/19 06:23 [entrez] AID - 10.1039/d5lc00152h [doi] PST - epublish SO - Lab Chip. 2025 Sep 23;25(19):5019-5029. doi: 10.1039/d5lc00152h. PMID- 19638082 OWN - NLM STAT- MEDLINE DCOM- 20101203 LR - 20090729 IS - 1440-1746 (Electronic) IS - 0815-9319 (Linking) VI - 24 IP - 6 DP - 2009 Jun TI - Chronic hepatitis B infection in an Australian antenatal population: seroprevalence and opportunities for better outcomes. PG - 998-1001 LID - 10.1111/j.1440-1746.2009.05841.x [doi] AB - BACKGROUND: In the antenatal population, screening for Hepatitis B virus (HBV) carrier status is routinely undertaken to guide preventative measures for the newborn. There is scarce information in the literature, however, regarding the subsequent management of Hepatitis B surface antigen (HBsAg) positive mothers. AIMS AND METHODS: Thus, we undertook this retrospective study to (i) determine the prevalence of HBsAg positivity among mothers attending two teaching hospital birth centers; (ii) determine whether HBsAg mothers received HBV education and underwent further evaluation of HBV infectivity status; and (iii) determine whether these mothers had further follow up for HBV infection post delivery. RESULTS: Between January 2003 and December 2006, 14, 857 mothers were screened for hepatitis B virus infection. Among these, 295 mothers were positive with HBsAg seroprevalence of 2%. A more detailed review of the available 206 medical records revealed that the majority (78%) had previous documentation of infection in earlier pregnancies. However none had received education regarding HBV infectivity. In addition, liver function tests were only performed in 78% of the mothers while Hepatitis B e antigen was tested in 65% of cases. Further, 93% of the mothers had no documentation of further follow up plans or referrals for their HBV infection. CONCLUSION: It is clear that chronic HBV infection is prevalent in the antenatal population. However, there are no strategies to ensure that infected mothers subsequently undergo further education for HBV or evaluation of infectivity. Clearly strategies are required to ensure improved follow up of hepatitis B infected mothers. FAU - Guirgis, Marianne AU - Guirgis M AD - Department of Gastroenterology and Hepatology, St George Hospital, University of NSW, New South Wales, Australia. FAU - Zekry, Amany AU - Zekry A FAU - Yan, Kenneth AU - Yan K FAU - Bu, Yang Min AU - Bu YM FAU - Lee, Alice AU - Lee A LA - eng PT - Journal Article PL - Australia TA - J Gastroenterol Hepatol JT - Journal of gastroenterology and hepatology JID - 8607909 SB - IM MH - Adult MH - Female MH - Hepatitis B, Chronic/blood/*epidemiology/transmission MH - Humans MH - Infant, Newborn MH - Infectious Disease Transmission, Vertical MH - Male MH - New South Wales/epidemiology MH - Pregnancy MH - Pregnancy Complications, Infectious/blood/*epidemiology MH - Prenatal Care MH - Retrospective Studies MH - Seroepidemiologic Studies EDAT- 2009/07/30 09:00 MHDA- 2010/12/14 06:00 CRDT- 2009/07/30 09:00 PHST- 2009/07/30 09:00 [entrez] PHST- 2009/07/30 09:00 [pubmed] PHST- 2010/12/14 06:00 [medline] AID - JGH5841 [pii] AID - 10.1111/j.1440-1746.2009.05841.x [doi] PST - ppublish SO - J Gastroenterol Hepatol. 2009 Jun;24(6):998-1001. doi: 10.1111/j.1440-1746.2009.05841.x. PMID- 12212241 OWN - NLM STAT- MEDLINE DCOM- 20030107 LR - 20101118 IS - 1000-5625 (Print) IS - 1000-5625 (Linking) VI - 25 IP - 1 DP - 2000 Feb 28 TI - ["Bu-yang huanwu tang" inhibited the pathogentic process of atherosclerosis induced by cholesterol-rich diet in rabbits]. PG - 33-5 AB - BACKGROUND AND OBJECTIVE: "Bu-yang huanwu tang", a decoction of Chinese herbs widely used in the treatment for cardio- and cerebro-vascular diseases, has been demonstrated to be able to inhibit platelet adhesion and aggregation, to lower blood lipids, to regulate vascular tone from animal experiments. The aim of this study is to determine whether this decoction inhibits the pathogentic process of atherosclerosis induced by cholesterol-rich diet in rabbits. METHODS: Three groups of rabbits received the following different diets for 9 weeks: 1. standard diet; 2. atherogenic diet(standard diet plus 1% cholesterol and 3.3% fat); 3. atherogenic diet plus this decoction(5 g.kg-1.d-1). Plasma lipids, 6-keto-PGF1 alpha, endothelin levels were detected and the histological atherosclerotic changes were evaluated. RESULTS: This decoction inhibited the progression of aortic and abdominal aortic intimal plaques and reduced aortic intimal thickening. CONCLUSION: The anti-atherogenic mechanism might be related to the decrease of plasma cholesterol and triglycerides and the increase of PGI2. The facts suggest that "Bu-yang huanwu tang" has antiatherogenic and antithrombotic effects. FAU - Liu, F Y AU - Liu FY AD - Thrombosis and Hemostasis Research Laboratory, Department of Physiology, Hunan Medical University, Changsha 410078. FAU - Wen, Z B AU - Wen ZB FAU - Zhou, C S AU - Zhou CS FAU - Yang, X P AU - Yang XP FAU - Shang, G P AU - Shang GP FAU - He, S L AU - He SL FAU - Li, J C AU - Li JC LA - chi PT - English Abstract PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - China TA - Hunan Yi Ke Da Xue Xue Bao JT - Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University JID - 9424769 RN - 0 (Cholesterol, Dietary) RN - 0 (Drug Combinations) RN - 0 (Drugs, Chinese Herbal) RN - 0 (Hypolipidemic Agents) RN - 0 (Platelet Aggregation Inhibitors) RN - 0 (buyang huanwu) SB - IM MH - Animals MH - Arteriosclerosis/*blood/*drug therapy/etiology MH - Cholesterol, Dietary/administration & dosage MH - Drug Combinations MH - Drugs, Chinese Herbal/*pharmacology/therapeutic use MH - Hyperlipidemias/blood MH - Hypolipidemic Agents/*pharmacology/therapeutic use MH - Male MH - *Phytotherapy MH - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use MH - Rabbits MH - Random Allocation EDAT- 2002/09/06 10:00 MHDA- 2003/01/08 04:00 CRDT- 2002/09/06 10:00 PHST- 2002/09/06 10:00 [pubmed] PHST- 2003/01/08 04:00 [medline] PHST- 2002/09/06 10:00 [entrez] PST - ppublish SO - Hunan Yi Ke Da Xue Xue Bao. 2000 Feb 28;25(1):33-5. PMID- 41555554 OWN - NLM STAT- MEDLINE DCOM- 20260120 LR - 20260123 IS - 2162-3279 (Electronic) VI - 16 IP - 1 DP - 2026 Jan TI - NSUN5 as a Prognostic Biomarker Correlates with Malignant Phenotype and Therapeutic Target in Glioma. PG - e71211 LID - 10.1002/brb3.71211 [doi] LID - e71211 AB - BACKGROUND: NSUN5 is a conserved RNA methyltransferase whose oncogenic role has been demonstrated in various cancers. However, its function and prognostic value in gliomas remain unclear. METHODS: In this study, we systematically analyzed the expression and functional associations of NSUN5 in glioma using data from The Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) databases. A total of 117 machine learning algorithm combinations were employed to construct and validate a prognostic model for glioma patients. In addition, in vitro experiments were performed to further validate the expression and biological functions of NSUN5. RESULTS: NSUN5 expression is significantly upregulated in glioma and is positively associated with tumor malignancy and poor prognosis. Immune infiltration analysis revealed a marked increase in M2 macrophages in the NSUN5 high-expression group, and NSUN5 levels were positively correlated with the expression of multiple inhibitory immune checkpoints. In addition, drug sensitivity analysis and molecular docking suggested that NSUN5 may influence the response to Olaparib. Finally, based on NSUN5-associated genes, we constructed 117 machine learning models and identified the optimal prognostic model, STRICOM, which demonstrated robust predictive performance for patient survival. CONCLUSION: High NSUN5 expression is closely associated with poor prognosis in glioma patients, highlighting its potential as a prognostic biomarker and therapeutic target. CI - © 2026 The Author(s). Brain and Behavior published by Wiley Periodicals LLC. FAU - Wenhao, Ye AU - Wenhao Y AD - Anhui Engineering Research Center for Neural Regeneration Technology and Medical New Materials, Bengbu Medical University, Bengbu, China. FAU - Huan, Wu AU - Huan W AD - West China School of Basic Medical Sciences and Forensic Medicine, Sichuan University, Chengdu, China. FAU - Xiaoyun, Zou AU - Xiaoyun Z AD - Anhui Engineering Research Center for Neural Regeneration Technology and Medical New Materials, Bengbu Medical University, Bengbu, China. FAU - Yuanyuan, Yang AU - Yuanyuan Y AD - Anhui Engineering Research Center for Neural Regeneration Technology and Medical New Materials, Bengbu Medical University, Bengbu, China. FAU - Junlei, Bi AU - Junlei B AD - Anhui Engineering Research Center for Neural Regeneration Technology and Medical New Materials, Bengbu Medical University, Bengbu, China. FAU - Changqing, Liu AU - Changqing L AD - Anhui Engineering Research Center for Neural Regeneration Technology and Medical New Materials, Bengbu Medical University, Bengbu, China. FAU - Mengyi, Zhao AU - Mengyi Z AD - Anhui Engineering Research Center for Neural Regeneration Technology and Medical New Materials, Bengbu Medical University, Bengbu, China. FAU - Yuyuan, Zhang AU - Yuyuan Z AD - Anhui Engineering Research Center for Neural Regeneration Technology and Medical New Materials, Bengbu Medical University, Bengbu, China. FAU - Jin, Lu AU - Jin L AD - Anhui Engineering Research Center for Neural Regeneration Technology and Medical New Materials, Bengbu Medical University, Bengbu, China. FAU - Hebao, Wen AU - Hebao W AD - Anhui Engineering Research Center for Neural Regeneration Technology and Medical New Materials, Bengbu Medical University, Bengbu, China. AD - School of Humanities and Health, Bengbu Medical University, Bengbu, China. FAU - Caiyun, Ma AU - Caiyun M AD - Anhui Engineering Research Center for Neural Regeneration Technology and Medical New Materials, Bengbu Medical University, Bengbu, China. AD - School of Life Science, Bengbu Medical University, Bengbu, China. LA - eng GR - Anhui Provincial Young Backbone Teachers' Domestic Visiting and Research Training Program/ GR - The Experimental Teaching and TeachingLaboratory Quality Engineering Project of Bengbu Medical University/ GR - Longhu Talent Project of Bengbu Medical University/ GR - Quality Engineering Project of Higher Education Institutions of Anhui Province/ GR - Natural Science Foundation of the Higher Education/ GR - Institutions of Anhui Province/ GR - National Natural Science Foundation of China/ PT - Journal Article PL - United States TA - Brain Behav JT - Brain and behavior JID - 101570837 RN - 0 (Biomarkers, Tumor) RN - EC 2.1.1.- (Methyltransferases) RN - EC 2.1.1.43 (SETD7 protein, human) RN - EC 2.1.1.43 (Histone-Lysine N-Methyltransferase) SB - IM MH - Humans MH - *Glioma/genetics/metabolism/diagnosis/pathology MH - Prognosis MH - Biomarkers, Tumor/metabolism/genetics MH - *Brain Neoplasms/genetics/metabolism MH - *Methyltransferases/metabolism/genetics MH - Machine Learning MH - Gene Expression Regulation, Neoplastic MH - Phenotype MH - Histone-Lysine N-Methyltransferase PMC - PMC12816160 OTO - NOTNLM OT - NSUN5 OT - glioma OT - prognostic biomarker OT - therapeutic target COIS- The authors declare no conflicts of interest. EDAT- 2026/01/20 07:43 MHDA- 2026/01/20 07:44 PMCR- 2026/01/19 CRDT- 2026/01/20 00:43 PHST- 2025/11/14 00:00 [revised] PHST- 2025/08/11 00:00 [received] PHST- 2026/01/02 00:00 [accepted] PHST- 2026/01/20 07:44 [medline] PHST- 2026/01/20 07:43 [pubmed] PHST- 2026/01/20 00:43 [entrez] PHST- 2026/01/19 00:00 [pmc-release] AID - BRB371211 [pii] AID - 10.1002/brb3.71211 [doi] PST - ppublish SO - Brain Behav. 2026 Jan;16(1):e71211. doi: 10.1002/brb3.71211. PMID- 27661603 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20180129 LR - 20181023 IS - 1539-4522 (Electronic) IS - 1559-128X (Linking) VI - 55 IP - 27 DP - 2016 Sep 20 TI - Nonsubsampled contourlet transform method for optical fringe pattern analysis in profilometry and interferometry. PG - 7718-25 LID - 10.1364/AO.55.007718 [doi] AB - A method based on a nonsubsampled contourlet transform, which is an overcomplete transform with multiresolution, directionality, and shift-invariance properties, is proposed to extract the fundamental frequency component of an optical fringe pattern in profilometry and interferometry. The nonsubsampled contourlet transform method overcomes the disadvantages of the original contourlet transform method, which lacks the shift-invariance property. Besides, it improves the frequency selectivity. A strategy is developed to automatically determine the optimal decomposition scale for removing the background intensity and suppressing the noise of the fringe pattern. The proposed method is precise, effective, and possesses a strong noise immune ability. Simulations and experiments verify the validity, and show the superiorities of the proposed method. FAU - Li, Sikun AU - Li S FAU - Wang, Xiangzhao AU - Wang X FAU - Tang, Feng AU - Tang F FAU - Bu, Yang AU - Bu Y FAU - Sasaki, Osami AU - Sasaki O LA - eng PT - Journal Article PL - United States TA - Appl Opt JT - Applied optics JID - 0247660 EDAT- 2016/09/24 06:00 MHDA- 2016/09/24 06:01 CRDT- 2016/09/24 06:00 PHST- 2016/09/24 06:00 [entrez] PHST- 2016/09/24 06:00 [pubmed] PHST- 2016/09/24 06:01 [medline] AID - 350190 [pii] AID - 10.1364/AO.55.007718 [doi] PST - ppublish SO - Appl Opt. 2016 Sep 20;55(27):7718-25. doi: 10.1364/AO.55.007718. PMID- 17214426 OWN - NLM STAT- MEDLINE DCOM- 20070327 LR - 20081121 IS - 1225-505X (Print) IS - 1225-505X (Linking) VI - 15 IP - 1 DP - 2006 Jun TI - [The academic trend of Oriental medicine during the Japanese colonial period as observed through the publication of medical books]. PG - 77-105 AB - This thesis examines the academical trend of Oriental Medicine in the Japanese colonial period observed through medical books published during the Japanese colonial period. This is a period in which Western Medicine was introduced, and due to the lean-to-one-side policy by the Japanese, Western Medicine became the mainstream medical science while Oriental Medicine was pushed to the outskirts. Even after all this, the academic activity was flourishing during this period compared to any other periods. This article is divided into various chapters each with its own theme in order to understand the academic trend of Oriental Medicine during the Japanese colonial period. Focusing on the publication of medical books, this article is divided and observed according to various themes such as the study of Dong-Eui-Bo-Gam (see text), the study of Bang-Yak-Hap-Pyeun (see text), the study of Sang-Han-Ron (see text), the study of Sa-sang (see text) constitutional medicine, the study of Eui-Hak-Ip-Mun (see text), the study about Bu-Yang-Ron (see text), On-Bo-Ron (see text), and pediatrics, compromise between Western and Oriental Medicine, the study of experience medicine, the study of acupuncture and moxibustion, and etc. FAU - Kim, Nam-Il AU - Kim NI AD - Department of Medical History, College of Oriental Medicine, Kyung Hee University. LA - kor PT - English Abstract PT - Historical Article PT - Journal Article PL - Korea (South) TA - Uisahak JT - Ui sahak JID - 9605018 MH - Books/history MH - Colonialism/*history MH - History, 20th Century MH - Humans MH - Japan MH - Medicine, East Asian Traditional/*history MH - Western World/history EDAT- 2007/01/12 09:00 MHDA- 2007/03/28 09:00 CRDT- 2007/01/12 09:00 PHST- 2007/01/12 09:00 [pubmed] PHST- 2007/03/28 09:00 [medline] PHST- 2007/01/12 09:00 [entrez] PST - ppublish SO - Uisahak. 2006 Jun;15(1):77-105. PMID- 23070363 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20130416 LR - 20121108 IS - 1477-9234 (Electronic) IS - 1477-9226 (Linking) VI - 41 IP - 46 DP - 2012 Dec 14 TI - Three novel 3D coordination polymers based on a flexible multisite cyclotetraphosphazene ligand. PG - 14038-41 LID - 10.1039/c2dt31852k [doi] AB - A novel flexible multisite cyclotetraphosphazene ligand, octakis(4-pyridylamino)cyclotetraphosphazene (OPCP), was synthesized through a new method, and it represents the first fully substituted pyridylaminocylcophosphazene ligand with eight coordinating arms. Self-assemblies of OPCP and different transition metal ions result in three novel 3D coordination polymers, in which the Cd(II) complex exhibits a quite strong blue emission. FAU - Li, Xingjun AU - Li X AD - State Key Laboratory of Structure Chemistry, Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou, 350002, China. FAU - Jiang, Feilong AU - Jiang F FAU - Chen, Lian AU - Chen L FAU - Wu, Mingyan AU - Wu M FAU - Chen, Qihui AU - Chen Q FAU - Bu, Yang AU - Bu Y FAU - Hong, Maochun AU - Hong M LA - eng PT - Journal Article DEP - 20121015 PL - England TA - Dalton Trans JT - Dalton transactions (Cambridge, England : 2003) JID - 101176026 EDAT- 2012/10/17 06:00 MHDA- 2012/10/17 06:01 CRDT- 2012/10/17 06:00 PHST- 2012/10/17 06:00 [entrez] PHST- 2012/10/17 06:00 [pubmed] PHST- 2012/10/17 06:01 [medline] AID - 10.1039/c2dt31852k [doi] PST - ppublish SO - Dalton Trans. 2012 Dec 14;41(46):14038-41. doi: 10.1039/c2dt31852k. Epub 2012 Oct 15.